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Ion channels are transmembrane proteins that create a gated and water-filled pore 
to allow the flow of ions down their electrochemical gradient between the in-
tracellular and extracellular environment.1, 2 They are selective for a wide range 
of cations and anions, such as Na+, K+, Ca2+, and Cl- ions. The distribution of 
ion channels has been found in cell membranes as well as the membranes of 
intracellular mitochondria, endoplasmic reticulum, and nucleus, which suggests 
their crucial physiological functions in a plethora of excitable and non-excitable 
tissues. Accordingly, ion channels are important targets for many drugs in current 
use. Indeed, application of ion channel modulators as medications was operative 
long before their existence had been demonstrated.3 For instance, in the 19th cen-
tury cocaine extraction from coca leaves gave rise to a pharmaceutical class of 
local anesthetics, which are selective sodium channel blockers.4 In addition to 
the widespread therapeutic properties, ion channels are also crucially related to 
human toxicology due to their involvement in human physiology. Kv11.1 (hERG) 
channel induced cardiotoxicity has become a thorny issue for the pharmaceutical 
industry in the past years. Blockade of the Kv11.1 channel leads to the prolonga-
tion of cardiac action potential duration (APD) and long QT syndrome, which in 
some individuals can degenerate into ventricular arrhythmias and sudden cardiac 
death.5 It has been pointed out that 50% of drugs recalled by the FDA from 1995 
to 2000 were also Kv11.1 blockers.
6 In this thesis, I, therefore, focus on parame-
ters that might determine the Kv11.1 toxicity of compounds at the molecular level, 
as well as possible strategies for relieving the Kv11.1-related cardiac side effects 
of drugs. In order to provide some background for the research and concepts that 
are discussed in this thesis, a brief overview of ion channels has been outlined. 
Subsequently, the target receptor, the Kv11.1 channel, is introduced, followed by 
a summary of objectives and contents of this thesis.
Ion channels
Several hundred genes in the human genome encode the pore-forming ion chan-
nels across plasma membranes.1 According to the precise control of channel gat-
ing, ion channels are classified as ligand- and voltage-gated channels, of which 
the opening and closure are mediated by a specific ligand and membrane voltage, 
respectively.7 
Ligand-gated ion channels
Ligand-gated ion channels (LGICs) are oligomeric protein assemblies that span 
the cell membrane and form both the binding site for an endogenous ligand and 
an ion-conducting pore, which converts a chemical signal into an ion flux through 
10   |   General introduction
the membrane.8, 9 Based on homology in their amino acid sequence and topology 
of their component subunits, LGICs are divided into three superfamilies, includ-
ing P2X, ionotropic glutamate, and Cys-loop receptors.10 They play an important 
role in fast synaptic transmission and in the modulation of cellular activity, in 
particular for basic brain functions like learning, memory and attention. 
P2X receptors
P2X receptors are non-selective cationic channels gated by extracellular ATP, 
which are permeable to Na+, K+, Ca2+, and in some cases also to Cl- ions.11 A P2X 
channel contains three subunits, and each subunit is composed of two transmem-
brane domains connected by a large, glycosylated extracellular loop, and intracel-
lular C- and N-terminus (Figure 1A).9 At present, there are seven P2X receptor 
subtypes found in mammals, which are termed P2X1 to P2X7.
12 These channels 
play paramount roles in various physiological processes such as nerve transmis-
sion, pain sensation, the response to inflammation, multiple facets of diabetes, 
and tumor cell growth, making them attractive drug targets in recent years.12-14
Ionotropic glutamate receptors
Ionotropic glutamate receptors are cation-selective ion channels that open their 
ion-conducting pores in response to the binding of glutamate.15 This channel is 
made up of four homologous subunits with each subunit containing three trans-
membrane segments, an intracellular C-terminus and extracellular N-terminus 
(Figure 1B).9 The ionotropic glutamate receptors are grouped into three subtypes 
according to their distinct responses to certain small molecule agonists: N-meth-
yl-D-aspartate (NMDA), α-amino-3-hydroxy-5-methyl-4-isoxazolepropion-
ic-acid (AMPA) and kainate (KA) receptors.10, 15, 16 These distinct ion channels 
are implicated in almost all aspects of nervous system development and function, 
and their dysfunctions can be linked to epilepsy or chronic neurodegenerative 
conditions like schizophrenia, Alzheimer’s and Parkinson’s diseases, as well as 
stroke.15, 16
Cys-loop receptors
The Cys-loop receptors, named from the conserved cysteine loop in their ex-
tracellular domain, constitute the largest subfamily amongst all LGICs.9, 17 The 
best characterized members of the Cys-loop receptor superfamily are nicotinic 
acetylcholine receptors (nAChRs), serotonin type 3 receptors (5-HT3Rs), GABA 
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nels (ZACs).18 Although these ion channels exhibit diverse kinetic and pharmaco-
logical profiles, they share a common structure of five identical subunits that are 
pseudo-symmetrically arranged to form a rosette with a central ion-conducting 
pore for either anion (GABAARs and GlyRs) or cation (nAChRs, 5-HT3Rs, and 
ZACs) flux.17, 19 As shown in Figure 1C, each subunit of the channel is made up 
of an extensive N-terminus and a short C-terminus on the extracellular side, and 
four transmembrane segments.8 All these receptors are very important targets for 
a wide variety of drugs, and their dysfunctions are associated with different kinds 
of diseases. For example, nAChRs have been demonstrated to play many critical 
roles in brain and body functions, indicating their therapeutic modulation of Alz-
heimer’s disease, epileptic disorders and chronic pain.20-22 Likewise, GABAARs 
have been unraveled to regulate the controlling neuronal activity in distinct brain 
regions, and dysfunction of this ion channel involves a range of central nervous 
system diseases such as anxiety, insomnia, muscle spasms, Alzheimer’s disease 
and schizophrenia.23, 24 
Figure 1. Schematic representation of a single subunit from the three superfamilies of 
ligand-gated ion channels across the membrane: (A) P2X receptors, (B) Ionotropic gluta-
mate receptors, and (C) Cys-loop receptors.9
Voltage-gated ion channels
Voltage-gated ion channels (VGICs) are integral transmembrane proteins that 
conduct selected inorganic ions at high rates across the membrane in response 
to changes in transmembrane voltage.25 The VGIC superfamily, with 143 mem-
bers in the human genome, forms the third largest family of signal-transduction 
proteins, following the G protein-coupled receptors and protein kinases.26, 27 As 
shown in Figure 2, ten families are included in this VGIC superfamily: volt-
age-gated sodium/calcium/potassium channels (Nav/Cav/Kv), calcium-activated 
A CB
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potassium channels (KCa), cyclic nucleotide-modulated (CNG) ion channels, hy-
perpolarization-activated cyclic nucleotide-modulated (HCN) channels, transient 
receptor potential (TRP) channels, two-pore channels (TPCs), inwardly rectify-
ing potassium channels (Kir) and two-pore potassium channels (K2P).
10, 28 All these 
channels are composed of a common cation-selective pore-forming module con-
taining two transmembrane segments and an intervening pore loop.10 Except for 
Kir and K2P channels, all other ion channels consist of four subunits symmetrically 
arranged around the central ion-conducting pore, and each subunit encompasses 
six transmembrane segments (S1-S6).10, 26, 27 Amongst these segments, S1-S4 seg-
ments form the voltage-sensor domain with four to eight positively charged resi-
dues in the S4 segment conferring voltage dependence, whereas S5 and S6 make 
up the pore domain including the ionic pore with the selectivity filter.1 Movement 
of the voltage sensors and pore domains constitutes three main conformational 
states of the VGICs: closed, open and inactivated states. On the other hand, Kir 
and K2P, which are composed of four and three subunits respectively, are struc-
turally the simplest VGICs with only pore-forming segments for each subunit. 
These two potassium channels are regulated by membrane lipids and intracellular 
‘ligands’, as diverse as G proteins, Mg2+ ions, polyamines and ATP.10 Apart from 
the main subunits, VGICs also possess some smaller, auxiliary subunits to mod-
ify their functions, increasing the diversity and complexity of this superfamily. 
VGICs play a fundamental role in most aspects of cell physiology and underlie 
complex integrative processes like learning and memory in the brain and coor-
dinated movements of the muscles, which makes them the molecular target for a 
number of therapeutic agents and also toxins.27
Potassium-selective channels with 78 members are the most diverse and 
widespread group of ion channels, whereas Kv channels, in humans encoded 
by 40 genes and divided into 12 subfamilies (Kv1-12), form the largest family 
among these potassium channels.29, 30 All Kv channels have a high level of struc-
tural similarity, and play a pivotal role in a variety of cellular processes, such 
as functioning of excitable cells, cell apoptosis, growth and differentiation, the 
release of neurotransmitters and hormones, and maintenance of cardiac activity.31 
Therefore, Kv channels constitute potential drug targets and provide tremendous 
opportunities for treating cancer, autoimmune diseases, metabolic, neurological 
and cardiovascular disorders. However, Kv channels also present a challenge to 
the development of Kv-targeted medications, of which the Kv11.1 channel is an 
explicit example with its promiscuity to drug binding, resulting in drug-induced 
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The Kv11.1 channel
Overview of the Kv11.1 channel
The Kv11.1 channel, of which the pore-forming α-subunits are encoded by the 
human ether-à-go-go-related gene (hERG), carries a rapidly activating delayed 
rectifier potassium current (IKr) underlying its essential role in cardiac action 
potential repolarization.32 In addition, the Kv11.1 channel has been found to be 
expressed in various brain regions, smooth muscle cells, endocrine cells, and a 
wide range of tumor cell lines, which implicates the channel’s therapeutic op-
portunities beyond the cardiac system.32, 33 However, due to its involvement in 
life-threatening cardiac arrhythmias, the terminology “hERG” or “Kv11.1” has 
become notorious in the drug discovery community. Hence, much attention has 






Figure 2. A phylogenetic tree of voltage-gated ion channels, and a schematic representa-
tion of the structure of each voltage-gated ion channel within this superfamily.28
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Figure 3. (A) The ventricular action potential waveform indicating the major ionic cur-
rents that contribute to its morphology and duration (INa: inward sodium current, Ito: 
transient outward potassium current; ICa: L-type inward calcium current; IK: outward re-
polarizing potassium current; IKs: slowly activating delayed rectifier potassium current; 
IKr: rapidly activating delayed rectifier potassium current; IK1: inward rectifier potassium 
current).34, 35 (B) Structure of the pores of the Kv11.1 channel and other Kv channels: the 
presence of a Pro-X-Pro (PXP) motif in the S6 helix of other Kv channels causes a kink 
and thereby reduces the size of the channel pore cavity.36 (C) Amino acids that are crucial 
for high-affinity binding of prototypical Kv11.1 blockers.
37 (D) Mechanism of cardiac 
arrhythmias induced by Kv11.1 blockade.
38
The Kv11.1 channel displays unusual gating properties that impact cardiac 
electrical function. Upon membrane depolarization the Kv11.1 channel opens 
slowly but inactivates rapidly, while it recovers rapidly from inactivation but de-
activates slowly during repolarization.5, 34 Therefore, the Kv11.1 channel conducts 
robust outward currents (IKr) relatively late in the ventricular action potential, 
accelerating the phase 3 repolarization without significantly disturbing the pre-
ceding plateau phase 2 (Figure 3A). Nevertheless, the Kv11.1 channel lacks a 
Pro-X-Pro (PXP) motif existing in other Kv channels (Figure 3B), resulting in 
a larger cavity that can accommodate a wide range of drugs.36 Furthermore, the 
Kv11.1 channel has multiple aromatic rings lining the pore (Figure 3C), which 
facilitates the binding of drugs containing aromatic rings at the channel.37 Col-
lectively, a number of drugs including cardiac and non-cardiac medications can 
bind to the Kv11.1 channel. As depicted in Figure 3D, drug block of the Kv11.1 
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tions (EADs) and heterogeneity of repolarization.38 This generates a lengthening 
of the QT interval in the electrocardiogram at the tissue level, which can further 
lead to life-threatening arrhythmias like Torsade de Pointes (TdP) and ventric-
ular fibrillation (VF). Therefore, it has become obligatory routine practice for 
all pharmaceutical and biotechnology companies to screen for Kv11.1 liability 
of drug candidates in the early stage of drug development. More details on the 
structural features and physiological functions of Kv11.1 channel will be stated 
in the chapter 2.
Ligands for the Kv11.1 channel
Blockers and modulatory activators
A large number of structurally diverse compounds have been shown to bind to the 
Kv11.1 channel. In most cases these drugs reduce the IKr by directly blocking the 
conduction pore or less frequently by interfering with channel trafficking to the 
surface membrane, and these drugs are referred to as Kv11.1 blockers.
32, 39, 40 In 
addition, some blockers like APETx1 exert their inhibitory effects on the Kv11.1 
current by modulating the gating properties of the channel.41, 42 On the other hand, 
a small amount of compounds have also been characterized as Kv11.1 activators, 
which have the opposite activity of blockers and thus enhance the IKr current.
39, 43 
Most Kv11.1 blockers share a common binding region within the aqueous 
inner cavity at the pore of the channel, where residues Tyr652 and Phe656 are 
found to be crucial for drug binding via hydrophobic and electrostatic interplays, 
including π–π and π–cation interactions.37, 39 Apart from the intracellular bind-
ing pocket, various scorpion, spider and sea anemone toxins inhibit the Kv11.1 
channel from the extracellular side or by binding to the voltage-sensor domain.42 
With regard to the Kv11.1 activators, different binding locations at the channel 
have been identified, depending on the mechanisms by which they potentiate 
the IKr. According to the primary action model, these Kv11.1 activators are sep-
arated into types 1 and 2 classes.32, 39 Type 1 Kv11.1 channel activators attenuate 
the inactivation and deactivation rates of the channel, whereas type 2 activators 
primarily impair the channel’s inactivation rate. Distinct from each other as well 
as blockers, type 1 and type 2 Kv11.1 activators bind to a site between the pore 
and voltage sensor and a region that is closer to the selectivity filter, respectively. 
Additionally, several type 2 Kv11.1 activators like NS1643 and PD307243 have 
been proposed to interact with the channel at the extracellular face.43, 44 Taken 
together, multiple binding sites exist at the Kv11.1 channel, which illustrates the 
potential for different ligands to display either competitive or allosteric interac-
tions depending on their binding sites relative to one another (Figure 4A).45
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Figure 4. Simple schematic representations of the ligand-channel interaction: (A) Arrows 
demonstrate a competitive (endogenous ligand with ligands A and B, ligand B with li-
gands A and C) or allosteric interaction (ligand C with ligand A and endogenous ligand) 
of different ligands based on their binding sites relative to one another,45 and (B) Sin-
gle-step binding of a ligand to the Kv11.1 channel .
Binding kinetics of ligands 
The specific ligand-receptor interaction is the chemical basis of virtually all bi-
ological activities of compounds.46 As shown in Figure 4B, binding of a Kv11.1 
ligand to the channel can be considered as a single-step reaction in the simplest 
scenario. At first, the ligand binds to the Kv11.1 channel with a second-order 
association rate (kon), and then detaches from the channel with a first-order disso-
ciation rate (koff). In a closed system, the extent of ligand-channel binding is com-
monly quantified in terms of the equilibrium dissociation constant (KD) defined as 
the value of koff/kon or its (often inhibitory) affinity (IC50 or Ki). To date, more and 
more evidence from a wide range of receptors has addressed the concept that in 
vivo efficacy of a ligand is not only described by the in vitro measured equilibri-
um dissociation constant, but also depends on its association and, more critically, 
dissociation rates.47-49 A ligand’s residence time (RT), i.e. the reciprocal of its 
dissociation rate, may be at the basis of the ligand’s duration of action and target 
selectivity.48 As for the Kv11.1 channel, a 30-fold safety margin, quantified as the 
ratio of IC50 and maximum plasma concentration (Cmax), has been proposed to 
define the cardiac safety of Kv11.1 blockers.
50 However, the binding of a Kv11.1 
ligand to the channel remains a dynamic process in which binding (association) 
and unbinding (dissociation) events develop over time.51 Moreover, the approach 
in which only the IC50 value is considered, is rather arbitrary and may not satis-
factorily account for the degree of ion channel inhibition reached in various con-
ditions, leading to unsatisfactory quantitative predictions.51, 52 Importantly, Kv11.1 
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have been reported to pose distinct proarrhythmic risks.52, 53 Therefore, binding 
kinetics of ligand-Kv11.1 interactions constitute a critical component in under-
standing the mechanism of action, and thus should be incorporated within the 
present screening strategy to improve the risk profiles of drug candidates.51, 52, 54
Objectives and outline of this thesis
Drug-induced arrhythmia due to blockade of the Kv11.1 channel has emerged 
as an unanticipated side effect of many pharmacological agents and is a major 
obstacle for drug development. Although much attention has been paid to screen-
ing Kv11.1 liability of drug candidates over the past decades, the current testing 
paradigm has important limitations and may have led to withdrawal of block-
busters on the present market or stopping the development of potentially valuable 
therapeutics. Therefore, investigating the mechanism of action of ligands at the 
Kv11.1 channel, where in particular the ligand binding kinetics may yield com-
prehensive understanding of Kv11.1-related cardiotoxicity, may further provide 
new strategies for circumventing this side effect in drug development. In addi-
tion, compounds that can relieve the unintended Kv11.1 blockade of drugs, e.g., 
allosteric modulators, are of considerable interest because of their potential to 
prevent drug-induced arrhythmia via combination therapy.
In Chapter 2, the gating kinetics and ligand binding characteristics at the 
Kv11.1 channel are extensively discussed, following the basic introduction of the 
channel biosynthesis, structure and function, and pharmacological target and an-
ti-target applications in drug development.
At the start of this project, high-throughput assays had not been reported to 
characterize allosteric modulators of the Kv11.1 channel, nor had ligand binding 
kinetics been determined at the channel. Thus, [3H]astemizole and [3H]dofetilide 
binding assays were developed and utilized to identify positive and negative al-
losteric modulators of the Kv11.1 channel in Chapter 3. 
Based on the work in chapter 3, a novel negative allosteric modulator 
(LUF7244) was identified in several different [3H]dofetilide binding assays in 
Chapter 4. LUF7244 was found to reduce the Kv11.1 affinity of dofetilide, as-
temizole, sertindole and cisapride in a [3H]dofetilide competitive displacement 
assay, and more importantly, to prevent the proarrhythmic effects induced by 
astemizole, sertindole and cisapride in a newly validated neonatal rat ventricular 
myocyte model. This research raises the possibility to resume the clinical use of 
unintended Kv11.1 blockers via pharmacological combination therapy. Following 
this, in Chapter 5 the synthesis of a series of possible allosteric modulators and 
the evaluation of their allosteric effects on [3H]dofetilide binding at the chan-
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nel are reported. Compared to LUF7244, several more potent negative allosteric 
modulators were obtained via small chemical modifications.
In Chapter 6, a novel [3H]dofetilide competition association assay was de-
veloped and validated to evaluate the kinetic parameters of fifteen prototypical 
Kv11.1 blockers at the channel. Next to that, an immobilized artificial membrane 
column was applied to measure the membrane affinity of these blockers to eluci-
date the effect of membrane affinity of ligands on their affinity and kinetic param-
eters. In addition to varied affinity values and association rates of Kv11.1 ligands 
at the channel, Chapter 7 focuses on the discovery of blockers with diversified 
dissociation rates or RTs. Compounds with very short (< 1 min) and much longer 
RTs (> 100 min) were disclosed in this chapter, which enabled the construction 
of a “kon-koff-KD” kinetic map for all these compounds. Additionally, results from 
patch clamp studies implicated the importance of RTs in regulating the functional 
IC50 values of Kv11.1 blockers.
Overall, allosteric modulation and binding kinetics of ligands at the Kv11.1 
channel have been thoroughly studied in this thesis. The general conclusions and 
future perspectives for this field of research have been summarized in Chapter 
8. Hopefully, the findings in this thesis will add to the current understanding in li-
gand-Kv11.1 interactions, and also provide effective opportunities for abrogating 
Kv11.1-induced cardiotoxicity. 
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Chapter 2








The Kv11.1 channel, encoded by the human ether-à-go-go-related gene (hERG), 
mediates a rapid delayed rectifying potassium current (IKr) underlying repolariza-
tion of the cardiac action potential. This channel has been proven to be involved 
in a diversity of physiologic and pathological processes. “Loss-of-function” mu-
tations in the gene or blockade of the channel by a wide range of prescription 
medications can prolong the cardiac action potential duration (APD), producing 
the long QT syndrome (LQTS) that is associated with a markedly increased risk 
of ventricular arrhythmias and sudden cardiac arrest. On the other hand, “gain-
of-function” mutations in the gene shorten the ventricular APD and cause the 
short QT syndrome (SQTS). Accordingly, the Kv11.1 channel has elicited intense 
scientific interest in the past several decades. The counter-intuitive gating kinetics 
of the channel have been suggested to play a specific role in suppressing arrhyth-
mias, and recent studies have pointed out the requirement of incorporating ligand 
binding kinetics with channel block affinity to refine the Kv11.1 liability of drug 
candidates. In this review, the biogenesis, structure, function, and pharmacolog-
ical applications of the Kv11.1 channel are briefly outlined first. Afterwards, the 
unusual gating kinetics of the channel together with the influences on its gating 
are summarized. Finally, binding and corresponding kinetics of ligands at the 
channel as well as assay conditions and techniques for measuring these parame-
ters are discussed.
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Introduction
Ion channels are membrane-spanning proteins that conduct ions across the cell 
and internal organelle membranes. They are involved in a tremendously diverse 
range of fundamental physiological processes, from rapid responses driven by 
the neuronal system or fast contractile forces produced by skeletal and smooth 
muscles to more protracted procedures such as cell growth, differentiation and 
migration.1 After G protein-coupled receptors (GPCRs), ion channels constitute 
the second largest target class for known drugs.2 Potassium-selective channels, 
represented by some 70 known loci in the mammalian genome, are the largest and 
most diverse group of ion channels.3 This superfamily of potassium channels is 
mainly divided into three groups: voltage-gated potassium channels (Kv), inward 
rectifying potassium channels (Kir) and calcium-activated potassium channels 
(KCa). Of these, Kv channels are the largest group, and they are encoded by 40 
genes and further divided into 12 subfamilies (Kv1-12).
4   
The Kv11 family name, “ether-à-go-go” (EAG) coined by Kaplan and Trout 
in 1969, was a humorous reference to the similarity between the go-go dancers 
of the 1960s and the way the legs of a mutant fly shake under ether anesthesia.5 
In this family, the Kv11.1 channel, of which the pore-forming subunit is encod-
ed by the human ether-à-go-go related gene (hERG), has received the greatest 
scientific scrutiny due to its association with potentially life-threatening cardiac 
arrhythmias. The Kv11.1 channel is often referred to by several partial synonyms: 
KCNH2 and hERG to the gene, IKr to the native current, and Kv11.1 to the fully 
assembled channel. Missense mutations on human chromosome 7 where KCNH2 
is located or pharmacological blockade of the Kv11.1 channel lead to a prolonga-
tion of the action potential (AP) duration (APD) that could translate into long QT 
syndrome (LQTS), Torsades de Pointes (TdP) and sudden death.5, 6 Electrophys-
iological studies on these mutants and Kv11.1 blockers have revealed that gating 
kinetics of the channel play an important role in IKr suppression.
7-9 Moreover, the 
assessment of Kv11.1 liability for drug candidates only with IC50 values is con-
sidered to be unrefined. Therefore, more attention should be paid to the binding 
kinetics of ligands at the channel in order to achieve a better understanding of 
the underlying mechanisms of drug actions and subsequently to evaluate more 
comprehensively their proarrhythmic profiles.10 In this context, this review will 
focus on gating kinetics and ligand binding kinetics investigated on the Kv11.1 
channel as well as a general introduction of the channel production cycle, its 
structure, physiological functions, and pharmacological applications during the 
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Production and degradation of the Kv11.1 channel 
The production of the Kv11.1 channel begins in the nucleus with transcribing 
KCNH2 to mRNA, which then acts with the ribosome to synthesize polypep-
tides. The resulting polypeptide chains are assisted by cytosolic chaperones (heat 
shock protein 70 [Hsp70] and 90 [Hsp90]) to prevent misfolding or protein deg-
radation, and are further used in the formation of channel subunits in the endo-
plasmic reticulum.11 The produced subunits assemble into a tetramer (immature 
channel) that is exported to the Golgi apparatus, where the channel undergoes a 
complex glycosylation to obtain a mature and stable conformation before being 
trafficked to the plasma membrane. The Kv11.1 trafficking is an essential process 
that contributes to the maturation of the channel ensuring its proper physiological 
functions.11 In some cases, the defective trafficking of mutant channels results in 
a QT interval prolongation, which can be rescued by pharmacological chaperones 
that stabilize the Kv11.1 channel by binding to specific sites of the channel inner 
pore.5 On the other side, degradation of mature channels occurs in lysosomes 
after being internalized in endocytic vesicles and tagged with ubiquitin. In addi-
tion, when the Kv11.1 maturation process is defective, its subunits are also tagged 
by ubiquitination for degradation and further transferred to the proteasomes or 
recycled via recycling endosomes. The Kv11.1 channel density at the cell surface 
is determined by the balance between the transport of mature channels to the cell 
membrane and their corresponding degradation. 
Structural features and physiological functions of the 
Kv11.1 channel
Structure
Consistent with other Kv channels, the Kv11.1 channel has a tetrameric structure 
formed by four α-subunits (Figure 1A) and auxiliary subunits. As shown in Fig-
ure 1B, each α-subunit is composed of six transmembrane segments that consti-
tute two major domains with helices S1-S4 contributing to the voltage-sensing 
domain (VSD) and helices S5-S6 together with the pore loop outlining the pore 
domain. The VSD undergoes conformational changes upon perturbation of the 
transmembrane potential through an array of positively charged residues located 
within S4 helices, whereby the lengthy S5-Pore linker, also known as the “turret”, 
is a peculiar feature of the Kv11.1 channel. The α-subunits co-assemble along the 
pore axis to form the cavity and selectivity filter (SF) of the channel to allow the 
central ion conduction. The stability of the SF (Figure 1C) is dominated by the 
28   |   Kinetic studies of the Kv11.1 channel
interaction of surrounding pore helices with filter residues.6 With regard to the 
auxiliary subunits, a β-subunit, MinK-related peptide 1 (MiRP1), has an import-
ant role in accelerating IKr deactivation and modulating the response of the Kv11.1 
channel to drugs.12 Missense mutations in the KCNE2 gene encoding the MiRP1 
have been identified to associate with LQTS and ventricular fibrillations.13 Nota-
bly, the expression levels of MiRP1 in atria and ventricular muscle appear to be 
low, and thus, exert minor effects on biophysical and pharmacological properties 
of the channel.14 However, it is highly expressed in Purkinje fibers of the ventric-










Figure 1. (A) The tetrameric structure of the Kv11.1 channel with the voltage-sensing 
domain (VSD) colored in green and pore region in yellow, and the red dot representing 
the potassium ions flow.5 (B) Schematic diagram of a single Kv11.1 subunit containing 6 
α-helical transmembrane domains (S1-S6).6 (C) Homology model of the selectivity filter 
(SF) of the Kv11.1 channel based on the crystal structure of the Kv1.2 channel.
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Like all other potassium channels, the structure of the Kv11.1 channel is 
mainly divided into transmembrane and cytoplasmic regions. The four α-subunits 
and auxiliary subunits are located in the transmembrane segment, while the NH2- 
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between S5 and the pore region contains a glycosylation site that is important for 
maturation and trafficking of the channel protein.8 The NH2-terminal contains a 
Per-Arnt-Sim (PAS) domain and a stretch of 240 amino acids that are responsi-
ble for protein trafficking and definition of the Kv11 family, respectively.
5, 16 On 
the other hand, the COOH-terminal linked to the S6 helice consists of a cyclic 
nucleotide binding site (cNBD), contributing to the opening and closure of the 
permeation pathway for ions. A major difference between the Kv11.1 channel and 
other 6-transmembrane domain potassium channels is derived from the vestibule 
site. The Kv11.1 channel has a larger central cavity due to the absence of a Pro-X-
Pro (PXP) motif from the S6 domain that causes the inner helices to bend in other 
potassium channels.17 This structural openness is also supported by drug-trapping 
experiments which indicate that the Kv11.1 channel can accommodate a wide 
variety of structurally diverse drugs and large molecules.18 These Kv11.1 blockers 
are able to access the binding sites inside the pore, within S6 domains and the 
end of pore helices, where the important residues for high-affinity blockade of 
compounds are located.3 
Physiological functions
The Kv11.1 channel is expressed in multiple organs including heart, central ner-
vous system (CNS), gastrointestinal tract (GIT) and endocrine system, and its 
physiological functions differ according to their distributions in these specific tis-
sues.6, 19 In the CNS of mammals this channel maintains the membrane potential 
and development of neurons of the spinal cord and carotid glomus cells, whereas 
it regulates the gut motility in the GIT. In the endocrine system the Kv11.1 chan-
nel has been found to be involved in insulin secretion and epinephrine release in 
chromaffin cells. Apart from these functions, the Kv11.1 channel has a dominant 
presence in normal human cardiomyocytes where its physiological function is 
best characterized. 
As shown in Figure 2, the generation of the myocardial AP reflects the se-
quential activation and inactivation of a series of ion channels, and the AP can 
be divided into five different phases.6, 20, 21 In Phase 0, a rapid depolarization oc-
curs when the openings of potassium channels decrease and fast sodium channels 
open. During Phase 1, there is an early and fast repolarization mainly due to the 
inactivation of sodium channels and activation of the transient outward potassi-
um channels (Ito). Thereafter, the activation of the long opening calcium channels 
(L-type Ca2+, ICa) produces a small steady influx of Ca
2+, which counteracts the 
outward K+ currents induced by an ultra-rapid potassium delayed rectifier. This 
leads to the formation of a prolonged plateau called Phase 2. The repolarization 
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in Phase 3 is rapid and robust, and it is initiated by deactivation of sodium and 
calcium channels and activation of Kv11.1 (IKr) and Kv7.1 (IKs) channels. The 
Kv11.1 channel plays a very important role in Phase 3 repolarization because of 
its unique gating kinetics: slow activation and fast inactivation coupled to fast 
recovery from inactivation and slow deactivation. This rapid and delayed rectifier 
potassium currents (IKr) terminate the cardiac AP and return the membrane poten-
tial to baseline (Phase 4). Since the Kv11.1 channel closes (de-activates) slowly 
towards the end of the repolarization, there is a constant efflux of potassium ions 
through the channel. Thus, the resting cell membrane potential is close to the 
Nernst equilibrium potential for potassium. This also contributes to the refrac-
toriness of cardiac cells in the early diastolic period immediately after repolar-
ization.5 When a premature beat occurs during the early diastolic period, a large 
outward current antagonizes the depolarization of the cell and thus propagation of 
the beat. In this case, functional reduction of IKr by “loss-of-function” mutations 
or pharmacological blockade on the Kv11.1 channel translates into a clinical set-
ting in patients prone to arrhythmias determined by premature beats. As shown 
in Figure 2, different waveforms in the electrocardiogram (ECG) reflect distinct 
phases of the APD in a cardiomyocyte.
Target and antitarget of the Kv11.1 channel in drug de-
velopment 
Roles in cancer 
Changes in the expression of the Kv11.1 channel have been associated with dys-
regulations of cell proliferation in a plethora of tumor types from different cell 
lineages. The Kv11.1 channel in tumor cells has been postulated to facilitate cell 
migration in diverse hematopoietic neoplasm through an integrin-related sig-
naling pathway and to enhance the proliferation, invasiveness and lymph node 
dissemination of cells as well as to reduce cell differentiation.23, 24 By contrast, 
the Kv11.1 channel has not been expressed at a significantly high levels in the 
corresponding non-cancerous cells. Therefore, the Kv11.1 channel, in different 
tissues, may be used as a biomarker for abnormal cell behaviors and proliferation. 
Nevertheless, the Kv11.1 channel has also been unraveled to induce cell apoptosis 
in various cell types by different mechanisms, independent of their capacity to 
inhibit cell proliferation via cell cycle arrest.24 Further exploration of this apoptot-
ic pathway together with the channel up-regulation in different tumor types may 
lead to the development of new anti-tumor therapies in the future. For instance, 
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stem cells. Kv11.1 channels are expressed in CD34
+/CD38-/CD123high cells and 
induce significant proliferation of leukemia cells, whereas they are not detected 
in normal bone marrow cells.25 Thus, a specific Kv11.1 blocker could be used 
to potentially prevent leukemia via reducing abnormal cell proliferation without 
affecting healthy cells that do not express the Kv11.1 channel. Taken together, 
the Kv11.1 channel may be used as a novel diagnostic and prognostic marker in 
human cancers as well as a new target for anti-neoplastic treatments. 
Roles in schizophrenia 
The contribution of the native Kv11.1 channel to the intrinsic electrical properties 
of neurons is poorly understood. Kv11.1-3.1 is the primate specific isoform of the 
Kv11.1 channel expressed in the CNS, and it has been associated with schizo-
phrenia.26 In this isoform the first 102 amino acids of the most abundant isoform 
Kv11.1-1a are replaced with 6 amino acids, which results in faster channel de-
activation but slower inactivation rates. Although both isomers are comparably 
expressed at the hippocampus and prefrontal cortex in a control group, the ex-
Figure 2. Standard model of the cardiomyocyte QT interval on an electrocardiogram (up-
per panel) and the corresponding action potential duration (lower panel). The QT interval 
is a measure of the duration of ventricular depolarization and subsequent repolarization.22
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pression ratio of Kv11.1-3.1 to Kv11.1-1a demonstrates an approximate 2.5-fold 
increase among patients with schizophrenia. Investigations on the Kv11.1 channel 
in neural cells may facilitate our understanding of the pathology of schizophrenia, 
and would provide a new solution for treating this mental disorder in the future.
Roles in smooth muscle related diseases
The Kv11.1 channel is pH sensitive, implying a molecular link for regulating elec-
trical signaling through acidity of the gastrointestinal lumen. Several antibiotics 
like erythromycin display such adverse reactions as cramps and diarrhea, which 
might be caused by unintentional blockade of the Kv11.1 channel.
24 Akbarali et 
al. reported that the Kv11.1 channel fine-tuned the resting membrane potential of 
the circular smooth muscle cells in opossum esophagi, and channel blockers ini-
tiated the contraction of muscle segments by depolarization.27 In human jejunum 
the Kv11.1 channel was immunohistochemically detected in circular and longitu-
dinal smooth muscle cells, where it was assumed to have a fundamental role in 
controlling the motility patterns by modulating the electrical behavior of muscle 
cell.28 Administration of methanesulfonanilide Kv11.1 blockers like E-4031 and 
MK-499 impacted the rhythmic contractions of jejunum. Altogether, these find-
ings could help in the search for new targets for the treatment of gastro-esopha-
geal reflux diseases, achalasia as well as intestinal motility disorders.
Human uterine contractions are triggered by an AP possessing a spike fol-
lowed by prolonged depolarization.29 Activation of the Kv11.1 channel results 
in the inactivation of the AP by suppressing the amplitude and duration of con-
traction before labor. In obese women, enhancement of the Kv11.1 activity by 
reducing the expression of β-inhibitory proteins shortened the duration of uterine 
APs and weakened contractions. This finding offers an explanation for the higher 
incidence of caesarian delivery in obesity, which should be further studied as it 
offers a new insight into the poor labor outcomes of obese women. 
Roles in endocrine dysregulations
In human pancreatic islets, the Kv11.1 channel has been proven to contribute to the 
regulation of insulin secretion and the firing of β-cells.30 Blockade of the Kv11.1 
channel is sufficient to cause hyper-excitability during application of the insulin 
releasing drugs. This suggests that alterations in the channel function might be 
associated with some hyperinsulinemic conditions. The role of the Kv11.1 chan-
nel in hyperinsulinemic conditions is awaiting further elucidation that may lead 
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Roles in arrhythmia
Cardiac arrhythmias, anything from mild palpitations to severe conditions that 
have the potential to induce cardiac arrest or sudden death, are a major mortality 
cause in developed countries. The Kv11.1 channel has been suggested to play a 
particularly pivotal role in the suppression of arrhythmias, yet it has also been 
found to account for 30-40% of congenital LQTS cases and is the most common 
cause of drug-induced arrhythmias and cardiac death all over the world.31, 32
The Kv11.1 channel as a target in arrhythmology
The short QT syndrome (SQTS) is a cardiac channelopathy associated with atri-
al fibrillation and sudden cardiac death.4 The SQTS type 1 variant (SQTS1) in-
volves mutations at KCNH2 that encodes the α-subunit of the Kv11.1 channel.
33, 
34 Brugada et al. identified two different missense mutations at position 588 in the 
S5-P loop region (i.e. N588K) of the Kv11.1 channel, which were linked to the 
hereditary SQTS. These mutations resulted in a dramatic increase in IKr leading to 
a heterogeneous shortening of the APD and refractoriness.5 For this SQTS1, class 
III antiarrhythmic drugs, also known as Kv11.1 blockers, may be a therapeutic 
approach for controlling dysregulations of the cardiac rhythm by lengthening the 
APD and increasing the myocardial refractoriness without significantly altering 
the conduction velocity.35 Notably, the sensitivity of SQTS1 to distinct Kv11.1 
blockers differs in normalizing the shortening of QT intervals. For example, qui-
nidine restored the shortened QT interval towards a normal range, whereby ad-
ministration of sotalol and ibutilide in the same condition failed to normalize the 
abnormal QT interval.36 This could be explained by the state-dependent inhibition 
of Kv11.1 blockers to the channel, as the N588K-Kv11.1 channel exhibits altered 
voltage-dependent inactivation kinetics compared to the wild type channel.
Missense mutations of the KCNH2 gene are also associated with LQTS type 
2 variant (LQTS2) and an increased risk for sudden cardiac death. There are four 
classes of mechanisms determining the LQTS2 abnormalities, acting on Kv11.1 
synthesis (class 1), intracellular transport or protein trafficking (class 2), channel 
gating (class 3) and potassium ion permeation (class 4). Anderson et al. performed 
two comprehensive analyses on 201 LQTS2-linked mutations in four structural 
domains (NH2- and COOH-terminus, S1-S4 [VSD], S5-S6 [pore region], extra-
cellular and intracellular linkers), and confirmed that the most common underly-
ing mechanism for LQTS2 was the disturbance of protein trafficking (class 2).37 
Therefore, correction of the Kv11.1 trafficking deficiency could become a useful 
therapeutic principle in rescuing LQTS2. Most mutations causing trafficking de-
fects can be pharmacologically amended by highly selective Kv11.1 blockers like 
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E-4031.38 This compound displayed the highest chance to successfully correct the 
LQTS2 in channels expressing mutations at the NH2-terminus, followed by those 
in the pore domain and then C-linker.37 Nevertheless, when the wild type Kv11.1 
channel was co-expressed, the correction ability of E-4031 changed priorities to 
mutations in the pore domain followed by the ones in the NH2-terminus and final-
ly these at the C-linker site. Additionally, Kv11.1 activators, which can augment 
the IKr, offer another novel anti-arrhythmic strategy for treatment of LQTS2. The 
first Kv11.1 activator RPR260243 was reported in 2005,
39 and only a limited num-
ber of such compounds have been available until now. Although these activators 
have shown pronounced antiarrhythmic effects in various in silico, in vitro and 
in vivo models, they are found to induce other proarrhythmic side effects such as 
increasing the APD dispersion31 and shortening the APD. Overall, activation of 
the Kv11.1 channel is a new research area, which remains to be exploited in the 
future. 
Kv11.1-related cardiotoxicity
As mentioned previously, mutations of the Kv11.1 channel affect heart conditions 
characterized by “loss-of-function” or “gain-of-function”, which are related to 
LQTS (Figure 3A) and SQTS (Figure 3B), respectively. A genetic heteroge-
neous disorder induced by “gain-of-function” mutations of the Kv11.1 channel 
is the congenital SQTS, which is identified by a shortened QT interval (< 330 
ms) and episodes of syncope, paroxysmal atrial fibrillation or life-threatening ar-
rhythmias.36 On the other hand, the LQTS represents a cardiac clinical condition 
involving the Kv11.1 channel, which is characterized by “loss-of-function” of the 
channel. LQTS can be either congenital or acquired. Congenital LQTS is caused 
by mutations disrupting the channel functions as described previously. Mutations 
often lead to deficiencies in protein trafficking, which reduces the amounts of 
functional Kv11.1 channels located in the cell membrane.
36 Although mutations at 
other ion channels can also result in LQTS, the reported LQTSs are dominated by 
the Kv11.1 and Kv7.1 channels. Acquired LQTS refers to drug induced prolonga-
tion of the QT interval. This response may be induced by a specifically designed 
drug that blocks the cardiac repolarizing currents through binding to either the 
Kv11.1 channel (e.g., dofetilide, sotalol, ibutilide) or to other ion channels in-
volved in cardiac repolarization (e.g., alfuzosin to the sodium channel).40 Howev-
er, almost all drugs known to cause acquired LQTS appear to preferentially block 
the Kv11.1 channel. Furthermore, QT prolongation may arise as a side effect from 
compounds designed to act on non-cardiac targets. Drugs that belong to different 
chemical classes and possess various therapeutic indications are able to exert 
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(e.g., terfenadine), gastrointestinal prokinetic agents (e.g., cisapride), psychoac-
tive agents (e.g., chlorpromazine) and antibiotics (e.g., cotrimoxazole).12 To date, 
the most common cause of withdrawal from or restrictions of drugs in the market 
is related to their potential to cause QT prolongations and TdP via blockade of the 
Kv11.1 channel. This underlines the importance of early evaluation of possible 
blockade of the Kv11.1 channel for drug candidates, desirably in the early phase 
of drug development. 
Several factors have been identified to account for the promiscuity of the 
Kv11.1 channel towards drug binding.
6, 12, 41 Firstly, two aromatic residues Tyr652 
and Phe656 are highly conserved in the Kv11.1 channel, and they are critical for 
the binding of structurally diverse drugs. A number of drugs can form a cation-π 
interaction between their positively charged nitrogen atoms and Tyr652 as well 
as a hydrophobic attraction of aromatic rings with Phe656. Secondly, the Kv11.1 
channel lacks a PXP motif on the S6 helix leading to a large size of the inner cav-
ity, which makes the channel accommodate a range of Kv11.1 blockers encom-
passing ample molecules. Lastly, multiple distinct binding sites for drugs at the 
Kv11.1 channel have been discovered, such as an intracellular binding pocket for 
dofetilide and an extracellular binding region for BeKm-1.42 This provides anoth-
er reasonable explanation for the promiscuity of the Kv11.1 channel towards drug 
binding. Therefore, it is now common practice for pharmaceutical industry to 
screen for Kv11.1 liability in new chemical entities and conduct thorough clinical 
QT studies for potential drug candidates. In spite of the seriousness of Kv11.1 re-
lated-cardiotoxicty of drugs, the exact molecular and physiological interrelation-
ships behind Kv11.1 blockade, QT prolongation and TdP remain to be explored. 
As shown in Figure 2, depolarization and repolarization of cardiac myocytes are 
complex processes that result from multiple competing and complementing ionic 
currents. For example, the potent Kv11.1 blocker verapamil does not display a 
repolarization liability due to its inhibition of the inward calcium current.40, 43 
In this context, a Comprehensive in vitro Proarrhythmia Assay (CiPA) has been 
proposed as a novel safety screening proposal intended to replace the current reg-
ulatory guideline by July 2015.44, 45 Other strategies considering both affinity and 
kinetic indicators have also been proposed in order to improve the assessment of 
arrhythmic side effects for drug candidates.46, 47  










Figure 3. Schematic diagrams depicting the correlation of ventricular action potential 
duration (APD) to body-surface electrocardiogram (ECG) in normal, LQTS and SQTS 
patient groups. (A) Representation of an LQTS; (B) Representation of an SQTS.48
Gating kinetics of the Kv11.1 channel
Voltage gated potassium channels regulate the selective conduction of K+ across 
biological membranes by opening and closing the pore via structural rearrange-
ment of the activation and/or inactivation gates. These gates are located at both 
intracellular and extracellular entrances of the SF, and the mediating process is 
referred to as gating kinetics.49 
The two gates of the Kv11.1 channel control the potassium flow through the 
channel. The activation gate is arranged at the intracellular side and formed by 
four S6 segments with slow movement to open and closed states, while the inac-
tivation gate is located at the extracellular region of the pore and constituted by 
four SF segments with rapid movement to an inactivated state. The pore of the 
Kv11.1 channel is more stable in the open conformation compared to other volt-
age-gated potassium channels.50 The voltage-sensor of the Kv11.1 channel con-
sists of positively charged residues on the S4 domain and mediates the channel 
opening.5 Additionally, the Kv11.1 channel has three extra negative charges in the 
VSD, which makes it different from other voltage-gated potassium channels that 
possess only three negative charges on S2 and S3 segments.51 All these negative 
charges stabilize the positive charges on the S4 segment by forming salt bridges, 
influencing the movement of the S4 relative to other transmembrane segments 
during the gating. 
Compared to most voltage-gated potassium channels, the gating kinetics of 
the Kv11.1 channel are unique: the transition rates of inactivation and recovery 
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(Figure 4).51 The time constant of inactivation for the Kv11.1 channel aligns from 
6.5 to 2.2 ms in the voltage range of -10 to +30 mV, whereas its activation time 
constant is more than 50 ms at a voltage of +50 mV. By comparison, the durations 
of inactivation and activation at the same voltage ranges for the Shaker channel 
were approximately 2000 ms and less than 2 ms, respectively. The quick removal 
of inactivation at the depolarizing pulse as well as a slow deactivation leads to the 
formation of a “hook” (tail) current following repolarization, which is typical for 
the Kv11.1 channel and can be observed in various macroscopic IKr recordings.
52 
Activation and deactivation
The activation and deactivation processes of the Kv11.1 channel are relatively 
slow compared to other voltage-gated potassium channels. The slow activation 
gating is caused by the slow movement of the VSD. The electrostatic interaction 
between Asp540 and Arg665 mediates the coupling between the VSD and S6 
segment. Mutations on these residues were found to affect the activation and 
deactivation rates of the Kv11.1 channel, implicating that they play an important 
role in stabilizing the intermediate states in the activation process.53 The slow 
deactivation kinetics is maintained by the unique cytosolic domains of the chan-
nel, in particular the proximal N-terminal domain.54 Smith et al. confirmed that 
deleting the NH2 terminus and adding a recombinant protein corresponding to the 
PAS domain accelerated the channel deactivation rate. Comparable to deletion 
of the entire NH2 terminus, disruption of the α-helix at the NH2 tail by substitu-
tions of glycine or serine led to an increase of the Kv11.1 deactivation rate. Sim-
ilarly, Kv11.1 channels, which have the N-terminal and PAS domains removed 
or Asp774, Glu788 and Asp803 mutated by arginine, exhibited much faster de-
activation gating kinetics in contrast to the wild type channels.55 However, this 
amendment did not alter the activation gating kinetics of the Kv11.1 channel. Of 
note, voltage dependency of activation and deactivation was insensitive to the 
potassium concentrations at the extracellular face of the channel.52
slow fast
Closed Open Inactivated
Activation/deactivation Inactivation/recovery from inactivation
Figure 4. Different Kv11.1 channel conformations in the closed, open and inactivated 
states.56
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Inactivation and recovery from inactivation
Inactivation kinetics of the Kv11.1 channel comprise the forward (inactivation) 
and backward (recovery from inactivation) transitions between the open and in-
activated states.32, 51 These procedures are extremely fast and voltage sensitive. 
At depolarized potentials the channel inactivation becomes faster than activation 
resulting in a steady-state rectification at positive voltages, whereas the chan-
nel deactivation is much slower compared to its recovery rate from inactivated 
state forming a hooked tail current that is specific for the Kv11.1 channel.
5, 57 The 
Kv11.1 channel only demonstrates a C-type inactivation, which is different from 
the N-type inactivation existing for other voltage-gated ion channels. The N-type 
inactivation of potassium channels is induced by an occlusion of the ion-conduct-
ing pore by the intracellular N-terminal domain, while the C-type inactivation of 
the Kv11.1 channel permits the interconversion between two conformations of 
the stable conducting and non-conducting SFs. Kinetic analyses have underlied 
the early and late pore helix motions during the inactivation process of the Kv11.1 
channel.58 To date, the C-type inactivation of ion channels has been better under-
stood than N-type inactivation.32 
Effect of gating kinetics on IKr
Ion conduction is highly dependent on the SF, which is composed of four pep-
tides with a conformational arrangement pointing toward the pore axis of the 
Kv11.1 channel. The gating kinetics influence the contributions of IKr to the AP 
repolarization phases.59 The Kv11.1 channel is activated during the AP upstroke 
and plateau phases, while a fast inactivation process of the channel greatly limits 
the amount of outward current at positive voltages (inward rectification). As the 
cell membrane repolarizes to negative voltages, the Kv11.1 channel recovers from 
inactivation and reenters the open state leading to an outward “resurgent” current 
that facilitates further repolarization. Thereafter, the outward IKr declines at the 
end of the AP due to the channel deactivation as well as a decreasing driving force 
for outward currents. The mechanism of Kv11.1 rectification is closely related to 
voltage-gated fast inactivation. Since the inactivation of channels takes place at a 
much faster rate than their activation, no significant outward currents are observ-
able during the depolarization to a high membrane potential. The rapid inactiva-
tion of the Kv11.1 channel and the resulting rectification are partially responsible 
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Factors modulating Kv11.1 gating kinetics 
Apart from voltage, the gating kinetics of the Kv11.1 channel are susceptible to 
many other factors such as temperature, extracellular pH, K+ and Ca2+ concentra-
tions.60 An increase in temperature shifted the voltage dependence of activation 
to a hyperpolarizing direction, whereas that of inactivation was shifted towards 
a depolarizing direction.61 Moreover, the rates of activation and deactivation in-
crease with higher temperatures, but less markedly than inactivation and the re-
verse recovery rates. In addition, Vandenberg et al. emphasized that the results 
obtained at room temperature could not be simply extrapolated to those of 37 °C 
by using a single temperature scale factor for the Kv11.1 channel due to the tem-
perature dependence of gating kinetics.61 When it comes to the extracellular pH, 
the IKr amplitude was decreased and kinetics of activation and deactivation were 
increased when the external pH was lowered from 7.4 to 6.0, whereas activation 
was accelerated by alternations of the external pH from 7.4 to 8.0.62 Regarding 
the extracellular potassium concentrations, increasing the K+ concentration from 
4 to 10 mmol·L-1 produced a +10 mV shift in voltage-dependent inactivation of 
the Kv11.1 channel and slowed the inactivation time course, while reducing the 
K+ concentrations 4 to 1 mmol·L-1 had little influence on inactivation voltage 
dependence, but accelerated the inactivation time course.63 By contrast, an in-
crease in Ca2+ concentration from 1.8 to 10 mM did not significantly influence the 
inactivation kinetics of the Kv11.1 channel, whereby it resulted in a reduction of 
IKr amplitude and activation kinetics but increased the deactivation rate.
64 Thus, 
Ca2+ may interact with externally accessible channel residues and further alter the 
membrane potential sensitivity of the voltage-sensor responsible for activation 
and deactivation, while this interaction does not change the inactivation gating 
mechanism. 
Influences of ligands on Kv11.1 gating kinetics
Kv11.1 activators are able to increase the ventricular IKr, which can be used to 
treat LQTS associated ventricular arrhythmias. These activators act primarily on 
the C-type inactivation mechanism that is strictly related to the inward rectifica-
tion. Based on different action modes, Kv11.1 activators are classified into type 1 
and 2 groups.15 The type 1 activators enhance the Kv11.1 function by attenuating 
the C-type inactivation and slowing down the deactivation rate of the channel. 
The study of RPR260242 revealed that this activator exerted a concentration-de-
pendent effect on reducing the deactivation rate of the Kv11.1 channel and also 
produced a positive shift in the voltage dependent inactivation, leading to an in-
crease in IKr amplitude.
65 RPR260242 was found to interact with two clusters 
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of residues located on separate domains of the channel. The first cluster had its 
residues located in regions S5 (L553 and F557) and S6 (N658 and V659). Inter-
action with this cluster affects the channel’s rearrangements that are associated 
with the deactivation and inactivation gating of the channel. On the other hand, 
residues for the second cluster are located in the S4-S5 linker (V549 and L550) 
and S6 (I662, L666 and Y667) segment. Binding of RPR260242 to this cluster is 
essential to mediate the slow deactivation kinetics induced by its interaction with 
the first cluster residues. Type 2 Kv11.1 activators augment the channel activity 
by primarily attenuating its C-type inactivation via slowing down the rapid onset 
of inactivation and shifting the half maximal inactivation voltage to more depo-
larized potentials. Perry et al. reported that PD-118057 shifted the half-point for 
inactivation of the Kv11.1 channel by +19 mV and increased the peak outward 
current of the Kv11.1 channel by 136%.
66 Scanning mutagenesis and molecular 
modeling suggested that PD-118057 bound to a hydrophobic pocket on two dif-
ferent channel subunits: L646 in the S6 domain for one subunit and L622 and 
F619 in the pore helix for an adjacent subunit.15, 66
Apart from these activators, a number of Kv11.1 blockers alter the gating 
kinetics of the Kv11.1 channel. Based on the existence of distinct binding regions 
for ligands at the channel, Kv11.1 blockers can be divided into small molecules 
and peptide analogs which interact with intracellular and extracellular binding 
pockets, respectively. The anesthetic drug midazolam was recently unraveled to 
inhibit IKr by binding to the same classical binding site within the channel pore 
as that for prototypical blockers.67 This compound resulted in a small negative 
shift of the activation curve of the Kv11.1 channel, while it did not significantly 
impact the channel’s steady-state inactivation. On the other hand, BeKm-1 is a 
peptide inhibitor interacting with the extracellular amino acid residues close to 
the external pore region of the Kv11.1 channel.
42 Zhang et al. found that BeKm-1 
drastically shifted the midpoint of the activation curve towards positive voltages, 
decreased the activation rate but accelerated the deactivation rate.68 These effects 
can be explained by the fact that binding of the BeKm-1 molecule to the channel 
contacted with the S5-P linker, impacting activation and deactivation kinetics of 
the Kv11.1 channel.









Binding and corresponding kinetics of ligand-channel interaction   |  41
Voltage-gated ion channels are primarily studied using the voltage clamp/patch 
clamp technique, which enables the clamping of the cell membrane potential 
to particular voltages using square or more complex waveforms that allows the 
measurement of specific activities in the ion channels.69 Since this method allows 
a direct and real-time measurement of ion channel activity, it has been regarded 
as the golden standard in performing electrophysiological investigations on ion 
channels. There are various patch clamp techniques and systems available, differ-







Figure 5. Example of a so-called action potential voltage clamp applied to transfected 
CHO cells expressing Kv11.1 channels (CHOKv11.1 cells). Two pre-recorded action po-
tentials from paced isolated ventricular myocytes (APs, lower panel) were used as the 
command voltage waveform for whole cell patch clamping the CHOKv11.1 cells. The 
first AP in this example is followed by a second one elicited by a premature stimulus 
after 90% repolarization of the first AP. The resulting Kv11.1 currents recorded from the 
CHOKv11.1 cells closely resemble the behavior of IKr in the native myocytes during the 
first and second AP (K+-current, upper panel).12
As shown in Figure 5,12 the profile of current flow (upper panel) through 
the channel can be split into six phases: (1) the initial phase is characterized by 
a slow opening and fast inactivation of the Kv11.1 channel, limiting the current 
flow; (2) decreasing the voltage enables the channels to recover from inactiva-
tion, increasing the current flow; (3) a diminishment in current flow is determined 
by the slow deactivation and a decrease in driving force for potassium ions. At 
this phase, many of the channels are still in open states but pass little current; (4) 
applying a premature stimulus induces an increase in outward current; (5) the 
outward current has a rapid decay due to the rapid channel inactivation at depo-
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larized potentials; (6) similar to the first phase, the large outward current in phase 
6 opposes the cellular depolarization and suppresses the propagation of a prema-
ture beat. The advantage of this AP voltage clamp technique is that one can study 
the behavior of a single type of ion channel currents during APs without being 
hampered by other (often larger) ion currents that are also activated during an AP 
in native cells. Herein, the AP voltage clamp example implicates a mechanism 
foundation for other standard patch clamp recordings on the Kv11.1 channel. 
The major difference between the Kv11.1 channel and other voltage-gated 
potassium channels is the presence of a very prominent tail current during the 
repolarization phase. Figure 6 shows an example for the application of a standard 
voltage patch clamp assay in determining the concentration-dependent effects 
of cisapride on the Kv11.1 channel in transfected CHO cells.
70 From a holding 
potential of -80 mV, the cell is shortly clamped at -50 mV to test a leak current at 
this potential when all Kv11.1 channels are in closed states. Since this potential is 
not enough to activate the Kv11.1 channel, this recording is performed to correct 
for small background currents that do not originate from the Kv11.1 channel. The 
recorded current at -50 mV is referred to as a baseline step or leak current. This 
step is followed by a depolarization to +40 mV, where the Kv11.1 channels are 
alternating between the open and non-conductive, inactivated states. When repo-
larizing back to -50 mV, the IKr reaches its highest peak also known as the “peak 
tail current” due to the fast recovery of inactivated ion channels. Afterwards, 
the channels slowly close (de-activate). A cell responding to this voltage clamp 
protocol (Figure 6A) with a typical current signature shown in Figure 6B is re-
garded to express the Kv11.1 channel.
The drug concentration required to inhibit 50% of the tail current (IC50) is usu-
ally determined by fitting the Hill equation to the compiled dose-response data. 
After the channels are exposed to compounds, a subsequent washout experiment 
is performed to characterize the reversibility of the inhibition. The patch clamp 
technique is able to identify the activity of moderately potent Kv11.1 blockers 
which could otherwise have been ignored in other assays leading to false negative 
results. Although the patch clamp technique is considered to be the “golden stan-
dard” in investigating the affinity and kinetic parameters of drugs at the Kv11.1 
channel, there are several limitations to this technique. For instance, Hill et al. 
identified a limitation of any kinetic studies on drug blockade at the Kv11.1 chan-
nel, which is the lag time associated with drug application and washout.10 Most 
systems used for kinetic investigations support a lag time between 10 to 40 milli-
seconds that still allows recording slow time constants but causes difficulties with 
capturing fast time constants. Thus, drugs having low affinity and faster unblock 
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their fast components. Additionally, this technique is low throughput and requires 
a skilled operator, which hamper profiling of large compound series.71 Therefore, 
higher throughput assays are warranted to characterize the binding parameters of 
drugs candidates at the Kv11.1 channel in the early phase of drug development. 
Recently, automated patch techniques have revolutionized the research field of 
experimental electrophysiology, and enabled a substantial increase in throughput 
without compromising the data quality.70, 72 Moreover, the throughput of patch 
clamp screening can be further improved by introducing the patch clamp electro-
physiology robots.70 
Radioligand binding assay
Since radioligand binding assays can provide reasonably accurate and efficient 
estimates of Kv11.1 affinity for compounds, they have become a different in vi-
tro screening tools used by the pharmaceutical industries.5 These assays rely on 
B
A
Figure 6. Example of Kv11.1 recordings showing the concentration-dependent effect (0-
100 nM) of cisapride: (A) the voltage clamp protocol for IKr measurements; (B) IKr record-
ings after administration of different dosages of cisapride and saline (0 nM cisapride).70
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competitive binding of test ligands with a high-affinity, radiolabelled blocker to 
study the affinity and kinetics of unlabeled ligands at the receptor. Up to now, 
radioligand binding assays at the Kv11.1 channel have been developed for several 
specific and potent Kv11.1 blockers including [
3H]dofetilide, [3H]astemizole, [3H]
MK-499 and [3H]BeKm-1. In the [3H]dofetilide binding assay, the radioligand 
is used in conjunction with cell lines or membrane preparations expressing the 
Kv11.1 channel followed by incubation with the test compound which then com-
petes for the binding site that is occupied by [3H]dofetilide.73 This can yield the 
experimenter a wealth of information whether the screened compound competi-
tively displaces [3H]dofetilide, its relative potency and, with further experimen-
tation outlined in this thesis, the ligand’s kinetics of interaction with that binding 
site. Diaz et al. demonstrated that the binding Ki values for 22 Kv11.1 blockers 
obtained in a [3H]dofetilide binding assay correlated well with their functional 
IC50 values derived from whole cell patch clamp studies.
74 Chiu et al. found that 
all their selected Kv11.1 blockers inhibited the binding of [
3H]astemizole in a 
competitive manner, and consequently, developed a [3H]astemizole binding assay 
that they claimed to be robust with adequate sensitivity.75 This assay is compara-
ble to [3H]dofetilide binding experiments in terms of measured binding affinity 
(Ki and Kd values), with only 2- to 5-fold variations. Competitive radioligand 
binding assays apparently provide a rapid and highly predictive tool, which can 
be utilized together with electrophysiological studies to identify compounds that 
inhibit the Kv11.1 channel. Nevertheless, the binding assays have the disadvan-
tage of being prone to produce false negative outcomes, for instance when the 
examined ligand binds to the channel at an allosteric site. Additionally, these 
assays may also provide false positives as channel modulation may need more 
than compound-channel binding. Accordingly, the role of radioligand binding as-
says in screening the Kv11.1 liability of drug candidates is still under discussion, 
and more researches should be conducted to improve the predictability of these 
assays.
Ion flux assay
Radioactive ion flux assay
Radiotracers are used to quantitate the flux of ions moving in or out of a cell 
through ion channels present on the cell membrane.71 The radiotracers of ions 
are specific for each class of ion channels, and 86Rb+ is commonly used for the 
voltage-gated potassium channels. However, 86Rb+ flux assays are heterogeneous, 
and also very slow due to the inconvenient radiotracer loading and wash steps. 
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state functions of ion channels. Additionally, an incomplete removal of extracel-
lular tracers after loading or a continuous leak of the tracers out of cells results 
in a low signal-to-noise ratio for this kind of assays. Hence, although radioactive 
ion flux assays have been used for more than 30 years in ion channel investiga-
tions, their application for screening drug activity at ion channels like the Kv11.1 
channel has become limited.
Non-radioactive ion flux assay
Ion flux assays with non-radioactive ion tracers using atomic adsorbance spec-
trometry (AAS) have been explored for a variety of voltage-gated ion channels.71 
For this analysis, non-radioactive tracer ions are loaded into cells expressing the 
targeted ion channels (i.e. the Kv11.1 channel). Ion flux is initiated after channel 
activation performed by depolarizing the cell membrane with a high K+ concen-
tration buffer. Then, the concentration of the tracer ions in the supernatants and/
or cells is measured, and the percentage of ion efflux (or influx) is calculated. 
This screening method has a moderate throughput, and it has been predominantly 
focused on potassium channels (e.g., Rb+ efflux assay for the Kv11.1 channel).
76 
The non-radioactive Rb+ efflux assay is a high-capacity method for functional 
analysis of the Kv11.1 channel, which is particularly useful for the identification 
and characterization of Kv11.1 blockers and activators. Since this efflux assay is 
a direct measure of the channel activity, it is likely not prone to disturbances that 
usually occur in other indirect procedures, such as false positives in radioligand 
binding assays. Tang et al. compared the IC50 values of five known Kv11.1 inhib-
itors (dofetilide, terfenadine, cisapride, sertindole and astemizole) obtained from 
both the Rb+ efflux assay and patch clamp technique.77 The former displayed 5- to 
20-fold higher IC50 values than the latter, yet the rank order of measured IC50 val-
ues for these compounds was identical in these two different experiments. This 
illustrates the capacity of the Rb+ efflux assay to rank unknown compounds that 
block the Kv11.1 channel by their potency, meeting the requirements for com-
pound profiling. In addition, Chaudhary et al. used the Rb+ efflux assay to evalu-
ate the Kv11.1 liability of astemizole, E-4031, cisapride, terfenadine, risperidone, 
quinidine and sotalol, and compared the results to those acquired in the patch 
clamp technique and [3H]dofetilide binding assay.78 IC50 values of test ligands 
gathered with the efflux assay were increased compared with those from the elec-
trophysiological technique, while the Rb+ efflux assay was less sensitive in deter-
mining the potency of compounds but had a higher throughput to identify potent 
Kv11.1 blockers than the radioligand binding assay. Hence, the Rb
+ efflux assay 
allows for the rapid screening of compounds in a non-invasive manner. However, 
this nonradioactive ion flux assay has a low temporal resolution indicative of less 
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information compared to the voltage clamp assay. Meanwhile, a high expression 
level of Kv11.1 channels is necessary to achieve an acceptable signal-to-noise 
ratio for this technique.79 Additionally, Rb+ appeared to inhibit the inactivation 
of the Kv11.1 channel resulting in an underestimation of potency for most drugs, 
which impairs its application in drug screening for Kv11.1 liability.
76
Other techniques
The electrophysiological properties of cardiomyocytes expressing various ion 
channels can also be investigated by micro-electrode arrays (MEAs). This novel 
technology is based on the integration of cardiac cell cultures or vibratome slices 
from cardiac tissues on microchips in order to monitor the changes in extracel-
lular electrograms.80 The detected field potential durations (FPDs) correlate well 
with the APDs of cardiomyocytes from patch clamp assays as well as with QT 
intervals in clinical ECGs, while the measured beat frequencies are in agreement 
with the heart rates.81, 82 Moreover, MEAs utilizing networks of cells demonstrate 
a higher complexity, which circumvents the danger of retrieving false positives 
encountered by single-cell based assays.82 In addition, the non-invasive nature 
of MEAs allows the study of drug effects on beating rate and rhythm, and en-
ables the detection of arrhythmia.81 However, the MEA devices are not suitable 
for stimulating and recording the electrophysiological parameters of single cells 
compared to patch clamp techniques. Furthermore, implantation of a micro-elec-
trode array might have negative effects on the measurements due to various bi-
ological responses of cells upon the external insertion.83 Altogether, screening 
compounds in cardiomyocytes, in particular human induced pluripotent stem 
cell-derived cardiac myocytes (hiPSC-CMs), with the MEAs technology is still 
awaiting optimization and will make a substantial contribution to safety pharma-
cology, which provides a promising means for preliminary drug profiling in the 
drug discovery pipeline.80, 84
xCELLigence Real-Time Cell Analyzer (RTCA) Cardio System is another in-
novative label-free real-time platform, which can be utilized to measure the beat-
ing functions of cardiomyocytes like hiPSC-CMs based on impedance measure-
ment.85 This assay is performed using specially designed microtiter plates with 
interdigitated golden electrodes to dynamically monitor the impedance changes 
of cardiomyocyte layers during rhythmic contractions.85, 86 This new technology 
displays a higher throughput than patch clamping, allowing for screening the 
cardiotoxic liability of compounds earlier during the drug research process. Fur-
thermore, the xCELLigence system enables the monitoring of ligand influenc-
es on cardiac functions in real time over prolonged intervals, which supports 
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protein trafficking of ion channels.85, 87 In addition to such advantages, there are 
several challenges for the application of xCELLigence RTCA Cardio System 
in preclinical cardiac safety assessment.87 For example, the predictive values of 
proarrhythmic drugs derived from the extracted parameters in this technology are 
not explicit, and are required to be further elucidated in the future.     
Factors affecting the measurements
All the methods used for investigating the affinity and kinetic parameters of li-
gands at the Kv11.1 channel are influenced by a range of external factors. Herein, 
we mainly focus on the impacts of assay conditions, species diversity and tem-
perature on the data interpretation for the Kv11.1 channel.
The patch clamp technique is a highly flexible method that can be performed 
in a variety of configurations and modes, providing a direct, precise and detailed 
measurement of the activity for an ion channel.79 Specific bath and pipette solu-
tions, voltage and current protocols based on research aims are essential to obtain 
reliable results. For instance, Kirsch et al. found that there was a 2-fold underes-
timation of the potency for pimozide at the Kv11.1 channel when the step-pulse 
protocol was changed from 2 s to 0.5 s at 35 °C.88 In radioligand binding assays, 
BSA concentration in the assay buffers might considerably reduce the speed of 
filtration and further result in the loss of a low affinity binding component for the 
Kv11.1 blockers. Consequently, variability amongst the results acquired in differ-
ent laboratories may stem, in part, from the varied assay conditions. 
Species diversity is another common factor that influences the ligands’ activ-
ity at the Kv11.1 channel in all techniques. Different binding and kinetic param-
eters of drugs at the Kv11.1 channel could be observed with cells from different 
species or tissues. There have been reported differences in IC50 values between 
the patch clamp measurements in Xenopus oocytes versus transfected mamma-
lian cell cultures (i.e. HEK293 and native Kv11.1 channel in cardiomyocytes).
89 
Next to protocol variations, these are also attributed to the restricted drug diffu-
sion at the oocytes surface membrane and yolk sac absorption, which does not 
occur in mammalian cells. Moreover, even when the Kv11.1 channel is assessed 
in the same species but in different cell cultures, variations might be noticeable 
in the activity and functionality of the channel. This could be related to the var-
ied contents or isoforms of the Kv11.1 proteins in different cell cultures. In this 
circumstance, tissue linearity experiments can be conducted to standardize the 
distinct results from different cell cultures.75 
Temperature is the most important factor that impacts the interpretation of 
data from different assays. Physiological temperature is supposed to be more 
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suitable to determine drug safety at the Kv11.1 channel, since channel gating, 
receptor binding and drug accumulation might be temperature-dependent. In the 
patch clamp study the measured IC50 values of sotalol and erythromycin at 35 °C 
were decreased by 2.9- and 7.1-fold respectively compared to these determined at 
room temperature.88 Furthermore, the binding kinetics of ligands at the ion chan-
nel can be remarkably affected by the temperature. For instance, erythromycin 
had an extremely slow onset of block and the time required to reach half-maximal 
effect was 156 s at 22 °C, whereas the same compound displayed a much faster 
onset of block and the time needed to approach half-maximal effect was 18 s at 
35 °C.88 The incubation temperature affects the time for ion exchange in ion flux 
assays,90 and also plays a paramount role in measuring the affinity and kinetic 
parameters of ligands in radioligand binding assays.91  
Binding of ligands and their kinetics at the Kv11.1 channel
Small molecules that act at the intracellular side
Astemizole, desmethylastemizole and norastemizole
Astemizole is a second generation histamine H1-receptor antagonist.
89 In addition 
to antihistamine effects, it causes a QT interval prolongation and cardiac arrhyth-
mia due to the unintended blockade of the Kv11.1 channel. Oxidative O- and 
N-demethylations of astemizole generate two metabolites desmethylastemizole 
and norastemizole, respectively. Desmethylastemizole and astemizole initiated 
equipotent blockade of the Kv11.1 channel, while norastemizole had weaker po-
tency at the channel.89 Taglialatela et al. investigated the concentration-dependent 
effect of astemizole on Xenopus oocytes transfected with the Kv11.1 channel by 
an extracellular perfusion, and calculated its IC50 as 480 nM.
92 This value was 
10 times higher than that previously reported by Suessbrich et al.,93 which was 
explained by a longer incubation time in the latter study leading to higher in-
tracellular drug concentrations and thus stronger potency. Binding of the parent 
drug and its metabolites occurs primarily in the open and inactivated states of the 
channel with a minimal block in the closed state.89 Blockade of astemizole and 
desmethylastemizole occurred faster at higher action frequencies. Recovery from 
astemizole blockade was minimal, while a partial recovery for desmethylastem-
izole was observed after a washout period of 30 minutes. However, the inhibi-
tion of norastemizole was incomplete and only occurred at high concentrations 
after channel activation. Astemizole and norastemizole were found to bind in the 
open state of the channel in the region of the hydrophobic inner vestibule after 
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residue lining in the inner vestibule dramatically reduced the blockade of these 
two compounds. 
Clozapine
Hill et al. performed the first study on directly measuring the binding and un-
binding kinetics of the typical antipsychotic clozapine at the Kv11.1 channel ex-
pressed in CHO cells using the patch clamp technique with a Dynaflow automat-
ed compound delivery system.10 They revealed two kinetically distinct blocking 
effects consistent with different binding kinetics to the open and inactivated states 
of the channel, while the binding affinity of clozapine for the two different states 
were almost identical. The block and unblock time courses of clozapine were not 
monophasic, which encompassed a fast and a slow phase. The fast component of 
block was related to the fast component of unblock, and vice versa. The current 
recovery rate from clozapine block during the washout experiment was indepen-
dent of the drug dosages applied in the system, whereas it was exposure time 
dependent with a slower recovery rate after a longer application of the drug. The 
molecular mechanism of clozapine blockade at the Kv11.1 channel has not been 
elucidated. However, it is believed that clozapine binds at the pore site towards 
the lumen on residues Tyr652 and Phe656 of the S6 domain, which is comparable 
to other prototypical Kv11.1 blockers.
95 
Clofilium and ibutilide
Clofilium and ibutilide, which are two structurally related class III antiarrhyth-
mic drugs, were found to have different time-dependent kinetics of block at the 
Kv11.1 channel in whole cell voltage clamped Xenopus oocytes.
18 The binding 
potency of ibutilide at the channel showed an IC50 value of 28 nM, while a precise 
measurement of the IC50 value for clofilium was difficult due to its extraordinarily 
slow onset of block. The steady-state inhibition of clofilium to the Kv11.1 channel 
was not approached even after a prolonged exposure to more than 1 hour. Never-
theless, the onset of block was reported to be faster when clofilium was applied 
from the intracellular side of excised membranes in excised patch clamp exper-
iments. Regarding the unblock rate, the inhibition of ibutilide was almost com-
pletely recovered after a 10-minute washout, whereby only 19% IKr was restored 
from clofilium block within the same washout period. This utra-slow recovery 
rate of clofilium from Kv11.1 blockade is similar to the findings for other potent 
channel blockers which demonstrate slow unbinding profiles because of drug 
trapping within the central cavity of the channel after closure of the activated 
gate upon membrane repolarization.96, 97 To investigate the trapping hypothesis, 
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both clofilium and ibutilide were tested at the Kv11.1 D540K mutant that permits 
untrapping at a hyperpolarized state by allowing the gate to remain open.18 Again, 
recovery from Kv11.1 blockade in the case of ibutilide was almost complete, yet 
little current recovery from clofilium inhibition to the channel was observed. This 
ruled out the possibility of drug tapping within the channel cavity, also known as 
a “foot in the door” mechanism, for clofilium. The binding sites of clofilium and 
ibutilide at the Kv11.1 channel were the same by alanine-scanning mutagenesis of 
Tyr652, Phe656, Thr623, Ser624 and Val625 residues. The S624A mutant locat-
ed at the base of the pore helix of the Kv11.1 channel was the only one that was 
found to enable the rapid IKr recovery from clofilium blockade.
Terfenadine
Terfenadine is a potent blocker of the Kv11.1 channel in the open state. The IC50 
of terfenadine in Xenopus oocytes expressing the Kv11.1 channel was 350 nM at 
22 ºC.93 Extracellular potassium concentrations significantly altered the Kv11.1 
potency of terfenadine with an IC50 of 3.5 mM at 96 mM K
+ reduced to 350 
nM in 2 mM K+.98 The steady-state block of the Kv11.1 channel by terfenadine 
was approached within 7 minutes superfusion of Ringer’s solution containing 
terfenadine, and the blockade was frequency-, voltage- and use-independent. The 
recovery of terfenadine from block at the closed state took place after a washout 
period of more than 30 minutes, which can be explained by drug trapping inside 
of the central cavity of the Kv11.1 channel.
99 Unlike clofilium, the closure-defi-
cient Kv11.1 D540K mutant was experimentally confirmed to facilitate the IKr 
recovery from terfenadine block at the Kv11.1 channel. Focusing on the molec-
ular binding perspective, terfenadine interacts with S624, Y652, F656 and T632 
residues, while amino acids Y652 and F656 are the most important determinants 
for the Kv11.1 sensitivity to terfenadine.
99 
Cisapride
Cisapride, a prokinetic agent, is a potent Kv11.1 blocker.
99 The IC50 value of cis-
apride at the Kv11.1 channel on the Xenopus oocytes was 630 nM. The onset of 
block of cisapride was rapid and the recovery from block was complete within 
approximate 2 minutes.100 Mutation studies for the binding site of cisapride at 
the Kv11.1 channel implicated that π-π interactions with Y652 and F656 residues 
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Propafenone
Witchel et al. used a concentration of 50 mM propafenone to induce a profound 
Kv11.1 channel blockade.
102 The tail current was blocked by 96% at -70 mV while 
the blockade dropped to 5% in the F656A mutant in Xenopus oocytes. This indi-
cates that the F656 residue is a critical determinant for the blockade of propafe-
none at the Kv11.1 channel, similar to other methanesulfonanilides like dofetilide 
and MK-499. Recovery of the Kv11.1 channel from propafenone blockade was 
very rapid in the open state, whereas it was virtually undetectable in the time 
scale tested in the closed state. A further study performed by Windisch et al. 
revealed that propafenone derivatives with short side chains were trapped in the 
closed channel and displayed a very slow unblock rate at the Kv11.1 channel, 
which was in contrast to the long side chain analogues displaying insignificant 
trapping.96 Altogether, the study provides direct evidence for a “foot in the door” 
type blockade of ligands at the Kv11.1 channel. 
Peptides that act at the extracellular side
APETx1 and Saxitoxin
APETx1 is a peptide purified from sea anemone, which acts as a gate modifier 
of the Kv11.1 channel.
103 APETx1 inhibited the IKr in a heterologous system with 
an IC50 value of 34 nM at room temperature, while the inhibition was maximal 
at 300 nM leaving 20% current unblocked even at concentrations up to 1 µM 
in COS-7 cells transfected with Kv11.1 channels. Its kinetics of block profile 
were characterized by a rapid onset of block, and the steady-state inhibition was 
reached within 1 minute. The block of APETx1 to the Kv11.1 channel was totally 
reversible upon a washout period of 100 s. Similar to the binding sites for gating 
modifier toxins of other voltage-gated potassium channels, mutations in the S3 
region of the Kv11.1 channel like G514C and E518C had dramatic impact on the 
responsiveness of the channel to APETx1.104
Saxitoxin inhibited the IKr by more than 90% at 3 µM in HEK293 cells ex-
pressing the Kv11.1 channel at 36 ± 1 ºC.
105 Current reduction reached steady state 
quickly, and the block was reversible upon washout with dissociation character-
istics opposing the simple first-order process. The concentration-dependency of 
saxitoxin alongside its kinetics of block onset and recovery suggested a complex 
binding of multiple molecules of saxitoxin to the extracellular side of the Kv11.1 
channel. Co-administration of methanesulfonanilide MK-499 showed that the 
Kv11.1 inhibition effects of the two drugs were additive, further indicating that 
saxitoxin did not bind to the intracellular side of the channel as MK-499. 
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BeKm-1
BeKm-1 is a scorpion toxin, which selectively blocked the IKr current with an 
IC50 value of 3.3 nM in a patch clamp study in transfected HEK93 cells at room 
temperature.106 The current block and unblock rates of wile type BeKm-1 at the 
Kv11.1 channel were 2.5 ×10
6 M-1·s-1 and 0.017 s-1, respectively.107 In radioli-
gand binding assays the association and dissociation kinetics of [125I]-BeKm-1 
were extremely fast at room temperature, while its on- and off-rate constants at 
0 ºC were 3.8×107 M-1·s-1 and 0.00051 s-1, separately.107 Additionally, wild-type 
BeKm-1 displaced the binding of [125I]-BeKm-1 with a half-maximal inhibitory 
concentration of 44 pM at 0 ºC.107 Collectively, discrepancies exist between quan-
titative results acquired in patch clamp and radioligand binding assays, albeit 
to the comparable rank orders of measured parameters from these two different 
techniques. BeKm-1 preferentially inhibited the IKr current through a closed state 
channel blockade mechanism,108 and interacted with the Kv11.1 channel at the 
extracellular site.42
Conclusions
The Kv11.1 channel is a voltage-gated potassium channel that shares structur-
al characteristics with the voltage-gated potassium channel family but displays 
unique gating kinetics. It is involved in a number of physiological conditions, and 
has the potential to become a new biomarker and therapeutic target for cancer, 
schizophrenia and other important diseases due to its high expression in diseased 
cells instead of normal cells. More importantly, the Kv11.1 channel plays an im-
portant role in maintaining cardiac stability under normal conditions being the 
target of class III antiarrhythmic drugs, but at the same time, when dysregulated, 
causes notorious side effects of severe arrhythmias. A surprisingly diverse group 
of drugs including cardiac and non-cardiac medications have been withdrawn 
from or restricted for use in the market due to their blockade of the Kv11.1 chan-
nel. Therefore, it is routine practice for pharmaceutical companies to screen the 
Kv11.1 liability of drug candidates before they are approved to enter the market 
by regulatory agencies.
In this review, we summarized the generation, degradation, structure and 
function of the Kv11.1 channel, and its corresponding intentional and unintention-
al roles in drug development. This provides valuable information and theoretical 
foundations for investigations on the Kv11.1 channel as well as a comprehensive 
overview of the channel.
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functions in physiological conditions. Almost all Kv11.1 ligands affect the gating 
kinetics of the channel during their interaction with the channel. We reviewed 
the closed, open and inactivated states of the channel and also the transitions 
among these different states. Moreover, the impact of several assay conditions 
and Kv11.1 ligands on the channel kinetics was discussed. This emphasizes the 
importance of considering the gating kinetics of the Kv11.1 channel in seeking for 
Kv11.1 activators and compounds with less Kv11.1-related cardiotoxicity. In addi-
tion, the differences between laboratories in evaluating the Kv11.1 ligands should 
be standardized by taking distinct assay conditions into consideration. 
Currently, the estimation of the risk of a drug to cause LQTS is only based 
on its IC50 value at the Kv11.1 channel. When a drug or drug candidate exhibits 
an IC50 value 30-fold higher than its effective therapeutic plasma concentration, 
this drug is considered to have a safe cardiac profile. Although this rule ensures 
the exclusion of potentially harmful drugs, it could also lead to the preliminary 
withdrawal of certain drug candidates that may be unproblematic. Furthermore, 
drug inhibition of the Kv11.1 channel is a dynamic process in which binding 
and unbinding events occur over time. Therefore, we also examined in this re-
view the binding and corresponding kinetics of different series of ligands to the 
Kv11.1 channel. Different techniques used to determine the binding and kinetic 
parameters of these ligands at the channel were summarized as well. All in all, 
we strongly plea for incorporation of kinetic assessment into ligand affinity at 
the channel in order to better predict the proarrhythmic propensities of Kv11.1 
blockers. To date, the roles of binding (association) and unbinding (dissociation) 
of ligands with respect to their Kv11.1 cardiac side effects have not been well 
elucidated, and thus, more attention should be paid to the studies on these kinetics 
in the future.
Overall, a thorough analysis of the Kv11.1 channel, in particular the gating 
kinetics and ligand binding kinetics, enables the improvement of drug targeted 
design and reduction of unwanted arrhythmic side effects on this channel. The 
outcome of these investigations would also substantially contribute to the devel-
opment of homology and mathematical models for better predicting the interac-
tions of Kv11.1 ligands with the channel, which could effectively facilitate the 
investigations on the Kv11.1 channel in the near future.
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Abstract
Drugs that block the cardiac Kv11.1 channel encoded by the human ether-à-go-
go gene (hERG) have been associated with QT interval prolongation leading 
to proarrhythmia, and in some cases, sudden cardiac death. Because of special 
structural features of the Kv11.1 channel, it has become a promiscuous target 
that interacts with pharmaceuticals of widely varying chemical structures and 
a reason for concern in the pharmaceutical industry. The structural diversity 
suggests that multiple binding sites are available on the channel with possible 
allosteric interactions between them. In the present study, three reference com-
pounds and nine compounds of a previously disclosed series were evaluated for 
their allosteric effects on the binding of [3H]astemizole and [3H]dofetilide to the 
Kv11.1 channel. LUF6200 was identified as an allosteric inhibitor in dissociation 
assays with both radioligands, yielding similar EC50 values in the low micromolar 
range. However, potassium ions increased the binding of the two radioligands in 
a concentration-dependent manner, and their EC50 values were not significantly 
different, indicating that potassium ions behaved as allosteric enhancers. Further-
more, addition of potassium ions resulted in a concentration-dependent leftward 
shift of the LUF6200 response curve, suggesting positive cooperativity and dis-
tinct allosteric sites for them. In conclusion, our investigations provide evidence 
for allosteric modulation of the Kv11.1 channel, which is discussed in the light of 
findings on other ion channels. 
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Introduction
The Kv11.1 channel, encoded by the hERG gene
1, is responsible for the rapid 
delayed rectifier K+ current (IKr) that plays a critical role in the repolarization 
of cardiomyocytes during the cardiac action potential2. It is made up of large 
intracellular N- and C-terminal domains3, 4 and four identical α-subunits, each of 
which is formed by six α-helical transmembrane domains and a looping “pore re-
gion”5, 6. In humans, blockade of the Kv11.1 channel by drugs can cause excessive 
lengthening of the action potential, which is reflected by a QT interval prolonga-
tion in the electrocardiogram (ECG)7, 8. The excessive action potential prolonga-
tion may combine to produce and sustain Torsade de Pointes (TdP), which can be 
self-limiting or degenerate into ventricular fibrillation rapidly leading to death6, 8. 
Therefore, it has become a routine practice in the pharmaceutical industry to test 
compounds for their Kv11.1 liability during early preclinical safety assessments 
according to FDA guidelines9. In recent years, most attention has been paid to 
assess the affinity for the Kv11.1 channel of potential drug candidates in order to 
avoid and discard modest-to-high affinity compounds during the lead finding and 
optimization process10. However, allosteric modulation of the Kv11.1 channel as 
an alternative way of interaction has not been studied in any details until now. 
With regard to G protein-coupled receptors (GPCRs), successful drugs that 
mediate their effects through the allosteric modulation of target activity have al-
ready reached the market, also in view of their potential greater selectivity, po-
tency and/or safety profile when compared to orthosteric ligands11, 12. Radioligand 
binding assays, in particular kinetic radioligand dissociation assays, have been 
widely utilized to quantify the allosteric effects of GPCR ligands13. As for ion 
channels, allosteric modulators have been reported for ligand-gated ion chan-
nels in particular. For example, GW791343 might be applied to treat inflamma-
tory disorders and pain due to its allosteric inhibition of the P2X7 receptor
14, 15. A 
negative allosteric modulator of the nicotinic acetylcholine receptor, UCI-30002, 
had been reported to have significant benefits as a strategy for treating nicotine 
addiction because of its high subtype-selectivity16. It has also become increasing-
ly apparent that new potent and selective allosteric modulators of the GABA-A 
receptor and 5-HT3 receptor may replace conventional antagonists and agonists 
for these targets17, 18. Allosteric modulation of voltage-gated ion channels such 
as several types of calcium, sodium and potassium channels and their possible 
clinical applications has been investigated as well, but to a lesser extent. As an 
example, a novel quinazolinone ligand (TTA-Q4) showed a positive allosteric in-
teraction with the T-Type calcium channel since it enhanced radioligand binding, 
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Figure 1. Compounds evaluated in this study. Terfenadine is a high-affinity reference 
Kv11.1 blocker, fluvoxamine is a low-affinity reference Kv11.1 blocker, PD118057 is a 
reference Kv11.1 activator, and all the other LUF compounds are members of a previously 
disclosed compound series interacting with the Kv11.1 channel.
Radioligand binding assays as a means of studying the Kv11.1
 channel have 
been developed over the years. Two radioligands, [3H]astemizole and [3H]dofeti-
lide, have mostly been used20-22. The purpose of the present study was to identify 
and investigate allosteric modulators of the Kv11.1 channel using these two radi-
oligands. The anti-depressant fluvoxamine23 and the channel opener PD11805724, 
25 (Figure 1), reported to have binding sites different from conventional Kv11.1 
blockers, were selected as representative reference compounds. We identified a 
number of dofetilide analogues (Figure 1) displaying allosteric modulation in a 
pilot experiment and these were further investigated as were the allosteric effects 
of potassium ions in the same binding assays. Our findings suggest potential ap-
plications for such allosteric modulators, which might provide novel solutions for 
drug cardiotoxicity due to blockade of the Kv11.1 channel.
Materials and methods
Chemicals and reagents
Astemizole, terfenadine, fluvoxamine and PD118057 were purchased from Sig-
ma Aldrich (Zwijndrecht, The Netherlands). Dofetilide and all the LUF com-
pounds were synthesized in our own laboratory, as published previously26. [3H]
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Astemizole (specific activity 78.9 Ci·mmol-1) and [3H]dofetilide (specific activity 
70.0 Ci·mmol-1) were purchased from Perkin Elmer (Groningen, The Nether-
lands). Bovine serum albumin (BSA, fraction V) was purchased from Sigma (St. 
Louis, MO). G418 was obtained from Stratagene (Cedar Creek, USA). All the 
other chemicals were of analytical grade and obtained from standard commercial 
sources. HEK293 cells stably expressing the Kv11.1 channel (HEK293Kv11.1) 
were kindly provided by Dr. Eckhard Ficker (University of Cleveland, USA).
Cell culture
HEK293Kv11.1 cells were cultured in a humidified atmosphere at 37 °C and 
7% CO2 in DMEM, containing 10% fetal calf serum, 50 IU mL
-1 penicillin, 50 
μg·mL-1 streptomycin and 1.25 μg·mL-1 G418 for selection. Cells were subcul-
tured twice a week (1:8). Then, the cells were subcultured 1:10 and transferred to 
large 15-cm diameter plates for membrane preparation.
Membrane preparation
HEK293Kv11.1 cells were grown to 80-90% confluence and detached from the 
plates by scraping them into 5 mL of PBS. Then, the detached cells were collect-
ed and centrifuged at 250 g for 10 min. The cell pellets were pooled and resus-
pended in 50 mM ice-cold Tris-HCl buffer containing 2 mM MgCl2, pH 7.4. An 
UltraTurrax (Heidolph Instruments, Schwabach, Germany) was used to homog-
enize the cell suspension. Membranes and the cytosolic fraction were separated 
by centrifugation at 100, 000 g in an Optima LE-80K ultracentrifuge (Beckman 
Coulter, Fullerton, CA) at 4 °C for 20 min. The pellets were resuspended in the 
Tris-HCl buffer, and the homogenization and centrifugation steps were repeat-
ed. The resulting pellets were resuspended in ice-cold incubation buffer (10 mM 
HEPES, 130 mM NaCl, 60 mM KCl, 0.8 mM MgCl2, 1 mM EGTA, 10 mM 
glucose, 0.1% BSA, pH 7.4) using the UltraTurrax. Aliquots (125 or 250 µL) 
were stored at -80 °C. The protein concentration of the membranes was measured 
using the BCA method27.
Kinetic radioligand association and dissociation assays
The incubation temperature and protein concentration were optimized for the ki-
netic studies. Three different temperatures (4, 15 and 25 °C) and five protein 
amounts (10, 15, 20, 30 and 50 µg) were investigated at the beginning of our re-
search program. The optimal conditions for [3H]astemizole kinetic studies proved 
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association experiments of [3H]astemizole were performed by incubating mem-
brane aliquots containing 30 µg protein in a total volume of 100 µL incubation 
buffer at 15 °C for 90 min with 2 nM [3H]astemizole. The amounts of radioligand 
bound to the receptor were measured at various time intervals during the incuba-
tion. The dissociation experiments were conducted by preincubating membrane 
aliquots containing 30 µg protein in a total volume of 100 µL incubation buffer 
at 15 °C for 90 min with 2 nM [3H]astemizole. After preincubation, dissociation 
was initiated by addition of 10 µM astemizole for a total period of 60 min. The 
amounts of [3H]astemizole still bound to the receptor were also measured at var-
ious time intervals. Separation of bound from free radioligand was performed by 
rapid filtration through Whatman GF/B filters using a Brandel harvester. Filters 
were subsequently washed six times with 2 mL ice-cold wash buffer (25 mM 
Tris-HCl, 130 mM NaCl, 60 mM KCl, 0.8 mM MgCl2, 0.05 mM CaCl2, 0.05% 
BSA, pH 7.4). Filter-bound radioactivity was determined by scintillation spec-
trometry using a liquid Scintillation Analyzer (Tri-Carb 2900TR) after addition 
of 3.5 mL Packard Emulsifier Safe and 2 h extraction. 
For the kinetic studies of [3H]dofetilide binding we used 20 µg of membrane 
protein at an incubation temperature of 25 °C with 5 nM [3H]dofetilide. The asso-
ciation experiments were performed for 120 min, whereas the dissociation assays 
were induced by 10 µM dofetilide after a total period of 120 min preincubation 
and followed for another 60 min. Incubations were terminated, and samples were 
obtained and analyzed as described for [3H]astemizole.
Kinetic radioligand dissociation assays-allosteric modulation
Single point dissociation assays
Dissociation experiments were mainly performed as described in the above para-
graph. After preincubation, dissociation was initiated by addition of 10 µM as-
temizole or dofetilide in the absence (control) or presence of 10 µM of other 
ligands. After 10 min of dissociation, samples were separated by rapid filtration 
through a 96-well GF/B filter plate using a Perkin Elmer Filtermate-harvester 
(Perkin Elmer, Groningen, The Netherlands). Filters were subsequently washed 
twelve times with ice-cold wash buffer. The filter-bound radioactivity was de-
termined by scintillation spectrometry using the 1450 Microbeta Wallac Trilux 
scintillation counter (Perkin Elmer) after addition of 37.5 µL Microscint and 2 h 
extraction. The binding of [3H]astemizole or [3H]dofetilide in the control was set 
as 100%.
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Dissociation assays
After preincubation, dissociation was initiated by addition of 10 µM astemizole 
or dofetilide in the absence (control) or presence of 10 µM of possible allosteric 
modulators for a total period of 60 min. The amounts of radioligand still bound to 
the receptor were measured at various time intervals. Incubations were terminat-
ed, and samples were obtained as described in “Single point dissociation assays”. 
Concentration dependency of allosteric modulators
In this setup the dissociation assay of [3H]dofetilide was performed at 15 °C and 
the preincubation time to achieve radioligand association was 180 min; the dis-
sociation assay for [3H]astemizole was the same as described in “Kinetic radioli-
gand association and dissociation assays”. After preincubation, dissociation was 
initiated by addition of 10 µM astemizole or dofetilide in the absence (control) 
or presence of different concentrations of allosteric modulators. Incubations were 
terminated after 10 min of dissociation, and samples were obtained as described 
in “Single point dissociation assays”.
Equilibrium radioligand binding assays
The [3H]astemizole and [3H]dofetilide equilibrium binding assays for the Kv11.1 
channel were performed as described before20-22, 28 with minor modifications. In 
short, membrane aliquots containing 30 μg protein for [3H]astemizole or 20 μg 
protein for [3H]dofetilide were incubated in a total volume of 100 μl incubation 
buffer at 25 °C for 60 min. Binding experiments were performed using a series 
of concentrations of potassium ions in the presence of 2 nM [3H]astemizole or 
5 nM [3H]dofetilide. Nonspecific binding was determined in the presence of 10 
µM astemizole and represented approximately 15% of the total binding. [3H]as-
temizole and [3H]dofetilide did not show specific binding to membranes prepared 
from HEK293 cells lacking the expressed Kv11.1 channel. The binding of [
3H]
astemizole and [3H]dofetilide in the presence of 100 mM KCl was set at 100% 
in all experiments, whereas nonspecific binding was set at 0%. Incubations were 
terminated by dilution with ice-cold wash buffer, and samples were obtained as 
described in “Kinetic radioligand association and dissociation assays”.
Cooperativity between different allosteric modulators 
The dissociation assay of [3H]dofetilide in the presence of different concentra-
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tion dependency of allosteric modulators”. After preincubation, dissociation was 
initiated by addition of 10 µM dofetilide in the absence (control) or presence of 
different concentrations of LUF6200. Incubations were terminated after 6 min of 
dissociation, and samples were obtained as described in “Single point dissocia-
tion assays”.
Data analysis
All data of radioligand binding assays were analyzed with Prism v. 5.0 (Graph-
Pad, San Diego, CA, USA). EC50 values for potassium ions were directly obtained 
from the non-linear regression concentration-effect curves. Dissociation rate con-
stants, koff, were obtained by computer analysis of the exponential decay of [
3H]
astemizole or [3H]dofetilide bound to the receptor. Association rate constants, kon, 
were calculated according to the equation kon = (kobs - koff )/[L*], where the kobs was 
obtained by computer analysis of the exponential association of [3H]astemizole 
or [3H]dofetilide bound to the receptor and [L*] was the amount of radioligand 
used for the association experiments. EC50 values from the dissociation experi-
ments were calculated by non-linear regression analysis of concentration-effect 
curves of dissociation in the presence of different concentrations of unlabeled 
ligands. The differences of binding parameters between compounds and control 
were analyzed by an unpaired student t test. Significance was determined as P 
< 0.05. All values obtained are means of at least three independent experiments 
performed in duplicate. 
Results
Optimization of assay conditions for [3H]astemizole and [3H]
dofetilide kinetic study
Assay conditions were optimized according to a general radioligand binding 
protocol in our laboratory29. Firstly, displacement assays for [3H]astemizole and 
[3H]dofetilide were performed at five different amounts of HEK293Kv11.1 mem-
branes (10, 15, 20, 30 and 50 µg). A suitable window of specific [3H]astemizole 
binding was obtained using 30 µg of membrane protein, whereas 20 µg of protein 
was required for [3H]dofetilide binding to achieve a similar window. These mem-
brane protein concentrations were also selected for the further kinetic study of 
two radioligands. Then, since it has been reported that compounds like AICAR or 
phenformine can also inhibit the Kv11.1 currents via activating AMP-dependent 
protein kinase30, the binding of [3H]astemizole and [3H]dofetilide at membranes 
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prepared from HEK293 cells lacking the expressed Kv11.1 channel were deter-
mined. Neither of the two radioligands showed any specific binding here, indi-
cating the direct binding of astemizole and dofetilide to the Kv11.1 channel. Sub-
sequently, the association and dissociation of [3H]astemizole and [3H]dofetilide 
were determined at three different temperatures (4, 15 and 25 °C). The optimal 
incubation temperature was found to be 15 °C for [3H]astemizole and 25 °C for 
[3H]dofetilide concerning the appropriate on- and off-rates and the practical con-
venience of the experiments. Nevertheless, these findings were not applied too 
stringently as concentration-dependent effects of allosteric modulators of [3H]
astemizole and [3H]dofetilide binding to the Kv11.1 channel were later conducted 
at 15 °C and concentration-effect curves for K+ ions were recorded at 25 °C in 
order to obtain comparable results between the two radioligand binding assays. 
Association and dissociation of [3H]astemizole from the HEK-
293Kv11.1 membranes
Because association and dissociation of [3H]astemizole from the HEK293Kv11.1 
membranes were both very fast at 25 °C, the kinetic study of [3H]astemizole 
binding was performed at 15 °C using 30 µg HEK293Kv11.1 membrane protein. 
The data were best described by non-linear regression using a mono-exponen-
tial model. As is shown in Figure 2A and Table 1, the binding equilibrium was 
reached within 90 min with a kon value of 0.068 ± 0.010 nM
-1·min-1. The dissoci-
ation rate and half-life time of [3H]astemizole were 0.055 ± 0.010 min-1 and 11 
± 1.4 min, respectively (Figure 2B and Table 1). The dissociation of [3H]astem-
izole at 10 min was almost half of the total binding, so the 10-min dissociation 
time was selected for assessing the allosteric effects of compounds on the Kv11.1 
channel in the follow-up experiments.
Figure 2. Association and dissociation curves of [3H]astemizole binding to the Kv11.1 
channel. (A: Association curve; B: Dissociation curve) Dissociation was started by addi-
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°C using 30 µg of HEK293Kv11.1 membrane protein. 
Table 1. The association rate (kon), dissociation rate (koff) and the kinetically derived Kd of 




Astemizolea 0.068 ± 0.010 0.055 ± 0.010 0.85 ± 0.045
Dofetilideb 0.032 ± 0.0026 0.20 ± 0.026 6.4 ± 1.3
Values are means (± S.E.M.) of at least three independent assays performed in duplicate.
aThe association and dissociation assays of [3H]astemizole were performed at 15 °C.
bThe association and dissociation assays of [3H]dofetilide were conducted at 25 °C. 
Association and dissociation of [3H]dofetilide from the HEK-
293Kv11.1 membranes 
As is depicted in Figure 3, the association of [3H]dofetilide reached equilibrium 
at around 30 min, and it completely dissociated from the Kv11.1 channel within 
60 min after addition of 10 µM dofetilide. By analyzing association and disso-
ciation curves using a mono-exponential model, the kon, koff and t1/2 values were 
0.032 ± 0.0026 nM-1·min-1 and 0.20 ± 0.026 min-1, respectively (Table 1). Similar 
to [3H]astemizole binding assay, a 10-min dissociation time point was chosen for 
the further study of allosteric modulators of the Kv11.1 channel. 
A B
Figure 3. Association and dissociation curves of [3H]dofetilide binding to the Kv11.1 
channel. (A: Association curve; B: Dissociation curve) Dissociation was started by addi-
tion of 10 µM dofetilide after 120 min preincubation. Experiments were performed at 25 
°C using 20 µg of HEK293Kv11.1 membrane protein. 
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Screening for allosteric modulators of [3H]astemizole and [3H]
dofetilide binding
Table 2. The specific binding of [3H]astemizole and [3H]dofetilide to the Kv11.1 channel 
after 10 min of dissociation in the absence (Bcontrol) or presence of 10 µM unlabelled li-
gands (B).
Compound %B/Bcontrol of [
3H]astemizole %B/Bcontrol of [
3H]dofetilide 
Control 100 ± 0 100 ± 0 
Terfenadine 98 ± 1 93 ± 7 
Fluvoxamine 129 ± 13 * 95 ± 12 
PD118057 133 ± 14 * 109 ± 2 *
LUF6145 109 ± 5 93 ± 2 
LUF6171 102 ± 6 104 ± 3
LUF6173 97 ± 8 71 ± 5 *
LUF6200 39 ± 4 *** 50 ± 1 ***
LUF6202 70 ± 2 *** 62 ± 4 *
LUF6206 86 ± 2 *** 70 ± 7 *
LUF6208 36 ± 6 *** 47 ± 5 **
LUF6209 39 ± 2 *** 43 ± 8 *
LUF6217 53 ± 4 *** 54 ± 5 *
Values are means (± S.E.M.) of three independent assays performed in duplicate. (* P < 
0.05; ** P < 0.01; *** P < 0.001 versus control)
We screened three reference ligands and an in-house library of Kv11.1 blockers 
(LUF compounds) to identify their allosteric effects on [3H]astemizole binding to 
the Kv11.1 channel using a single point dissociation assay. This protocol resulted 
in several compounds that potentially increased (allosteric inhibitors) and de-
creased (allosteric enhancers) the dissociation of the radioligand. All the data are 
listed in Table 2 and shown in Figure 4. Fluvoxamine and PD118057 appeared 
to increase the specific binding of [3H]astemizole by 29 and 33% above control 
after 10 min, suggesting that they might behave as allosteric enhancers of [3H]
astemizole binding. On the contrary, some of the compounds synthesized in our 
laboratory including LUF6200, LUF6208, LUF6209 and LUF6217 substantially 
reduced the binding of [3H]astemizole, supporting their role as allosteric inhibi-
tors by accelerating the dissociation of the radioligand. Among them, LUF6200, 
6208 and LUF6209 were the most potent allosteric inhibitors with only 39 ± 4, 36 
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dition, LUF6202 and LUF6206 also displayed significant allosteric inhibition ef-
fects, but to a lesser extent. Other compounds (terfenadine, LUF6145, LUF6171 
and LUF6173) had no significant allosteric modulatory effects in this experiment. 
Figure 4. Bar graphs of the percentage specific binding of [3H]astemizole to the Kv11.1 
channel after 10 min of dissociation induced by 10 µM astemizole in the absence (con-
trol) or presence of 10 µM of different compounds. The specific binding of [3H]astem-
izole in the absence of compounds was set as 100%. Experiments were performed at 15 
°C using 30 µg HEK293Kv11.1 membrane protein. 
The effects of the same compounds in the single point dissociation exper-
iments of [3H]dofetilide binding to the Kv11.1 channel are shown in Figure 5 
and Table 2. The results obtained from this assay were almost the same as those 
derived from the [3H]astemizole binding assay. The only two exceptions were 
that fluvoxamine exerted no allosteric enhancement here and that LUF6173 now 
showed significant allosteric inhibition of [3H]dofetilide binding.
Figure 5. Bar graphs of the percentage specific binding of [3H]dofetilide to the Kv11.1 
channel after 10 min of dissociation induced by 10 µM dofetilide in the absence (control) 
or presence of 10 µM of different compounds. The specific binding of [3H]dofetilide in 
the absence of compounds was set as 100%. Experiments were performed at 25 °C using 
20 µg HEK293Kv11.1 membrane protein. 
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Subsequently, fluvoxamine, PD118057 and one potent representative al-
losteric inhibitor (LUF6200) were selected for the further experiments to validate 
their allosteric modulation effects.
Dissociation of [3H]astemizole from the Kv11.1 channel: effects of 
fluvoxamine, PD118057 and LUF6200
The dissociation of [3H]astemizole from the the Kv11.1 channel was induced by 
10 µM astemizole in the absence (control) or presence of 10 µM of fluvoxamine, 
PD118057 or LUF6200 during a 60-min time course at 15 °C. The results are 
depicted in Figure 6. The dissociation rates of [3H]astemizole in the presence 
of fluvoxamine and PD118057 were 0.040 ± 0.0091 min-1 and 0.055 ± 0.0053 
min-1, respectively, which were not significantly different from the control (koff 
= 0.055 ± 0.010 min-1). Moreover, the three curves in the absence or presence of 
fluvoxamine and PD118057 practically overlapped with each other. Thus, in this 
more detailed experiment, we verified that fluvoxamine and PD118057 did not 
allosterically enhance [3H]astemizole binding at a concentration of 10 µM. Inter-
estingly, LUF6200 increased the dissociation rate of radioligand binding notably 
to a koff value of 0.21 ± 0.011 min
-1 (P = 0.0005), which corresponded to a 3.7-fold 
increase in the dissociation rate found for [3H]astemizole alone.
Figure 6. Dissociation curves of [3H]astemizole induced by 10 µM astemizole in the 
absence (control) or presence of 10 µM fluvoxamine, PD118057 and LUF6200. Experi-
ments were performed at 15 °C using 30 µg HEK293Kv11.1 membrane protein.
Dissociation of [3H]dofetilide from the Kv11.1 channel: effects of 
PD118057 and LUF6200
Since fluvoxamine was found to have no allosteric capacity in both the [3H]as-
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LUF6200 were tested for their allosteric effects on [3H]dofetilide binding to the 
Kv11.1 channel (Figure 7). The results demonstrated that LUF6200 accelerated 
the dissociation rate of [3H]dofetilide from 0.20 ± 0.026 min-1 to 1.5 ± 0.17 min-1 
(P = 0.0016), while the koff of [
3H]dofetilide in the presence of 10 µM PD118057 
was 0.20 ± 0.015 min-1, displaying no enhancement effects on the binding of [3H]
dofetilide. This further proved that LUF6200 was an allosteric inhibitor but that 
PD118057 was not an allosteric enhancer of the binding of Kv11.1 radioligands. 
Figure 7. Dissociation curves of [3H]dofetilide by 10 µM dofetilide in the absence (con-
trol) or presence of 10 µM PD118057 and LUF6200. Experiments were was performed at 
25 °C using 20 µg HEK293Kv11.1 membrane protein.
Concentration dependence of allosteric effects of LUF6200 on 
[3H]astemizole and [3H]dofetilide binding
Figure 8. Concentration dependence curves of LUF6200 for accelerating the [3H]astem-
izole or [3H]dofetilide dissociation from the Kv11.1 channel. Membranes were first 
pre-equilibrated with [3H]astemizole or [3H]dofetilide, then the dissociation was induced 
by 10 µM astemizole or dofetilide in the absence (control) or presence of different con-
centrations of LUF6200 and the reaction was terminated after 10 min. The results are 
expressed as the ratio of the specific binding of [3H]astemizole or [3H]dofetilide in the 
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presence of 10 µM astemizole or dofetilide plus various concentrations of LUF6200 (B) 
over that in the presence of 10 µM astemizole or dofetilide alone (Bcontrol). Experiments 
were were performed at 15 °C using 30 µg HEK293Kv11.1 membrane protein for [
3H]
astemizole and 20 µg membrane protein for [3H]dofetilide binding.
The influence of increasing concentrations of LUF6200 on the dissociation of 
[3H]astemizole and [3H]dofetilide induced by 10 µM astemizole or dofetilide is 
shown in Figure 8. After 10 min of dissociation, the process was terminated by 
washing and rapid filtration. LUF6200 accelerated the dissociation of [3H]astem-
izole and [3H]dofetilide in a concentration-dependent manner with similar, not 
statistically significantly different, EC50 values of 4.9 ± 0.52 and 3.4 ± 0.97 µM, 
respectively (P = 0.45). 
Concentration dependent effects of potassium ions on [3H]astem-
izole and [3H]dofetilide binding
To assess the influence of increasing concentrations of potassium ions on the 
binding of [3H]astemizole and [3H]dofetilide, we determined the specific binding 
of [3H]astemizole and [3H]dofetilide at different concentrations of KCl after 60 
min preincubation at 25 °C. The results are shown in Figure 9. The binding of 
both [3H]astemizole and [3H]dofetilide were elevated with increasing concentra-
tions of potassium ions and reached a plateau as of a concentration of 30 mM. 
The mean EC50 values in the two different radioligand binding assays were 7.2 ± 
0.60 mM and 8.1 ± 0.47 mM for [3H]astemizole and [3H]dofetilide, respectively, 
which were not significantly different (P = 0.30). It is also worth noting that when 
no potassium ions were added to incubation mixture, the specific binding of [3H]
astemizole and [3H]dofetilide was negligible (data not shown).
Figure 9. Dose-response curves of the specific binding of [3H]astemizole and [3H]dofeti-
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using 30 µg HEK293Kv11.1 membrane protein for [
3H]astemizole binding and 20 µg 
membrane protein for [3H]dofetilide binding.
Effects of potassium ions on the acceleration of the [3H]dofetilide 
dissociation rate induced by LUF6200
In order to investigate whether the two modulators described above acted at differ-
ent sites to produce these effects, the concentration-dependent effect of LUF6200 
on [3H]dofetilide dissociation was studied in the presence of four different con-
centrations of KCl (Figure 10). The data obtained are represented in two formats. 
Figure 10A shows that addition of potassium ions decreased the dissociation, 
whereas LUF6200 dose-dependently enhanced that dissociation. Figure 10B 
demonstrates that addition of potassium ions resulted in a concentration-depen-
dent leftward shift of the LUF6200 concentration-effect curve. The EC50 values 
of LUF6200 in the presence of 2, 5, 10 and 60 mM potassium ions were 11 ± 
1.7, 6.4 ± 0.74, 4.7 ± 0.53 and 3.5 ± 0.12 µM, respectively. This indicates that 
LUF6200 and potassium ions act at distinct allosteric sites on the Kv11.1 channel, 
and that potassium ions enhanced the allosteric effect of LUF6200. 
A B
C
Figure 10. Concentration-effect curves of LUF6200 for accelerating the [3H]dofetilide 
dissociation from the Kv11.1 at 2, 5, 10 and 60 mM potassium ions before (A) and after 
normalization (B), and the positive cooperativity effect of potassium ions on LUF6200 in 
enhancing [3H]dofetilide dissociation (C). Membranes were first pre-equilibrated with 
[3H]dofetilide at different concentrations of potassium ions, then the dissociation was in-
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duced by 10 µM dofetilide in the absence (control) or presence of different concentrations 
of LUF6200 and the reaction was terminated after 6 min. The results in B are expressed 
as the ratio of the specific binding of [3H]dofetilide in the presence of 10 µM dofetilide 
plus various concentrations of LUF6200 (B) over that in the presence of 10 µM dofetilide 
alone (Bcontrol). Experiments were performed at 15 °C using 20 µg HEK293Kv11.1 mem-
brane protein. The experimental data of different concentrations of potassium ions affect-
ing the modulating potency of LUF6200 are exhibited with standard error of the mean 
from three independent experiments (C).
Last, the cooperativity between LUF6200 and potassium ions was further 
analyzed according to a cooperativity model studied by us previously31, and the 
curve connecting all the data is displayed in Figure 10C. We discriminated three 
possible situations31, in which two compounds showed positive (δ > 1), neutral 
(δ = 1) or negative cooperativity (δ < 1). In the present study, our data points 
complied with δ > 1, thus further supporting a positive cooperativity between the 
binding of LUF6200 and potassium ions.
Discussion
In the present study, we evaluated the allosteric effects of a series of compounds 
with diverse chemical structures on the Kv11.1 channel using both [
3H]astemizole 
and [3H]dofetilide binding assays, and also addressed the influence of potassium 
ions on the binding of two radioligands. To the best of our knowledge, this study 
is the first time to utilize radioligand binding assays for the characterization of 
allosteric modulators for the Kv11.1 channel. From these initial results, one po-
tent allosteric inhibitor (LUF6200) was identified and several other compounds 
including LUF6208, LUF6209, LUF6217, LUF6202 and LUF6206 were also 
shown to possess allosteric inhibitory effects in two radioligand binding assays. 
Moreover, potassium ions increased the binding of [3H]astemizole and [3H]dofet-
ilide to the Kv11.1 channel. Additionally, fluvoxamine and PD118057, known 
to have binding sites distinct from most other Kv11.1 blockers, exhibited no al-
losteric effects in this investigation.
A common binding site for a wide spectrum of Kv11.1 blockers, including as-
temizole and dofetilide, has been implied through different methods32, 33. Howev-
er, the amino acid residues involved in the interaction of these structurally diverse 
compounds may be different32. Therefore, in this study two different radioligands 
([3H]astemizole and [3H]dofetilide) were adopted in order to study, validate and 
compare the behavior of putative allosteric modulators. Since an altered dissoci-
ation rate is unequivocally indicative of an allosteric interaction34, [3H]astemizole 
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to reveal the allosteric effects of different ligands. The results in this paper show 
that both [3H]astemizole and [3H]dofetilide exhibit fast association rates and dis-
sociate from the Kv11.1 channel after addition of an excess of unlabelled as-
temizole or dofetilide, indicative of the reversible binding of the two ligands. 
Additionally, both the association and dissociation curves of the two radioligands 
are better fitted with a single-site than a two-site model, which is different from 
the two binding sites model for [3H]dofetilide reported by Duff et al.35 Howev-
er, the latter experiments were performed on intact cells instead of membrane 
preparations used in our study. The diffusion into and possible trapping of [3H]
dofetilide inside the intact cells might affect the association and dissociation of 
the radioligand significantly.
Subsequently, single time point dissociation assays were conducted to screen 
for allosteric modulators of the Kv11.1 channel. LUF6200 was selected as a rep-
resentative allosteric inhibitor from the screening experiments due to its potent 
effects on both [3H]astemizole and [3H]dofetilide binding. Besides, terfenadine, 
which occupies the same binding site as astemizole and dofetilide36, did not dis-
play allosteric effects in either of the two radioligand screening assays, suggest-
ing the validity and accuracy of our methods. To further characterize the allosteric 
effects of LUF6200, a full radioligand dissociation assay was performed in the 
presence of this compound. LUF6200 caused a 3.7- and 7.5-fold increase in the 
dissociation rates of [3H]astemizole and [3H]dofetilide, respectively. This further 
supports the notion that LUF6200 is an allosteric inhibitor of conventional Kv11.1 
blockers binding to the Kv11.1 channel. The EC50 values from the two different ra-
dioligand dissociation assays were almost the same and in the micromolar range, 
which suggests that astemizole and dofetilide occupy the same binding site on 
the Kv11.1 channel. In a previous study from our laboratory, LUF6200 displaced 
[3H]astemizole binding from the Kv11.1 channel under equilibrium conditions 
with a very low Ki value of 1.2 ± 0.6 nM
26. As is evident from Figure 8, there is 
little or negligible allosteric inhibition observed for LUF6200 at a concentration 
lower than 0.1 µM. Taken together, we conclude that LUF6200 interacts with the 
Kv11.1 channel in a complicated fashion: it behaves as an orthosteric blocker at 
lower concentrations and as an allosteric inhibitor at higher concentrations. 
Two major binding regions have been hypothesized for the Kv11.1 chan-
nel, one in the transmembrane region, the other extracellularly37, 38. Most Kv11.1 
blockers bind to the central transmembrane cavity of the channel, whereas agents 
described as facilitators, activators or enhancers of the Kv11.1
 channel usually 
interact with a region facing away from the inner cavity37. For instance, A-935142 
has recently been stated to possess a binding site responsible for Kv11.1 cur-
rent enhancement which is different from the pore binding site for traditional 
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Kv11.1 blockers
39. The binding sites of several peptide blockers like saxitoxin 
and BeKm-1 are located in the extracellular parts of the Kv11.1 channel
40, 41 and 
some metal ions bind to different regions of the pore of the channel in compar-
ison to most other Kv11.1 blockers
42, 43. Additionally, it has been reported that 
a few nontoxin Kv11.1 blockers are unlikely to fit within the inner cavity and 
must bind elsewhere23, 44. Thus, multiple binding sites of these diverse compounds 
or ions at the Kv11.1 channel imply the plausible allosteric modulation between 
them. They might allosterically increase (allosteric inhibitors/negative allosteric 
modulators) or decrease (allosteric enhancers/positive allosteric modulators) the 
dissociation rates of typical Kv11.1 blockers from the channel. The current study 
does not allow determining the location of the putative binding site of LUF6200. 
Its nanomolar potency as a classical blocker suggests that it interacts with the 
central cavity; for its allosteric property a different binding site or different con-
formation of the channel may play a role, and further studies such as cross linker 
and western blotting experiments are required to elucidate the exact binding sites 
of this compound.
The results in this paper also show that fluvoxamine does not behave as an 
allosteric modulator when tested in a rigorous kinetic assay. However, it has been 
reported that the binding of fluvoxamine to the Kv11.1 channel did not involve 
amino acids such as Y652 and F656 that are crucial to the binding of other gener-
al Kv11.1 blockers
45, 46; hence, it was suggested that fluvoxamine probably binds 
to an extracellular site at the outer mouth of the channel23. In addition, the ac-
tivator PD118057 did not exert allosteric enhancement in both [3H]astemizole 
and [3H]dofetilide dissociation assays. PD118057 has been identified to bind to a 
hydrophobic binding pocket instead of the shared binding site for Kv11.1 blockers 
at the channel47. The results obtained for these two compounds suggest that even 
though a compound binds to a distinct region of the Kv11.1 channel, its allosteric 
effects on the binding of other Kv11.1 blockers are still uncertain and need to be 
validated in more detailed experiments. 
Since it has been reported that the extracellular potassium concentration af-
fected the binding of [3H]dofetilide to neonatal mouse myocytes48, we also studied 
the allosteric effects of potassium ions and found that these monovalent cations 
increase both [3H]astemizole and [3H]dofetilide binding in a concentration-de-
pendent manner with very similar EC50 values. In earlier studies on a variety of 
ion channels, it was reported that metal ion binding to the pore of an ion channel 
may affect the occupancy of the binding site for other ligands and thus decrease 
their binding42, 49. This is in contrast to the observation in our study. Thus, we as-
sume that K+ ions possibly function as an allosteric enhancer of Kv11.1 blockers 
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cupying their binding site. Since two distinct allosteric sites on the human GnRH 
receptor 31 and three different allosteric sites on the dopamine D4 receptor
50 have 
been reported, we wondered whether LUF6200 and potassium ions exert their ef-
fect through two distinct allosteric sites on the Kv11.1 channel as well. Potassium 
ions both enhance the allosteric effect of LUF6200 and shift the LUF6200 dose–
response curve to the left, supporting that the two modulators are indeed acting 
at different binding sites at the Kv11.1 channel. Furthermore, a curve described in 
Figure 10C indicated a positive cooperativity between LUF6200 and potassium 
ions. Taken together, we anticipate that there are at least two different sites of al-
losteric modulation for Kv11.1 blockers at the channel and that they interact with 
each other as well.
It is hypothesized that the ceiling effect of allosteric modulators of ligand-gat-
ed ion channels has important advantages over classic orthosterically acting com-
pounds or open channel blockers, because it offers a much larger safety margin 
when it comes to drug administration and patient compliance51. A similar scenario 
may also be feasible for the Kv11.1 channel. For allosteric inhibitors one might 
argue that when non-cardiovascular drugs (e.g., astemizole) are combined with 
allosteric inhibitors of the Kv11.1 channel, their cardiac side effects might be 
diminished. On the other hand, when allosteric enhancers are administered to-
gether with antiarrhythmic drugs such as dofetilide whose desired target is the 
Kv11.1 channel, the therapeutic dose might be lowered, thereby possibly prevent-
ing adverse drug reactions such as TdP. Taken together, the discovery of allosteric 
modulators for the Kv11.1 channel might open new avenues for treating clinical 
conditions related to the Kv11.1 channel as well as potentially reducing Kv11.1 
cardiotoxicity of other non-cardiovascular drugs by combination therapy. 
In summary, the present study provides evidence for the allosteric effects of 
dofetilide analogues on the binding of Kv11.1 blockers to the Kv11.1 channel us-
ing both [3H]astemizole and [3H]dofetilide binding assays. LUF6200 emerges as 
an allosteric inhibitor with micromolar potency. Potassium ions allosterically en-
hance the binding of typical Kv11.1 blockers in concentrations that are physiolog-
ically relevant. Moreover, LUF6200 and potassium ions act at distinct allosteric 
sites on the Kv11.1 channel, and these binding sites show positive cooperativity. 
In addition, neither fluvoxamine nor PD118057 exhibit significant allosteric ef-
fects on the binding of two radioligands. This new information may be relevant 
for a further analysis of Kv11.1-related cardiotoxicity and provide novel solutions 
for proarrhythmic side effects induced by Kv11.1 blockers.
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Abstract
Drug-induced ventricular arrhythmias (DiVAs) due to unintentional blockade of 
the Kv11.1 (hERG) channel are a major safety concern in drug development. In 
the past years, several highly prescribed drugs have been withdrawn for their 
ability to cause life-threatening arrhythmias. Here, we investigated whether the 
proarrhythmic risk of existing drugs could be reduced by Kv11.1 allosteric modu-
lators. Using [3H]dofetilide binding assays with membranes of human Kv11.1-ex-
pressing HEK293 cells, two existing compounds (VU0405601 and ML-T531) 
and a newly synthesized compound (LUF7244) were found to be negative al-
losteric modulators of dofetilide binding to the Kv11.1 channel with LUF7244 
showing the strongest effect at 10 µM. The Kv11.1 affinity of typical blockers (i.e. 
dofetilide, astemizole, sertindole and cisapride) were significantly decreased by 
LUF7244. Treatment of neonatal rat ventricular myocyte (NRVM) monolayers 
with astemizole or sertindole caused heterogeneous prolongation of action poten-
tial (AP) duration and a high incidence of early afterdepolarizations upon 1-Hz 
electrical point stimulation, occasionally leading to unstable, self-terminating 
reentrant tachyarrhythmias. Pretreatment of NRVMs with LUF7244 prevented 
these proarrhythmic effects. NRVM monolayers treated with LUF7244 alone dis-
played electrophysiological properties indistinguishable from those of untreated 
NRVM cultures. Prolonged exposure of NRVMs to LUF7244 or LUF7244 plus 
astemizole did not affect their viability, excitability and contractility as assessed 
by molecular, immunological and electrophysiological assays. Conclusively, al-
losteric modulation of the Kv11.1 channel efficiently suppresses DiVAs in vitro 
by preventing potentially arrhythmogenic changes in AP characteristics, raising 
the possibility to resume the clinical use of unintended Kv11.1 blockers via phar-
macological combination therapy.
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Introduction
Drug-induced ventricular arrhythmias (DiVAs) are a frequently encountered clin-
ical problem, which has resulted in the restricted use or market withdrawal of 
existing cardiac and non-cardiac drugs and still represents a major obstacle for 
the development of new drugs.1 Inhibition of the rapid component of the delayed 
rectifier K+ current (IKr) has been identified as the major culprit in the develop-
ment of DiVAs. The consequential slowing of cardiac repolarization, manifested 
in the surface electrocardiogram as a prolongation of the QT interval, increases 
the likelihood of early afterdepolarizations (EADs), which may give rise to ec-
topic beats. Drug-induced IKr blockade also increases spatial dispersion of repo-
larization and refractoriness due to differences in relative IKr and IKs (the slow 
component of the delayed rectifier K+ current) densities between cardiomyocytes 
in different regions of the ventricular wall.2 Together these electrophysiological 
alterations promote the development of a special type of polymorphic ventricular 
arrhythmias known as “Torsades de Pointes” (TdPs), which mostly resolve spon-
taneously but occasionally degenerate into fatal ventricular fibrillation.3
The molecular correlate of IKr is the Kv11.1 protein encoded by the KCNH2 
gene (also known as ether-à-go-go–related gene 1 [ERG or ERG1]), possibly in 
combination with the MiRP1 or MinK protein, which are encoded by the KCNE1 
and KCNE2 gene, respectively.4 Kv11.1 represents the pore-forming α subunit of 
the IKr channel, while MiRP1 and MinK are thought to be accessory β subunits 
involved in the modulation of its activity. Several structural features of Kv11.1 
render the IKr channel particularly susceptible to blockade by a heterogeneous 
collection of chemical compounds including various non-cardiac drugs (e.g., as-
temizole, sertindole and cisapride). 
An obvious strategy to reduce the proarrhythmic risk of drugs with unintend-
ed IKr blockade is by lowering their Kv11.1 affinity via chemical modifications. 
Alternatively, supplementary drugs that lessen the proarrhythmic risk of inadver-
tent Kv11.1 blockers can be developed potentially allowing the (i) reintroduction 
of medicines previously recalled from the market because of their Kv11.1-related 
cardiotoxicity and (ii) admission of new drugs with fortuitous IKr-blocking effects. 
Paradoxically, screening of drugs for possible IKr-blocking side effects has result-
ed in the serendipitous discovery of various Kv11.1 activators.
5 Besides their po-
tential usefulness in treating inherited long QT syndrome (LQTS), these Kv11.1 
activators may also be used to counteract Kv11.1 blockade-associated DiVAs. 
Indeed, Kang et al. showed that the action potential (AP) duration (APD)-pro-
longing effect of the IKr-blocking, class III antiarrhythmic drug dofetilide could 
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RPR260243.6 However, due to the APD-shortening effect, Kv11.1 activators car-
ry the risk of possibly inducing short QT syndrome.5 Recently, Potet et al. de-
scribed a compound designated VU0405601 that upon pretreatment significantly 
reduced the APD-prolonging effect of dofetilide in Langendorff-perfused rabbit 
hearts and dose-dependently mitigated the Kv11.1-blocking effects of seven dif-
ferent drugs in a fluorescence-based thallium flux assay performed with HEK293 
cells stably overexpressing the human KCNH2 gene (HEK293Kv11.1 cells).
7 
VU0405601 exerted its effects on the Kv11.1 channel in whole-cell voltage clamp 
experiments using HEK293Kv11.1 cells only when applied extracellularly. This 
suggests that VU0405601 binds to the extracellular domain of the Kv11.1 channel 
rather than to its central cavity leading us to hypothesize that VU0405601 coun-
teracts the APD-prolonging effect of Kv11.1 blockers by an allosteric mechanism.
Allosteric modulators bind to their targets at a site topologically different 
from that of the endogenous ligand. Of note, since the Kv11.1 channel does not 
have an endogenous ligand, the authors refer to the site where typical blockers 
(i.e. dofetilide and astemizole) bind as the orthosteric site. From this so-called al-
losteric or regulatory site they generally display higher selectivity across receptor 
subtypes and thus provide a safer pharmacological profile than ligands binding to 
the orthosteric or active site.8 Whereas allosteric modulators targeting ligand-gat-
ed ion channels and G protein-coupled receptors have been well established as 
research tools and therapeutic agents,8-10 very little progress has been made in 
the discovery and clinical development of such compounds for voltage-gated ion 
channels, in particular the Kv11.1 channel.
In this study, different in vitro radioligand binding assays were used to inves-
tigate whether two previously reported compounds (i.e. VU04056017 and ML-
T53111) and a new compound designated LUF7244 could allosterically modulate 
the binding of the potent Kv11.1 blocker dofetilide to the channel’s central cavi-
ty.12, 13 Radioligand binding assays were also employed to study LUF7244’s influ-
ence on the interaction between (i) the Kv11.1 channel and three different block-
buster drugs (i.e. astemizole, sertindole and cisapride) that have been withdrawn 
from the market due to their Kv11.1-related cardiotoxicity
14 and (ii) astemizole 
and its intended target, the human histamine H1 receptor (hH1R). The radioligand 
binding assays were complemented with optical voltage mapping experiments 
in confluent monolayers of neonatal rat ventricular myocytes (NRVMs). These 
experiments were performed in the absence and presence of LUF7244 and/or 
any of the three blockbuster drugs. Electrophysiological parameters analyzed in-
cluded conduction velocity (CV), APD at 40 and 90% repolarization (APD40 and 
APD90, respectively), APD dispersion and EAD incidence. In addition, the effects 
of LUF7244 alone and together with astemizole on the viability, excitability and 
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contractility of the NRVMs were investigated. The results of this study indicate 
that negative allosteric modulation of the Kv11.1 channel may provide a safe and 
effective means to prevent the proarrhythmic effects of IKr blockers that bind to 
the channel’s central cavity.
Materials and methods
Materials
Dofetilide was synthesized in-house as previously described.15 Bovine se-
rum albumin (BSA, fraction V) and the fortuitous Kv11.1 blockers astemizole, 
sertindole and cisapride were purchased from Sigma-Aldrich (St. Louis, MO). 
Tritium-labeled dofetilide (specific activity: 82.3 Ci·mmol-1) and astemizole 
(specific activity: 78.4 Ci·mmol-1) were obtained from PerkinElmer (Groningen, 
The Netherlands). The synthesis of VU0405601, ML-T531, as well as the design 
and synthesis of  LUF7244 and its derivatives will be detailed elsewhere. G418 
was purchased from Stratagene (Cedar Creek, TX). All other chemicals were of 
analytical grade and obtained from standard commercial sources. HEK293Kv11.1 
cells were kindly provided by Dr. Eckhard Ficker (Case Western Reserve Uni-
versity, Cleveland, OH).16 Expression plasmid pcDNA3.1-hH1Rwt was a gift of 
Prof. Thue W. Schwartz (University of Copenhagen, Copenhagen, Denmark). All 
animal experiments were approved by the Animal Experiments Committee of 
Leiden University Medical Center and conformed to the Guide for the Care and 
Use of Laboratory Animals as stated by the US National Institutes of Health. 
Radioligand binding assays
Cell culture and membrane preparations
HEK293Kv11.1 cells were cultured and membranes were prepared and stored as 
described previously.17
HEK293 cells were cultured in a humidified atmosphere at 37 °C and 7% 
CO2 in Dulbecco’s modified Eagle’s medium (DMEM; Sigma-Aldrich, D6546) 
supplemented with 10% fetal bovine serum (Sarstedt, Nümbrecht, Germany), 50 
IU·mL-1 penicillin (Sarstedt) and 50 μg·mL-1 streptomycin (Sarstedt). When the 
cells had reached 50-60% confluence, the culture medium was refreshed and 500 
µL of 150 mM NaCl containing 15 μg of pcDNA3.1-hH1Rwt DNA and 45 μg 
of linear 25-kDa polyethylenimine (Polysciences Europe, Eppelheim, Germany) 
was added per 100-mm culture dish (Sarstedt). Cells were harvested 48 h after 






Materials and methods   |  95
were prepared and stored as described for HEK293Kv11.1 cells except that incu-
bation buffer I (50 mM Tris-HCl [pH 7.4]) was used instead of incubation buffer 
II (10 mM HEPES-NaOH [pH 7.4], 130 mM NaCl, 60 mM KCl, 0.8 mM MgCl2, 
1 mM EGTA, 10 mM glucose, 0.1% BSA).  
Radioligand displacement assays
[3H]Dofetilide binding assays for the Kv11.1 channel were performed in incuba-
tion buffer II as described previously.17 Briefly, membrane aliquots containing 20 
µg protein were incubated with 5 nM [3H]dofetilide in a total volume of 100 μl 
at 25 °C for 1 hour. Radioligand displacement experiments were carried out with 
various concentrations of the test compounds. Total binding was determined in 
the presence of unsupplemented incubation buffer II, whereas non-specific bind-
ing was evaluated in incubation buffer II containing 10 µM astemizole. Displace-
ment experiments with different concentrations of dofetilide, astemizole, sertin-
dole and cisapride were conducted in the absence (control) or presence of 10 µM 
LUF7244. Incubations were terminated by dilution with ice-cold wash buffer (25 
mM Tris-HCl [pH 7.4], 130 mM NaCl, 60 mM KCl, 0.8 mM MgCl2, 0.05 mM 
CaCl2, 0.05% BSA). Free radioligand was separated from bound [
3H]dofetilide 
by rapid filtration through a UniFilter-96 GF/B microplate using a PerkinElmer 
MicroBeta Filtermate-96 harvester. The radioactivity was determined using a 
Wallac 1450 MicroBeta TriLux liquid scintillation counter (PerkinElmer) after 
extraction with 25 µl MicroScint 20 (PerkinElmer).
[3H]Astemizole binding assays for the hH1R were performed in incubation 
buffer I. Membrane aliquots containing 15 µg protein were incubated with 3.5 
nM [3H]astemizole in a total volume of 100 μl at 25 °C for 3 h. Total binding 
was determined in the presence of unsupplemented incubation buffer I, whereas 
non-specific binding was evaluated in incubation buffer I containing 100 µM 
astemizole. LUF7244 displacement assays were carried out with various con-
centrations of this compound, while displacement assays with different concen-
trations of astemizole were conducted in the absence (control) or presence of 10 
µM LUF7244. Incubations were terminated by dilution with ice-cold wash buffer 
II (50 mM Tris-HCl [pH 7.4]), and samples were obtained as mentioned above.
Kinetic dissociation assays
Kinetic dissociation assays of [3H]dofetilide were performed as described previ-
ously17 with the following modifications. Single-point dissociation experiments 
were conducted by addition of 10 µM dofetilide in the absence (control) or pres-
ence of 10 or 50 µM of the selected compounds after preincubating membranes 
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with [3H]dofetilide at 25 °C for 2 h. After 6 min of dissociation, incubations were 
terminated and samples were obtained as described under “Radioligand displace-
ment assays”. Traditional dissociation experiments were carried out with 10 µM 
dofetilide in the absence (control) or presence of 50 µM of the test compounds 
at 25 °C for a total period of 2 h after preincubation with the radioligand. The 
amounts of [3H]dofetilide still bound to the receptor were measured at various 
time intervals. The concentration-dependent effect of LUF7244 was determined 
by addition of 10 µM dofetilide in the absence (control) or presence of different 
concentrations of LUF7244. After 6 min of dissociation, incubations were termi-
nated and samples were obtained as described under “Radioligand displacement 
assays”.
Functional assays in NRVMs
Isolation and culture of NRVMs
NRVMs were isolated and cultured as described previously.18 Briefly, neonatal 
rats were anaesthetized with 4-5% isoflurane inhalation anesthesia. After ade-
quate anesthesia had been confirmed by the absence of reflexes, the heart was 
quickly excised. Ventricles were separated from the remainder of the heart, cut 
into small pieces with a fine scissor and a scalpel and dissociated by collagenase 
type l (Worthington, Lakewood, NJ) digestion. The resulting cell suspension was 
applied to Primaria culture dishes (Corning Life Sciences, Amsterdam, The Neth-
erlands) and incubated for 75 min at 37 °C in a humidified atmosphere of 5% 
CO2 to allow preferential attachment of cardiac fibroblasts. The unattached cells 
(mainly cardiomyocytes) were collected, passed through a cell strainer (70-μm 
mesh pore size; BD Biosciences, Breda, The Netherlands) and applied at a densi-
ty of 8×105 cells per well of a 24-well cell culture plate (Corning Life Sciences) 
to fibronectin (Sigma-Aldrich)-coated, round glass coverslips. Proliferation of 
residual cardiac fibroblasts (10-15%) was inhibited by incubating the cells for 2 
h in culture medium containing 10 µg·mL-1 mitomycin C (Sigma-Aldrich) at 24 
h after seeding (i.e. at day 1 of culture). Cells were subsequently maintained in a 
1:1 mixture of DMEM (Life Technologies Europe, Bleiswijk, The Netherlands; 
catalog number: 22320) and Ham’s F10 medium (Life Technologies Europe) sup-
plemented with 5% horse serum (Life Technologies Europe), 2% BSA and sodi-
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Immunocytochemical analyses
NRVMs were plated on fibronectin-coated, 15-mm diameter round glass covers-
lips at a density of 4×104 cells. At day 9 of culture, the cells were washed thrice 
with ice-cold phosphate-buffered saline (PBS), fixed for 30 min in buffered 4% 
formaldehyde (Added Pharma, Oss, The Netherlands) of 4 °C and permeabilized 
by a 10-minute incubation at room temperature (RT) with 0.1% Triton X-100 in 
PBS. Next, the cells were double-immunostained for Kv11.1 (rabbit polyclon-
al antibodies raised against the C terminus of human Kv11.1, Merck Millipore, 
Billerica, MA, catalog number: AB5930) and α-actinin (mouse monoclonal anti-
body, Sigma-Aldrich, clone: EA-53). Incubation with primary antibodies (diluted 
1:200 in PBS-0.1% normal donkey serum) and corresponding donkey Alexa Flu-
or 488/568-conjugated secondary antibodies (1:400 dilution, Life Technologies 
Europe) lasted for 2 h. To visualize their nuclei, the cells were incubated for 10 
min at RT with 10 µg·mL-1 Hoechst 33342 (Life Technologies Europe) in PBS. 
After each processing step, the cells were washed three times with PBS of RT. To 
minimize photobleaching, coverslips were mounted in VECTASHIELD mount-
ing medium (Vector Laboratories, Burlingame, CA). Photomicrographs were ob-
tained with the aid of a digital color camera-equipped fluorescence microscope 
(Nikon Eclipse 80i; Nikon Instruments Europe, Amstelveen, The Netherlands).
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) 
analyses
Cultures of NRVMs and of neonatal rat cardiac fibroblasts (NRCFs; maintained 
in NRVM medium) were washed once with ice-cold PBS after which the cells 
were lysed in TRIzol Reagent (Life Technologies Europe) and total RNA was 
isolated using the RNeasy Mini kit (QIAGEN Benelux, Venlo, The Netherlands). 
The RNA was reverse transcribed with the iScript cDNA synthesis kit (Bio-Rad, 
Hercules, CA) and the resulting cDNA was amplified by PCR using the Bioline 
SensiFAST SYBR No-ROX kit (GC biotech, Alphen aan den Rijn, The Nether-
lands). The forward and reverse primers for the amplification of rat Kcnh2-specific 
cDNA were localized in different exons and had the following sequences, respec-
tively: 5′ TAGCCTCCTCAACATCCC 3′ and 5′ CCATGTCTGCACTTAGCC 
3′. For normalization purposes, rat 18S rRNA (Rn18s)-specific cDNA was ampli-
fied in parallel using the following forward and reverse primer, respectively: 5’ 
GTAACCCGTTGAACCCCATT 3’ and 5’ CCATCCAATCGGTAGTAGCG 3’. 
PCR amplifications were carried out in a CFX96 Touch Real-Time PCR detection 
system (Bio-Rad) using a 2-step cycling protocol (20-40 cycles of 95 °C 10 sec, 
60 °C 30 sec) after a 5-minute incubation at 95 °C. Quantitative analyses were 
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based on the 2-ΔΔCT method using CFX Manager software (Bio-Rad). For these 
analyses, PCRs were performed in triplo on three independent samples.
Optical mapping
APs were investigated on a whole-culture scale by optical mapping using the 
potentiometric dye di-4-ANEPPS (Life Technologies Europe) as described pre-
viously.19 The measurements were carried out at 37 °C on 9-day-old confluent 
NRVM monolayer cultures (see above). Optical signals were captured using a 
MiCAM ULTIMA-L imaging system (SciMedia, Costa Mesa, CA). To validate 
the experimental model, cells were incubated for 20 min in culture medium con-
taining 0, 10, 30, 100 or 300 nM of the hH1R antagonist and unintended Kv11.1 
blocker astemizole and dimethylsulfoxide (DMSO) at a final concentration of 
0.03%. In a subsequent experiment, NRVM cultures were first exposed for 30 min 
to 10 μM LUF7244 or its solvent (i.e. culture medium containing 0.1% DMSO). 
Next, astemizole (final concentration of 100 nM) or vehicle was added to the cul-
ture medium raising the DMSO concentration to 0.13%. Following an incubation 
period of 30 min at 37 °C, optical recordings were started in the continued pres-
ence of the appropriate vehicle/drug combinations (Figure 4A). Optical traces 
were analyzed using Brain Vision Analyzer 1208 software (Brainvision, Tokyo, 
Japan). To minimize noise artifacts, calculations were based on the average of 
the signals at a selected pixel and its eight nearest neighbors. CV, APD40, APD90 
and APD40 dispersion were determined using NRVM cultures showing uniform 
AP propagation and 1:1 capture after 1-Hz local stimulation. Each of these elec-
trophysiological parameters was the average of values obtained from 6 different 
positions equally distributed across the cell cultures. The effects of LUF7244 
on the Kv11.1-inhibiting antipsychotic drug sertindole and gastroprokinetic agent 
cisapride were assessed in the same way as for astemizole expect that the final 
concentration of sertindole and cisapride was 1 µM.
To study the effects of long-term Kv11.1 allosteric modulation in the absence 
and presence of an unintended Kv11.1 blocker on cardiac excitability, confluent 
NRVM cultures were incubated for 3 days in culture medium containing 100 nM 
astemizole and/or 10 µM LUF7244 prior to potentiometric dye loading, short-
term drug treatment (see above) and optical mapping in the continued presence of 
drug(s) at culture day 9. Confluent NRVM monolayers exposed to culture medi-
um containing vehicle (i.e. DMSO at a final concentration of 0.13%) only, served 
as negative controls for this experiment. Just prior to optical mapping, movies of 
the cells were made using a Carl Zeiss Axiovert 40C microscope equipped with a 
LD A-Plan 20x/0.3 Ph1 objective (Zeiss Nederland, Sliedrecht, The Netherlands) 
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a 15-ms rectangular pulse.
Apoptosis assay
To investigate the effects of long-term Kv11.1 allosteric modulation in the absence 
or presence of simultaneous Kv11.1 blockade on cell viability, externalized phos-
phatidylserine (as early marker of apoptosis) was detected using Alexa-568-con-
jugated annexin V (Life Technologies Europe). NRVM cultures in 24-well plates 
were treated cells for 72 h with 100 nM astemizole and/or 10 µM LUF7244 as 
described under “Optical mapping”. Mock-treated cells and cells incubated for 
24 h in culture medium containing 1 µM doxorubicin (Sigma-Aldrich) served as 
negative and positive controls, respectively. Next, the cells were washed once 
with ice-cold PBS and incubated for 15 min at RT with annexin V conjugate di-
luted 40-fold in binding buffer (10 mM HEPES-NaOH [pH 7.4], 140 mM NaCl, 
2.5 mM CaCl2) of 4 °C containing 10 µg·mL
-1 Hoechst 33342. After a single 
wash with binding buffer of 4 °C, photomicrographs were taken using a Leica 
DMI6000 B inverted microscope equipped with a Leica DFC300 FX digital color 
camera (both from Leica Microsystems, Rijswijk, The Netherlands).
Data analysis
Data of the radioligand binding assays were analyzed with Prism 5.0 (Graph-
Pad, San Diego, CA). Half maximal inhibitory concentrations (i.e. IC50 values) in 
displacement assays were directly obtained from non-linear regression analysis 
of dose-response curves. Apparent inhibitory binding constants (Ki values) were 
derived from the IC50 values according to the Cheng-Prusoff relationship
20: Ki 
= IC50/(1 + [L*]/KD), where [L*] is the concentration of radioligand and KD is 
its dissociation constant determined by saturation assay21. Dissociation rate con-
stants (koff) were obtained by computer analysis of the exponential decay of [
3H]
dofetilide bound to the Kv11.1 channel. Half maximal effective concentrations 
(i.e. EC50 values) from kinetic dissociation assays were calculated by non-linear 
regression analysis of concentration-effect curves of dissociation in the presence 
of different concentrations of unlabeled ligands. All values obtained from radioli-
gand binding assays in this study are means of at least three independent exper-
iments performed in duplicate. The number of samples per experimental group 
in the optical mapping experiments varied from 5 to 24 as indicated. Whenever 
appropriate, data are expressed as mean ± standard error of the mean (SEM) or as 
mean ± standard deviation (SD). Statistical analysis was performed with a two-
tailed unpaired Student’s t-test.
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Results
Characterization of allosteric modulators of [3H]dofetilide bind-
ing to the Kv11.1 channel
The interaction of two previously reported ligands VU405601 and ML-T531 as 
well as the newly designed and synthesized compound LUF7244 (Figure 1A) 
with the human Kv11.1 channel was studied in different [
3H]dofetilide binding 
assays. As shown in Figure 1B and Table 1, all three compounds reduced [3H]
dofetilide binding at the Kv11.1 channel with relatively low affinity, i.e. with IC50 
values of 7.8 ± 0.4 μM, 12 ± 1 μM and 3.9 ± 0.7 μM for VU0405601 and ML-
T531 and LUF7244, respectively. Moreover, all displacement curves demonstrat-
ed Hill coefficients significantly different from unity (data not shown), implying 
that VU0405601, ML-T531 and LUF7244 might not competitively displace [3H]
dofetilide from the Kv11.1 channel but may occupy distinct binding pockets in the 
channel protein to allosterically modulate binding of the radioligand. 
A B
C D
Figure 1. Characterization of allosteric modulators of dofetilide binding to the Kv11.1 
channel in a [3H]dofetilide binding assay performed with membranes of HEK293Kv11.1 
cells. (A) Chemical structures of VU0405601, ML-T531 and LUF7244. (B) Displacement 
curves of VU0405601, ML-T531 and LUF7244. (C) Percentage specific binding of [3H]
dofetilide to the Kv11.1 channel after 6 min of dissociation induced by 10 µM dofetilide in 
the absence (control) or presence of 10 µM of VU0405601, ML-T531 or LUF7244. The 
specific binding of [3H]dofetilide in the absence of the test compounds was set as Bcontrol, 
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of [3H]dofetilide induced by 10 µM dofetilide in the absence (control) or presence of 50 
µM VU0405601, ML-T531 or LUF7244. Experiments were performed at 25 °C using 20 
µg of HEK293Kv11.1 membrane protein.
Subsequently, single-point dissociation assays were performed to screen 
for allosteric effects of these compounds on the binding of [3H]dofetilide to the 
Kv11.1 channel. The results are summarized in Figure 1C and Table 1. At a 
concentration of 10 µM, VU0405601, ML-T531 and LUF7244 significantly in-
creased the dissociation of [3H]dofetilide from the Kv11.1 channel, indicating that 
these compounds are negative allosteric modulators of dofetilide binding to the 
channel. LUF7244 appeared to be the most potent negative allosteric modulator 
with 43 ± 2% dofetilide binding left compared to control conditions, while 10 µM 
VU0405601 and ML-T531 reduced dofetilide binding to 66 ± 3% and 78 ± 3%, 
respectively.
The allosteric effects of VU0405601, ML-T531 and LUF7244 on the Kv11.1 
channel were further investigated in traditional radioligand dissociation exper-
iments to determine whether co-administration of these compounds with an 
excess unlabeled dofetilde would change the dissociation rate of [3H]dofetilide 
from the Kv11.1 channel. In order to obtain larger effects, the three compounds 
were tested at a concentration of 50 µM instead of 10 µM as used in the sin-
gle-point dissociation assay. As shown in Figure 1D and Table 1, all compounds 
significantly accelerated the dissociation of dofetilide, in line with the results 
from the single-point dissociation experiments. The off-rate of [3H]dofetilide was 
allosterically increased 2.2-fold (from 0.22 ± 0.02 to 0.49 ± 0.09 min-1) with 50 
µM VU0405601. The koff value of [
3H]dofetilide rose to 0.33 ± 0.03 min-1 in the 
presence of 50 µM LUF7244, which was comparable to the effect of ML-T531 
(koff, dofetilide = 0.30 ± 0.02 min
-1).
Table 1. The half maximal inhibitory concentrations (IC50), percentage specific binding 
of [3H]dofetilide to the Kv11.1 channel after 6 minutes of dissociation in the absence or 
presence of 10 µM of the indicated compounds (%B/Bcontrol), and dissociation rates (koff) 
of [3H]dofetilide in the absence or presence of 50 µM of the indicated compounds.
IC50 (nM) %B/Bcontrol koff (min
-1)
Dofetilide - 100 ± 0 0.22 ± 0.02 
+ VU0405601 7757 ± 350 66 ± 3 (***) 0.49 ± 0.09 (**)
+ ML-T531 12000 ± 1213 78 ± 3 (***) 0.30 ± 0.02 (**)
+ LUF7244 3855 ± 724 43 ± 2 (***) 0.33 ± 0.03 (**)
Values are means (± SEM) of at least three independent assays performed in duplicate. 
(** P < 0.01 versus control; *** P < 0.001 versus control)
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Effects of LUF7244 on the binding of typical Kv11.1 blockers to 
the channel
Since LUF7244 was the most potent amongst the three allosteric modulators at the 
lower test concentration of 10 µM and may therefore have the best safety profile, 
its potency to increase the dissociation of [3H]dofetilide from the Kv11.1 channel 
was investigated. The corresponding concentration-effect curve is shown in Fig-
ure 2A. From this graph, the modulatory potency (i.e. the EC50) of LUF7244 was 
calculated to be 4.6 ± 0.8 µM. Notably, LUF7244 could not completely abrogate 




Figure 2. Assessment of the effects of LUF7244 on the binding of Kv11.1 blockers to the 
channel in a [3H]dofetilide binding assay performed with membranes of HEK293Kv11.1 
cells. (A) Effect of different concentrations of LUF7244 on the dofetilide-induced disso-
ciation of [3H]dofetilide from the Kv11.1 channel. After preincubating of HEK293Kv11.1 
cell membranes with [3H]dofetilide, radioligand dissociation was induced by 10 µM 
dofetilide in the absence or presence of different concentrations of LUF7244 and the in-
cubation was terminated after 6 min. The results are expressed as the ratio of the specific 
binding of [3H]dofetilide in the presence of 10 µM dofetilide plus various concentrations 
of negative allosteric modulators (B) over that in the presence of 10 µM dofetilide alone 
(Bcontrol). (B) Chemical structures of dofetilide, astemizole, sertindole and cisapride. (C) 
Displacement curves of dofetilide and astemizole in the absence or presence of 10 µM 
LUF7244. (D) Displacement curves of sertindole and cisapride in the absence or pres-
ence of 10 µM LUF7244. Experiments were performed at 25 °C using 20 µg of HEK-
293Kv11.1 membrane protein.
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pounds besides dofetilide to the Kv11.1 channel, three additional Kv11.1 block-
ers (i.e. astemizole, sertindole and cisapride) from distinct therapeutic classes 
were selected (Figure 2B). As shown in Figure 2C and 2D, the [3H]dofetilide 
displacement curves of all four drugs were shifted rightwards in the presence of 
10 µM LUF7244, implicating that their Kv11.1 affinity were diminished by this 
negative allosteric modulator. The Ki values of dofetilide, astemizole, sertindole 
and cisapride in the absence or presence of 10 µM LUF7244 are listed in Table 
2. LUF7244 most strongly modulated cisapride binding to the Kv11.1 channel, 
increasing its Ki value by 4.0-fold from 21 ± 1 to 85 ± 7 nM. Similarly, the 
Kv11.1 affinity of astemizole, dofetilide and sertindole were reduced by 3.2-, 2.6- 
and 2.1-fold in the presence of LUF7244. Thus, the negative allosteric effect of 
LUF7244 on the Kv11.1 channel significantly lowered the channel’s affinity for 
several chemically and therapeutically distinct Kv11.1 blockers.
Table 2. The Kv11.1 affinity (Ki) of dofetilide, astemizole, sertindole and cisapride in the 
absence (control) or presence of 10 µM LUF7244.
Ki (nM) Ki, + 10 µM LUF7244 (nM) Fold Change
Dofetilide 6.0 ± 0.5 16 ± 4 (**) 2.6
Astemizole 1.2 ± 0.2 3.7 ± 0.1 (***) 3.2
Sertindole 20 ± 2 40 ± 4 (**) 2.1
Cisapride 21 ± 1 85 ± 7 (***) 4.0
Values are means (± SEM) of at least three independent assays performed in duplicate. 
(** P < 0.01 versus control; *** P < 0.001 versus control)
Effects of LUF7244 on the binding of [3H]astemizole to the hH1R
A B
Figure 3. Assessment of the effects of LUF7244 on the binding of astemizole to the hH1R 
in a [3H]astemizole binding assay performed with membranes of HEK293hH1R cells. (A) 
Displacement curve of LUF7244. (B) Displacement curves of astemizole in the absence 
or presence of 10 µM LUF7244. Experiments were performed at 25 °C using 15 µg of 
HEK293hH1R membrane protein.
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To be of practical use in preventing DiVAs, LUF7244 should not interfere with 
the desired activities of unintended Kv11.1 blockers. We therefore tested whether 
LUF7244 affected binding of the antihistamine drug astemizole to the hH1R. As 
displayed in Figure 3A, LUF7244 did not decrease the binding of [3H]astemizole 
to the hH1R. Furthermore, the displacement curve of astemizole binding to the 
hH1R was not significantly shifted rightwards by LUF7244 (Figure 3B). Thus, 
LUF7244 reduces the affinity of the Kv11.1 channel for astemizole without af-
fecting the binding of astemizole to its intended target receptor (i.e. the hH1R).
Analysis of Kv11.1 protein expression in NRVMs
Figure 4. Biochemical characterization of the NRVM model. (A) Basic experimental set-
up of the optical voltage mapping experiments. (B) Phase-contrast image of a typical con-
fluent NRVM monolayer used for optical voltage mapping. (C) Immunocytological anal-
ysis of Kv11.1 protein expression in NRVM cultures. The Kv11.1 protein (green) is mainly 
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NRVMs and hardly detectable in the α-actinin-negative non-cardiomyocytes. (D) Analy-
sis of Kcnh2 mRNA levels in NRVMs and NRCFs by RT-PCR.  
Next, the electrophysiological consequences of allosteric modulation of the bind-
ing of typical Kv11.1 blockers at the channel by LUF7244 (see Figure 4A) was 
examined in confluent monolayer cultures of NRVMs (Figure 4B) as relevant 
in vitro model for studying cardiac arrhythmias.22 Double immunostaining for 
Kv11.1 and sarcomeric α-actinin showed that all cardiomyocytes in the NRVM 
cultures expressed the Kv11.1 protein (Figure 4C). The Kv11.1 signal had a punc-
tate or linear appearance and was concentrated around nuclei and along the sar-
colemma (Figure 4C). No significant Kv11.1 protein expression was observed in 
the low percentage of α-actinin- cells (mainly NRCFs) present in the NRVM cul-
tures. Consistently, comparison of Kcnh2 transcript levels between NRVMs and 
NRCFs by RT-qPCR demonstrated 39-fold higher (n=3, P < 0.01) Kcnh2 mRNA 
expression in NRVMs than in NRCFs (Figure 4D).
Electrophysiological consequences of Kv11.1 blockade by astem-
izole in NRVMs
Due to its relatively high specificity for the Kv11.1 channel,
23 astemizole was 
selected to study the electrophysiological consequences of Kv11.1 blockade by 
optical voltage mapping. NRVMs treated with astemizole displayed a concentra-
tion-dependent lengthening of APD and EAD incidence (Figure 5 and Figure 6). 
As displayed in Figure 5A and 5B, the APD40 and APD90 values of NRVMs were 
increased from 112 ± 16 and 295 ± 62 ms in vehicle-treated cultures (n = 24) to 
156 ± 39 and 355 ± 66 ms in cultures containing 100 nM astemizole (n = 24, P < 
0.001 and P < 0.01), respectively. Furthermore, exposure to 100 nM astemizole 
resulted in the occurrence of EADs in 25% of the NRVM cultures, whereas no 
EADs were observed under control conditions (Figure 5C and 5D). Intriguingly, 
results presented in Figure 5E and 5F demonstrated that the APD40 dispersion 
between NRVMs in the presence of 100 nM astemizole was significantly higher 
than that in its absence (39 ± 11 versus 16 ± 5 ms; n = 24, P < 0.001), indicative 
of aggravated repolarization heterogeneity due to the inhibition of IKr by astem-
izole. Occasionally, the astemizole-induced EADs resulted in short episodes of 
reentrant excitation (Figure 7) reminiscent of spontaneously terminating TdP ep-
isodes. Nonetheless, as indicated by the activation maps shown in Figure 5G and 
corresponding quantitative analysis depicted in Figure 5H, the CV in NRVM 
cultures was not significantly influenced by 100 nM astemizole (20 ± 4 cm·s-1 vs 
21 ± 3 cm·s-1 in control cultures; n = 10, P = 0.48). Overall, these data validate the 
utility of NRVM cultures as an in vitro model for investigating the AP-prolonging 
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Figure 5. Electrophysiological characterization of the NRVM model by optical voltage 
mapping following 1-Hz electrical stimulation. Representative filtered optical signal trac-
es (A and C), corresponding APD dispersion and activation maps (E and G, respectively) 
and quantitative analyses (bar graphs in B, D, F and H) of NRVM cultures exposed for 30 
min to 100 nM astemizole or vehicle (control) and subjected to optical voltage mapping 
immediately afterwards. Astemizole treatment resulted in APD prolongation (APD40 and 
APD90, A and B), the occurrence of EADs (C and D) and an increase in APD40 dispersion 
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A B
Figure 6. Assessment by optical voltage mapping of the effect of different concentra-
tions of astemizole on the APD (APD40 and APD90, A) and EAD incidence (B) in NRVM 
monolayers. ** P < 0.01 and *** P < 0.001.
Figure 7. Optical voltage trace showing an unstable, self-terminating tachyarrhythmia in 
an astemizole-treated NRVM culture following 1-Hz electrical point stimulation.
Effects of LUF7244 on Kv11.1 blockade-associated proarrhyth-
mic changes in NRVM cultures
To investigate the functional consequences of negative allosteric modulation 
of Kv11.1’s interaction with typical Kv11.1 blockers, di-4-ANNEPS-loaded 
NRVM cultures were incubated for 20 min in culture medium containing 10 µM 
LUF7244 before addition of astemizole, sertindole or cisapride. Since the Ki val-
ues of sertindole and cisapride for Kv11.1 are more than 10 times higher than that 
of astemizole (Table 2), these drugs were tested at a final concentration of 1 µM 
instead of 100 nM as was used for astemizole. After incubation for 30 min, the 
NRVMs were optically mapped. As shown in Figure 8A, the APD-prolonging and 
EAD-promoting effects of astemizole were effectively suppressed by LUF7244. 
The APD40 and APD90 were significantly shortened from 156 ± 39 ms to 118 ± 18 
ms (n = 24, P < 0.001) and from 355 ± 66 ms to 282 ± 63 ms (n = 24, P < 0.01), 
respectively, i.e. LUF7244 was able to reduce APD40 and APD90 to control val-
ues (Figure 8B). Moreover, in the presence of 10 µM LUF7244 EADs were no 
longer observed in NRVM cultures exposed to 100 nM astemizole (Figure 8C). 
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LUF7244 also prevented the increase in APD40 dispersion caused by astemizole 
(Figure 8D and 8E). Reassuringly, the CVs in the NRVM cultures treated with 
vehicle, LUF7244, astemizole or LUF7244 plus astemizole did not significantly 






Figure 8. Assessment by optical voltage mapping of the ability of LUF7244 to counteract 
the proarrhythmic effects of astemizole on NRVMs. Representative filtered optical signal 
traces (A and F), APD dispersion maps (D) and quantitative analysis (bar graphs in B, C, 
E, G and H) of control NRVM cultures and of NRVM cultures that had been treated with 
100 nM astemizole or with 10 µM LUF7244 followed by 100 nM astemizole immedi-
ately before optical mapping. Pretreatment of NRVM cultures with LUF7244 completely 
prevented the astemizole-induced APD prolongation (APD40 and APD90, B), occurrence 
of EADs (C) and increase in APD40 dispersion (D and E). Treatment of NRVM cultures 
with 10 µM LUF7244 only did not change AP morphology (F), APD (G) or APD40 dis-
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did not reduce APD or significantly affect APD40 dispersion (Figure 8F-8H), 
suggesting that this negative allosteric modulator poses very little, if any, risk for 
the development of arrhythmias associated with abnormal APD shortening. Very 
similar results of LUF7244 were obtained in NRVM cultures exposed to sertin-
dole or cisapride (Figure 9). LUF7244 can thus suppress the proarrhythmic side 
effects of drugs from different therapeutic classes by allosteric modulation of the 
Kv11.1 channel without exerting, by itself, any obvious adverse electrophysiolog-







Figure 9. Assessment by optical voltage mapping of the ability of LUF7244 to counteract 
the proarrhythmic effects of sertindole and cisapride on NRVMs. Pretreatment of NRVM 
cultures with LUF7244 completely prevented the increase in APD (APD40 and APD90, A 
and D), EAD incidence (B and E) and APD40 dispersion (C and F) induced by exposure 
of the cells to 1 µM sertindole or cisapride. ** P < 0.01 and *** P < 0.001.
Effects of prolonged exposure of NRVMs to LUF7244 and/or as-
temizole on cell viability, excitability and contractility
To study the effects of prolonged allosteric modulation and/or blockade of the 
Kv11.1 channel on the viability of cardiomyocytes, 6-day-old NRVM cultures 
were incubated for 72 h in culture medium containing 10 µM LUF7244 and/or 
100 nM astemizole. Subsequent staining with fluorescently labeled annexin V to 
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detect cell surface-exposed phosphatidylserine yielded only very weak signals 
for cells exposed to vehicle, LUF7244, astemizole or LUF7244 plus astemizole, 
while NRVMs incubated for 24 h with the proapoptotic drug doxorubicin dis-
played strong annexin V fluorescence (Figure 10A). These results indicate that 
prolonged exposure to 10 µM LUF7244 alone or in combination with 100 nM 
astemizole does not trigger programmed cell death.
Optical voltage mapping of 9-day-old NRVM cultures that had been 
mock-treated or treated for 72 h with 10 µM LUF7244 and/or 100 nM astemizole 
produced very similar results as were obtained for cells that had only briefly been 
exposed to these compounds (compare Figure 5 and 8 with Figure 10B and 10C) 
and provided no indications for a drug-related reduction in excitability. More-
over, after electrical field stimulation cells in all four treatment groups displayed 
rhythmic contractions following the pacing frequency of 1 Hz (data not shown).
A
B C
Figure 10. Effects of prolonged exposure of NRVMs to LUF7244 and/or astemizole on 
cell viability and excitability. A: Analysis by Alexa-568-conjugated annexin V staining 
of cell surface expression of phosphatidylserine as early marker of apoptosis. NRVM 
cultures exposed for 72 hours to vehicle, 10 µM LUF7244, 100 nM astemizole or 10 µM 
LUF7244 plus 100 nM astemizole showed very weak signals, while NRVMs incubated 
for 24 hours with 1 µM of the proapoptotic drug doxorubicin displayed strong annex-
in V fluorescence. B: Quantitative comparison of APDs (APD40 and APD90) in NRVM 
cultures exposed for 72 hours to vehicle, 10 µM LUF7244, 100 nM astemizole or 10 
µM LUF7244 plus 100 nM astemizole. C: Quantitative comparison of CV in NRVM 
cultures exposed for 72 hours to vehicle, 10 µM LUF7244, 100 nM astemizole or 10 µM 
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Discussion
Major findings
In radioligand binding assays the structurally related compounds VU0405601, 
ML-T531 and LUF7244 were found to weaken the interaction between the hu-
man Kv11.1 channel and the class III antiarrhythmic agent dofetilide as well as 
the unintended Kv11.1 blockers astemizole, sertindole and cisapride. VU405601, 
ML-T531 and LUF7244 exerted their negative effects on the binding of typical 
Kv11.1 blockers to the channel’s central cavity by an allosteric mechanism. Im-
portantly, LUF7244 decreased the Kv11.1 affinity of astemizole without influenc-
ing its affinity at the hH1R, being astemizole’s intended target. Optical voltage 
mapping showed that incubation of NRVM monolayers with astemizole, sertin-
dole or cisapride led to a significant increase in APD, APD dispersion and, except 
for cisapride, EAD incidence demonstrating the usefulness of this cellular model 
system for studying Kv11.1 blockade-related proarrhythmic risk. Pretreatment of 
the NRVMs with LUF7244 effectively prevented the proarrhythmic changes in-
duced by astemizole, sertindole and cisapride without significantly shortening 
APD by itself and without adversely affecting NRVM viability, excitability and 
contractility. These findings provide a rationale for further exploring allosteric 
modulation as a strategy to prevent DiVAs.
NRVM monolayers as model for studying drug-induced LQTS
Many different methods have been exploited to assess drugs for their Kv11.1 
blockade-associated arrhythmogenicity.3, 24 The interaction between a drug and 
the Kv11.1 channel is usually first investigated by computational and biochemical 
assays. Next, the Kv11.1 liability of suspicious drugs are typically evaluated by 
electrophysiological measurements on CHO or HEK293 cells expressing the hu-
man Kv11.1 channel. Despite their practical advantages, these non-excitable cel-
lular models do not recapitulate the complex regulatory circuits governing Kv11.1 
channel activity in cardiomyocytes and are unsuitable for studying AP generation 
and propagation. We hence employed NRVM monolayers to study the effects of 
LUF7244 on the proarrhythmic potential of three inadvertent Kv11.1 blockers. 
The reasons to specifically use NRVMs for this purpose are that these cells (i) 
can be relatively easily isolated and cultured, (ii) are well-characterized and (iii) 
do express functional Kv11.1 channels.
25 However, to the best of our knowledge, 
it is the first time that this model is being used to test compounds for their ability 
to prevent DiVAs resulting from unintended Kv11.1 blockade.
Although mechanistic insight into DiVAs is limited, there is broad consen-
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sus about spatial dispersion of repolarization and EAD-induced triggered activity 
providing the substrate and trigger for the genesis of drug-induced TdP, respec-
tively.2 The EADs typically arise during phase 2 of the cardiac AP due to drug-de-
pendent decreases in IKr causing increases of APD and QT interval. In support 
of the validity of our model, astemizole dose-dependently increased the APD 
and EAD incidence in monolayers of NRVMs (Figure 6). Also sertindole and 
cisapride had APD-prolonging effects (Figure 9A and 9D) and each of the three 
fortuitous Kv11.1 blockers increased APD dispersion (Figure 5F, Figure 9C and 
9F). While 100 nM astemizole, 1 µM sertindole and 1 µM cisapride increased 
APD and APD dispersion to a similar extent, cisapride did not significantly in-
crease EAD incidence in contrast to the other two drugs. This finding is in line 
with a previous study26 and may be explained by cisapride’s inhibitory effect on 
the ICa,L in NRVMs.
Initially, EAD-dependent ectopic activity at multiple competing foci was 
thought to generate the undulating electrocardiographic patterns of TdP. Recent-
ly, meandering ICa,L-mediated reentrant circuits initiated by EADs at single foci 
have been proposed as an alternative explanation for the highly characteristic 
electrocardiographic signature of TdP.27, 28 In support of the latter idea, exposure 
of NRVMs to Kv11.1 blockers occasionally gave rise to unstable, self-terminating 
reentrant tachyarrhythmias reminiscent of spontaneously terminating TdP epi-
sodes. Pretreatment with LUF7244 rendered NRVM monolayers unsusceptible 
to the Kv11.1-blocking effects of astemizole, sertindole and cisapride. In the pres-
ence of LUF7244, these Kv11.1 blockers no longer caused heterogeneous APD 
prolongation and, due to the reduced opportunity for L-type Ca2+ channel reacti-
vation, no longer gave rise to EADs. This raises the perspective to use LUF7244 
as an antiarrhythmic additive to drugs with unintended IKr-suppressing effects. 
Thus, radioligand binding assays in combination with optical voltage mapping 
experiments of NRVM cultures offer convenient preclinical test systems for eval-
uating chemical entities that can potentially reduce Kv11.1-related cardiotoxicity. 
LUF7244’s mode of action
The chemical structure of LUF7244 resembles those of ML-T531 and VU0405601. 
In a recent study, 10 µM of ML-T531 was shown to reduce the APD of human 
induced pluripotent stem cells (hiPSC)-derived cardiomyocytes from an LQT1 
patient to that of control cells by augmenting IKr.
11 However, the effects of ML-
T531 on the APD of hiPSC-derived cardiomyocytes from a healthy individual 
and the ability of ML-T531 to inhibit the APD-prolonging effects of unintended 
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pressing CHO cells showed that ML-T531 reduces the deactivation rate of the 
Kv11.1 channel and causes a shift of its inactivation curve towards more positive 
voltages. Shortly after the discovery of ML-T531, VU0405601 was identified as 
a compound that, at a final concentration of 5 µM, protected Langendorff-per-
fused rabbit hearts from the proarrhythmic effects of exposure to 100 nM dofet-
ilide.7 Although VU0405601 only partially reversed the dofetilide-dependent 
increase in APD, its administration prior to dofetilide strongly reduced the pac-
ing-induced arrhythmia incidence from 42% to 4%, which was very close to the 
2% of pacing-induced premature ventricular contractions observed in untreated 
hearts.7 Exposure of isolated rabbit ventricular myocytes to 5 µM of VU0405601 
only marginally reduced APD, which is consonant with our finding that 10 µM 
LUF7244 did not noticeably affect the APD of NRVMs. However, at a final con-
centration of 50 µM, VU0405601 decreased the APD50 and APD90 of rabbit ven-
tricular myocytes by 35 ± 6% and 32 ± 4%, respectively. Patch clamp analysis 
of HEK293Kv11.1 cells linked the APD-shortening effect of 50 µM VU0405601 
to shifts in the V½ of activation and inactivation and to changes in the kinetics of 
(de)activation and (de)inactivation causing an increase in IKr. 
In this study, we found that VU0405601, ML-T531 and LUF7244 displayed 
comparatively low Kv11.1 affinity with Hill coefficients significantly different 
from unity for their [3H]dofetilide displacement curves. This suggests that these 
ligands bind to the Kv11.1 channel at sites distinct from that of dofetilide, indic-
ative of an allosteric mode of action.10, 29, 30 The binding of a drug to a receptor at 
an allosteric site (i.e. a site topologically distinct from that of the test ligand) trig-
gers a conformational change within the receptor ultimately causing an alteration 
of the ligand’s dissociation rate from its cognate (i.e. orthosteric) binding site.10, 
31 Altered ligand dissociation rates have been found representative of allosteric 
interactions in various drug targets such as muscarinic and adenosine receptors.10, 
32-34 Consistently, VU0405601, ML-T531 and LUF7244 significantly accelerated 
the dissociation of dofetilide from the Kv11.1 channel, strengthening the con-
clusion that they are negative allosteric modulators of dofetilide binding to the 
Kv11.1 channel. Our finding for VU0405601 is in agreement with the results of 
Potet et al., who presented indirect evidence that VU0405601 binds from outside 
to the ectodomain of the Kv11.1 channel,
7 while astemizole, cisapride, dofetilide 
and sertindole all bind to the channel’s central cavity from inside35-37. In addition, 
the [3H]dofetilide displacement curves of dofetilide, astemizole, sertindole and 
cisapride were shifted rightwards by LUF7244 (Figure 2C and 2D) providing 
further proof for its negative allosteric effect.10, 34 Collectively, the results of the 
different radioligand binding assays provide strong evidence that VU0405601, 
ML-T531 and LUF7244 are negative allosteric modulators of dofetilide binding 
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to the Kv11.1 channel. Binding of VU0405601, ML-T531 and LUF7244 likely 
alters the 3D structure of the Kv11.1 channel, which decreases its affinity for typ-
ical Kv11.1 blockers by increasing the dissociation rates of these blockers from 
the channel. Of note, the vast majority of fortuitous Kv11.1 blockers exert their 
effects by occupying the central cavity of the Kv11.1 channel and thereby ob-
structing the transport of K+ ions through the channel’s pore.38 There are, how-
ever, also examples of drugs that reduce IKr by inhibiting, directly or indirectly, 
the trafficking of Kv11.1 to the plasma membrane.
39 Given their specific mode of 
action, it is unlikely that the IKr-inhibiting effects of these drugs can be abolished 
by LUF7244 or a related compound.
Since both VU0405601 and ML-T531 dose-dependently increased the 
Kv11.1 current density and given the structural similarity of these compounds 
with LUF7244, it is very likely that also LUF7244 can directly act as a (allosteric) 
Kv11.1 activator. Accordingly, the ability of LUF7244 to counteract astemizole-, 
sertindole- and cisapride-related arrythmogenesis may be the combined result 
of its inhibitory effect on the binding of these unintended Kv11.1 blockers to 
the channel and of its direct enhancing effect on the Kv11.1 channel’s activity. 
However, the fact that exposure of NRVMs to 10 µM LUF7244 alone did not sig-
nificantly change AP characteristics suggests that LUF7244’s Kv11.1-activating 
activity is not of critical importance for its ability to suppress the proarrhythmic 
effects of inadvertent Kv11.1 blockers. Moreover, possible effects of LUF7244 
on other cardiac ion channels besides the Kv11.1 channel must be considered. 
The absence of a noticeable change in AP shape and duration following exposure 
of NRVMs to LUF7244 also argues against a possible effect of this allosteric 
modulator on cardiac ion channels different from the Kv11.1 channel. In keeping 
with this notion, Nav1.5, IKs and Kv1.5 activities were not affected or only slightly 
reduced by 50 µM VU0405601.7 Likewise, ML-T531 at a final concentration of 
10 µM had a minor suppressive effect on IKs and did not influence Nav1.5, Cav1.2, 
Kv4.3 or Kir2.1 activities.
11 Thus, the antiarrhythmic propensity of LUF7244 
is dominated by its negative allosteric impact on the binding of typical Kv11.1 
blockers to the channel. 
The fact that LUF7244 significantly decreased the Kv11.1 affinity of drugs 
with very different chemical structures (Figure 2B) in membrane radioligand 
binding assays and prevented these drugs from causing APD prolongation in 
NRVMs makes it likely that LUF7244 will be effective in reducing the cardiotox-
icity of a broad range of Kv11.1 blockers. Further support for this notion comes 
from the fact that VU0405601, which was here shown to inhibit dofetilide in-
teraction with the Kv11.1 channel by a similar mechanism to LUF7244, could 
abolish the blockade of Kv11.1 by seven different drugs.
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to which LUF7244 increased the Ki values of dofetilide, astemizole, sertindole 
and cisapride suggests that the sensitivity of different Kv11.1 blockers to confor-
mational changes in the Kv11.1 proteins differs. Accordingly, different LUF7244 
concentrations may be required to abrogate the proarrhythmic effects of distinct 
Kv11.1 blockers.
Although at a final concentration of 50 µM LUF7244’s ability to weaken the 
interaction between [3H]dofetilide and the Kv11.1 channel was similar to those 
of VU0405601 and ML-T531 (Figure 1D), the new modulator was much more 
effective than the other two compounds at a final concentration of 10 µM (Figure 
1C). Moreover, even 50 µM VU0405601 only modestly inhibited the APD-pro-
longing effect of 1 µM dofetilide (Ki for human Kv11.1: 6.0 nM) on rabbit ven-
tricular myocytes,7 while 10 µM LUF7244 totally blocked the APD prolongation 
caused by exposure of NRVMs to 100 nM astemizole (Ki for human Kv11.1: 1.2 
nM). These findings together with the substantial decrease in the APD of normal 
rabbit ventricular myocytes caused by 50 µM VU0405601 (see above), suggests 
that LUF7244 may possess a more favorable safety profile than VU0405601 or 
ML-T531.
Clinical applicability of allosteric Kv11.1 modulators
A major concern and obstacle for medicinal chemists involved in the develop-
ment of drugs to remedy congenital and acquired LQTS is excessive APD short-
ening resulting in the short QT syndrome (SQTS).5, 40 For instance, at a concen-
tration of 10 µM, the potent Kv11.1 activator ICA-105574 shortened the APD 
in Langendorff-perfused guinea pig hearts by 34% and induced non-TdP like 
ventricular arrhythmias in 2 out of 8 animals.41 Likewise, in a transgenic rabbit 
model of LQT1, shortening of the QTc interval by another Kv11.1 activator des-
ignated NS1643 was accompanied by an increased incidence of pacing-induced 
ventricular fibrillation.42_  However, the fact that LUF7244 at a concentration 
that completely abolished the proarrhythmic effects of astemizole, sertindole and 
cisapride does not shorten the APD of NRVMs and therefore may not give rise to 
drug-induced short QT syndrome (SQTS) raises hope for its clinical applicability.
For the experiments in NRVM monolayers, the final astemizole concentration 
was 100 nM in most cases, while sertindole and cisapride were used at a final 
concentration of 1 µM. These concentrations are much higher than the thera-
peutic blood concentrations of these fortuitous Kv11.1 blockers, which are 2-50 
µg·L-1 (i.e. 4.4-109 nM) for astimizole, 40-80 µg·L-1 (i.e. 86-172 nM) for cis-
apride and 50-100 µg·L-1 (i.e. 113-227 nM) for sertindole.43 The proarrhythmic 
effects of these drugs on NRVMs were completely prevented by 10 µM (i.e. 3.7 
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mg·L-1) LUF7244, a concentration that did not negatively influence the binding 
of astemizole to the hH1R and did not noticeably affect the viability, contractility 
and excitability of the cardiomyocytes. Accordingly, blood LUF7244 concen-
trations well below 10 µM may suffice to counteract the proarrhythmic effects 
of unintended Kv11.1 blockers in humans. However, before LUF7244 or other 
allosteric modulators can be clinically applied as “co-drugs” or otherwise, they 
should be subjected to rigorous preclinical and clinical testing with appropriate 
pharmacokinetic and pharmacodynamics assessments to determine their bene-
fit-risk profiles.
Limitations 
Due to the difficulty to obtain and culture adult human ventricular myocytes, 
in this study NRVMs were used as 2D model system to investigate the effects 
of LUF7244 on Kv11.1 blockade-associated proarrhythmic changes in cardiac 
electrophysiology. However, adult human and neonatal rat ventricular myocytes 
have different AP morphologies because of qualitative and quantitative differenc-
es in the molecular components shaping the APs. Also, changes in cardiomyocyte 
electrophysiological properties may work out differently in a 2D cell layer than in 
the 3D heart. Nonetheless, studies on NRVM monolayers have greatly contribut-
ed to our current understanding of cardiac electrophysiology. Moreover, in spite 
of the differences in ventricular ion channel composition between humans and 
rats, their Kv11.1 proteins are very similar showing 95% amino acid identity for 
the largest isoforms. Consistently, the results of the radioligand binding assays, 
which were carried out with the human Kv11.1 protein, correlated very well with 
those of the optical mapping studies using NRVMs. Yet, ultimately, the ability of 
LUF7244 to counteract the proarrhythmic effects of unintended Kv11.1 blockers 
should be investigated in human subjects.
As mentioned above, LUF7244 did not inhibit the binding of astemizole to 
its intended target in radioligand binding assays and did not compromise the via-
bility, excitability or contractility of NRVMs at a concentration sufficient to fully 
abrogate the proarrhythmic consequences of drug-induced Kv11.1 blockade in 
these cells. Despite these encouraging results, certainty about the lack of specific 
adverse/interfering effects of this negative allosteric modulator of Kv11.1 channel 
in humans can only be obtained through clinical studies. Moreover, now that the 
ability of LUF7244 to reduce the channel binding affinity of Kv11.1 blockers has 
been established, allosteric modulators with higher safety and/or efficacy than 
LUF7244 are likely to arise in the near future. The design of such compounds 
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Kv11.1 channel.
Conclusions
Allosteric modulators at the Kv11.1 channel could provide a new pharmacological 
treatment for drug-induced LQTS by preventing the potentially arrhythmogenic 
changes in AP characteristics caused by unintended Kv11.1 blockers. Through 
combined administration with a negative allosteric modulator, use of “old” drugs 
that have been banned because of their “Kv11.1 liability” may be resumed and 
new drugs with Kv11.1-blocking effects may not have to be excluded from clin-
ical application.
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We synthesized and evaluated a series of compounds for their allosteric modu-
lation at the Kv11.1 (hERG) channel. Most compounds were negative allosteric 
modulators of [3H]dofetilide binding to the channel, in particular 7f, 7h-j and 
7p. Compounds 7f and 7p were the most potent negative allosteric modulators 
amongst all ligands, dramatically increasing the dissociation rate of dofetilide in 
the radioligand kinetic binding assay, while remarkably reducing the affinity of 
dofetilide and astemizole in a competitive displacement assay. Additionally, both 
7f and 7p displayed peculiar displacement characteristics with Hill coefficients 
significantly distinct from unity as shown by e.g., dofetilide, further indicative 
of their allosteric effects on dofetilide binding. Our findings in this investigation 
yielded several promising negative allosteric modulators for future functional and 
clinical research with respect to their antiarrhythmic propensities, either alone or 
in combination with known Kv11.1 blockers. 
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Introduction
The past decades have witnessed an emerging interest in the identification of 
allosteric modulators of G protein-coupled receptors (GPCRs), ligand-gated ion 
channels (LGICs) and enzymes.1-3 Allosteric modulators are ligands that bind to a 
binding site on a target protein that is not overlapping with and spatially distinct 
from the so-called orthosteric binding site, i.e. the site where e.g., hormones and 
neurotransmitters bind.4 Negative allosteric modulators reduce receptor binding 
and/or function associated with orthosteric ligands, whereas positive allosteric 
modulators enhance these.2, 4, 5 The therapeutic potential of allosteric modulators 
has been demonstrated in clinical trials, with a number of such drugs now on the 
market. Allosterically acting ligands provide novel opportunities for drug dis-
covery due to a possible higher subtype-selectivity (allosteric sites are usually 
less conserved than orthosteric binding sites) and fewer side effects compared 
with traditional orthosteric compounds due to their ‘ceiling’ effect.2, 3 However, 
research on the allosteric modulation of voltage-gated ion channels (VGICs) is 
largely lacking, in particular for the Kv11.1 (hERG) channel.  
The Kv11.1 channel, encoded by the human ether-à-go-go-related gene 
(hERG), plays a vital role in regulating cardiac repolarization of the action po-
tential of human ventricular myocytes.6, 7 Genetic dysfunction or pharmacolog-
ical inhibition of the Kv11.1 channel leads to prolongation of the action poten-
tial duration (APD), QT interval lengthening, and the development of Torsades 
de Pointes (TdP). A staggering array of drugs including antiarrhythmic agents, 
antihistamines, antibiotics and antipsychotics are known to block the Kv11.1 
channel via a common, promiscuous binding region within the aqueous inner 
cavity of the pore.8, 9 More recently, a small number of compounds, referred to 
as Kv11.1 activators, have been proposed to remediate repolarization disorders 
in the heart, including acquired and congenital long QT syndromes, due to their 
up-regulation of Kv11.1 currents.
7, 10, 11 These activators were found to bind at 
sites that are distinct from each other and also different from the binding resi-
dues of prototypical Kv11.1 blockers.
9 For instance, RPR260243 ((3R,4R)-4-[3-
(6-methoxyquinolin-4-yl)-3-oxopropyl]-1-[3-(2,3,5-trifluorophenyl)prop-2ynyl]
piperidine-3-carboxylic acid) that was designated as a type 1 activator interact-
ed with a putative binding site at the cytoplasmic end facing away from the in-
ner cavity of the channel, while type 2 activators like NS1643 (1,3-bis[2-hy-
droxy-5-(trifluoromethyl)phenyl]urea) appeared to interact with residues located 
on the outer mouth of the pore.8, 12, 13 Furthermore, some of these activators were 
found to reduce the affinity and subsequently reverse the action potential prolon-
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channel with RPR260243 slightly reduced the affinity of the reference hERG 
blocker dofetilide (N-[4-(2-{[2-(4-methane sulfonamidophenoxy)ethyl](methyl)
amino}ethyl)phenyl] methanesulfonamide), leading to a reduction of dofetilide’s 
prolongation of the action potential.12, 14 Likewise, NS3623 (1-[4-bromo-2-(2H-
tetrazol-5-yl)phenyl]-3-[3-(trifluoro- methyl)phenyl]urea) produced a reversal 
of E-4031 (N-[4-[[1-[2-(6-Methyl-2-pyridinyl)ethyl]-4-piperidinyl]carbonyl]
phenyl]methanesulfonamide dihydrochloride)-induced QT prolongation in both 
anaesthetized and conscious guinea pigs.15 In this sense, the so-called activators 
might be negative allosteric modulators of the action of Kv11.1 blockers, and so 
normalize the pharmacologically induced action potential prolongation. Indeed, 
the allosteric terminology at the Kv11.1 channel has been introduced in our pre-
vious study and a recent review.4, 16 Classic methods for screening allosteric mod-
ulators have been based on techniques used to identify Kv11.1 blockers, such as 
voltage-dependent fluorescence experiments and laborious patch clamp assays. 
However, these methods do not allow high throughput screening in the search for 
new hit and lead molecules,.17 Moreover, although negative allosteric modulators 
of the Kv11.1 channel may be therapeutically promising, the current generation 
of modulators is not very potent and this raises concerns about their selectivity 
and liability for cardiac and non-cardiac side effects.9, 11 Therefore, it would be of 
particular importance to design and synthesize more novel allosteric modulators 
with higher potencies at the Kv11.1 channel. 
Recently, Zhang et al. characterized a potent modulator (ML-T531, com-
pound 7a in this study) for the Kv11.1 channel after screening a large compound 
library using an automated electrophysiological technique, and found that it nor-
malized APD prolongation induced by dysfunction of the Kv7.1 channel.
18 This 
was the first experimental evidence that Kv11.1 modulators can prevent long QT 
type 1 (LQT1) in addition to type 2 (LQT2) syndrome. The concept that Kv7.1 
and Kv11.1 activators can mutually rescue Kv7.1-related LQT1 and Kv11.1-in-
duced LQT2 syndromes has been put forward previously, and was also validated 
by using a highly selective Kv7.1 modulator, R-L3 ((3R)-5-(2-fluorophenyl)-3-
(1H-indol-3-ylmethyl)-1-methyl-3H-1,4-benzodiazepin-2-one)), which sup-
pressed early afterdepolarizations initiated by the Kv11.1 blocker dofetilide in 
rabbit myocytes.17, 19, 20 Apart from ML-T531, a chemically similar compound 
(VU0405601, compound 7r) was discovered in a fluorescence-based thallium 
influx assay, and this ligand allosterically diminished the affinity of dofetilide 
at the channel and relieved the arrhythmia induced by dofetilide.21 Altogether, 
negative allosteric modulators of the Kv11.1 channel could be beneficial in LQT 
syndromes induced by genetic loss-of-function or pharmacological inhibition of 
both Kv11.1 and Kv7.1 channels. In the present study, we selected ML-T531 and 
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VU0405601 as our starting point, and synthesized a series of new ligands with 
modifications at the three aromatic rings present in the basic scaffold of the lead 
compounds. Based on the results from a previously validated single point disso-
ciation assay,16 their structure-activity relationships were analyzed. Subsequent-
ly, a selection of potent negative allosteric modulators were comprehensively 
characterized in [3H]dofetilide dissociation and displacement assays, and their 
influences on affinity of two specific Kv11.1 blockers (dofetildie and astemizole 
(1-[(4-fluorophenyl)methyl]-N-[1-[2-(4-methoxyphenyl)ethyl]- 4-piperidyl]ben-
zoimidazol-2-amine)) were evaluated as well.
Results and discussion
Chemistry
The synthetic route of all final compounds is depicted in Scheme 1 except that 
compound 7r was synthesized as previously described.21 Small systematic chem-
ical variations were made by introducing different functional groups at the three 
aromatic rings of the reference compound (ML-T531, 7a). Compounds based on 
modifications at the two phenyl rings (7a-p) were synthesized as follows. Frie-
del-Crafts acylation of substituted anisols (1a-c) and benzoyl chlorides (2d-l and 
2n-p) resulted in the formation of different substituted-benzophenone derivatives 
(3b-l and 3n-p).22 Apart from acid chlorides 2o and 2p that were synthesized 
from the corresponding carboxylic acids 8o and 8p (Scheme 2), all other inter-
mediates were commercially available. Demethylation of the methoxy group for 
compounds 3b-l and 3n-p with AlCl3 or BBr3 in the case of 3c led to 4b-l and 
4n-p with high yields (65-97%).22, 23 Notably, demethylation of 3c using AlCl3 
conditions resulted in the undesired debrominated product 4a. Subsequently, re-
action of 4a-p with 2-methylbromoacetate and hydrolysis of 5a-p with LiOH 
produced compounds 6a-p. Eventually, final compounds 7a-p were obtained via 
a peptide coupling, using EDCI*HCl (7e and 7l) or the superior HATU, between 
the acids (6a-p) and 3-aminopyridine in yields of 23-98%.21 Fluorenone ana-
logue 7q was synthesized as follows: i) an oxidative dehydrogenative cyclization 
of benzophenone 4a resulted in fluorenone intermediate 4q, and ii) subsequent 
HATU peptide coupling conditions led to the formation of final compound 7q.24 
To further investigate the influences of the 3-pyridine ring on the allosteric mod-
ulation capacities of ligands, a variety of substituted 3-aminopyridines (7f1-f8) 
and other nitrogen-containing heterocyclic rings (7f9-f11) were synthesized in a 
similar approach as described above. All intermediates were commercially avail-
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pyridine (9f5) through an amination using ammonia and copper sulphate penta-
hydrate (Scheme 2).25
Scheme 1. Synthesis of compounds 7a-q and 7f1-f11.
a) AlCl3, DCM, 0 ºC to r.t., 2 h; b) AlCl3, toluene, 130 ºC, 2 h; c) 2-methylbromoacetate, 
K2CO3, DMF, 65 ºC, overnight; d) LiOH, THF, MeOH, 105 ºC, 30 min; e) 3-aminopyri-
dine, Et3N, HATU or EDCI*HCl (7e and 7l), DMF, overnight.
Scheme 2. Synthesis of intermediates (2o, 2p and 10f5) 
a) SOCl2, 100 ºC, 2h;  b) NH3 (aq), CuSO4·5H2O, 140 ºC, 20 h.
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Structure-activity relationships
Initially, all synthesized compounds were tested for their abilities to increase or 
decrease the dissociation of [3H]dofetilide from the HEK293Kv11.1 cell mem-
brane preparations at 10 µM in a single point dissociation assay,16 and the re-
sults are summarized in Table 1-3. Compound 7a, also referred to as ML-T531 
in literature, has been reported to be the most potent Kv11.1 activator, which 
normalizes the prolonged APDs of patient-derived cardiomyocytes.18 Thus, a se-
ries of compounds with different substituents on the phenylcarbonyl ring were 
synthesized and evaluated for their allosteric modulation at the Kv11.1 channel 
(Table 1). Similar to compound 7a, all compounds behaved as negative allosteric 
modulators of the Kv11.1 channel as they significantly increased the dissocia-
tion of dofetilide from the channel except 7l and 7n. The latter observation is in 
agreement with the previous finding that the effect of 7n on Kv11.1 currents was 
insignificant and negligible,18 indicative of the reliability of our high-throughput 
single point dissociation assay. Introduction of halogens at the ortho position (7d, 
7e and 7g) did not significantly impact the negative allosteric effect of the lead 
compound 7a, whereas halogen substituents at the meta position (7h-k) displayed 
a more prominent enhancement of dofetilide dissociation compared to 7a. No-
tably, introduction of a bromo substituent at the ortho position (7f) dramatically 
decreased the relative binding of dofetilide to 44 ± 1% from 78 ± 3% for 7a, 
which implicated that ortho-bromo derivatives could be the starting point for de-
signing more potent allosteric modulators of the Kv11.1 channel in the following 
step. With respect to the para position, methyl and chloro substituents (7l and 
7n) totally abolished the negative allosteric modulation properties of this series 
of compounds, while the 4-fluoro derivative slightly increased the allosteric ef-
fect (7m versus 7a). The bigger size of the methyl and chloro substituents at the 
para-position may be the reason for this decrease in effect. Additionally, electron 
donating (7l) and withdrawing (7n) groups seemed to reduce the allosteric pro-
files of 7a to the same extent, implying a negligible role of electronic effects in 
affecting allostery of compounds at the Kv11.1 channel. When bromo and fluoro 
substituents were simultaneously introduced to the ortho and meta positions, re-
spectively, additional allosteric inhibition was observed for 7p but 7o exerted a 
much lower allosteric effect compared to compounds 7f and 7h. This confirms 
that steric hindrance at the phenyl ring might not be beneficial for the potency of 
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Table 1. Allosteric modulation of [3H]dofetilide binding at the Kv11.1 channel by 10 µM 








Compd R %B/Bcontrol Compd R %B/Bcontrol
7a H 78 ± 3 7j 3-Br 57 ± 5
7d 2-F 85 ± 4 7k 3-I 62 ± 3
7e 2-Cl 71 ± 2 7l 4-CH3 97 ± 5
7f 2-Br 44 ± 1 7m 4-F 65 ± 2
7g 2-I 72 ± 2 7n 4-Cl 104 ± 2
7h 3-F 47 ± 2 7o 2-Br, 3-F 85 ± 1
7i 3-Cl 43 ± 2 7p 2-Br, 5-F 38 ± 3
Since compounds with a bromo substituent (7f and 7p) at the ortho position 
of the phenylcarbonyl ring were among the most potent modulators, a variety of 
compounds with the same ortho-bromo substitution but different nitrogen-con-
taining heterocyclic aromatic rings were designed to investigate the influences 
of the pyridine moiety on allosteric modulation of the Kv11.1 channel. As dis-
played in Table 2, none of these compounds showed more prominent negative 
allosteric activities than the starting compound 7f. By contrast, introduction of 
methyl, methoxyl, chlorine and phenyl groups amongst 3-pyridyl analogues (7f1-
f8) abrogated the negative allosteric effects, and compounds 7f2 and 7f4 even 
appeared to decrease the dissociation of dofetilide albeit not significantly. It is 
worth noting that substituents with opposite electronic effects such as 7f1 and 
7f3 could not be distinguished with respect to their allosteric activities, which is 
in agreement with our earlier finding for derivatives 7l and 7n shown in Table 1. 
This further proves that electronic effects were not the determinants of allosteric 
characteristics for this series of ligands. In addition, replacement of the pyri-
dine ring with chlorine-substituted diazine (7f9), pyrimidine (7f10) and pyrazine 
(7f11) moieties led to significant decreases of the negative allosteric effects on 
the Kv11.1 channel compared to 7f. Altogether, a non-substituted pyridine moiety 
is preferred for binding to the allosteric sites at the Kv11.1 channel. As compound 
7r (VU0405601) was found to significantly increase the IC70 value of dofetilide 
and thus prevent its Kv11.1 inhibition,
21 substituents at the phenolic ring were also 
explored in Table 3. Introducing bromine at the phenolic ring wholly eliminated 
their allosteric effects (7b-c versus 7a), whereby linkage of the two phenyl rings 
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(7q) resulted in a comparably negative allosteric potency to the lead compound 
7a. Consistent with the previous publication,21 substitution of the general benzo-
phenone moiety by a bromine-substituted naphthyl ring moderately increased the 
negative allosteric effect (7r versus 7a). 








Compd R %B/Bcontrol Compd R %B/Bcontrol























107 ± 15 7f11 N
N
92 ± 2
7f6 N 108 ± 16
Taken together, all three aromatic rings played critical roles in modifying the 
allosteric effects of this series of compounds at the Kv11.1 channel. In general, 
introducing halogen substituents with comparatively less steric hindrance at the 
phenylcarbonyl ring, and avoiding substituents at the pyridine and phenolic rings 
were favorable for enhancing the negative allosteric potencies of these modu-
lators. Among all compounds shown in Table 1-3, 7f, 7i and 7p were the most 
potent negative allosteric modulators by reducing [3H]dofetilide binding during 
dissociation to 44 ± 1, 43 ± 2 and 38 ± 3% respectively, which demonstrated their 
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Table 3. Allosteric modulation of [3H]dofetilide binding at the Kv11.1 channel by 10 µM 

















96 ± 7 7r
Br
66 ± 3
Subsequently, several of the more potent allosteric modulators were selected 
in [3H]dofetilide dissociation and displacement assays to exploit their pharma-
cological characteristics at the Kv11.1 channel in more detail. Since the disinte-
gration characteristics of a radioligand-receptor complex can only be altered by 
the binding of a compound to a site distinct from the radioligand binding site, the 
effects of these synthesized compounds on the dissociation rate of [3H]dofetilide 
can be unequivocally indicative of their allosteric actions.26 In this respect, the 
dissociation behavior of [3H]dofetilide was investigated in the absence (control) 
or presence of potent modulators (Figure 1 and Table 4). As concentration-de-
pendent allosteric modulation has been observed in a plethora of receptors,5, 27-29 
we evaluated a higher concentration (50 mM) of modulators in this assay, also to 
assess whether we could surpass the effects measured at 10 μM. The dissociation 
rate of the radioligand induced by an excess concentration of unlabeled dofetilide 
alone was 0.19 ± 0.01 min-1, which was significantly increased by the select-
ed compounds (7f, 7h-j and 7p), once more illustrating their negative allosteric 
modulation of the Kv11.1 channel. Compound 7p was the most potent modulator 
that accelerated the koff of dofetilide to 0.78 ± 0.20 min
-1, while 7j was least effi-
cacious with a dissociation rate of 0.27 ± 0.03 min-1 for dofetilide. The ranking 
order of all five compounds in enhancing the dissociation rate of dofetilde was 
identical to the one obtained in the single point dissociation assay except for 
compound 7f, which had a more prominent negative allosteric action in this as-
say. Next, the concentration-dependent effects of two representative compounds 
at increasing the dissociation of [3H]dofetilide from the Kv11.1 channel were as-
sessed as in Figure 2, and the determined EC50 values for 7f and 7p were 12 ± 2
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and 4.6 ± 0.4 µM, respectively. This is in agreement with their activities in the 
other kinetic assays. It should be mentioned that a full concentration-effect curve 
of 7f could not be recorded due to its limited solubility at higher concentrations. 
Furthermore, there was still 25% [3H]dofetilide binding at the Kv11.1 channel left 
in the presence of 100 µM 7p, which indicates that the binding of Kv11.1 block-
ers cannot be completely displaced via conformational changes of the channel 
caused by these negative allosteric modulators. More recently, curve-shifts that 
deviate from a simple competitive interaction at an equilibrium situation were 
revealed to be indicative of allostery.4 Consequently, we determined the effect of 
the potent modulators (7f, 7h-j and 7p) on the equilibrium affinity of two proto-
typical Kv11.1 blockers, dofetilide and astemizole (Figure 3 and Table 5).
Figure 1. Dissociation curves of [3H]dofetilide by 10 µM dofetilide in the absence (con-
trol) or presence of 50 µM 7f and 7p. Experiments were performed at 25 °C with 20 µg 
HEK293Kv11.1 membranes. 
Table 4. Dissociation rates of [3H]dofetilide in the absence (control) or presence of 50 µM 
7f, 7h-j and 7p, and EC50 values of two representative compounds (7f and 7p) at acceler-
ating dissociation of [3H]dofetilide from the Kv11.1 channel.
Compd koff, dofetilide (min
-1) fold EC50 (µM)
control 0.19 ± 0.01 - -
+ 7f      0.57 ± 0.05*** 3.0 12 ± 2
+ 7h  0.30 ± 0.04* 1.6 -
+ 7i   0.33 ± 0.03** 1.7 -
+ 7j 0.27 ± 0.03* 1.4 -
+ 7p 0.78 ± 0.20* 4.1 4.6 ± 0.4
Values are means (± SEM) of at least three independent experiments performed in dupli-
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Figure 2. Concentration-dependent effects of 7f and 7p in accelerating dissociation of 
[3H]dofetilide from the Kv11.1 channel. Membrane proteins were first pre-equilibrated 
with [3H]dofetilide, then the dissociation was induced by 10 µM dofetilide in the absence 
or presence of different concentrations of compounds and the incubation was terminated 
after 6 min. The results are expressed as the ratio of the specific binding of [3H]dofetilide 
in the presence of 10 µM dofetilide plus various concentrations of negative allosteric 
modulators (B) over that in the presence of 10 µM dofetilide alone (Bcontrol). Experiments 
were performed at 25 °C with 20 µg HEK293Kv11.1 membranes. 
As shown in Figure 3A and 3B, the displacement curves of both dofetilide and 
astemizole were right-ward shifted by compound 7f and 7p at 10 µM, which is 
another indication of the negative allosteric properties of 7f and 7p. The affinity 
of dofetilide (Ki = 4.8 ± 0.5 nM) and astemizole (Ki = 1.3 ± 0.1 nM) were com-
parable to our previous findings,30 and their apparent Ki values were increased in 
the presence of all tested compounds. The Ki values of dofetilide shifted to 6.8 ± 
0.5 nM (7j) and 22 ± 5 nM (7p), while the values for astemizole were 1.8 ± 0.5 
nM (7j) and 8.2 ± 1.5 nM (7p). Apart from compound 7f, the fold increase in Ki 
values for dofetilide and astemizole by these modulators was very comparable, 
and fully in line with our findings in the other dissociation assays. This dimin-
ishing of the affinity of Kv11.1 blockers through negative allosteric modulation 
is very appealing and may even help in mitigating acquired LQT syndromes via 
relieving drug-induced Kv11.1 blockade. The [
3H]dofetilide equilibrium displace-
ment curves of 7f and 7p shown in Figure 4 were rather steep with pseudo Hill 
coefficients (-1.8 for both compounds) much larger than unity, further indicating 
their allosteric actions on dofetilide binding at the Kv11.1 channel.
29 For the sake 
of comparison, the displacement curve of dofetilide was also included in Figure 
4, and the derived Hill slope was equal to -1.0 illustrating the competitive and 
‘orthosteric’ binding of dofetilide and the reliability of this assay. 
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A B
Figure 3. Displacement curves of dofetilide (A) and astemizole (B) in the absence (con-
trol) or presence of 10 µM 7f and 7p in a [3H]dofetilide binding assay. Experiments were 
performed at 25 °C with 20 µg HEK293Kv11.1 membranes. 
Table 5. The Kv11.1 ffinities of dofetilide and astemizole in the absence (control) or pres-
ence of 10 µM 7f, 7h-j and 7p.
Compd Ki, dofetilide (nM) fold Ki, astemizole (nM) fold
control 4.8 ± 0.5 - 1.3 ± 0.1 -
+ 7f 12 ± 3* 2.5  5.3 ± 1.3* 4.1
+ 7h  8.9 ± 0.8* 1.9 2.5 ± 0.9 1.9
+ 7i 16 ± 4* 3.3       3.7 ± 0.1*** 2.8
+ 7j  6.8 ± 0.5* 1.4 1.8 ± 0.5 1.4
+ 7p 22 ± 5* 4.6  8.2 ± 1.5* 6.3
Values are means (± SEM) of at least three independent experiments performed in dupli-
cate (* P < 0.05, *** P < 0.001 versus control).
Kv11.1 activators have been introduced as a new potential anti-arrhythmic 
strategy based on augmentation of the repolarization reserve of cardiomyocytes.31 
In this context, reference compounds 7a and 7r have also been defined as ac-
tivators.18, 21 Compound 7r had been found to decrease the affinity of Kv11.1 
blockers dofetilide and droperidol, and to reduce the action potential prolonga-
tion by dofetilide in isolated rabbit ventricular cardiomyocytes. In a similar fash-
ion, RPR26024, the first known Kv11.1 activator, dose-dependently reversed the 
action potential-prolonging effects of dofetilide in guinea pig myocytes.12 We 
hypothesized that the Kv11.1 activators might exert their antiarrhythmic effects 
through negative allosteric modulation of the binding of Kv11.1 blockers to the 
channel, and verified that this was the case for compound 7r. Additionally, com-
pound 7a had been found to relieve APD prolonged by a genetic dysfunction of 
the Kv7.1 channel.
18 Several negative allosteric modulators synthesized in this 
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implicates their roles as lead compounds in eventually treating patients with LQT 
syndromes induced by pharmacological blockade of the Kv11.1 channel or due to 
genetic defects of the potassium channels.
Figure 4. Displacement curves of [3H]dofetilide by dofetilide (control), 7f and 7p. Exper-
iments were performed at 25 °C with 20 µg HEK293Kv11.1 membranes. 
Conclusion
In summary, modifications of the three aromatic rings of the basic scaffold from 
reference compounds 7a and 7r lead to a series of compounds comprising of 
novel negative allosteric modulators of dofetilide binding to the Kv11.1 channel. 
Structure-activity relationships demonstrate that all the three aromatic rings play 
pivotal roles in determining the allosteric effects of these ligands at the Kv11.1 
channel. Introducing halogen substituents at the meta-position of phenylcarbon-
yl ring together with non-substituted pyridine and phenolic rings enhances the 
negative allosteric effects of these modulators. In the kinetic dissociation assays, 
these compounds significantly accelerate the dissociation of [3H]dofetilide from 
the Kv11.1 channel. Moreover, several potent modulators shift the displacement 
curves of prototypical Kv11.1 blockers (dofetilide and astemizole) to the right, 
and thus, diminish their Kv11.1 affinity at the channel. This is another indication 
of their negative allosteric properties, and also implicates their potential antiar-
rhythmic propensities in reducing acquired LQT syndromes induced by phar-
macological blockade. Furthermore, these negative allosteric modulators may 
also become a new class of medicines for alleviating congenital LQT syndromes 
linked to both Kv11.1 and Kv7.1 channels like compound 7a. Since compounds 7f 
and 7p are more potent than reference compounds 7a and 7r, they may serve as 
lead compounds for further optimization to relieve action potential prolongation 
through Kv11.1 channels or other potassium channels. 
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Experimental section
Chemistry
All solvents and reagents were purchased from commercial sources and were 
of analytical grade. Demineralised water is simply referred to as H2O, as was 
used in all cases unless stated otherwise (i.e. brine). 1H and 13C NMR spectra 
were recorded on a Bruker AV 400 liquid spectrometer (1H NMR, 400 MHz; 
13C NMR, 100 MHz) at ambient temperature. Chemical shifts are reported in 
parts per million (ppm), are designated by δ and are downfield to the internal 
standard tetramethylsilane (TMS) in CDCl3. Coupling-constants are reported in 
Hz and are designated as J. Analytical purity of the final compounds was de-
termined by high pressure liquid chromatography (HPLC) with a Phenomenex 
Gemini 3m C18 110A column (50 x 4.6 mm, 3 μm), measuring UV absorbance 
at 254 nm. Sample preparation and HPLC method was - unless stated otherwise 
- as follows: 0.3-0.8 mg of compound was dissolved in 1 mL of a 1:1:1 mixture 
of CH3CN/H2O/tBuOH and eluted from the column within 15 minutes, with a 
three component system of H2O/CH3CN/1% TFA in H2O, decreasing polarity of 
the solvent mixture in time from 80/10/10 to 0/90/10. All compounds showed 
a single peak at the designated retention time and are at least 95% pure. Liquid 
chromatography–mass spectrometry (LC-MS) analyses were performed using 
Thermo Finnigan Surveyor - LCQ Advantage Max LC-MS system and a Gemini 
C18 Phenomenex column (50 × 4.6 mm, 3 µm). The sample preparation was the 
same as for HPLC analysis. The elution method was set up as follows: 1-4 min 
isocratic system of H2O/CH3CN/1% TFA in H2O, 80:10:10, from the 4
th min, a 
gradient was applied from 80:10:10 to 0:90:10 within 9 min, followed by 1 min 
of equilibration at 0:90:10 and 1 min at 80:10:10. Thin-layer chromatography 
(TLC) was routinely performed to monitor the progress of reactions, using alumi-
num coated Merck silica gel F254 plates. Purification by column chromatography 
was achieved by use of Grace Davison Davisil silica column material (LC60A 
30-200 micron). Solutions were concentrated using a Heidolph laborota W8 2000 
efficient rotary evaporation apparatus and by a high vacuum on a Binder APT 
line Vacuum Drying Oven. Microwave reactions were carried out in a Biotage 
Initiator using sealed tubes and at a set reaction temperature. The procedure for 
a series of similar compounds is given as a general procedure for all within that 
series, annotated by the numbers of the compounds. 
Chlorination of bromo-fluoro-substituted-benzoic acids. To 2-bro-
mo-5-fluorobenzoic acid 8p (500 mg, 2.28 mmol) was added thionyl chloride 
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1 mL of SOCl2 was added after 20 min). The thionyl chloride was evaporated and 
the product, 2-bromo-5-fluorobenzoyl chloride (2p), was used without further 
purification. 454 mg yield = 84%.
2-Bromo-3-fluorobenzoyl chloride (2o). Methode chlorination of bromo-
-fluoro-substituted-benzoic acids. Continued without further purification, 436 mg 
yield = 81%.
3-Amino-5-methoxy pyridine (10f5). 3-Bromo-5-methoxypyridine (9f5) 
(500 mg, 2.66 mmol), ammonium hydroxide (15 mL) and coppersulfate pentahy-
drate (33 mg, 0.13 mmol) were heated at 140 °C in the microwave in a closed 
tube for 20 h. The reaction mixture was cooled to room temperature and the 
crude material separated between ethyl acetate and water. The organic layer was 
washed with water (3 times) and brine, dried over MgSO4, filtered and concentra-
ted in vacuo to give 84 mg, yield 25% of the desired product as solids. 1H NMR 
(400 MHz, CDCl3): δ 7.72 (d, J = 5.4 Hz, 2H), 6.51 (t, J = 2.4 Hz, 1H), 3.79 (s, 
3H) ppm; HPLC-MS: m/z 125.0
General method for the Friedel Crafts acylation (3b-l and 3n-p). 
To a cooled mixture of the substituted benzoyl chloride 2b-l and 2n-q (5.71 
mmol, 1.0 equiv.) and the (substituted)-anisole 1a-c (7.14 mmol, 1.25 equiv.) 
in CH2Cl2 (0.2 M) or carbon disulfide (3b) was added AlCl3 (7.14 mmol, 1.25 
equiv.) in portions over 20 min under a nitrogen atmosphere. After 24 h at room 
temperature full conversion was observed with TLC (Pet. ether/EtOAc 19/1) and 
the reaction mixture was poured into a 3 M aq. HCl solution. The organics were 
extracted 3 times from the aqueous layer with CH2Cl2, washed with water and 
brine, dried over MgSO4 and concentrated in vacuo. The obtained crude material 
was triturated with petroleum ether to obtain the pure products as white solids.
(2-Bromo-4-methoxyphenyl)-phenylmethanone (3b). Started from 3-bro-
moanisole (1b) and benzoyl chloride. Yellow oil 2.20 g after column chromatog-
raphy (2.5-5% EtOAc/Pet. ether), yield = 75%. 1H NMR (400 MHz, CDCl3): δ 
7.80 (d, J = 7.2 Hz, 2H), 7.58 (d, J = 7.2 Hz, 1H), 7.45 (t, J = 8.0 Hz, 2H), 7.32 
(d, J = 8.8 Hz, 1H), 7.19 (d, J = 2.0 Hz, 1H), 6.92 (dd, J = 8.6, 2.2 Hz, 1H), 3.86 
(s, 3H) ppm. NMR in accordance with literature.32
(3-Bromo-4-methoxyphenyl)-phenylmethanone (3c).33 Started from 2-bro-
moanisole (1c) and benzoyl chloride. White solids 2.78 g, yield = 64%. 1H NMR 
(400 MHz, CDCl3): δ 8.07 (d, J = 2.0 Hz, 1H), 7.80 (dd, J = 8.4, 2.0 Hz, 1H), 
7.77-7.73 (m, 2H), 7.60 (tt, J = 7.2, 1.2 Hz, 1H), 7.49 (t, J = 7.2 Hz, 2H), 6.96 
(d, J = 8.8 Hz, 1H), 3.99 (s, 3H), 3.86 (s, 3H) ppm. NMR in accordance with 
literature data.34
(2-Fluorophenyl)(4-methoxyphenyl)methanone (3d). Started from anisole 
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(1a) and 2-fluorobenzoyl chloride (2d). White solids 365 mg, yield = 34%. 1H 
NMR (400 MHz, CDCl3): δ 7.83 (d, J = 8.4 Hz, 2H), 7.52-7.46 (m, 2H), 7.25 (t, 
J = 7.6 Hz, 1H), 7.14 (t, J = 8.4 Hz, 1H), 6.94 (d, J = 8.4 Hz, 2H), 3.86 (s, 3H) 
ppm. NMR in accordance with literature data.35
(2-Chlorophenyl)(4-methoxyphenyl)methanone (3e). Started from anisole 
(1a) and 2-fluorobenzoyl chloride (2e). Pinkish solids 2.43 g, yield = 66%. 1H 
NMR (400 MHz, CDCl3): δ 7.79 (dt, J = 8.8, 2.0 Hz, 2H), 7.47-7.38 (m, 2H), 
7.36-7.33 (m, 2H), 6.94 (dt, J = 8.8, 2.0 Hz, 2H), 3.88 (s, 3H) ppm. NMR in ac-
cordance with literature data.36
(2-Bromophenyl)(4-methoxyphenyl)methanone (3f). Started from anisole 
(1a) and 2-bromobenzoyl chloride (2f). White solids 586 mg, yield = 88%. 1H 
NMR (400 MHz, CDCl3): δ 7.79 (d, J = 8.4 Hz, 2H), 7.64 (d, J = 7.6 Hz, 1H), 
7.41 (t, J = 7.6 Hz, 1H), 7.35-7.31 (m, 2H), 6.94 (d, J = 8.4 Hz, 2H), 3.88 (s, 3H) 
ppm. NMR in accordance with literature data.36
(2-Iodophenyl)(4-methoxyphenyl)methanone (3g). Started from anisole 
(1a) and 2-iodobenzoyl chloride (2g). White solids 422 mg, yield = 66%. 1H 
NMR (400 MHz, CDCl3): δ 7.91 (d, J = 8.0 Hz, 1H), 7.78 (d, J = 8.8 Hz, 2H), 
7.44 (t, J = 7.2 Hz, 1H), 7.28 (d, J = 6.8 Hz, 1H), 7.17 (t, J = 7.6 Hz, 1H), 6.94 
(d, J = 8.8 Hz, 2H), 3.88 (s, 3H) ppm. NMR in accordance with literature data.37
(3-Fluorophenyl)(4-methoxyphenyl)methanone (3h). Started from anisole 
(1a) and 3-fluorobenzoyl chloride (2h). White solids 576 mg, yield = 53%. 1H 
NMR (400 MHz, CDCl3): δ 7.82 (d, J = 8.8 Hz, 2H), 7.53 (d, J = 7.6 Hz, 1H), 
7.47-7.42 (m, 2H), 7.28-7.24 (m, 1H), 6.97 (d, J = 8.8 Hz, 2H), 3.89 (s, 3H) ppm. 
NMR in accordance with literature data.38 
(3-Chlorophenyl)(4-methoxyphenyl)methanone (3i).39 Started from 
anisole (1a) and 3-chlorobenzoyl chloride (2i). Pink solids 2.64 g, yield = 71%. 
1H NMR (400 MHz, CDCl3): δ 7.80 (dt, J = 8.8, 2.0 Hz, 2H), 7.73 (t, J = 1.6 Hz, 
1H), 7.62 (dt, J = 8.0, 1.2 Hz, 1H), 7.53 (dd, J = 8.0, 1.2 Hz, 1H), 7.41 (t, J = 8.0 
Hz, 2H), 6.97 (dt, J = 9.2, 1.2 Hz, 2H), 3.89 (s, 3H) ppm.
(3-Bromophenyl)(4-methoxyphenyl)methanone (3j). Started from anisole 
(1a) and 3-bromobenzoyl chloride (2j). White solids 649 mg, yield = 49%. 1H 
NMR (400 MHz, CDCl3): δ 7.88 (t, J = 1.6 Hz, 1H), 7.80 (d, J = 8.8 Hz, 2H), 
7.70-7.65 (m, 2H), 7.37 (t, J = 7.6, 1H), 6.97 (d, J = 8.8 Hz, 2H), 3.89 (s, 3H) 
ppm. NMR in accordance with literature data.35
(3-Iodophenyl)(4-methoxyphenyl)methanone (3k). Started from anisole 
(1a) and 3-iodobenzoyl chloride (2k). White solids 300 mg, yield = 47%. 1H 
NMR (400 MHz, CDCl3): δ 8.08 (s, 1H), 7.90 (d, J = 8.0 Hz, 1H), 7.80 (d, J = 8.8 
Hz, 2H), 7.70 (d, J = 7.6 Hz, 1H), 7.22 (t, J = 8.0 Hz, 1H), 6.98 (d, J = 8.8 Hz, 
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(4-Methoxyphenyl)(4-methylphenyl)methanone (3l). Started from anisole 
(1a) and 4-methylbenzoyl chloride (2l). White solids 2.31 g, yield = 68%. 1H 
NMR (400 MHz, CDCl3): δ 8.81 (dt, J = 8.8, 2.0 Hz 2H), 7.67 (d, J = 8.0 Hz, 2H), 
7.27 (d, J = 8.4 Hz, 2H), 6.96 (dt, J = 8.8, 2.0 Hz, 2H), 3.88 (s, 3H) ppm. NMR 
in accordance with literature data.35
(4-Chlorophenyl)(4-methoxyphenyl)methanone (3n). Started from anisole 
(1a) and 4-chlorobenzoyl chloride (2n). White solids 1.02 g, yield = 73%. 1H 
NMR (400 MHz, CDCl3): δ 7.80 (dt, J = 8.8, 2.0 Hz, 2H), 7.71 (d, J = 8.4 Hz, 
2H), 7.45 (d, J = 8.2 Hz, 2H), 6.96 (d, J = 8.4 Hz, 2H), 3.89 (s, 3H) ppm. NMR 
in accordance with literature data.35
(2-Bromo-3-fluorophenyl)(4-methoxyphenyl)methanone (3o). Started 
from anisole (1a) and 2-bromo-3-fluorobenzoyl chloride (2o). White solids 316 
mg, yield = 56%. 1H NMR (400 MHz, CDCl3): δ 7.78 (d, J = 8.8 Hz, 2H), 7.42-
7.36 (m, 1H), 7.23 (td, J = 8.2, 1.2 Hz, 1H), 7.12 (dd, J = 7.6, 0.4 Hz, 1H), 6.95 
(d, J = 8.8 Hz, 2H), 3.89 (s, 3H) ppm.
(2-Bromo-5-fluorophenyl)(4-methoxyphenyl)methanone (3p). Started 
from anisole (1a) and 2-bromo-5-fluorobenzoyl chloride (2p). White solids 438 
mg, yield = 74%. 1H NMR (400 MHz, CDCl3): δ 7.79 (d, J = 8.8 Hz, 2H), 7.61-
7.58 (m, 1H), 7.06 (d, J = 7.6 Hz, 2H), 6.95 (d, J = 9.2 Hz, 2H), 3.89 (s, 3H) ppm
General method for demethylation of 3b, 3d-l and 3n-p with aluminum tri-
chloride (4b, 4d-l and 4n-p).21
AlCl3 (2.5 equiv.) was slowly added to a solution of 3b, 3d-l and 3n-p (1.0 equiv.) 
in toluene (0.15 M) under a N2 atmosphere. The mixture was refluxed at 130 °C 
for 2 h and by TLC (Pet. ether/EtOAc 4/1) full conversion was shown. The cooled 
mixture was poured into an 3 M HCl (aq.) solution, the organics were extracted 
with ethyl acetate (3 times), washed with brine, dried over MgSO4 and concen-
trated to give the desired 4-(benzoyl)phenols (4b, 4d-l and 4n-p) as solids. 
(2-Bromo-4-hydroxyphenyl)-phenylmethanone (4b). Brownish solids 1.36 
g, yield = 65%. 1H NMR (400 MHz, CDCl3): δ 7.81 (dd, J = 8.4, 1.2 Hz, 2H), 7.60 
(t, J = 7.4 Hz, 1H), 7.46 (t, J = 7.6 Hz, 2H), 7.27 (d, J = 6.8 Hz, 1H), 7.16 (d, J = 
2.4 Hz, 1H), 6.86 (dd, J = 8.4, 2.4 Hz, 1H), 6.36 (s br, 1H) ppm.
(2-Fluorophenyl)(4-hydroxyphenyl)methanone (4d).41 White solids 343 
mg, yield = 100%. 1H NMR (400 MHz, CDCl3): δ 7.78 (d, J = 8.4 Hz, 2H), 7.51-
7.48 (m, 2H), 7.26-7.24 (m, 1H), 7.18-7.12 (m, 1H), 6.91 (d, J = 8.4 Hz, 2H), 
6.58 (s br, 1H) ppm.
(2-Chlorophenyl)(4-hydroxyphenyl)methanone (4e).42 White solids 2.17 
g, yield = 95%. 1H NMR (400 MHz, DMSO): δ 10.62 (s, 1H), 7.60-7.56 (m, 3H), 
7.53 (td, J = 8.4, 2.0 Hz, 1H), 7.47 (td, J = 8.4, 1.6 Hz, 1H), 7.42 (dd, J = 7.6, 1.6 
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Hz, 1H), 6.88 (d, J = 8.8 Hz, 2H) ppm.
4-(2-Bromophenyl)(4-hydroxyphenyl)methanone (4f).43 Brown oil, yield 
= quantitative. 1H NMR (400 MHz, CDCl3): δ 7.73 (d, J = 8.4 Hz, 2H), 7.63 (d, 
J = 7.6 Hz, 1H), 7.40 (t, J = 7.6 Hz, 1H), 7.33 (t, J = 8.8 Hz, 1H), 6.89 (d, J = 8.4 
Hz, 2H), 6.69 (s br, 1H) ppm. 
4-(4-Hydroxyphenyl)(2-iodophenyl)methanone (4g). White solids 393 mg, 
yield = 97%. 1H NMR (400 MHz, CDCl3): δ 7.90 (d, J = 8.0 Hz, 1H), 7.71 (d, J 
= 8.8 Hz, 2H), 7.43 (td, J = 7.6, 0.8 Hz, 1H), 7.27 (dd, J = 7.6, 1.6 Hz, 1H), 6.90 
(d, J = 8.8 Hz, 2H) ppm. NMR data in accordance with literature.44
4-(3-Fluorophenyl)(4-hydroxyphenyl)methanone (4h). White solids 172 
mg, yield = 73%. 1H NMR (400 MHz, CDCl3): δ 7.77 (d, J = 8.4 Hz, 2H), 7.53 
(d, J = 8.0 Hz, 1H), 7.48-7.43 (m, 2H), 7.30-7.18 (m, 1H), 6.95 (d, J = 8.0, 0.8 
Hz, 2H) ppm. NMR data in accordance with literature.45
4-(3-Chlorophenyl)(4-hydroxyphenyl)methanone (4i). Off white solids 
2.35 g, yield = 95%. 1H NMR (400 MHz, DMSO): δ 10.54 (s, 1H), 7.71-7.63 (m, 
4H), 7.60-7.53 (m, 2H), 6.90 (dt, J = 8.8, 2.0 Hz, 2H) ppm. NMR data in accor-
dance with literature.46
4-(3-Bromophenyl)(4-hydroxyphenyl)methanone (4j). White solids 168 
mg, yield = 88%. 1H NMR (400 MHz, CDCl3): δ 7.88 (t, J = 1.6 Hz, 1H), 7.77 
(d, J = 8.8 Hz, 2H), 7.70 (dt, J = 8.0, 1.2 Hz, 1H), 7.66 (d, J = 7.6 Hz, 1H), 7.36 
(t, J = 8.0 Hz, 1H), 6.93 (d, J = 8.4 Hz, 2H), 6.92 (s br, 1H) ppm. NMR data in 
accordance with literature.47
4-(4-Hydroxyphenyl)(3-iodophenyl)methanone (4k). Brown solids 209 
mg, yield = 73%. 1H NMR (400 MHz, CDCl3): δ 8.08 (s, 1H), 7.90 (d, J = 8.0 
Hz, 1H), 7.77 (d, J = 8.4 Hz, 2H), 7.70 (d, J = 7.6 Hz, 1H), 7.22 (t, J = 8.0 Hz, 
1H), 6.93 (d, J = 8.8 Hz, 2H), 5.74 (s br, 1H) ppm. NMR data in accordance with 
literature.46
4-(4-Hydroxyphenyl)(4-methylphenyl)methanone (4l).48 Brown solids 
2.03 g, yield = 94%. 1H NMR (400 MHz, DMSO): δ 10.39 (s,1H), 7.64 (d, J = 
8.4 Hs, 2H), 7.57 (d, J = 8.0 Hz, 2H), 7.33 (d, J = 8.0 Hz, 2H), 7.88 (d, J = 8.8 
Hz, 2H), 2.39 (s, 3H) ppm.
4-(4-Chlorophenyl)(4-hydroxyphenyl)methanone (4n). Off white solids 
821 mg, yield = 85%. 1H NMR (400 MHz, CDCl3): δ 7.76 (d, J = 8.8 Hz, 2H), 
7.71 (d, J = 8.8 Hz, 2H), 7.46 (d, J = 8.4 Hz, 2H), 6.93 (d, J = 8.8 Hz, 2H), 6.15 
(s br, 1H). NMR data in accordance with literature.49
(2-Bromo-3-fluorophenyl)(4-hydroxyphenyl)methanone (4o). Off white 
solids 301 mg, yield = 100 %. 1H NMR (400 MHz, CDCl3): δ 8.32 (s br, 1H), 
7.72 (dd, J = 6.8, 2.0 Hz, 2H), 7.41-7.35 (m, 1H), 7.22 (td, J = 8.4, 2.0 Hz, 1H), 
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(2-Bromo-5-fluorophenyl)(4-hydroxyphenyl)methanone (4p). White sol-
ids 236 mg, yield = 56%. 1H NMR (400 MHz, CDCl3): δ 8.49 (s br, 1H), 7.72 (dt, 
J = 8.8, 2.4 Hz, 2H), 7.60-7.57 (m, 1H), 7.09-7.04 (m, 2H), 6.93 (dd, J = 8.8, 2.4 
Hz, 2H) ppm.
(3-Bromo-4-hydroxyphenyl)-phenylmethanone (4c). At -78 oC 3c (873 
mg, 3.00 mmol, 1.0 equiv.) was dissolved in 20 mL of CH2Cl and a solution of 
BBr3 in CH2Cl (1 M) (15 mL, 15 mmol, 5 equiv.) was added under a N2 atmo-
sphere. The mixture was stirred at room temperature and after 24 h cooled again 
to -78 oC and quenched with water. The organics were extracted with CH2Cl2 (4 
times) from the aqueous layer, dried over MgSO4 and concentrated. The pure 4c 
(584 mg of a yellowish solid yield = 70%) was obtained by column chromatog-
raphy eluting with a gradient of CH2Cl2 to 2% MeOH in CH2Cl2. 
1H NMR (400 
MHz, CDCl3): δ 8.03 (d, J = 2.0 Hz, 1H), 7.77-7.18 (m, 3H), 7.59 (tt, J = 7.6, 
1.6 Hz, 1H), 7.50 (t, J = 7.6 Hz, 2H), 7.10 (d, J = 8.4 Hz, 1H), 6.00 (s, 1H) ppm.
General method for O-alkylation yielding compounds 5a-q. 
To a solution of 5a-q (1.0 eq.) in DMF (0.2 M) was added K2CO3 (2.0 equiv.) 
and 2-methyl bromoacetate (2.0 equiv.). The mixture was stirred at 65 °C for 24 
h, after which it was cooled to room temperature and the mixture was separated 
between ethyl acetate and water. The organic layer was washed with water (3 
times), brine, dried over MgSO4, and concentrated. This gave the desired O-al-
kylated products (5a-q) as one spot on TLC (1 EtOAc/4 Pet. ether) and used 
as crude material in the next reaction or purified as specified in the individual 
examples.
Methyl 2-(4-benzoylphenoxy)acetate (5a).50 Recrystallized from EtOAc/
Pet. ether. White solids 1.52 g, yield = 56%. 1H NMR (400 MHz, CDCl3): δ 7.83 
(d, J = 8.8 Hz, 2H), 7.76 (d, J = 8.0 Hz, 2H), 7.57 (t, J = 8.0 Hz, 1H), 7.48 (t, J = 
8.0 Hz, 2H), 6.97 (d, J = 8.8 Hz, 2H), 4.73 (s, 2H), 3.83 (s, 3H) ppm.
Methyl 2-(4-benzoyl-3-bromophenoxy)acetate (5b). Used as crude in the 
next reaction, yield = quantitative. 1H NMR (400 MHz, CDCl3): δ 7.79 (d, J = 
7.6 Hz, 2H), 7.59 (t, J = 7.2 Hz, 1H), 7.46 (t, J = 7.6 Hz, 2H), 7.32 (d, J = 8.4 Hz, 
1H), 7.20 (d, J = 1.6 Hz, 1H), 6.93 (dd, J = 8.4, 1.6 Hz, 1H), 4.69 (s, 2H), 3.83 
(s, 3H) ppm. 
Methyl 2-(4-benzoyl-2-bromophenoxy)acetate (5c). Started from 4c (2.11 
mmol) and this gave 606 mg of the product as a colorless oil after column chro-
matography using the gradient 1/1 Pet. ether/CH2Cl2 to CH2Cl2, yield = 82%. 
1H 
NMR (400 MHz, CDCl3): δ 8.08 (d, J
 = 2.0 Hz, 1H), 7.78-7.74 (m, 3H), 7.60 (t, 
J = 7.6 Hz, 1H), 7.49 (t, J = 7.6 Hz, 2H), 6.83 (d, J = 7.6 Hz, 1H), 4.82 (s, 2H), 
3.83 (s, 3H) ppm.
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Methyl 2-(4-(2-fluorobenzoyl)phenoxy)acetate (5d). Used as crude in the 
next reaction, yield = quantitative. 1H NMR (400 MHz, CDCl3): δ 7.84 (d, J = 8.4 
Hz, 2H), 7.54-7.48 (m, 2H), 7.28-7.24 (m, 1H), 7.16 (t, J = 9.2 Hz, 1H), 6.96 (d, 
J = 8.8 Hz, 2H), 4.72 (s, 2H), 3.82 (s, 3H) ppm.
Methyl 2-(4-(2-chlorobenzoyl)phenoxy)acetate (5e). Colorless oil 2.36 g, 
yield = 83%. 1H NMR (400 MHz, DMSO): δ 7.76 (dt, J = 8.8, 1.6 Hz, 2H), 7.61-
7.54 (m, 2H), 7.51-7.45 (m, 2H), 7.09 (dt, J = 8.8, 2.0 Hz, 2H), 4.94 (s, 2H), 3.70 
(s, 3H) ppm.
Methyl 2-(4-(2-bromobenzoyl)phenoxy)acetate (5f). Colorless oil after 
column chromatography using the gradient 4/1 Pet. ether/EtOAc 341 mg, yield = 
75%. 1H NMR (400 MHz, CDCl3): δ 7.79 (d, J = 8.8 Hz, 2H), 7.64 (d, J = 7.6 Hz, 
1H), 7.41 (t, J = 7.2 Hz, 1H), 7.36-7.30 (m, 2H), 6.94 (d, J = 8.8 Hz, 2H), 4.71 (s, 
2H), 3.82 (s, 3H) ppm.
Methyl 2-(4-(2-iodobenzoyl)phenoxy)acetate (5g). Used as crude material 
in the next reaction, brown oil 444 mg, yield = 93%. 1H NMR (400 MHz, CDCl3): 
δ 7.91 (d, J = 8.0 Hz, 1H), 7.78 (d, J = 8.8 Hz, 2H), 7.44 (t, J = 7.6 Hz, 1H), 7.27 
(dd, J = 7.6, 1.2 Hz, 1H), 7.17 (td, J = 7.6, 1.6 Hz, 1H), 6.95 (d, J = 9.2 Hz, 2H), 
4.73 (s, 2H), 3.81 (s, 3H) ppm.
Methyl 2-(4-(3-fluorobenzoyl)phenoxy)acetate (5h). Used as crude mate-
rial in the next reaction, brown oil 244 mg, yield = quantitative. 1H NMR (400 
MHz, CDCl3): δ 7.82 (dd, J = 8.8, 2.8 Hz, 2H), 7.52 (dd, J = 7.6, 0.8 Hz, 1H), 
7.48-7.44 (m, 2H), 7.28 (d, J = 7.2 Hz, 1H), 6.98 (dd, J = 8.8, 2.4 Hz, 2H), 4.72 
(s, 2H), 3.82 (s, 3H) ppm.
Methyl 2-(4-(3-chlorobenzoyl)phenoxy)acetate (5i). Washed crude mixture 
with Pet. ether, off white solids 2.86 g, yield = 93%. 1H NMR (400 MHz, DMSO): 
δ 7.78-7.70 (m, 3H), 7.68 (t, J = 1.6 Hz, 1H), 7.62 (dt, J = 8.0, 1.6 Hz, 1H), 7.58 
(t, J = 7.6 Hz, 1H), 7.11 (d, J = 8.8 Hz, 2H), 4.95 (s, 2H), 3.72 (s, 3H) ppm.
Methyl 2-(4-(3-bromobenzoyl)phenoxy)acetate (5j). Washed crude mix-
ture with Pet. ether, off white solids 253 mg, yield = 99%. 1H NMR (400 MHz, 
CDCl3): δ 7.89 (t, J = 2.0 Hz, 1H), 7.81 (d, J = 8.8 Hz, 2H), 7.72-7.66 (m, 2H), 
7.36 (t, J = 7.6 Hz, 1H), 6.98 (d, J = 8.8 Hz, 2H), 4.74 (s, 2H), 3.84 (s, 3H) ppm.
Methyl 2-(4-(3-iodobenzoyl)phenoxy)acetate (5k). Washed crude mix-
ture with Pet. ether, off white solids 243 mg, yield = 99%. 1H NMR (400 MHz, 
CDCl3): δ 8.08 (t, J = 1.6 Hz, 1H), 7.90 (d, J = 7.6 Hz, 1H), 7.81 (dt, J = 8.2, 2.0 
Hz, 2H), 7.70 (dt, J = 8.0, 1.2 Hz, 1H), 7.22 (t, J = 8.0 Hz, 1H), 6.98 (d, J = 8.8 
Hz, 2H), 4.73 (s, 2H), 3.83 (s, 3H) ppm.
Methyl 2-(4-(4-methylbenzoyl)phenoxy)acetate (5l). Washed crude mix-
ture with Pet. ether, off white solids 2.71 g, yield = 99%. 1H NMR (400 MHz, 






Experimental section   |  143
2H), 6.96 (d, J = 8.4 Hz, 2H), 4.72 (s, 2H), 3.83 (s, 3H), 2.44 (s, 3H) ppm.
Methyl 2-(4-(4-fluorobenzoyl)phenoxy)acetate (5m). Started from the 
commercially available 4m. Washed crude mixture with Pet. ether, white solids 
2.53 g, yield = 95%. 1H NMR (400 MHz, DMSO): δ 7.80-7.76 (m, 2H), 7.73 (dt, 
J = 8.8, 2.0 Hz, 2H), 7.38 (tt, J = 9.2, 2.4 Hz, 2H), 7.09 (dt, J = 8.8, 2.0 Hz, 2H), 
4.95 (s, 2H), 3.72 (s, 3H) ppm.
Methyl 2-(4-(4-chlorobenzoyl)phenoxy)acetate (5n). Used as crude materi-
al in the next reaction, yield was quantitative. 1H NMR (400 MHz, CDCl3): δ 7.80 
(d, J = 8.8 Hz, 2H), 7.71 (d, J = 8.4 Hz, 2H), 7.46 (d, J = 8.4 Hz, 2H), 6.98 (d, J 
= 8.8 Hz, 2H), 4.73 (s, 2H), 3.83 (s, 3H) ppm. 
Methyl 2-(4-(2-bromo-3-fluorobenzoyl)phenoxy)acetate (5o). Off white 
solids 275 mg, yield = 73%. 1H NMR (400 MHz, CDCl3): δ 7.77 (d, J = 8.8 Hz, 
2H), 7.43-7.38 (m, 1H), 7.24 (td, J = 8.4, 1.2 Hz, 1H), 7.11 (d, J = 7.6 Hz, 1H), 
6.95 (d, J = 8.8 Hz, 2H), 4.73 (s, 2H), 3.79 (s, 3H) ppm.
Methyl 2-(4-(2-bromo-5-fluorobenzoyl)phenoxy)acetate (5p). Used as 
crude material in the next reaction, yield = 98%. 1H NMR (400 MHz, CDCl3): δ 
7.78 (d, J = 8.4 Hz, 2H), 7.62-7.57 (m, 1H), 7.10-7.04 (m, 2H), 6.96 (d, J = 8.4 
Hz, 2H), 4.73 (s, 2H), 3.80 (s, 3H) ppm.
Methyl 2-((9-oxo-9H-fluoren-3-yl)oxy)acetate (5q). Started from 4b (2.11 
mmol) and this gave 309 mg as yellow solids after column chromatography using 
CH2Cl2 as an eluent, yield = 92%. 
1H NMR (400 MHz, CDCl3): δ 7.64-7.60 (m, 
2H), 7.48-7.45 (m, 2H), 7.33-7.27 (m, 1H), 7.07 (d, J = 2.4 Hz, 1H), 6.71 (dd, J 
= 8.0, 2.0 Hz, 1H), 4.74 (s, 2H), 3.84 (s, 3H) ppm.
General saponification procedure to obtain acids 6a-q. 
To a solution of 5a-i (1.0 eq.) in a mixture of equal amounts of THF and methanol 
(0.5 M solution) was added an aqueous 1 M solution of LiOH (5.0 eq.). After 1 
hour at 100 oC the saponification of the esters 6a-q was completed shown by TLC 
(EtOAc/Pet. ether 1/3). While the mixture was cooled on ice, the pH was adjusted 
to pH = 1 using a 2 M HCl solution (aq.). The resulting precipitate was collected 
by filtration, washed with water, Pet. ether and co-evaporated with acetone to 
dryness. 
2-(4-Benzoylphenoxy)acetic acid (6a).51 White solids 1.37 g, yield = 95%. 
1H NMR (400 MHz, CDCl3 + drop of DMSO): δ 9.50 (s br, 1H), 7.82 (d, J = 8.4 
Hz, 2H), 7.75 (d, J = 7.6 Hz, 2H), 7.58 (t, J = 7.6 Hz, 1H), 7.47 (t, J = 7.6 Hz, 
2H), 7.00 (d, J = 8.8 Hz, 2H), 4.69 (s, 2H) ppm.
2-(4-Benzoyl-2-bromophenoxy)acetic acid (6b). White solids 548 mg, 
yield = 95%. 1H NMR (400 MHz, CDCl3): δ 8.06 (d, J = 2.0 Hz, 1H), 7.77-7.34 
(m, 3H), 6.60 (t, J = 7.6 Hz, 1H), 7.50 (t, J = 8.0 Hz, 2H), 6.89 (d, J = 8.4 Hz, 
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1H), 4.78 (s, 2H) ppm.
2-(4-Benzoyl-3-bromophenoxy)acetic acid (6c). Brown solids 1.28 g, yield 
= 78%. 1H NMR (400 MHz, CDCl3): δ 8.88 (s, br, 1H), 7.80 (d, J = 8.0 Hz, 2H), 
7.63-7.58 (m, 1H), 7.50-7.44 (m, 2H), 7.34 (d, J = 8.4 Hz, 1H), 7.23 (d, J = 2.4 
Hz, 1H), 6.96 (dd, J = 8.8, 2.4 Hz, 1H), 4.76 (s, 2H) ppm.
2-(4-(2-Fluorobenzoyl)phenoxy)acetic acid (6d). Off white solids 312 mg, 
yield = 67%. 1H NMR (400 MHz, DMSO): δ 13.12 (s br, 1H), 7.73 (d, J = 8.4 Hz, 
2H), 7.67-7.61 (m, 1H), 7.53 (td, J = 7.8, 1.2 Hz, 1H), 7.40-7.34 (m, 2H), 7.07 (d, 
J = 8.8 Hz, 2H), 4.82 (s, 2H) ppm. 
2-(4-(2-Chlorobenzoyl)phenoxy)acetic acid (6e). White solids 1.77 g, yield 
= 79%. 1H NMR (400 MHz, DMSO): δ 7.67 (dt, J = 8.8, 2.0 Hz, 2H), 7.62-7.53 
(m, 2H), 7.51-7.43 (m, 2H), 7.05 (d, J = 9.2 Hz, 2H), 4.81 (s, 2H) ppm.
2-(4-(2-Bromobenzoyl)phenoxy)acetic acid (6f). Off white solids 8.60 g, 
yield = 86%. 1H NMR (400 MHz, CDCl3): δ 9.17 (s, br, 1H), 7.80 (d, J = 8.4 Hz, 
2H), 7.63 (d, J = 8.0 Hz, 1H), 7.43-7.30 (m, 3H), 6.95 (d, J = 8.8 Hz, 2H), 4.75 
(s, 2H) ppm.
2-(4-(2-Iodobenzoyl)phenoxy)acetic acid (6g). White solids 302 mg, yield 
= 71%. 1H NMR (400 MHz, DMSO): δ 7.96 (d, J = 7.6 Hz, 1H), 7.64 (d, J = 8.8 
Hz, 2H), 7.54 (t, J = 7.6 Hz, 1H), 7.35 (d, J = 7.6 Hz, 1H), 7.28 (t, J = 7.6 Hz, 
1H), 7.06 (d, J = 8.8 Hz, 2H), 4.81 (s, 2H) ppm.
2-(4-(3-Fluorobenzoyl)phenoxy)acetic acid (6h). Brown solids 94 mg, 
yield = 45%. 1H NMR (400 MHz, DMSO): δ 7.76 (d, J = 8.8 Hz, 2H), 7.63-7.56 
(m, 1H), 7.52-7.46 (m, 3H), 7.08 (d, J = 9.2 Hz, 2H), 4.82 (s, 2H) ppm. 
2-(4-(3-Chlorobenzoyl)phenoxy)acetic acid (6i). White solids 2.65 g, yield 
= 97%. 1H NMR (400 MHz, DMSO): δ 7.75-7.69 (m, 3H), 7.67 (s, 1H), 7.61 (t, J 
= 7.6 Hz, 1H), 7.57 (t, J = 7.6 Hz, 1H), 7.04 (d, J = 8.8 Hz, 2H), 4.71 (s, 2H) ppm.
2-(4-(3-Bromobenzoyl)phenoxy)acetic acid (6j). White solids 146 mg, 
yield = 61%. 1H NMR (400 MHz, DMSO): δ 7.86 (d, J = 8.0 Hz, 1H), 7.81 (s, 
1H), 7.74 (d, J = 8.0 Hz, 2H), 7.67 (d, J = 7.2 Hz, 1H), 7.51 (t, J = 8.0 Hz, 1H), 
7.08 (J = 8.0 Hz, 2H), 4.81 (s, 2H) ppm. 
2-(4-(3-Iodobenzoyl)phenoxy)acetic acid (6k). White solids 118 mg, yield 
= 51%. 1H NMR (400 MHz, DMSO): δ 8.01 (d, J = 7.6 Hz, 1H), 7.97 (s, 1H), 
7.73 (d, J = 8.4 Hz, 2H), 7.67 (d, J = 7.6 Hz, 1H), 7.35 (t, J = 7.6 Hz, 1H), 7.08 
(d, J = 8.8 Hz, 2H), 4.82 (s, 2H) ppm.
2-(4-(4-Methylbenzoyl)phenoxy)acetic acid (6l). Off white solids 2.16 g, 
yield = 81%. 1H NMR (400 MHz, DMSO): δ 7.70 (d, J = 8.8 Hz, 2H), 7.60 (d, 
J = 8.0 Hz, 2H), 7.34 (d, J = 8.0 Hz, 2H), 7.04 (d, J = 9.2 Hz, 2H), 4.76 (s, 2H), 
2.40 (s, 3H) ppm. NMR data in accordance with literature.52
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tallization from MeOH 1.55 g, yield = 64%. 1H NMR (400 MHz, DMSO): δ 
13.20 (s br, 1H), 7.80-7.75 (m, 2H), 7.73 (d, J = 8.8 Hz, 2H), 7.37 (t, J = 8.8 Hz, 
2H), 7.07 (d, J = 8.8 Hz, 2H), 4.81 (s, 2H) ppm.
2-(4-(4-Chlorobenzoyl)phenoxy)acetic acid (6n).53 White solids 730 mg, 
yield 71%. 1H NMR (400 MHz, DMSO): δ 7.73-7.70 (m, 4H), 7.61 (d, J = 7.6 
Hz, 2H), 7.05 (d, J = 8.0 Hz, 2H), 4.74 (s, 2H) ppm.
2-(4-(2-Bromo-3-fluorobenzoyl)phenoxy)acetic acid (6o).White solids 225 
mg, yield = 85%. 1H NMR (400 MHz, CDCl3): δ 8.89 (s br, 1H), 7.80 (d, J = 8.8 
Hz, 2H), 7.43-7.37 (m, 1H), 7.25 (td, J = 8.4, 1.6 Hz, 1H), 7.12 (d, J = 7.2 Hz, 
1H), 6.97 (d, J = 8.8 Hz, 2H), 4.77 (s, 2H) ppm.
2-(4-(2-Bromo-5-fluorobenzoyl)phenoxy)acetic acid (6p). White solid 231 
mg, yield = 83%. 1H NMR (400 MHz, CDCl3): δ 10.07 (s, 1H), 7.78 (d, J = 8.8 
Hz, 2H), 7.61-7.56 (m, 1H), 7.10-7.03 (m, 2H), 6.96 (d, J = 8.8 Hz, 2H), 4.75 (s, 
2H) ppm.
2-((9-Oxo-9H-fluoren-3-yl)oxy)acetic acid (6q). Yellow solids 255 mg, 
yield = 87%. 1H NMR (400 MHz, DMSO): δ 13.20 (br s, 1H), 7.81 (d, J = 7.6 
Hz, 1H), 7.62-7.54 (m, 3H), 7.46 (s, 1H), 7.38 (t, J = 7.6 Hz, 1H), 6.84 (d, J = 6.8 
Hz, 1H), 4.87 (s, 2H) ppm.
General peptide coupling method (7a-r and 7f1-f11). 
To a solution of 6a-r (1.0 equiv.) and Et3N (1.5 equiv.) in DMF (0.125 M) was 
added 3-aminopyridine (1.1 equiv.) and HATU (1.1 equiv.) or EDCI*HCl (7e 
and 7l). The mixture was stirred at room temperature for 20 h. The mixture was 
separated between ethyl acetate and water. The organic layer was washed with 
water twice, brine, dried over MgSO4 and concentrated. Column chromatography 
using mixtures of 5% methanol/dichloromethane or EtOAc:Pet.ether 2:1 gave the 
pure desired products.
2-(4-Benzoylphenoxy)-N-(pyridin-3-yl)acetamide (7a).18 White solid, 211 
mg, yield = 69%. 1H NMR (400 MHz, CDCl3): δ 8.70 (s br, 1H), 8.44 (s br, 1H), 
8.40 (s br, 1H), 8.22 (d, J = 8.0 Hz, 1H), 7.89 (d, J = 8.4 Hz, 2H), 7.77 (d, J = 7.6 
Hz, 2H), 7.60 (t, J = 7.6 Hz, 1H), 7.50 (t, J = 7.6 Hz, 2H), 7.34 (d, J = 7.2 Hz, 
1H), 7.09 (d, J = 8.8 Hz, 2H), 4.74 (s, 2H) ppm; 13C NMR (101 MHz, CDCl3): δ 
195.3, 166.4, 160.2, 137.4, 132.4, 132.2, 131.2, 129.5, 128.1, 127.8, 114.1, 67.2 
ppm.; HPLC tR = 7.28 min. purity 100%; ESI-MS: 333.13 [M+H]
+.
2-(4-Benzoyl-3-bromophenoxy)-N-(pyridin-3-yl)acetamide (7b). White 
solid, 158 mg, yield = 51%. 1H NMR (400 MHz, CDCl3): δ 8.71 (s, 1H), 8.43 (d, 
J = 4.8 Hz, 2H), 8.24 (d, J = 8.0 Hz, 1H), 7.80 (d, J = 7.6 Hz, 2H), 7.61 (t, J = 7.6 
Hz, 1H), 7.47 (t, J = 7.8 Hz, 2H), 7.39-7.31 (m, 3H), 7.03 (d, J = 8.4 Hz, 1H), 4.71 
(s, 2H) ppm; HPLC tR = 7.15 min. purity 98%; ESI-MS: 411.13 [M+H]
+.
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2-(4-Benzoyl-2-bromophenoxy)-N-(pyridin-3-yl)acetamide (7c). White 
solid, 293 mg, yield = 71%. 1H NMR (400 MHz, CDCl3): δ 8.80 (s, 1H), 8.74 (d, 
J = 2.4 Hz, 1H), 8.44 (d, J = 4.8 Hz, 1H), 8.27-8.23 (m, 1H), 8.15 (d, J = 1.6 Hz, 
1H), 7.83 (dd, J = 8.4, 2.0 Hz, 1H), 7.80-7.74 (m, 2H), 7.63(t, J = 7.6 Hz, 1H), 
7.52 (t, J = 7.6 Hz, 2H), 7.35 (dd, J = 8.4, 4.8 Hz, 1H), 7.00 (d, J = 8.8 Hz, 1H), 
4.78 (s, 2H) ppm; HPLC tR = 7.29 min. purity 100%; ESI-MS: 411.07 [M+H]
+.
2-[4-(2-Fluorobenzoyl)phenoxy]-N-(pyridin-3-yl)acetamide (7d). White 
solid, 150 mg, yield = 78%. 1H NMR (400 MHz, CDCl3): δ 8.71 (s, 2H), 8.39 (d, 
J = 3.6 Hz, 1H), 8.20 (d, J = 8.0 Hz, 1H), 7.84 (d, J = 8.4 Hz, 2H), 7.55-7.49 (m, 
2H), 7.31-7.24 (m, 2H), 7.15 (t, J = 8.4 Hz, 1H), 7.02 (d, J = 9.2 Hz, 2H), 4.70 (s, 
2H) ppm; HPLC tR = 6.67 min. purity 98%; ESI-MS: 351.13 [M+H]
+.
2-[4-(2-Chlorobenzoyl)phenoxy]-N-(pyridin-3-yl)acetamide (7e). Used 
EDCI*HCl instead of HATU. White solid, 72 mg, yield = 20%. 1H NMR (400 
MHz, CDCl3): δ 8.70-8.60 (m, 2H), 8.39 (d, J = 4.4 Hz, 1H), 8.19 (d, J = 8.0 Hz, 
1H), 7.81 (d, J = 8.4 Hz, 2H), 7.45-7.28 (m, 5H), 7.02 (d, J = 8.4 Hz, 2H), 4.71 (s, 
2H) ppm; HPLC tR = 7.04 min. purity 100%; ESI-MS: 367.13 [M+H]
+.
2-[4-(2-Bromobenzoyl)phenoxy]-N-(pyridin-3-yl)acetamide (7f). White 
solid, 9 mg, yield = 23%. 1H NMR (400 MHz, CDCl3): δ 8.68 (d, J = 2.0 Hz, 1H), 
8.42 (d, J = 4.4 Hz, 1H), 8.36 (s, 1H), 8.22 (dt, J = 8.4, 0.8 Hz, 1H), 7.85 (d, J = 
8.8 Hz, 2H), 7.65 (dd, J = 7.6, 0.8 Hz, 1H), 7.43 (td, J = 7.4, 1.2 Hz, 1H), 7.38-
7.31 (m, 3H), 7.06 (d, J = 8.8 Hz, 2H), 4.72 (s, 2H) ppm; HPLC tR = 7.09 min. 
purity 98%; ESI-MS: 411.07 [M+H]+.
2-[4-(2-Iodobenzoyl)phenoxy]-N-(pyridin-3-yl)acetamide (7g). White so-
lid, 113 mg, yield = 63%. 1H NMR (400 MHz, CDCl3): δ 8.68 (s, 1H), 8.43 (d, 
J = 4.4 Hz, 1H), 8.34 (s, 1H), 8.23 (d, J = 8.4 Hz, 1H), 7.93 (d, J = 8.0 Hz, 1H), 
7.85 (d, J = 8.4 Hz, 2H), 7,46 (t, J = 7.6 Hz, 1H), 7.33 (dd, J = 8.4 Hz, 4.8 Hz, 
1H), 7.29 (d, J = 7.6 Hz, 1H), 7.20 (td, J = 7.6 Hz, 1.2 Hz, 1H), 7.07 (d, J = 8.8 
Hz, 2H), 4.73 (s, 2H) ppm; HPLC tR = 7.19 min. purity 100%; ESI-MS: 459.00 
[M+H]+.
2-[4-(3-Fluorobenzoyl)phenoxy]-N-(pyridin-3-yl)acetamide (7h). White 
solid, 80 mg, yield = 67%. 1H NMR (400 MHz, CDCl3): δ 8.83 (s, 1H), 8.73 (d, J 
= 2.4 Hz, 1H), 8.39 (d, J = 4.0 Hz, 1H), 8.21 (d, J = 8.8 Hz, 1H), 7.82 (d, J = 8.8 
Hz, 2H), 7.52-7.42 (m, 3H), 7.32-7.27 (m, 2H), 7.04 (d, J = 8.8 Hz, 2H), 4.73 (s, 
2H) ppm; HPLC tR = 6.88 min. purity 100%; ESI-MS: 351.13 [M+H]
+.
2-[4-(3-Chlorobenzoyl)phenoxy]-N-(pyridin-3-yl)acetamide (7i). White 
solid, 319 mg, yield = 87%. 1H NMR (400 MHz, CDCl3): δ 8.72 (d, J = 2.0 Hz, 
1H), 8.44-8.40 (m, 2H), 8.27 (dd, J = 8.4, 2.0 Hz, 1H), 7.88 (d, J = 8.8 Hz, 2H), 
7.74 (t, J = 1.6 Hz, 1H), 7.63 (dt, J = 7.6, 1.6 Hz, 1H), 7.58-7.55 (m, 1H), 7.44 (t, 
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2H) ppm; HPLC tR = 7.33 min. purity 100%; ESI-MS: 367.07 [M+H]
+.
2-[4-(3-Bromobenzoyl)phenoxy]-N-(pyridin-3-yl)acetamide (7j). White 
solid, 63 mg, yield = 25%. 1H NMR (400 MHz, DMSO): δ 10.42 (d, 1H), 8.79 (d, 
J = 2.0 Hz, 1H), 8.30 (d, J = 4.0 Hz, 1H), 8.07 (d, J = 8.4 Hz, 1H), 7.85 (d, J = 
8.0 Hz, 1H), 7.81 (s, 1H), 7.78 (d, J = 8.8 Hz, 2H), 7.67 (d, J = 8.0 Hz, 1H), 7.51 
(t, J = 7.6 Hz, 1H), 7.39-7.36 (m, 1H), 7.18 (d, J = 8.8 Hz, 2H), 4.90 (s, 2H) ppm; 
HPLC tR = 7.42 min. purity 98%; ESI-MS: 411.13 [M+H]
+.
2-[4-(3-Iodobenzoyl)phenoxy]-N-(pyridin-3-yl)acetamide (7k). White so-
lid, 91 mg, yield = 71%. 1H NMR (400 MHz, DMSO): δ 8.79 (d, J = 2.4 Hz, 1H), 
8.30 (dd, J = 4.8, 1.2 Hz, 1H), 8.07 (dt, J = 8.0, 1.6 Hz, 1H), 8.01 (d, J = 8.0 Hz, 
1H), 7.98 (t, J = 1.2 Hz, 1H), 7.77 (d, J = 8.8 Hz, 2H), 7.68 (d, J = 7.6 Hz, 1H), 
7.39-7.33 (m, 2H), 7.17 (d, J = 8.8 Hz, 2H), 4.89 (s, 2H) ppm; HPLC tR = 7.50 
min. purity 98%; ESI-MS: 459.07 [M+H]+.
2-[4-(4-Methylbenzoyl)phenoxy]-N-(pyridin-3-yl)acetamide (7l). Used 
EDCI*HCl instead of HATU. White solid, 81 mg, yield = 26%. 1H NMR (400 
MHz, CDCl3): δ 8.69 (d, J = 1.6 Hz, 1H), 8.45-8.38 (m, 2H), 8.23 (dd, J = 7.2, 1.2 
Hz, 1H), 7.85 (d, J = 8.8 Hz, 2H), 7.68 (d, J = 8.0 Hz, 2H), 7.33 (dd, J = 8.4, 4.8 
Hz, 1H), 7.28 (d, J = 7.2 Hz, 2H), 7.07 (d, J = 8.8 Hz, 2H), 4.73 (s, 2H), 2.45 (s, 
3H) ppm; HPLC tR = 7.09 min. purity 98%; ESI-MS: 347.13 [M+H]
+.
2-(4-(4-Fluorobenzoyl)phenoxy)-N-(pyridin-3-yl)acetamide (7m). White 
solid, 187 mg, yield = 53%. 1H NMR (400 MHz, CDCl3): δ 8.72 (d, J = 2.4 Hz, 
1H), 8.44-8.40 (m, 2H), 8.30-8.23 (m, 1H), 7.85 (d, J = 8.8 Hz, 2H), 7.83-7.77 
(m, 2H), 7.35 (dd, J = 8.4, 4.8 Hz, 1H), 7.17 (t, J = 8.8 Hz, 2H), 7.09 (d, J = 8.8 
Hz, 2H), 4.74 (s, 2H) ppm; HPLC tR = 6.89 min. purity 99%; ESI-MS: 351.13 
[M+H]+.
2-[4-(4-Chlorobenzoyl)phenoxy]-N-(pyridin-3-yl)acetamide (7n).18 White 
solid, 903 mg, yield = 98%. 1H NMR (400 MHz, DMSO): δ 10.41 (s, 1H), 8.79 
(d, J = 2.4 Hz, 1H), 8.30 (dd, J = 4.4, 1.2 Hz, 1H), 8.07 (dt, J = 8.0, 1.6 Hz, 1H), 
7.77 (d, J = 8.8 Hz, 2H), 7.72 (dd, J = 8.8, 2.0 Hz, 2H), 7.62 (d, J = 8.4 Hz, 2H), 
7.38 (dd, J = 8.4, 4.8 Hz, 1H), 7.17 (d, J = 8.8 Hz, 2H), 4.89 (s, 2H) ppm; HPLC 
tR = 7.27 min. purity 100%; ESI-MS: 367.13 [M+H]
+. 
2-[4-(2-Bromo-3-fluorobenzoyl)phenoxy]-N-(5-methoxypyridin-3-yl)
acetamide (7o).  White solid, 69 mg, yield = 25%. 1H NMR (400 MHz, CDCl3): 
δ 8.68 (d, J = 2.0 Hz, 1H), 8.42 (d, J = 4.4 Hz, 1H), 8.37 (s, 1H), 8.22 (d, J = 8.4 
Hz, 1H), 7.85 (d, J = 8.4 Hz, 2H), 7.44-7.39 (m, 1H), 7.33 (dd, J = 8.2, 4.8 Hz, 
1H), 7.26 (t, J = 8.0 Hz, 1H), 7.13 (d, J = 7.6 Hz, 1H), 7.07 (d, J = 8.8 Hz, 2H), 
4.72 (s, 2H) ppm; HPLC tR = 7.25 min. purity 98%; ESI-MS: 429.07 [M+H]
+.
2-[4-(2-Bromo-5-fluorobenzoyl)phenoxy]-N-(5-methoxypyridin-3-yl)
acetamide (7p). White solid, 108 mg, yield = 39%. 1H NMR (400 MHz, CDCl3): 
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δ 8.67 (s, 1H), 8.43 (d, J = 4.4 Hz, 1H), 8.28 (s, 1H), 8.21 (d, J = 8.4 Hz, 1H), 
7.86 (d, J = 8.8 Hz, 2H), 7.61 (dd, J = 8.4, 4.8 Hz, 1H), 7.33 (dd, J = 8.0, 4.8 Hz, 
1H), 7.14-7.03 (m, 4H), 4.73 (s, 2H) ppm; HPLC tR = 7.22 min. purity 100%; 
ESI-MS: 429.07 [M+H]+.
2-[(9-Oxo-9H-fluoren-3-yl)oxy]-N-(pyridin-3-yl)acetamide (7q). Started 
from 4q and 3-aminopyridine. Yellow solid, 170 mg, yield = 51%. 1H NMR (400 
MHz, DMSO): δ 10.52 (s, 1H), 8.89 (d, J = 2.4 Hz, 1H), 8.37 (dd, J = 4.8, 1.2 Hz, 
1H), 8.17 (d, J = 8.4 Hz, 1H), 7.81 (d, J = 7.2 Hz, 1H), 7.65-7.55 (m, 3H), 7.53-
7.47 (m, 2H), 7.39(t, J = 7.2 Hz, 1H), 6.95 (dd, J = 8.0, 2.0 Hz, 1H), 4.95 (s, 2H) 
ppm; HPLC tR = 6.73 min. purity 99%; ESI-MS: 331.07 [M+H]
+.
2-[(1-Bromonaphthalen-2-yl)oxy]-N-(pyridin-3-yl)acetamide (7r).21 Whi-
te solid, 235 mg, yield = 74%. 1H NMR (400 MHz, CDCl3): δ 9.07 (s br, 1H), 
8.77 (d, J = 2.4 Hz, 1H), 8.42 (dd, J = 4.8, 1.2 Hz, 1H), 8.28 (ddd, J = 8.4 Hz, 1.2, 
1.2 Hz, 1H), 8.24 (d, J = 8.8 Hz, 1H), 7.89 (d, J = 8.8 Hz, 1H), 7.84 (d, J = 8.0 
Hz, 1H), 7.65 (dd, J = 6.8, 0.8 Hz, 1H), 7.49 (dd, J = 7.2, 0.8 Hz, 1H), 7.34 (dd, 
J = 8.4, 3.6 Hz, 1H), 7.25 (d, J = 8.4 Hz, 1H), 4.83 (s, 2H); 13C NMR (101 MHz, 
CDCl3): δ 166.2, 151.2, 145.9, 141.4, 134.0, 132.8, 130.6, 129.8, 128.4, 128.3, 
127.0, 126.3, 125.5, 123.8, 114.7, 109.9, 69.0 ppm. HPLC tR = 7.95 min. purity 
99%; ESI-MS: 357.00 [M+H]+.
2-[4-(2-Bromobenzoyl)phenoxy]-N-(6-methylpyridin-3-yl)acetamide 
(7f1). Started from 6f and 5-amino-2-methylpyridine. White solid, 47 mg, yield 
= 73%. 1H NMR (400 MHz, CDCl3): δ 8.54 (d, J = 2.4 Hz, 1H), 8.35 (s, 1H), 8.07 
(dd, J = 8.4, 2.4 Hz, 1H), 7.84 (d, J = 8.8 Hz, 2H), 7.65 (d, J = 7.6 Hz, 1H), 7.43 
(td, J = 7.2, 0.8 Hz, 1H), 7.37-7.33 (m, 2H), 7.17 (d, J = 8.4 Hz, 1H), 7.05 (d, J 
= 8.8 Hz, 2H), 4.70 (s, 2H), 2.54 (s, 3H) ppm; HPLC tR = 7.09 min. purity 99%; 
ESI-MS: 425.07 [M+H]+.
2-[4-(2-Bromobenzoyl)phenoxy]-N-(6-methoxypyridin-3-yl)acetamide 
(7f2). Started from 6f and 5-amino-2-methoxypyridine. White solid, 50 mg, yield 
= 94%. 1H NMR (400 MHz, CDCl3): δ 8.31-8.20 (m, 2H), 7.91 (dd, J = 7.8, 2.0 
Hz, 1H), 7.83 (d, J = 8.4 Hz, 2H), 7.64 (d, J = 7.6 Hz, 1H), 7.42 (t, J = 7.2 Hz, 
1H), 7.37-7.32 (m, 2H), 7.04 (d, J = 8.8 Hz, 2H), 6.75 (d, J = 8.8 Hz, 1H), 4.69 
(s, 2H), 3.92 (s, 3H) ppm; HPLC tR = 9.06 min. purity 98%; ESI-MS: 441.07 
[M+H]+.
2-[4-(2-Bromobenzoyl)phenoxy]-N-(6-chloropyridin-3-yl)acetamide 
(7f3). Started from 6f and 5-amino-2-chloropyridine. Yellow solid, 51 mg, yield 
= 82%. 1H NMR (400 MHz, CDCl3): δ 8.47 (d, J = 2.8 Hz, 1H), 8.30 (s, 1H), 
8.21 (dd, J = 8.8, 2.8 Hz, 1H), 7.85 (d, J = 8.0 Hz, 2H), 7.65 (d, J = 8.0 Hz, 1H), 
7.43- 7.32 (m, 4H), 7.05 (d, J = 8.8 Hz, 2H), 4.71 (s, 2H) ppm; HPLC tR = 9.65 
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2-[4-(2-Bromobenzoyl)phenoxy]-N-(5-methylpyridin-3-yl)acetamide 
(7f4). Started from 6f and 3-amino-5-methylpyridine. White solid, 55 mg, yield 
= 86%. 1H NMR (400 MHz, CDCl3): δ 8.47 (d, J = 2.0 Hz, 1H), 8.40 (s, 1H), 
8.24 (s, 1H), 8.04 (s, 1H), 7.83 (dd, J = 7.8, 2.0 Hz, 2H), 7.65 (dd, J = 7.2, 0.8 
Hz, 1H), 7.43 (td, J = 7.0, 1.2 Hz, 1H), 7.37-7.33 (m, 2H), 7.05 (d, J = 8.8 Hz, 
2H), 4.71 (s, 2H), 2.36 (s, 3H) ppm. HPLC tR = 7.18 min. purity 99%; ESI-MS: 
425.07 [M+H]+. 
2-[4-(2-Bromobenzoyl)phenoxy]-N-(5-methoxypyridin-3-yl)acetamide 
(7f5). Started from 6f and 3-amino-5-methoxypyridine. White solid, 274 mg, 
yield = 100%. 1H NMR (400 MHz, CDCl3): δ 8.78 (s, 1H), 8.23 (d, J = 1.6 Hz, 
1H), 8.09 (d, J = 2.4 Hz, 1H), 7.90 (t, J = 2.4 Hz, 1H), 7.80 (dt, J = 9.2, 2.0 Hz, 
2H), 7.63 (dd, J = 7.8, 1.2 Hz, 1H), 7.41 (td, J = 7.8, 1.2 Hz, 1H), 7.34 (td, J = 
7.8, 2.0 Hz, 1H), 7.30 (dd, J = 7.6, 2.0 Hz, 1H), 7.02 (dt, J = 8.8, 2.4 Hz, 2H), 
4.70 (s, 2H), 3.85 (s, 3H) ppm. HPLC tR = 7.44 min. purity 99%; ESI-MS: 441.07 
[M+H]+.  
2-[4-(2-Bromobenzoyl)phenoxy]-N-(4-methylpyridin-3-yl)acetamide 
(7f6). Started from 6f and 3-amino-4-methylpyridine. White solid, 90 mg, yield 
= 70%. 1H NMR (400 MHz, CDCl3): δ 8.92 (s, 1H), 8.34 (d, J = 4.4 Hz, 1H), 8.28 
(s, 1H), 7.84 (d, J = 8.8 Hz, 2H), 7.64 (d, J = 7.6 Hz, 1H), 7.43 (td, J = 7.2, 0.8 
Hz, 1H), 7.35 (td, J = 7.8, 2.0 Hz, 1H), 7.33 (dd, J = 7.4, 2.0 Hz, 1H), 7.16 (d, J 
= 4.8 Hz, 1H), 7.05 (d, J = 8.8 Hz, 2H), 4.76 (s, 2H), 2.25 (s, 3H) ppm. HPLC tR 
= 7.05 min. purity 100%; ESI-MS: 425.13 [M+H]+.   
2-[4-(2-Bromobenzoyl)phenoxy]-N-(4-methoxypyridin-3-yl)acetamide 
(7f7). Started from 6f and 3-amino-4-methoxypyridine. Yellow solid, 35 mg, 
yield = 72%. 1H NMR (400 MHz, CDCl3): δ 9.48 (s, 1H), 8.66 (s, 1H), 8.33 (d, 
J = 5.2 Hz, 1H), 7.85 (d, J = 8.8 Hz, 2H), 7.65 (d, J = 8.0 Hz, 1H), 7.44-7.32 (m, 
3H), 7.05 (d, J = 8.8 Hz, 2H), 6.85 (d, J = 5.6 Hz, 1H), 4.72 (s, 2H), 3.95 (s, 3H) 
ppm. HPLC tR = 7.13 min. purity 99%; ESI-MS: 441.13 [M+H]
+.   
2-(4-(2-Bromobenzoyl)phenoxy)-N-(quinolin-3-yl)acetamide (7f8). Star-
ted from 6f and 3-aminoquinoline. White solid, 44 mg, yield = 83%. 1H NMR 
(400 MHz, CDCl3): δ 8.85 (d, J = 2.4 Hz, 1H), 8.79 (s, 1H), 8.60 (s, 1H), 8.06 (d, 
J = 8.4 Hz, 1H), 7.86-7.81 (m, 3H), 7.68-7.63 (m, 2H), 7.55 (t, J =8.0 Hz, 1H), 
7.40 (t, J = 7.6 Hz, 1H), 7.37-7,31 ( m, 2H), 7.07 (d, J = 7.6 Hz, 2H), 4.76 (s, 2H) 
ppm. HPLC tR = 8.10 min. purity 99%; ESI-MS: 461.07 [M+H]
+.
2-[4-(2-Bromobenzoyl)phenoxy]-N-(6-chloropyridazin-3-yl)acetamide 
(7f9). Started from 6f and 3-amino-6-chloro-pyridazine. White solid, 32 mg, 
yield = 6%. 1H NMR (400 MHz, CDCl3) δ 9.49 (s, 1H), 8.57 (d, J = 8.8 Hz, 1H), 
7.86 (d, J = 7.6 Hz, 2H), 7.65 (d, J = 8.0 Hz, 1H), 7.57 (d, J = 9.2 Hz, 1H), 7.43-
7.30 (m, 3H), 7.07 (d, J = 7.1 Hz, 2H), 4.77 (s, 2H) ppm. HPLC tR = 9.37 min. 
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purity 97%; ESI-MS: 445.93 [M+H]+.
2-[4-(2-Bromobenzoyl)phenoxy]-N-(pyrimidin-5-yl)acetamide (7f10). 
Started from 6f and 5-aminopyrimidine. White solid, 24 mg, yield = 26%. 1H 
NMR (400 MHz, CDCl3): δ 9.08 (s, 2H), 9.03 (s, 1H), 8.45 (s, 1H), 7.81 (d, J = 
8.8 Hz, 2H), 7.65 (d, J = 8.0 Hz, 1H), 7.43 (td, J = 7.4, 1.2 Hz, 1H), 7.39-7.31 (m, 
2H), 7.05 (d, J = 8.8 Hz, 2H), 4.75 (s, 2H) ppm. HPLC tR = 8.27 min. purity 99%; 
ESI-MS: 412.07 [M+H]+.
2-(4-(2-Bromobenzoyl)phenoxy)-N-(pyrazin-2-yl)acetamide (7f11). Star-
ted from 6f and 2-aminopyrazine. White solid, 14 mg, yield = 53%. 1H NMR (400 
MHz, CDCl3) δ 9.62 (s, 1H), 8.87 (s, 1H), 8.43 (s, 1H), 8.31 (s, 1H), 7.85 (dt, J 
= 8.8, 2.0 Hz, 2H), 7.65 (dd, J = 7.6, 0.8 Hz, 1H), 7.43 (td, J = 7.6, 1.2 Hz, 1H), 
7.39-7.32 (m, 2H), 7.06 (dt, J = 9.2, 2.8 Hz, 2H), 4.75 (s, 2H) ppm. HPLC tR = 
8.68 min. purity 98%; ESI-MS: 412.00 [M+H]+.
Biology
Materials and methods
Dofetilide was synthesized in our own laboratory,54 and astemizole was purchased 
from Sigma Aldrich (Zwijndrecht, The Netherlands). Tritium-labeled dofetilide 
(specific activity 82.3 Ci·mmol-1) was purchased from PerkinElmer (Groningen, 
The Netherlands). Bovine serum albumin (BSA, fraction V) was purchased from 
Sigma (St. Louis, MO, USA). G418 was obtained from Stratagene (Cedar Creek, 
USA). All the other chemicals were of analytical grade and obtained from stan-
dard commercial sources. HEK293 cells stably expressing the Kv11.1 channel 
(HEK293Kv11.1) were kindly provided by Dr. Eckhard Ficker (University of 
Cleveland, USA). 
Cell culture and membrane preparation
HEK293Kv11.1 cells were cultured, and membranes were prepared and stored as 
described previously.16
Radioligand kinetic dissociation assays
Kinetic dissociation assays of [3H]dofetilide were performed in incubation buffer 
(10 mM HEPES, 130 mM NaCl, 60 mM KCl, 0.8 mM MgCl2, 1 mM EGTA, 10 
mM glucose, 0.1% BSA, pH 7.4) as described previously with the following mod-
ifications.16 Single point dissociation experiments were conducted by addition 
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compounds after preincubation at 25 °C for 2 h. After 6 minutes of dissociation, 
incubations were terminated by dilution with ice-cold wash buffer (25 mM Tris-
HCl, 130 mM NaCl, 60 mM KCl, 0.8 mM MgCl2, 0.05 mM CaCl2, 0.05 % BSA, 
pH 7.4). Separation of bound from free radioligand was performed by rapid filtra-
tion through a 96-well GF/B filter plate using a PerkinElmer Filtermate-harvester 
(PerkinElmer, Groningen, The Netherlands). The filter-bound radioactivity was 
determined by scintillation spectrometry using the P-E 1450 Microbeta Wallac 
Trilux scintillation counter (PerkinElmer) after addition of 25 µL Microscint and 
extraction. Full dissociation assays were carried out with 10 µM dofetilide in the 
absence (control) or presence of 50 µM selected compounds for a total period 
of 2 h after preincubation. The amounts of radioligand still bound to the recep-
tor were measured at various time intervals. Concentration-dependent effects of 
compounds 7f and 7p were determined by addition of 10 µM dofetilide in the 
absence (control) or presence of different concentrations of 7f and 7p. After 6 
min of dissociation, the incubations were terminated and samples were obtained 
as described above.
Radioligand displacement assay
[3H]Dofetilide binding assays for the Kv11.1 channel were performed in incuba-
tion buffer as described previously.16 Briefly, membrane aliquots containing 20 
μg protein were incubated with 5 nM [3H]dofetilide in a total volume of 100 μl 
incubation buffer at 25 °C for 1 h. Radioligand displacement experiments were 
carried out with various concentrations of tested compounds. Total binding was 
determined in the presence of incubation buffer, whereas nonspecific binding was 
evaluated with 10 µM astemizole. Incubations were terminated by dilution with 
ice-cold wash buffer, and samples were obtained as described in the “radioligand 
kinetic dissociation assays”. The displacement assays of dofetilide and astem-
izole were conducted in the absence (control) or presence of 10 µM 7f, 7h-j and 
7p.
Data analysis
All data of radioligand binding assays were analyzed with Prism v. 5.0 (Graph-
Pad, San Diego, CA, USA). Dissociation rate constants, koff, were obtained by 
computer analysis of the exponential decay of [3H]dofetilide bound to the Kv11.1 
channel. EC50 values from kinetic dissociation assays were calculated by non-lin-
ear regression analysis of concentration-effect curves of dissociation in the pres-
ence of different concentrations of unlabeled ligands. IC50 values in displacement 
assays were directly obtained from non-linear regression analysis of dose-re-
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sponse curves. Apparent inhibitory binding constants (Ki values) were derived 
from the IC50 values according to the Cheng-Prusoff relationship:
55 Ki = IC50/(1 + 
[L*]/KD), where [L*] is the concentration of radioligand and KD its dissociation 
constant from the saturation assay.30 All values obtained from radioligand binding 
assays in this study are means of at least three independent experiments per-
formed in duplicate, and data are presented as mean ± SEM. Statistical analysis 
was performed with a two-tailed unpaired Student’s t-test.
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Chapter 6
Kv11.1 (hERG)-induced cardiotoxicity: a 
molecular insight from a binding kinetics 
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Abstract
Drug-induced arrhythmia due to blockade of the Kv11.1 channel (also known as 
the hERG K+ channel) is a frequent side effect and arouses major safety concerns 
during the drug development process. Previous studies have primarily focused on 
equilibrium parameters, i.e. affinity or potency, of drug candidates at the channel. 
The aim of this study was to determine the kinetics of the interaction with the 
channel for a number of known Kv11.1 blockers and to explore a possible correla-
tion with the affinity or physicochemical properties of these compounds. In this 
context, the affinity and kinetic parameters of fifteen prototypic Kv11.1 inhibitors 
were evaluated in a number of [3H]dofetilide binding assays. The lipophilicity 
(logKW-C8) and membrane partitioning (logKW-IAM) of these compounds were de-
termined by means of HPLC analysis. Accordingly, a novel [3H]dofetilide com-
petition association assay was set up and validated, which allowed us to deter-
mine the binding kinetics of the Kv11.1 blockers used in this study. Interestingly, 
the compounds’ affinity (Ki values) were correlated to their association rates rath-
er than dissociation rates. Overall lipophicility or membrane partitioning of the 
compounds were not correlated to their affinity and rate constants for the channel. 
In conclusion, a compound’s affinity for the Kv11.1 channel is determined by the 
rate of association with the channel, while overall lipophilicity and membrane af-
finity are not. In more general terms, our findings provide novel insights into the 
mechanism of action for a compound’s activity at the Kv11.1 channel. This may 
yield further understanding in how Kv11.1-induced cardiotoxicty is governed and 
how it can be circumvented in the future.
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Introduction 
The Kv11.1 channel, a voltage-gated potassium channel previously known as 
hERG (human ether-à-go-go related gene), encodes the pore-forming subunit of 
the rapid component of the delayed rectifier K+ channel, IKr, which contributes 
to phase 3 repolarization in cardiac action potentials1-4. Genetic defects or drug 
blockade of the Kv11.1 channel normally cause delayed repolarization of car-
diac action potentials and Torsades de Pointes (TdP)5. In some cases, TdP can 
degenerate into ventricular fibrillation and lead to sudden death6, 7. Currently, a 
number of drugs have been withdrawn from the market due to their blockade of 
the Kv11.1 channel, including astemizole and cisapride
8. In addition, either ‘black 
box’ warnings or significant restrictions have been rendered for several other 
drugs, such as droperidol and ibutilide8. Withdrawing or restricting drugs due to 
their Kv11.1 liability in less than 1% of the patient population causes unpredict-
able and huge costs to industry, and brings troubles for patients as well owing 
that some effective drugs would be beneficial for the vast majority of patients 8, 9.
In the past decades, a series of techniques including whole cell patch-clamp 
technologies, radioligand binding assays and ion flux assays have been devel-
oped and used to screen for Kv11.1 liability of compounds
5, 10. From these, equi-
librium radioligand displacement assays have been suggested as a low-cost and 
high throughput technology alternative to other available methods and are widely 
employed to obtain the affinity of compounds at the Kv11.1 channel
11-13. These 
studies provide equilibrium parameters, such as IC50 or Ki values. For instance, 
a 30-fold margin between Kv11.1 IC50 and maximum free plasma concentration 
(Cmax) has been recommended to assess drug safety with respect to arrhythmo-
genesis 14. However, the kinetics of the interaction between a drug and the Kv11.1 
channel may be equally, or even more, important. Knowledge of association and 
dissociation rate constants has already led to better insights in the action of drugs 
at other targets, such as enzymes and G protein-coupled receptors15, 16. 
In the present study, we hypothesized that a slow association rate (kon) to 
and/or a fast dissociation rate constant (koff) from the channel may be benefi-
cial to reduce or avoid Kv11.1-related cardiovascular side effects. Hence, a de-
tailed understanding of a ligand’s binding kinetics at the channel may provide 
clues to enable the optimization of its kinetic profiles, and potentially ‘rescue’ 
it from removal of the drug discovery pipeline. In this context, we describe the 
development and validation of a [3H]dofetilide competition association assay in 
HEK293Kv11.1 cell membranes to determine the kinetic binding parameters of 
15 unlabelled reference compounds from different “Redfern” categories14 (Table 
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data of those compounds, and compared these parameters with the compounds’ 
physicochemical properties. Since the interaction of drugs with membrane phos-
pholipids is not only driven by lipophilicity, but also electrostatic interactions 
with both acidic and basic moieties on phosphate head groups17, 18, a regular col-
umn and an immobilized artificial membrane (IAM) column, were used to derive 
two hydrophobic parameters for these compounds, i.e. logKW-C8 and logKW-IAM, 
respectively. Finally, both hydrophobic parameters were compared with the com-
pounds’ affinity and kinetic data. Taken together, the present study provides a 
novel approach to study the kinetics of the interaction between a drug and the 
Kv11.1 channel, which may help to more precisely assess Kv11.1 liability of drug 
candidates in the future.
Methods
Materials
Astemizole, sertindole, terfenadine, moxifloxacin, amiodarone, chlorpromazine, 
ibutilide, clofilium, pimozide, cisapride, ranolazine, sotalol, thioridazine and all 
the solutes for HPLC determinations were purchased from Sigma Aldrich (Zwi-
jndrecht, The Netherlands). Dofetilide and E-4031 were synthesized in our own 
laboratory19, 20. Tritium-labeled dofetilide (specific activity 65~87 Ci·mmol-1) was 
purchased from Perkin Elmer (Groningen, The Netherlands). Bovine serum albu-
min (BSA, fraction V) was purchased from Sigma (St. Louis, MO, USA). G418 
was obtained from Stratagene (Cedar Creek, USA). The chemicals for HPLC were 
of HPLC grade; all the other chemicals were of analytical grade and achieved 
from standard commercial sources. HEK293 cells stably expressing the Kv11.1 
channel (HEK293Kv11.1) were kindly provided by Dr Eckhard Ficker (Universi-
ty of Cleveland, USA). The molecular target nomenclature (Kv11.1) conforms to 
‘The Concise Guide to PHARMACOLOGY 2013/14: Ion Channels’21.
Cell culture and membrane preparation
HEK293Kv11.1 cells were cultured and membranes were prepared and stored as 
described previously22.
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a+ drugs with possible TdP risk, and ++ drugs with known TdP risk. Information on these 
compounds was retrieved from CredibleMeds® available at: http://crediblemeds.org/ (ac-
cessed 10 April 2014).
bRedfern categories for most compounds were derived from the literature (Redfern et al., 
2003); they are 1: Class Ia and III antiarrythmics; 2: Withdrawn from market due to TdP; 
3: Measurable incidence / numerous reports of TdP in humans; 4: Isolated reports of TdP 
in humans; 5: No reports of TdP in humans. * Redfern categories for these compounds 
were deduced according to the definition for different categories. 
Radioligand saturation assay
Membrane aliquots containing 20 µg of protein were incubated in a total volume 
of 100 µL of incubation buffer (10 mM HEPES, 130 mM NaCl, 60 mM KCl, 
0.8 mM MgCl2, 1 mM EGTA, 10 mM Glucose, 0.1% BSA, pH 7.4) at 25 °C 
for 120 min to ensure that the equilibrium was reached at all concentrations of 
radioligand. Total binding was determined at a range of concentrations (0.2 ~ 
22 nM) of [3H]dofetilide, whereas nonspecific binding was determined at three 
different concentrations of radioligand in the presence of 10 µM astemizole and 
analyzed by linear regression. Incubations were terminated by dilution with ice-
cold wash buffer (25 mM Tris-HCl, 130 mM NaCl, 60 mM KCl, 0.8 mM MgCl2, 
0.05 mM CaCl2, 0.05% BSA, pH 7.4). Separation of bound from free radioligand 
was performed by rapid filtration through Whatman GF/B filters using a Brandel 
harvester. Filters were subsequently washed 6 times with 2 mL ice-cold wash 
buffer. Filter-bound radioactivity was determined by scintillation spectrometry 
using a liquid Scintillation Analyzer (Tri-Carb 2900TR) after addition of 3.5 mL 
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of Packard Emulsifier Safe and 2 h extraction. 
Radioligand association and dissociation assay
Kinetic association experiments were performed by incubating membrane ali-
quots containing 20 µg of protein in a total volume of 100 µL incubation buffer at 
25 °C for 120 min with 16 different concentrations (0.7~16 nM) of [3H]dofetilide. 
The amount of radioligand bound to the receptor was measured at various time 
intervals during the incubation. Incubations were terminated, and samples were 
obtained and analyzed as described in “radioligand saturation assay”. Further 
traditional association and dissociation assays were performed as described pre-
viously22. 
Radioligand displacement assay
The [3H]dofetilide binding assay for the Kv11.1 channel was performed as de-
scribed previously22. In short, membrane aliquots containing 20 μg protein were 
incubated in a total volume of 100 μl incubation buffer at 25 °C for 60 min. 
Radioligand displacement experiments were conducted using 11 concentrations 
of the competing ligand in the presence of 5 nM [3H]dofetilide. At this concen-
tration, total radioligand binding did not exceed 10% of the radioligand added to 
prevent ligand depletion. Nonspecific binding was determined in the presence 
of 10 µM astemizole and represented approximately 15% of the total binding. 
[3H]Dofetilide did not bind to membranes prepared from empty HEK293 cells 
lacking the Kv11.1 channel (data not shown). Total binding was determined in the 
presence of incubation buffer and was set at 100% in all experiments, whereas 
nonspecific binding was set at 0%. Incubations were terminated by dilution with 
ice-cold wash buffer. Separation of bound from free radioligand was performed 
by rapid filtration through a 96-well GF/B filter plate using a Perkin Elmer Filter-
mate-harvester (Perkin Elmer, Groningen, The Netherlands). Filters were subse-
quently washed 12 times with ice-cold wash buffer. The filter-bound radioactivity 
was determined by scintillation spectrometry using the P-E 1450 Microbeta Wal-
lac Trilux scintillation counter (Perkin Elmer) after addition of 25 µL Microscint 
and 2 h extraction.
Radioligand competition association assay
The binding kinetics of unlabelled reference compounds were determined at 25 
°C using the competition association assay according to a previously published 
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of their Ki values) of unlabelled dofetilide, astemizole and E-4031 were tested. 
We assessed the binding kinetics of all other unlabelled reference compounds in 
a simplified one-concentration competition association assay based on Guo et al. 
24. The experiments were initiated by incubating membrane aliquots containing 
20 µg of protein in a total volume of 100 µL of incubation buffer in the absence 
(control) or presence of a certain concentration of unlabelled ligands at 25 °C 
for 120 min with 5 nM [3H]dofetilide. The amounts of radioligand bound to the 
receptor were measured at various time intervals during the incubation. Incuba-
tions were terminated, and samples were obtained and analyzed as described in 
“radioligand displacement assay”.
Determination of logKW-C8 and logKW-IAM parameters by HPLC
LogKW-C8 values were measured on a Supelcosil LC-ABZ, 5 cm × 4.6 mm, 5 µm 
column according to a methodology described previously25, 26. In short, retention 
times of the compounds were determined at three different methanol percentages. 
These retention times were converted to k values by using the formula k = (tR – 
t0)/tR in which tR is the retention time and t0 the retention time of a “nondelayed” 
compound (pure methanol). The calculated log k values were plotted against the 
methanol concentrations and extrapolated to a 0% methanol situation yielding the 
logKW-C8 values for 15 reference compounds (intercept of y axis).
An isocratic method was applied to measure the logKW-IAM values of all tested 
compounds on a 10 cm x 4.6 mm, 10 μm Regis IAM PC DD2 column27. Reten-
tion times of the compounds were determined at three different concentrations of 
acetonitrile. The kIAM values were calculated by the equation kIAM = (tR – t0)/tR in 
which tR represents retention times of tested compounds, whereas t0 is determined 
by injecting a sodium nitrate solution in the HPLC system The log kIAM values 
for a compound were plotted against the applied acetonitrile concentrations. The 
intercept with the Y-axis of the straight line through these data points yielded the 
extrapolated logKW-IAM values for the 15 reference compounds.
Data analysis
All data of radioligand binding assays were analyzed using the non-linear regres-
sion curve fitting program Prism v. 5.1 (GraphPad, San Diego, CA, USA). KD 
and Bmax values of [
3H]dofetilide at HEK293Kv11.1 membranes were obtained 
by computational analysis of saturation curves. Apparent inhibitory binding con-
stants (Ki values) were derived from the IC50 values according to the Cheng and 
Prusoff equation Ki = IC50/(1 + [L*]/KD), where [L*] was the concentration of 
radioligand and KD was its dissociation constant from the saturation assay 
28. In 
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the kinetic association experiments, the on- and off-rates were derived from the 
linear regression analysis using the equation kobs = kon[L*] + koff, where the kobs 
value was obtained by computer analysis of the exponential association of [3H]
dofetilide bound to the receptor with [L*] being the concentration of radioligand. 
The association and dissociation rates were used to calculate the kinetic KD value 
using the following equation KD = koff/kon . The association and dissociation rates 
for unlabelled compounds were calculated by fitting the data into the competition 
association model using “kinetics of competitive binding”23: 
KA = k1[L] + k2
KB = k3[I] + k4




KF = 0.5 (KA + KB + S)


































Where X is the time (min), Y the specific binding of [3H]dofetilide, k1 and 
k2 are the kon (M
-1·min-1) and koff (min
-1) of [3H]dofetilide obtained from the tra-
ditional association and dissociation assay, L the concentration of [3H]dofetilide 
(nM), Bmax the maximum specific binding (dpm) and I the concentration of the 
unlabelled compound (nM). Fixing these parameters allowed the following pa-
rameters to be calculated: k3, which is the kon value (M
-1·min-1) of the unlabelled 
compound and k4, which is the koff value (min
-1) of the unlabelled compound. 
LogKW-C8 and logKW-IAM values were derived from linear regression analysis as 
mentioned above. The molecular weight (M.W.), logP and pKa values were cal-
culated using a structure-based calculation plug-in provided by ChemAxon (Bu-
dapest, Hungary). All values obtained from radioligand binding assays in this 
study are means of at least three independent experiments performed in duplicate. 
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The binding of [3H]dofetilide to HEK293Kv11.1 cell membranes was saturable 
and best described by a one-site binding model. A representative saturation curve 
and the averaged data of three independent experiments performed in duplicate 
are shown in Figure 1 and Table 2, respectively. The KD and Bmax values obtained 
from this assay were 2.4 ± 0.1 nM and 1.6 ± 0.1 pmol·mg-1 protein, respectively. 
The KD value for [
3H]dofetilide from this assay was used to calculate Ki rather 
than IC50 values from the displacement assay for 15 reference compounds.
Figure 1. Saturation of [3H]dofetilide binding to HEK293Kv11.1 membranes. Total bind-
ing was determined at increasing concentrations of [3H]dofetilide. Nonspecific binding 
was determined at three concentrations of [3H]dofetilide, and nonspecific binding at other 
concentrations of radioligand was extrapolated by linear regression. Specific binding was 
calculated as the difference between the total and nonspecific binding. The KD value was 
2.4 ± 0.1 nM, and the Bmax value was 1.6 ± 0.1 pmol·mg-1 protein. Experiments were per-
formed at 25 °C using 20 µg of HEK293Kv11.1 membrane protein. 
[3H]Dofetilide association and dissociation assay
A B
Figure 2: Characterization of the association and dissociation rates of [3H]dofetilide to 
HEK293Kv11.1 membranes in the kinetic association assay. (A) Representative associ-
ation curves of [3H]dofetilide at four different concentrations; (B) A plot of kobs values 
versus the concentration of [3H]dofetilide. Experiments were performed at 25 °C using 
20 µg of HEK293Kv11.1 membrane protein.
Initial experiments were performed to fully characterize the association and dis-
sociation rates of [3H]dofetilide to and from HEK293Kv11.1 membranes, respec-
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tively. As the association rate of a ligand is dependent upon the concentration 
used, kinetic association experiments with a range of [3H]dofetilide concentra-
tions were conducted. In Figure 2A, curves are shown for four of such concentra-
tions (0.76, 2.7, 3.8 and 7.1 nM). A plot of the kobs values against more, including 
higher, concentrations of [3H]dofetilide (Figure 2B) was consistent with a linear 
correlation (r2 = 0.86, P < 0.0001), indicating that the binding of [3H]dofetilide 
to the Kv11.1 channel followed the law of mass action for a simple bimolecular 
interaction and that the equation kon = (kobs - koff)/[L*] was applicable in this study. 
The kon and koff values obtained from this plot were 0.017 nM
-1·min-1 and 0.12 
min-1, respectively (Table 2). When koff was divided by kon, a kinetically derived 
KD value of 7.1 nM was obtained. These values were in agreement with values 
for apparent on- and off-rates and kinetic KD of [
3H]dofetilide assessed at one (5 
nM) concentration (kon = 0.032 ± 0.003 nM
-1·min-1, koff = 0.20 ± 0.03 min
-1 and KD 
= 6.4 ± 1.3 nM) derived from the traditional association and dissociation assays 
published previously22.
Table 2. Binding parameters of dofetilide from different equilibrium and kinetic binding 
assays.

















-1·min-1) - 0.017 0.032 ± 0.003 - 0.048 ± 0.011
koff (min
-1) - 0.12 0.20 ± 0.03 - 0.13 ± 0.02
KD (nM) 2.4 ± 0.1 7.1c    6.4 ± 1.3c - 2.7 ± 0.3c
Ki (nM) - - - 5.4 ± 0.8 -
Values are means (± S.E.M.) of three independent assays performed in duplicate.
aData were derived from linear regression of one independent association assay of  [3H]
dofetilide at different concentrations.
bData from our previous study22.
cKinetic KD = koff/kon.. 
[3H]Dofetilide displacement assay
Competition binding assays were performed to generate Ki values for 15 refer-
ence compounds. Compounds were selected based on structural diversity and 
having a wide range of Kv11.1 binding affinity, and included both anti-arrhyth-
mic drugs and drugs for other therapeutic areas (e.g., astemizole and terfenadine
for the treatment of allergic conditions). All compounds produced a concentra-
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ment curves were best described by a one-site competition model (Figure 3). All 
Ki values are listed in Table 3. Among the 15 compounds, clofilium had the high-
est affinity to the Kv11.1 channel, displacing [
3H]dofetilde with a Ki value of 0.55 
± 0.09 nM, whereas moxifloxacin exhibited the lowest affinity of 252 ± 121 µM. 
Ranolazine and sotalol showed similar and relatively weak inhibition of the chan-
nel with Ki values of 21 ± 6 and 25 ± 1 µM, respectively. Additionally, amiodarone, 
thioridazine and chlorpromazine displayed modest Kv11.1 blockade with Ki values 
from 0.3 to 3 µM. All other compounds demonstrated relatively high affinity to the 
Kv11.1 channel, between 2.5 ± 0.2 nM (astemizole) and 63 ± 4 nM (terfenadine). 
A B
Figure 3. Displacement curves of [3H]dofetilide from HEK293Kv11.1 membranes by 
different known Kv11.1 channel blockers. (A) Dofetilide, astemizole, E-4031, sertindole, 
terfenadine, moxifloxacin, amiodarone and chlorpromazine; (B) Ibutilide, clofilium, pi-
mozide, cisapride, ranolazine, sotalol and thioridazine. Experiments were performed at 
25 °C using 20 µg of HEK293Kv11.1 membrane protein. 
[3H]Dofetilide competition association assay
With the kon (k1) and koff (k2) values of [
3H]dofetilide obtained from the traditional 
association and dissociation assays, it was possible to determine the kon (k3) and 
koff (k4) values of unlabelled compounds by performing so-called competition 
association experiments. Firstly, we validated the competition association assay 
at the Kv11.1 channel using three concentrations of ‘cold’ dofetilide equivalent 
to 0.3-, 1- and 3-fold of its Ki value. A representative experiment is shown in 
Figure 4. The kon (k3) and koff (k4) values for dofetilide determined in this assay 
were 0.048 ± 0.011 nM-1·min-1 and 0.13 ± 0.02 min-1, respectively, and in good 
agreement with the kinetic parameters determined in the traditional association 
and dissociation assays, as shown in Table 2. Furthermore, the kinetic KD value 
(2.7 ± 0.3 nM) derived from this assay was similar to the KD value (2.4 ± 0.1 nM) 
obtained from the [3H]dofetilide saturation assay. In addition, these KD values 
were in the same range as dofetilide’s affinity constant that stemmed from the 
displacement assay (Ki = 5.4 ± 0.8 nM) and the kinetically derived KD values 
from kinetic association assay and traditional kinetic experiments (7.1 nM or 6.4 
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± 1.3 nM, respectively). Overall, the results presented here demonstrated that 
the competition association assay could be applied to determine the association 
and dissociation rates of other unlabeled ligands at the Kv11.1 channel. It is note-
worthy that a good experimental window was achieved using a concentration of 
dofetilide at 1-fold its Ki value in the competition association assay, as displayed 
in Figure 4. Reassuringly, when astemizole and E-4031 were tested in this stan-
dard three-concentration assay, similar findings were observed as well (data not 
shown). Thus, the other unlabelled ligands were only tested at 1-fold their Ki 
values rather than three different concentrations in the further competition asso-
ciation experiments in order to improve the throughput of this method.
Table 3. The affinity constants and kinetic parameters of 15 compounds at the Kv11.1 






Dofetilide 5.4 ± 0.8 0.048 ± 0.011 0.13 ± 0.02 2.7 ± 0.3
Astemizole 2.5 ± 0.2 0.17 ± 0.03 0.083 ± 0.003 0.53 ± 0.07
E-4031 13 ± 0.7 0.026 ± 0.003 0.27 ± 0.02 10 ± 1
Sertindole 34 ± 5 0.048 ± 0.007 0.86 ± 0.17 18 ± 1
Terfenadine 63 ± 4 0.0071 ± 0.0025 0.25 ± 0.03 39 ± 7
Moxifloxacin 252347 ± 120995 (4.7 ± 1.0)×10-6 0.28 ± 0.06 64531 ± 10276
Amiodarone 308 ± 33 (6.0 ± 0.7)×10-4 0.23 ± 0.02 387 ± 37
Chlorpromazine 2518 ± 301 (1.3 ± 0.2)×10-4 0.36 ± 0.05 2714 ± 154
Ibutilide 5.1 ± 0.4 0.046 ± 0.006 0.20 ± 0.02 4.6 ± 1.1
Clofilium 0.55 ± 0.09 0.23 ± 0.07 0.10 ± 0.01 0.54 ± 0.17
Pimozide 28 ± 7 0.071 ± 0.020 0.22 ± 0.07 3.2 ± 0.4
Cisapride 54 ± 10 0.031 ± 0.009 0.59 ± 0.14 20 ± 2
Ranolazine 21379 ± 5776 (1.5 ± 0.4)×10-5 0.23 ± 0.04 16672 ± 1820
Sotalol 24663 ± 1379 (1.7 ± 0.3)×10-5 0.32 ± 0.03 19740 ± 1591
Thioridazine 1065 ± 41 (2.3 ± 0.4)×10-4 0.24 ± 0.05 1050 ± 48
Values are means (± S.E.M.) of three independent assays performed in duplicate.
aKi values were derived from the [
3H]dofetilide displacement assay.
bkon (k3) and koff (k4) values of unlabelled compounds were determined in the [
3H]dofeti-
lide competition association assay.
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Figure 4. Competition association assay of [3H]dofetilide in the absence (control) or 
presence of 0.3-, 1- and 3-fold of unlabeled dofetilide’s Ki value. Experiments were per-
formed at 25 °C using 20 µg of HEK293Kv11.1 membrane protein.
Figure 5. Representative competition association curves of [3H]dofetilide in the absence 
(control) or presence of unlabelled sertindole, clofilium and cisapride at a concentration 
of 1-fold their Ki values. Experiments were performed at 25 °C using 20 µg of HEK-
293Kv11.1 membrane protein.
Subsequently, kinetic parameters of 12 other known Kv11.1 blockers were 
evaluated and representative normalized curves for several compounds are de-
picted in Figure 5. The on- and off-rates of all compounds determined by these 
experiments are shown in Table 3. The association rates for all the compounds 
were quite distinct with kon values ranging from (4.7 ± 1.0) × 10
-6 nM-1·min-1 
(moxifloxacin) to 0.23 ± 0.07 nM-1·min-1 (clofilium), i.e. an almost 50,000-fold 
difference between the fastest and slowest associating compounds. On the other 
hand, the dissociation rates of these 15 compounds were more similar, with the 
highest value of 0.86 ± 0.17 min-1 for sertindole and lowest koff of 0.083 ± 0.003 
min-1 for astemizole, i.e. only a 10-fold difference. Considering the kinetical-
ly-derived KD values shown in Table 3, clofilium was the most potent inhibitor to 
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the Kv11.1 channel with a kinetic KD value of 0.54 ± 0.17 nM, while moxifloxacin 
had the lowest affinity (KD = 65 ± 10 µM) to the channel. These results were in 
the same rank order as the Ki values derived from the equilibrium displacement 
assay.
Correlations of equilibrium Ki with kinetic KD, kon, and koff val-
ues
A plot of the logarithms of kinetic KD values (i.e. koff/kon) derived from the [
3H]
dofetilide competition association assays and the logarithms of equilibrium Ki 
values obtained from the displacement experiments was made, and a significant 
correlation (Figure 6A) was observed. This showed an excellent consistence of 
the results from two different methods and indicated a high reliability of the [3H]
dofetilide competition association assay. More interestingly, a significant inverse 
relationship was also found between pkon and pKi values for unlabelled com-
pounds in Figure 6B. On the contrary, there was no significant linear relationship 
between pkoff and pKi values (r
2 = 0.15, P = 0.15, data not shown). Together, this 
suggested that the [3H]dofetilide competition association assay was successfully 
validated for assessing the kinetics of other unlabelled competitive compounds, 
and that the affinity of these compounds at the Kv11.1 channel was mainly con-
trolled by their on-rates rather than off-rates. 
A B
Figure 6. Correlations between the affinity constant (Ki) and (A) the kinetically derived 
equilibrium dissociation constants, KD (r
2 = 0.98, P < 0.0001) and (B) the association 
rates, kon for unlabelled ligands at the Kv11.1 channel (r
2 = 0.95, P < 0.0001). Ki, KD and 
kon values are listed in Table 3.
Lipophilicity (logKW-C8) and membrane partition coefficient 
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The isocratical logKW-C8 values (‘lipophilicity’) were evaluated at pH 7.4 and are 
detailed in Table 4. The lipophilicity of 15 reference compounds covered a wide 
numerical range, varying from 0.56 (sotalol) to 5.52 (amiodarone). We also cal-
culated logP values as a measure for lipophilicity, and plotted these against the 
logKW-C8 data (Table 4). A significant correlation was found between them (r
2 = 
0.81, P < 0.0001), which implied that for this series of compounds calculated logP 
values can be used interchangeably with the experimentally determined values. 
Table 4. The lipophicility, membrane partition coefficients and other physicochemical 
properties of 15 Kv11.1 blockers.
Compound logKW-C8
a logKW-IAM
b M.W.c logPc pKa
c
Dofetilide 0.84 2.08 441.57 0.59 8.99
Astemizole 3.52 3.40 458.57 5.39 8.75
E-4031 1.29 1.98 401.52 1.73 8.01
Sertindole 3.97 3.38 440.94 3.77 8.59
Terfenadine 4.05 4.01 471.67 6.48 9.02
Moxifloxacin 1.12 1.57 401.43 1.97 9.42
Amiodarone 5.52 3.30 645.31 7.64 8.47
Chlorpromazine 3.39 3.36 318.86 4.54 9.20
Ibutilide 0.90 2.53 384.58 3.25 10.40
Clofilium 2.00 -0.35 338.98 2.91 n.a.d
Pimozide 4.69 3.80 461.55 5.83 8.38
Cisapride 3.12 2.66 465.95 2.49 8.24
Ranolazine 2.17 2.39 427.54 2.83 7.17
Sotalol 0.56 0.66 272.36 0.05 9.43
Thioridazine 3.53 3.80 370.58 5.47 8.93
aLogKW-C8 values were derived from HPLC experiments on a Supelcosil LC-ABZ, 5 cm 
× 4.6 mm, 5 µm column.
bLogKW-IAM values were derived from HPLC experiments on a 10 cm x 4.6 mm, 10 μm 
Regis IAM PC DD2 column.
cValues were derived from the structure-based calculation plug-in by ChemAxon.
dn.a. not applicable; this compound is permanently charged.
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To mimic the interactions of our ligands with membrane phospholipids, an 
IAM HPLC column that is a reflection of the lipid environment of a fluid cell mem-
brane on a solid matrix was used to determine membrane partition coefficients 
(logKW-IAM) for all reference compounds. Their logKW-IAM values were measured 
at pH 7.4 and are summarized in Table 4. Terfenadine had the highest logKW-IAM 
value of 4.01, indicating that this compound possessed the highest affinity for 
membrane phospholipids. On the contrary, the logKW-IAM for clofilium was only 
- 0.35, most likely due to its quaternary ammonium moiety, which demonstrated 
that this compound hardly interacted with phospholipid membranes. 
Subsequently, the possible correlation between logKW-C8 and logKW-IAM was 
studied, and the result is shown in Figure 7. A significant linear relationship (r2 
= 0.52, P < 0.0024) was observed for these two parameters even when including 
the outlier clofilium. Obviously, a similar significant correlation was also found 
between calculated logP and logKW-IAM values (r
2 = 0.52, P = 0.0022, data not 
shown). Next, the relationship between affinity constants or kinetic rate constants 
of the 15 Kv11.1 inhibitors and their membrane interactions were investigated, 
as shown in Figure 8A – 8C. Apparently, no relationships were found for any of 
them (P > 0.05), demonstrating that membrane interactions did not affect affinity 
and binding kinetics of these ligands at the Kv11.1 channel. Similarly, there were 
no correlations between logKW-C8 and pKi, pkon or pkoff values (data not shown). 
Figure 7. Correlation between logKW-C8 and logKW-IAM values at pH 7.4 for 15 Kv11.1 in-
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A B
C
Figure 8. Correlation of logKW-IAM values and binding parameters of 15 Kv11.1 inhibitors. 
No significant relationship between logKW-IAM and values of (A) pKi (r
2 = 0.00011, P = 
0.97), (B) pkon (r
2 = 0.0087, P = 0.74) or (C) pkoff was observed (r
2 = 0.051, P = 0.42). All 
data used in these plots are listed in Table 3 and Table 4.
Role of other calculated physicochemical properties in ligand-re-
ceptor binding kinetics
Lastly, two other physicochemical properties of the unlabelled compounds, mo-
lecular weight (M.W.) and acid/base constant (pKa) (Table 4), were compared 
with their on-/off- rates and dissociation constants. As depicted in Figure 9, no 
significant correlations were observed between the logarithms of on-rates of the 
compounds in this study and their molecular properties. Moreover, there were no 
obvious relationships between the logarithms of off-rates or equilibrium Ki val-
ues and these physicochemical properties either (P > 0.05, data not shown). These 
results implied that the binding kinetics of compounds at the Kv11.1 channel was 
not governed by their overall, macroscopic, physicochemical properties.
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A B
Figure 9. Lack of correlation between the association rates (pkon values) of selected com-
pounds and their physicochemical properties. (A) No significant correlation was observed 
with M.W. (r2 = 0.049, P = 0.43); (B) No significant correlation was observed with pKa (r
2 
= 0.000076, P = 0.98). M.W. and pKa values are shown in Table 4.
Discussion and conclusions
Since the introduction of the competition association assay 23, more and more 
researchers have utilized this method to study the binding kinetics of unlabelled 
ligands at their targets, such as muscarinic receptors and the adenosine A2A recep-
tor24, 29, 30. In addition, a few examples in literature have been reported to apply 
this technique for the determination of ligand binding kinetics at ligand-gated ion 
channels31. To the best of our knowledge, the current study is the first to assess 
binding kinetics of ligands interacting with voltage-gated ion channels, in partic-
ular the Kv11.1 channel. 
It might be argued that our study has some limitations. The stably-transfected 
HEK293Kv11.1 cells lack the (co-)expression of two ancillary β-subunits, minK 
and MiRP13. Discrepancies could also exist between membrane binding assays 
and whole cell experiments, which are more relevant to the channel’s natural 
orientation. For instance, the kinetics of the drug-Kv11.1 interaction have been 
reported to be use- and frequency-dependent in whole cell patch clamp assays 
due to special gating kinetics of the channel32, 33. In our membrane binding assays, 
we speculate that the channels maintain the same configurations, and thus the 
kinetic parameters in this investigation should resemble the actual binding pro-
cess between Kv11.1 blockers and the channel. To perform straightforward and 
accurate kinetic determinations, experiments were carried out at 25 ºC with mem-
brane preparations of stably-transfected HEK293Kv11.1 cells. We reason that all 
parameters obtained at 25 ºC in this investigation lead to a similar compound 
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another target based on van’t Hoff and Eyring equations34.
The linear plot of kobs values obtained at increasing concentrations of [
3H]
dofetilide (Figure 2B) strongly supported a pseudo-first-order kinetic behavior 
of its binding to the Kv11.1 channel, which provided the theoretical foundation 
for all kinetic analyses in our present study. Other mechanisms of action such as 
induced-fit or conformational selection would have resulted in deviations from 
linearity; in such cases, the Motulsky and Mahan model and equations would not 
have been applicable35, 36. All 15 reference compounds had a pseudo-Hill coef-
ficient close to unity in the [3H]dofetilide displacement assay (data not shown), 
which indicated a competitive mode of inhibition with regard to the radioligand. 
This is another indication of the simple bimolecular interaction model and cor-
roborated a pseudo-first-order kinetic behavior of the binding to the Kv11.1 chan-
nel. This finding was in accordance with previous studies describing the presence 
of a single affinity state for Kv11.1 inhibitors at the channel
37, 38. Subsequently, 
a newly developed [3H]dofetilide competition association assay was applied to 
study the binding kinetics of 15 unlabelled reference compounds with diverse 
chemical structures at the Kv11.1 channel (Table 1). The kon, koff and KD values of 
dofetilide from this assay were comparable to the values derived from saturation 
and kinetic association experiments and traditional association and dissociation 
assays22, indicative of the accuracy and reliability of this new assay. Moreover, 
the excellent linear correlation between these kinetically derived KD values of 
15 reference compounds and their Ki values from the equilibrium displacement 
assay further supported the latter (Figure 6A). Taken together, this led us to con-
clude that a novel [3H]dofetilide competition association assay was successfully 
developed and validated.
Correlations between the affinity data (Ki) and the kinetic parameters (on- 
and off-rates) were also investigated in the present study. Surprisingly, there 
was a significant inverse correlation between pKi and pkon values for reference 
compounds (Figure 6B), whereas no relationship was found between pKi and 
pkoff values (data not shown). Although this correlation between affinity and 
association rates has been shown to be the case for β2-adrenoceptor agonists
39 
and OX2-receptor antagonists
40, this phenomenon is supposed to be unusual and 
counter-intuitive. Dogma has it that the collision theory sets the maximum value 
for kon as the diffusion limit for a ligand and a target, which is about 10
8 ~ 109 
M-1·s-1 41. In this view, there can only be small variations in the on-rate constants 
and thus the equilibrium affinity changes are mainly dictated by the off-rates of 
ligands15, 41, 42. In contrast to these classical assumptions, association rates of our 
selected structurally diverse compounds varied around 50,000-fold, whereas their 
dissociation rates differed only 10-fold. This clearly indicated that apart from 
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off-rates, on-rates also play a pivotal role in regulating affinity of ligands to their 
targeted receptors, at least for the Kv11.1 channel.  
Recently, it has been reported that drug-receptor association rates and corre-
sponding affinity were enhanced due to concentrating effects and lateral diffusion 
of membrane associated β2-adrenoceptor ligands and kon values were positive-
ly correlated to their lipophilicity and membrane interactions18, 43. Furthermore, 
Sykes et al.18 observed that dissociation rates were much more correlated to the 
corrected ‘true’ affinity, which considers drug concentration gradients in the local 
environment due to membrane affinity, than the apparent affinity. Additionally, 
it was recommended that any prediction of pharmacodynamic properties should 
take membrane interactions as well as lipophilicity into account17. Hence, the 
potential influence of membrane affinity on ligand binding to the Kv11.1 chan-
nel was investigated by the determination of both logKW-C8 and logKW-IAM values. 
However, when pKi and pkon were compared to logKW-C8 and logKW-IAM, no sig-
nificant relationships were observed in our case (Figure 8). This indicated that 
membrane interactions of our ligands did not influence their association rates and 
binding affinity to the Kv11.1 channel, and that the apparent affinity of these ref-
erence compounds is their ‘true’ affinity. Interestingly, when logKW-C8 and logKW-
IAM were compared to each other, clofilium was observed to deviate from the sig-
nificant linear correlation (Figure 7). Herein, we hypothesized that the lipophilic 
alkyl chains of clofilium compensated for its hydrophilic quaternary ammonium 
group and thus dominated its lipophilicity in the octanol-water system, while 
the positive charge at the nitrogen played a more critical role in the IAM sys-
tem and weakened its membrane interactions. With regard to dissociation rates, 
no correlations were found to either logKW-C8 or logKW-IAM values as well (data 
not shown). This was in accordance with previous findings18, 44 and demonstrated 
that the dissociation rate of a drug was not affected by its local concentrations 
and thus independent of membrane affinity. Of note, typical Kv11.1 inhibitors are 
known to bind to the inner cavity in the intracellular part of the channel3. How-
ever, all experiments in the present study were performed with HEK293Kv11.1 
membranes instead of intact cells and were thus independent of transmembrane 
transport of ligands. From Figure 6B, it follows that a significant relationship 
between affinity and association rates for 15 Kv11.1 inhibitors was found, which 
showed that ligand-Kv11.1 rather than ligand-membrane association controlled 
their affinity. Apparently, an aqueous entry pathway predominates the binding of 
Kv11.1 blockers to the channel, and an additional compartment induced by the 
lipid membranes does not play a significant role. 
We questioned whether it would be possible to correlate other general phys-
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This was not the case, since typical features such as molecular weight and the 
basicity of the Kv11.1 blockers were not correlated to any of the equilibrium or 
kinetic binding parameters tested. However, it has been stated previously that 
physicochemical properties of drugs are relevant for their kinetic parameters41, 45. 
For instance, Miller et al.46 reported that molecular weight was one of the most 
important factors to affect the dissociation kinetics of ligands from their biolog-
ical targets including enzymes (kinases) and G protein-coupled receptors. From 
the present study, it follows that the effects of general molecular properties on the 
binding kinetics of a ligand to Kv11.1 channel are negligible compared to other 
targets. 
Previous studies have also suggested that koff values, or drug-target residence 
times (RTs, the reciprocal of koff), play an important role in the duration of phar-
macological effects15, 24, 42. In other words, an increased drug–target RT could 
elicit an improved or prolonged drug effect 47. Nevertheless, when adverse ef-
fects result directly from drug occupancy at the pharmacological target, such as 
chlorpromazine binding to D2 receptor or clopidogrel to P2Y12 receptor, a long 
RT would result in so-called ‘on-target’ drug toxicity, and thus a short RT is fa-
vored48. In our hands, however, the dissociation rates and hence residence times 
of selected 15 Kv11.1 inhibitors were very similar (Table 3). On the contrary, 
association rates of our reference compounds varied widely, and are therefore 
potentially more important to predict the safety of Kv11.1 inhibitors.
Previously, Redfern et al.14 have assigned drugs into five categories of tor-
sadogenic propensity and proposed a “30-fold safety margin” between Cmax and 
Kv11.1 IC50 values as a marker to predict TdP. However, it is known that TdP are 
not only induced by inhibition of the Kv11.1 channel but also regulated by other 
potassium channels, sodium and calcium channels14, 49. Therefore, a Comprehen-
sive in vitro Proarrhythmia Assay (CiPA) has recently been introduced to assess 
drug-induced proarrhythmic risk more efficiently and accurately49, 50. The kinet-
ics of drug block and unblock were suggested to be incorporated together with 
drug potency at ion channels in arrhythmia evaluation during the interpretation of 
this paradigm49. Although the present study focuses on the Kv11.1 channel only, 
it provides a new medium throughput method to determine the association and 
dissociation rates of Kv11.1 blockers, which can be used subsequently for other 
ion channels as well, if a radioligand is available. Interestingly, Veroli et al.51 
derived from mathematical models that fast binding Kv11.1 blockers in the un-
trapped configuration and trapped blockers induced greater action potential and 
QT prolongation. This strengthens the application of our method in the future, 
and suggests that using slow association and/or fast dissociation characteristics as 
a “novel marker” might be beneficial for reducing Kv11.1 cardiotoxicity of drug 
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candidates. 
In conclusion, a novel [3H]dofetilide competition association assay has been 
successfully developed and validated to characterize the kinetic binding param-
eters of unlabelled compounds at the Kv11.1 channel. Importantly, association 
rates of Kv11.1 blockers were divergent, i.e. not diffusion limited, and excellently 
correlated to their affinity values. In addition, membrane interactions and other 
molecular properties do not influence the affinity and kinetic binding parameters 
of ligands at the Kv11.1 channel. Altogether, this is quite unlike the mechanisms 
of interaction proposed for other drug target classes, such as kinases and G pro-
tein-coupled receptors. Hence, we postulate that association rates can be used 
to assess a compound’s Kv11.1 liability, apart from its affinity. However, further 
studies involving compounds with a wide range of koff values are required to as-
sess the effect of residence time on drug-induced Kv11.1 cardiotoxicity. Overall, 
we believe that this research provides novel insights into the kinetic study of ion 
channels, which can hopefully help to avoid Kv11.1-induced cardiotoxicity of 
drug candidates in the future. 
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Abstract
We explored structure-kinetics relationships and structure-affinity relationships 
in four series of Kv11.1 (hERG) blockers. We learned that despite dramatic dif-
ferences in affinity and association rates, there were hardly any variations in the 
dissociation rate constants of these molecules with residence times (RTs) of a few 
minutes only. Hence, we synthesized sixteen novel molecules, in particular in the 
pyridinium class of compounds, to further address this peculiar phenomenon. We 
found molecules with very short RTs (< 1 min) and much longer RTs (> 100 min). 
This enabled us to construct a kon-koff-KD kinetic map for all compounds, provid-
ing a possible framework for a further and more precise categorization of Kv11.1 
blockers. Additionally, two representative compounds were tested in patch clamp 
assays, and their RTs were compared with patch clamp IC50 values. Our findings 
strongly suggest that the simultaneous study of ligand affinity and kinetic param-
eters may help to explain and predict Kv11.1-mediated cardiotoxicity. 
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Introduction
Cardiac safety has become a major concern facing the pharmaceutical industries 
and regulatory agencies over the last several decades. A substantial number of 
drugs, including both cardiac and non-cardiac medications, have been restricted 
in their applications or withdrawn from the market due to their Kv11.1-induced 
cardiotoxicity.1, 2 The Kv11.1 channel, often referred to as the human ether-à-go-
go-related gene (hERG) K+ channel, mediates the most important component of 
phase 3 repolarization of human ventricular myocytes.3 Blockade of the Kv11.1 
channel can lead to the prolongation of action potential durations (APDs) and 
an elevated risk of lethal arrhythmias such as Torsade de Pointes (TdP).4 As a 
consequence, measurement of Kv11.1 liability of drugs is a critical component 
of regulatory guidelines for preclinical QT studies.5, 6 In this regard, a 30-fold 
safety margin between Kv11.1 IC50 and Cmax values (maximum free plasma con-
centrations) has been proposed to define the cardiac safety of compounds.7 How-
ever, this approach of considering IC50 values solely is rather arbitrary and crude, 
which might explain unsatisfactory quantitative predictions and sometimes ex-
cludes useful medications that are not problematic.6, 8, 9 For instance, the IC50 val-
ue of ketoconazole (1-[4-(4-{[(2R,4S)-2-(2,4-Dichlorophenyl)-2-(1H-imidazol-
1-ylmethyl)-1,3-dioxolan-4-yl] methoxy}phenyl)piperazin-1-yl]ethan-1-one) at 
the Kv11.1 channel is relatively close to its effective therapeutic plasma concen-
tration (11-fold difference), yet it has been proven to be a safe drug in clinical 
trials due to the fact that this drug has a slow binding rate and is not trapped into 
the channel.9, 10 Therefore, knowledge of association and dissociation kinetics of 
drugs at the Kv11.1 channel may be important in defining their propensities to 
prolong the QT interval. 
The concept of structure-affinity relationships (SARs) describing the interde-
pendency between compound structures and binding affinity has been extensive-
ly explored over the past decades.11, 12 However, similar studies illustrating the 
dependency between compound structures and binding kinetics, coined as struc-
ture-kinetics relationships (SKRs), have been less well investigated to date. Re-
cently, drug-target kinetics, in particular receptor-ligand residence times (RTs), 
have been shown to also determine the therapeutic potential of drug candidates in 
vivo, and to be predictive of drug efficacy and safety.13, 14 Consequently, there is 
an emerging awareness of the importance of measuring the kinetics of drug-tar-
get interactions. SKRs are now being reported and discussed for ligand binding 
to G protein-coupled receptors (GPCRs) and enzymes.11, 15-17 With regard to ion 
channels, measuring the interaction kinetics of drugs with the Kv11.1 channel 
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Proarrhythmia Assay (CiPA) strategies to hopefully provide significant improve-
ments of proarrhythmic assessments.18, 19 Recent studies have demonstrated that 
Kv11.1 blockers with similar potency (IC50 values) but distinct binding kinetics 
can have markedly diverse proarrhythmic potential, suggesting the necessity to 
extend Kv11.1 inhibition assays with studies on investigating the dynamics of 
drug-channel interactions.1, 8, 9 In addition, particular interest has arisen in the 
so-called trapping phenomenon, characterized by capture of a drug within the 
Kv11.1 channel and thus a slow dissociation rate from the channel, which harbors 
an enhanced proarrhythmic risk caused by the drug.20, 21 Moreover, a substantial 
underestimation of cardiac risks has been observed in assessing the ventricular 
action potential due to neglecting drug-binding kinetics at cardiac Kv11.1 chan-
nels.8 Therefore, there is an urgent need to add the dimension of binding and 
unbinding kinetics to the more routinely determined affinity values in order to 
evaluate the arrhythmogenic potential of drug candidates in vitro. 
In our previous studies, we have successfully validated a [3H]dofetilide com-
petition association assay that can determine the association/dissociation rates 
and RTs of compounds accurately and efficiently.2 In the present study a structur-
ally diverse set of Kv11.1 blockers with four different scaffolds were newly syn-
thesized or selected from our in-house library published previously,22-25 and their 
kinetic parameters (kon, koff, KD and RTs) as well as affinity (Ki) were determined 
in [3H]dofetilide binding assays. A kon-koff-KD ‘kinetic map’ was delineated for 
all compounds together with three reference compounds: astemizole (1-[(4-flu-
orophenyl)methyl]-N-[1-[2-(4-methoxyphenyl)ethyl]-4-piperidyl]benzoimid-
azol-2-amine, a notorious Kv11.1 blocker), dofetilide (N-[4-(2-{[2-(4-methane 
sulfonamidophenoxy)ethyl] (methyl)amino}ethyl)phenyl]methanesulfonamide, 
a specific Kv11.1 blocker with restricted usage in the market) and ranolazine 
((RS)-N-(2,6-dim-ethylphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)-propyl]
pipe-razin-1-yl]acetamide, a safe Kv11.1 blocker).
2, 26-28 Two compounds were 
further tested in a manual patch clamp assay. The SARs and SKRs derived for the 
compounds in this study reveal new features and aspects of the blockers’ interac-
tions with the Kv11.1 channel. This information is expected to provide valuable 
information for circumventing Kv11.1-induced cardiotoxicity during the preclin-
ical stages of the drug discovery pipeline.
Results and discussion
Chemistry
Compounds 19, 20, 24, 25, 27-30 and 39-46 were newly synthesized in order to 
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obtain compounds with various RT values besides a diverse range of Ki and kon 
values. All other compounds were selected from our in-house library based on 
their distinct affinity and kinetic parameters, and synthesis of these compounds 
has been reported in our previously published studies.22-25 
As shown in Scheme 1, clofilium (4-(4-Chlorophenyl)butyl-diethyl-hep-
tylammonium) derivatives 19 and 20 were prepared from 4-iodotoluene in a 
3-step sequence as following: Sonogashira cross-coupling of 4-iodotoluene and 
propargyl alcohol, formation of the corresponding tosylate and displacement of 
the tosylate with the corresponding secondary amine.24 
Scheme 1. Synthesis of clofilium derivatives (19 and 20)
i) PdCl2(PPh3)2, CuI, Et3N, THF, r.t.; ii) tosyl chloride, KOH, Et2O, 0 °C to r.t.; iii) K2CO3, 
DMF, r.t.  
To investigate the effect of flexibility in the side chains of aliphatic pyridini-
um derivatives, several symmetrical 2,6-substituted N-methylated-pyridine com-
pounds with different alkyl chain lengths (24, 25 and 27-30) were synthesized 
according to Scheme 2. The first series of compounds (S23a-e) were derived 
from commercially available 2,6-dibromo-pyridine and 1-alkynes with various 
lengths via a Sonogashira coupling reaction.25 The final compounds (24, 25 and 
27-29) were synthesized in relatively high yields by reduction of triple bonds to 
single bonds and methylation of neutral pyridines. 30 was obtained directly from 
S23e by methylation of the central nitrogen with a good yield of 94%. 
Next, influences of different substituents at the phenyl rings on affinity 
and kinetic parameters of Kv11.1 blockers were explored, and a series of sub-
stituted biphenyl pyridines (39-46) were synthesized. As displayed in Scheme 
3, compound S32 was obtained by Sonogashira reaction of 2,6-dibromo-pyri-
dine and ethynyltrimethylsilane with Pd(PPh3)4 and CuI as catalysts instead of 
PdCl2(PPh3)2 and CuI displayed in Scheme 2.
29 After one-pot deprotection and 
Castro-Stephens coupling with 1-bromo-4-iodobenzene,30 S32 was converted to 
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Scheme 2. Synthesis of symmetrical 2,6-substituted N-methylated pyridines with various 
alkyl chain lengths
i) PdCl2(PPh3)2, CuI, Et3N, r.t.; ii) 10% Pd/C, H2, THF, MeOH, r.t.; iii) CF3SO2OCH3, 
CH2Cl2, 0 °C to r.t. 
Scheme 3. Synthesis of symmetrical 2,6-substituted N-methylated pyridines with differ-
ent biphenyl substituents
A) Synthesis of compounds 39, 40, 43, 44 and 46: i) Pd(PPh3)4, CuI, diisopropylamine, 
toluene, r.t.; ii) CuCl ,PPh3, potassium benzoate, 1-bromo-4-iodobenzene, DMI, 120 
°C; iii) Pd(PPh3)4, K2CO3, toluene, ethanol, substituted-phenylboronic acid, 50 °C; iv) 
CF3SO2OCH3, CH2Cl2, 0 °C to r.t.
B) Synthesis of compound 45: i)  BBr3, CH2Cl2, -78 °C to r.t.
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Glaser homo-coupling and intra-polymerization of reacting molecules.31 Suzuki 
reactions were further performed with S33 and different substituted phenylbo-
ronic acids to yield the neutral pyridine compounds (S34a-e),32 from which final 
compounds (39, 40, 43, 44 and 46) were derived via methylation of the central 
nitrogen in moderate to high yields. Subsequently, demethylation of 44 with bo-
ron tribromide led to the formation of compound 45. Notably, synthetic routes 
mentioned above were not suitable for producing neutral biphenyl pyridines with 
methoxy and chlorine substituents at the meta-position of the second benzene 
ring. Hence, 41 and 42 were synthesized by different methods shown in Scheme 
4. In the first step, Suzuki reactions were applied between the substituted phen-
ylboronic acid and 1-bromo-4-iodobenzene in the presence of different palla-
dium catalysts to produce S43a and S43b in moderate yields of 27% and 40%, 
respectively. S43a and S43b further reacted with ethynyltrimethylsilane through 
Sonogashira reaction,33 resulting in high yields of S44a and S44b. Compound 
41 was eventually obtained from S44a with a yield of 36% through three steps: 
deprotection, Sonogashira reaction and methylation, whereas 42 was obtained 
from S44b via a one-pot Sonogashira reaction and methylation in a yield of 45%. 
Scheme 4. Synthesis of symmetrical 2,6-substituted N-methylated pyridines (41 and 42)
A) Synthesis of compounds S44a-b: i) 2M K2CO3, Pd(PPh3)4, toluene, ethanol, 80 °C; ii) 
2M K2CO3, Pd(OAc)2, PPh3, toluene, ethanol, 80 °C; iii) PdCl2(PPh3)2, CuI, PPh3, THF, 
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Biology
The binding affinity and kinetic parameters of all compounds were determined 
in [3H]dofetilide competitive displacement and competition association assays 
on HEK293 cell membranes stably transfected with the Kv11.1 channel (HEK-
293Kv11.1) as described previously by our group.
2 As shown in Figure 1, com-
pounds with a wide range of IC50 values demonstrated a monophasic binding 
behavior instead of a biphasic pattern reported for a [3H]astemizole binding as-
say,23, 25 indicating that the binding process of compounds followed a single-step 
bimolecular interaction scheme, and thus, fulfilled the theoretical requirements 
B) Synthesis of compound 41: i) 2M NaOH, diethyl ether, methanol; ii) PdCl2(PPh3)2, 
CuI, Et3N, 2, 6-dibromo-pyridine; iii) CF3SO2OCH3, CH2Cl2, 0 °C to r.t.  
C) Synthesis of compound 42: i) CuCl, PPh3, potassium benzoate, 2, 6-dibromo-pyridine, 
DMI, 120 °C; ii) CF3SO2OCH3, CH2Cl2, 0 °C to r.t.  
Figure 1. Representative displacement curves of specific [3H]dofetilide binding by 9, 25, 
31, 37, 38 and 40. Experiments were performed at 25 °C using 20 µg of HEK293Kv11.1 
membrane protein.
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for the Motulsky-Mahan approach to evaluate the binding kinetics of unlabeled 
ligands.34 Figure 2 shows the competition association assay for three representa-
tive compounds (31, 37 and 38) with different binding kinetics, in particular vary-
ing RTs. Compound 37 had a shorter RT than [3H]dofetilide with an association 
curve slowly and monotonically approaching equilibrium versus time, whereas 
38 possessed a longer RT compared to the radioligand, indicated by a typical 
‘overshoot’ and then a decline in the association curve.15 Meanwhile, 31 exhibited 
a RT similar to dofetilide, evidenced by the same curve shape compared to the 
association curve of radioligand alone. As the Ki values of all tested compounds 
calculated from the IC50 values mentioned above,
35 were in good agreement with 
kinetically derived KD data (KD = koff/kon, Figure 3A), only Ki values were used 
to summarize the SARs in this study. The consistency of Ki and KD values ex-
tended our previous finding to a more general observation,2 proving the reliability 
of the [3H]dofetilide competition association assay in assessing the kinetics of 
unlabeled ligands at the Kv11.1 channel. In addition, the kon values for all ligands 
were significantly correlated to their Ki values (P < 0.0001, Figure 3B), which is 
in agreement with our published data.2 In the same publication affinity and kinetic 
parameters of the parental compounds dofetilide, E-4031 and clofilium were also 
measured and reported.2  Furthermore, a provisional kon-koff-KD ‘kinetic map’ was 
constructed based on the compounds’ varying affinity and kinetic parameters in 
order to divide these compounds into four different groups (quadrants) of poten-
tially negligible (quadrant IV), moderate (quadrant I and III) and high arrhyth-
mic (quadrant II) side effects (Figure 4). Finally, we selected two compounds (21 
and 38) with comparable binding affinity but distinct association and dissociation 
rates or RTs to be studied in a whole-cell patch clamp assay using the same HEK-
293Kv11.1 cells (Figure 5).
Figure 2. Representative competition association curves of [3H]dofetilide in the absence 
(control) or presence of unlabeled 31, 37 and 38 at their IC50 value concentrations. Ex-
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A B
Figure 3. Correlation between pKi and pKD (A, r
2 = 0.95, P < 0.0001) or pkon (B, r
2 = 0.68, 
P < 0.0001) values of all tested compounds as obtained from [3H]dofetilide competitive 
displacement experiments and competition association assays, respectively.
Structure-affinity relationships (SARs) and structure-kinetics 
relationships (SKRs)
Derivatives of dofetilide
First, we explored the effects of pKa values of the central nitrogen on affinity, 
association rates and RTs of compounds 1-8 (Table 1), in which the pKa values 
were taken from our previous publication.22 Briefly, increasing the pKa values 
via different N-alkyl substituents resulted in an increase of affinity of these com-
pounds (1-5, 7 and 8) at the Kv11.1 channel. Association rates of these compounds 
were less sensitive to pKa alterations but showed a similar trend as the affinity. 
For instance, compound 8 (pKa = -4.95) displayed the lowest affinity and smallest 
kon value, while 3 (pKa = 9.61) had the highest affinity and fastest association rate 
at the channel. These changes corresponded rather well with the principle that 
reducing pKa values of the central nitrogen of Kv11.1 blockers decreases the pro-
portion of molecules in the protonated form at physiological pH and further make 
fewer active species available for the productive π-cation interactions with amino 
acid Tyr652 lining the inner cavity of the channel.36, 37 Additionally, zwitterionic 
compound 6 with a CH2COOH substituent at the central nitrogen had a lower 
affinity and slower association rate than 8, indicating that the negatively charged 
carboxylate group caused unfavorable interactions of the Kv11.1 blocker with the 
channel.38 Overall, however, the RTs (1/koff) of 1-8 were not much impacted by 
pKa values of the central nitrogen and zwitterionic propensity of molecules, with 
values between 0.56 ± 0.06 (7) and 3.8 ± 1.0 min (3). 
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Compd R1 R2 R3 n1 n2 Ki (nM) kon (nM
-1·min-1) koff (min
-1) KD (nM) RT (min)
1 4-NO2 4-NO2 H 2 2 47±1 0.0054±0.0015 0.27±0.06 53±6 3.7±0.8
2 4-NO2 4-NO2 CH3 2 2 24±2 0.041±0.004 0.82±0.09 20±4 1.2±0.1
3 4-NO2 4-NO2 CH2CH3 2 2 4.2±0.5 0.15±0.06 0.26±0.07 3.0±0.2 3.8±1.0
4 4-NO2 4-NO2 CH2CH2F 2 2 65±13 0.0096±0.0019 0.30±0.08 41±11 3.3±0.9
5 4-NO2 4-NO2 CH2CN 2 2 203±6 0.0046±0.0012 0.40±0.05 99±26 2.5±0.3
6 4-NO2 4-NO2 CH2COOH 2 2 588±31 0.0013±0.0001 0.35±0.10 260±52 2.9±0.8
7 4-NO2 4-NO2 COCH3 2 2 251±32 0.0098±0.0034 1.8±0.2 132±5 0.56±0.06
8 4-NO2 4-NO2 COCF3 2 2 355±14 0.0025±0.0003 0.61±0.09 247±27 1.6±0.3
9 4-NO2 4-NO2 CH3 4 2 1.6±0.3 0.64±0.29 0.26±0.05 0.73±0.39 3.8±0.7
10 4-NO2 4-NO2 CH3 4 1 66±6 0.0028±0.0008 0.22±0.05 85±7 4.5±1.0
11 3, 4-di-Cl 3, 4-di-Cl CH3 2 2 5571±507 (6.2±3.0)x10
-5 0.19±0.01 5807±228 5.3±0.2
12 H 4-OCH3 CH3 2 2 944±58 (5.6±0.9)x10
-4 0.30±0.07 591±197 3.3±0.7
Next, the lengths of side alkyl linkers and substituents on the phenyl rings 
were investigated for the analysis of SARs and SKRs. Comparable to our own 
studies on distance-related flexibility,24, 39 elongation of the alkyl chain between 
the central nitrogen and phenoxy moiety enhanced the Kv11.1 affinity and asso-
ciation rates (9 versus 2), while shortening the other alkyl linker with the phenyl 
ring lowered the affinity and association rates (10 versus 2 and 9). Nonetheless, 9 
(RT = 3.8 ± 0.7 min) and 10 (RT = 4.5 ± 1.0 min) demonstrated similar dissocia-
tion characteristics at the Kv11.1 channel compared to other compounds in Table 
1, suggesting that varying chain lengths between the central nitrogen and the two 
peripheral aromatic rings exerted negligible effects on the dissociation process 
of this type of ligands from the Kv11.1 channel. In addition, replacement of NO2 
groups on the phenoxy and phenyl rings with 3,4-di-Cl or other groups like OCH3 
dramatically decreased the Kv11.1 affinity and association rates of ligands (11 and 
12 versus 2). Compound 11 had the lowest affinity (Ki = 5571 ± 507 nM), slowest 
association rate (kon = 6.2 ± 3.0)×10
-5 nM-1·min-1) but longest RT of 5.3 ± 0.2 min 
at the Kv11.1 channel amongst all dofetilide derivatives (1-12). This implies that 
addition of electron-withdrawing groups on the aromatic rings reduces the affini-
ty and association kinetics of Kv11.1 blockers by hampering their π-stacking and 
hydrophobic interactions with Phe656 and Tyr652 residues lining the pore cavity 
of the Kv11.1 channel,
36, 40 whereby this hindered interaction did not obviously 
disturb the dissociation of ligands. Overall, the association rates of this series of 
compounds were (negatively) correlated to their Ki values (see also Figure 3B), 
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Kv11.1 channel are mainly regulated by the compounds’ association rates.
2 Un-
like the widely varying Ki and kon values, RTs of these dofetilide analogues were 
largely similar.
Derivatives of E-4031
Benzoylpiperidine analogues (13, 14 and 16) demonstrated comparable Ki and 
kon values at the Kv11.1 channel. This implicates that: i) electron withdrawing or 
donating groups at the two peripheral rings, ii) slightly lengthening the carbon 
chain between the central nitrogen atom and the phenyl ring and iii) permanent 
protonation of the basic nitrogen, had much smaller effects on Kv11.1 affinity and 
association kinetics of E-4031 (N-[4-[1-[2-(6-Methylpyridin-2-yl)ethyl]piperi-
dine-4-carbonyl]phenyl]) derivatives (Table 2) compared to the dofetilide series 
(Table 1). However, when the benzoylpiperidine was replaced by benzoylpip-
erazine (15), the Ki value was drastically increased to 5418 ± 374 nM and its 
association rate was substantially decreased to (2.7 ± 0.6)×10-4 nM-1·min-1. Dis-
tinct from the variations in affinity and association rates, all E-4031 derivatives 
displayed comparably short RTs between 2.0 ± 0.5 (14) and 2.9 ± 0.8 min (16) at 
the Kv11.1 channel. 







Compd R1 R2 X R3 n Ki (nM) kon (nM
-1·min-1) koff (min
-1) KD (nM) RT (min)
13 4-Cl 3, 4-di-Cl CH - 2 54±3 0.021±0.009 0.39±0.06 36±22 2.6±0.4
14 4-CH3 H CH - 3 60±2 0.017±0.003 0.49±0.12 34±14 2.0±0.5
15 H H N - 2 5418±374 (2.7±0.6)x10-4 0.46±0.03 1812±313 2.2±0.1
16 4-Cl H CH CH3 2 48±1 0.048±0.022 0.35±0.09 18±9 2.9±0.8
Derivatives of clofilium
Comparable to our own and other studies,24, 25, 41 increasing the rigidity by in-
troduction of alkene and alkyne moieties in the chain between the phenyl ring 
and central nitrogen atom diminished the Kv11.1 affinity and association rates of 
clofilium derivatives (18 and 21 versus 17, Table 3), whereby permanent proton-
ation of the central nitrogen atom with a CH2CH3 group resulted in a dramatic 
enhancement of the affinity and association rate (Ki = 1.8 ± 0.2 nM and kon = 
0.17 ± 0.07 nM-1·min-1 for 22). Therefore, rigidity and protonation play pivotal 
roles in determining the affinity and association rates of clofilium analogues at 
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the Kv11.1 channel. However, permanently protonating the central nitrogen ob-
viously imposed more significant effects on Kv11.1 affinity and association rates, 
and thus compensated for the negative influences exerted by increasing rigidity 
via introduction of an alkyne bond (22 versus 17). According to different in-silico 
Kv11.1 models, protonation of the central nitrogen atom facilitates the π-cation 
interaction of ligands with the crucial binding residue (Tyr652) that faces into 
the S6 domain of the channel.36, 42-44 With regard to dissociation characteristics, 
compounds 17 and 18 had similar RTs at the Kv11.1 channel (2.7 ± 0.3 and 2.0 
± 0.5 min for 17 and 18, respectively), while 21 and 22 having an alkyne moiety 
displayed longer RTs. Subsequently, two novel compounds with an alkyne group 
but different side chain lengths (19 and 20) were synthesized in order to obtain 
more variations in dissociation rate constants or RTs. Both compounds exhibited 
comparably low affinity and slow association rates at the Kv11.1 channel, indi-
cating the flexibility adjusted by side chain lengths imposed insignificant effects 
on weakening Kv11.1 affinity and association kinetics of this series of ligands. 
Likewise, the dissociation rates of 19 and 20 were identical with comparatively 
longer RTs of 7.7 ± 1.6 and 6.7 ± 2.0 min, respectively. Altogether, introduction 
of an alkyne group in these clofilium analogues slightly increased their RTs at the 
Kv11.1 channel (19-22 versus 17-18). With all these clofilium derivatives (Table 
3), their association rates illustrated the same overall tendency as the affinity 
shown in Figure 3B. Most importantly, compound 22 showed the highest affinity, 
fastest association rate and longest RT, implying a strong and prolonged inhibi-
tion of the Kv11.1channel. 
Table 3. Binding affinity and kinetic parameters of clofilium derivatives
R1 A N n
R2
Compd R1 R2 A n Ki (nM) kon (nM
-1·min-1) koff (min
-1) KD (nM) RT (min)
17 4-Cl-C6H4CH2 - CH2CH2  6 31±5 0.048±0.019 0.37±0.04 16±10 2.7±0.3
18 C6H5CH2 - HC CH 6 119±2 0.0098±0.0042 0.50±0.12 86±45 2.0±0.5
19 4-CH3-C6H5 - C C 6 3282±613 (3.2±2.0)x10-4 0.13±0.03 1188±122 7.7±1.6
20 4-CH3-C6H5 - C C 2 1196±141 (3.1±0.7)x10-4 0.15±0.05 637±339 6.7±2.0
21 (C6H5)2CH - C C 6 97±13 0.0035±0.0008 0.27±0.06 100±52 3.7±0.8
22 4-Cl-C6H5 CH2CH3 C C 6 1.8±0.2 0.17±0.07 0.13±0.04 1.2±0.6 7.7±2.6
Derivatives of pyridinium
As compounds with high lipophilicity can bind to residue Phe656 of the Kv11.1 
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maticity is not essential for their Kv11.1 binding.
25, 37 In this context, eight ali-
phatic pyridinium analogues with various side chains (23-30) were synthesized 
or selected to define their SARs and SKRs (Table 4). Several general observa-
tions can be made: i) permanently protonating the central nitrogen atom by a 
methyl substituent (23 versus other compounds), and ii) increasing flexibility via 
stretching the side alkyl chain from n = 3 to n = 6 (24 versus 25-27) enhanced 
the Kv11.1 affinity of compounds. However, the binding affinity were decreased 
with iii) the continuous prolongation of side chains up to n=7 (24 versus 28-29) 
and iv) replacement of alkane with alkyne (29 versus 30). All these results are in 
excellent agreement with protonation and rigidity rules,45 and with the fact that 
the large aperture at the bottom of the Kv11.1 channel cavity has boundaries that 
accommodate molecules with defined sizes.46 Likewise, protonation, flexibility of 
side chains and rigidity by an alkyne moiety exerted the same overall effects on 
association rates of these aliphatic pyridines, which implicates that the affinity of 
aliphatic pyridinium blockers were correlated to their association rate constants 
at the Kv11.1 channel (see also for dofetilide, E-4031 and clofilium derivatives, 
Figure 3B). Intriguingly, RTs in this series of compounds tended to be longer and 
different from the three other compound classes mentioned above as well as from 
our previous data.2 The newly synthesized compound 29 had the longest RT of 36 
± 2 min, whereas 24 showed the shortest RT with 4.3 ± 0.8 min. In addition, pyr-
idines with n-octyl side chains (23, RT = 19 ± 1 min) presented a comparable RT 
to 26 (25 ± 1 min) and 28 (16 ± 4 min) at the Kv11.1 channel. Apparently, perma-
nent protonation of the central nitrogen atom (23 versus 26) and prolongation of 
side alkyl chains (28 versus 23 and 26) had much less influence on RTs compared 
to their roles in overall affinity and association rates. It is noteworthy that more 
rigidity induced by an alkyne moiety diminished the RT to 8.3 ± 1.7 min for 30. 
Altogether, increasing rigidity of aliphatic pyridine blockers can decrease their 
affinity, association rates and RTs simultaneously (30 versus 29), and thus, it may 
provide an efficient solution for circumventing Kv11.1 side effects of drug can-
didates. In a second series of pyridinium analogues (31-33), the Kv11.1 affinity 
and association rates were also increased by permanent protonation of the central 
nitrogen atom (32 versus 31) but decreased with an alkyne moiety (33 versus 32). 
However, the RTs of 31-33 were comparable between 7.7 ± 0.7 (32) and 9.1 ± 1.7 
min (33), indicating different dissociation profiles of these compounds compared 
to aliphatic pyridinium analogues of which rigidity affected the RTs significantly.
Next, a series of biphenyl substituted pyridinium derivatives (34, 35 and 38-
46) together with their precursors (36 and 37) were synthesized or selected to 
achieve more variations in RTs. As shown in Table 4, permanent protonation 
and rigidification by alkyne imposed the same effects on Kv11.1 affinity as our 
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findings for other derivatives (34 versus 35-46 and 35 versus 36-46, respective-
ly). Additionally, decreasing bulkiness via removal of the second benzene rings 
or replacing the aromatic phenyl rings close to the central nitrogen atom with 
cyclohexyl diminished the affinity of Kv11.1 blockers (36-37 versus 38), possi-
bly caused by reduced π-stacking and hydrophobic interactions.36 Furthermore, 
introduction of different groups at the second benzene rings lowered their Kv11.1 
affinity compared to the non-substituted compound (39-45 versus 38), indicating 
a possible steric hindrance of these groups in ligand binding.22, 25 Although the kon 
values showed a comparable decline to affinity because of the increased rigidity 
by an alkyne moiety (35 versus 38-46) and reduction of the aromatic rings (36 
versus 37), the negative relationship between Ki and kon values was not conspic-
uous for this series of compounds. For instance, compound 38 showed a smaller 
Ki value as well as slower association rate than 39. On the contrary, the RTs of 
these compounds were significantly increased by replacing ethyl with alkyne (35 
versus 38-46). Moreover, decreasing bulkiness of these pyridinium analogues led 
to shorter RTs (36-37 versus 38-46). Compound 36 and 37 showed the shortest 
RTs amongst all these derivatives, providing evidence that reduced bulkiness fa-
cilitates unbinding dynamics of Kv11.1 blockers at the channel. Our findings are 
contradictory to the classic ‘foot-in-door’ mechanism, in which bulky residues 
of Kv11.1 blockers prevent the closure of the channel gate and thus promote the 
channel recovery from blockade.20 The explanation for our results is that less 
hydrophobic interactions and smaller sizes of molecules can accelerate the disso-
ciation of such ligands from the channel. Compound 38 without any substituents 
on the benzene rings had the longest RT of 105 ± 4 min at the Kv11.1 channel, 
while substituents at the second benzene rings (39-46) often had distinct and 
lowering effects on RTs. While introducing CH3 (40) and Cl (42) at the meta-po-
sition did not affect RTs significantly, a substituent at the ortho-position (39) of 
the benzene rings reduced the RT, like at the para-position (43-46) but to a lesser 
extent (43 versus 39). Secondly, a methoxy group at the meta-position of the 
second benzene rings was less favorable for maintaining long RTs (41 versus 40 
and 42). A similar observation was made for the two compounds with 4-OCH3 
(44) and 4-OH (45) groups at the second benzene rings, of which RTs were de-
creased to 24 ± 4 and 19 ± 3 min, respectively, particularly when compared with 
46 (63 ± 4 min) and 43 (30 ± 6 min). Collectively, we have successfully obtained 
compounds with divergent RTs (i.e. approx. 300-fold difference, between 37 and 
38) next to varied affinity and association rates, which provides the possibility 
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Compd A R n Ki (nM) kon (nM
-1·min-1) koff (min
-1) KD (nM) RT (min)
23 CH2CH2 - 5 36870±10861 (2.8±0.4)x10-7 0.052±0.002 190546±27585 19±1
24 CH2CH2 CH3 3 12±1 0.020±0.005 0.23±0.04 12±0 4.3±0.8
25 CH2CH2 CH3 4 0.28±0.01 0.25±0.08 0.10 ± 0.02 0.44±0.05 10± 2
26 CH2CH2 CH3 5 3.5±0.3 0.023±0.004 0.040±0.002 1.9±0.5 25±1
27 CH2CH2 CH3 6 3.4±0.9 0.018±0.003 0.069±0.005 4.0±0.6 14±1
28 CH2CH2 CH3 7 17±3 0.0017±0.0002 0.064±0.015 37±5 16±4
29 CH2CH2 CH3 9 108±10 (1.8±0.2)x10
-4 0.028±0.001 153±10 36±2




Compd A R Ki (nM) kon (nM
-1·min-1) koff (min
-
1) KD (nM) RT (min)
31 CH2CH2 - 3654±81 (1.6±0.3)x10-5 0.11±0.01 6631±536 9.1±0.8
32 CH2CH2 CH3 6.0±0.5 0.022±0.003 0.13±0.01 6.1±1.2 7.7±0.7




Compd R1 A R2 B Ki (nM) kon (nM
-1·min-1) koff (min
-1) KD (nM) RT (min)
34 - C C C6H5 C6H4 >100 µM n.d. n.d. n.d. n.d.
35 CH3 CH2CH2 C6H5 C6H4 63±9 0.0016±0.0003 0.098±0.021 60±4 10±2
36 CH3 C C H C6H10 1208±36 (3.3±1.2)×10-4 0.30±0.05 1074±268 3.3±0.6
37 CH3 C C H C6H4 498±107 0.0086±0.0020 2.9±0.3 368±61 0.34±0.04
38 CH3 C C C6H5 C6H4 86±12 (7.5±1.0) ×10-5 0.0095±0.0003 132±19 105±4
39 CH3 C C 2-CH3-C6H5 C6H4 577±41 (3.5±0.3)×10-4 0.071±0.004 203±19 14±1
40 CH3 C C 3-CH3-C6H5 C6H4 122±15 (1.4±0.2)×10-4 0.010±0.003 72±18 100±30
41 CH3 C C 3-OCH3-C6H5 C6H4 176±10 (3.7±0.4)×10-4 0.047±0.009 125±13 21± 4
42 CH3 C C 3-Cl-C6H5 C6H4 139±20 (8.3±0.9)×10-5 0.011±0.002 135±14 91±17
43 CH3 C C 4-CH3-C6H5 C6H4 303±49 (8.6±1.0)×10-5 0.033±0.006 440±78 30±6
44 CH3 C C 4-OCH3-C6H5 C6H4 247±44 (4.5±0.2)×10-4 0.042±0.007 105±16 24± 4
45 CH3 C C 4-OH-C6H5 C6H4 153±32 (5.1±0.7)×10-4 0.053±0.008 103±3 19±3
46 CH3 C C 4-Cl-C6H5 C6H4 71±9 (1.6±0.2)×10-4 0.016±0.001 100±10 63±4
n.d.: not detectable.
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Kinetic map
Using the kinetic data in Tables 1-4, we plotted the dissociation rates (pkoff, y axis) 
against association rates (pkon, x axis) of all our compounds together with three 
reference compounds (astemizole, dofetilide and ranolazine) into a kinetic map 
(Figure 4). The parallel diagonal dashed lines represent the kinetically derived 
KD values. In this kon-koff-KD map, compounds with the same affinity or associ-
ation rates may have divergent dissociation rates or RTs, and vice versa. There-
fore, risk assessment and possible mitigation of inhibitory efficacies of Kv11.1 
blockers should take association rates (kon) and RTs into account rather than af-
finity alone. In this context, all ligands were divided into four quadrants (I, II, III 
and IV) according to our hypothesis that high affinity, fast association rates and 
slow dissociation rates (long RTs) contribute together to serious Kv11.1-induced 
cardiotoxicity. The affinity and kinetic parameters of astemizole, dofetilide and 
ranolazine were derived from our previous investigation.2 Astemizole was distrib-
uted into quadrant II, as it is a specific Kv11.1 blocker and has been withdrawn 
from the market.26, 27 On the other hand, ranolazine was assigned to quadrant IV, 
since it inhibits the Kv11.1 channel but does not cause proarrhythmic events.
28 In 
addition, dofetilide is restrictedly used in the United States due to its low and fi-
nite TdP by blocking the Kv11.1 channel,
27, 47, 48 and consequently, it was scattered 
into quadrant III. Obviously, compounds in quadrant II have high affinity (KD < 
316 nM), fast association rates (kon > 3.2×10
-4 nM-1·min-1) and slow dissociation 
rates or long RTs (> 10 min) at the Kv11.1 channel, indicating that they may cause 
serious arrhythmias via blockade of the channel. On the other hand, quadrant IV 
comprises compounds with low affinity (KD > 316 nM), slow association rates 
(kon < 3.2×10
-4 nM-1·min-1) and fast dissociation rates or short RTs (< 10 min) at 
the channel, suggesting their possible cardiac safety in terms of Kv11.1 inhibition. 
Quadrants I and III encompass moderately active Kv11.1 blockers with either 
relatively low affinity, slow kon (< 3.2×10
-4 nM-1·min-1) and koff (RT > 10 min, 
I) or comparatively high affinity, fast kon (> 3.2×10
-4 nM-1·min-1) and koff (RT < 
10 min, III). Most likely these two different classes of compounds have modest 
Kv11.1-related cardiac side effects. Taken together, this arbitrary and provisional 
kinetic map that can be further extended with other suspected Kv11.1 blockers 
sheds light on Kv11.1-induced cardiotoxicity of drugs by bringing together their 
affinity as the traditional safety parameter with their kinetic parameters of asso-
ciation and dissociation rates (or RTs) at the channel. Therefore, a similar map 
would provide valuable information on how to accurately and comprehensively 
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Figure 4. Kinetic map of all tested compounds in which the dissociation rate (pkoff, koff: 
min-1) is plotted on the y axis, whereas the association rate (pkon, kon: nM
-1·min-1) is plotted 
on the x axis. Identical KD values can result from different combinations of kon and koff val-
ues (KD = koff/kon, diagonal dashed lines). Quadrants (I, II, III, IV) are arbitrarily defined 
by red horizontal and green vertical lines according to the varied kon, koff and KD values in 
combination with three reference compounds astemizole (red dot), dofetilide (yellow dot) 
and ranolazine (green dot). The intersection of red and green lines are arranged on the 
diagonal dashed line representing a KD value of 316 nM, while their intercepts with y and 
x axis are 1 (RT = 10 min) and 3.5 (kon = 3.2×10
-4 nM-1·min-1), respectively. Note that the 
kinetic parameters of compound 34 could not be determined due to its rather low Kv11.1 
affinity and thus is excluded in this map.
Patch clamp study
A whole-cell voltage patch clamp assay was applied to determine the functional 
hERG current blockade by 21 and 38, two compounds with similar affinity but 
different RTs. As shown in Figure 5A, the IC50 values for 21 and 38 from their 
concentration-effect curves in the patch clamp assay were 182 ± 6 and 107 ± 6 
nM, respectively. However, 21 and 38 had almost identical affinity in the radioli-
gand binding assay with Ki values of 97 ± 13 and 86 ± 12 nM, respectively. RTs 
of ligands have been found to be correlated to their efficacies in functional assays 
rather than affinity at the adenosine A2A receptor.
49 Thus, we surmised that the 
difference in IC50 values obtained in functional patch clamp assays for these two 
compounds might be caused by their different RTs, with 38 (long RT of 105 ± 4 
min) displaying a higher potency in Kv11.1 current inhibition than 21 (short RT 
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of 3.7 ± 0.8 min). The time-dependent inhibition of the Kv11.1 current for 21 and 
38 was also assessed in the whole-cell patch clamp assay. As shown in Figure 
5B, compound 21 with a faster association rate (0.0035 ± 0.0008 nM-1·min-1) in 
the radioligand binding assay almost completely inhibited Kv11.1 currents within 
10 min, whereas 15 min was required for 38 (kon = (7.5 ± 1.0)×10
-5 nM-1·min-1) 
to approach the equilibrated current inhibition. Therefore, association rates mea-
sured in the [3H]dofetilide competition association assay may be linked to the 
current inhibition rates of compounds in the functional patch clamp experiments. 
Although different wash-in times for Kv11.1 blockers have been observed on an 
automated patch clamp platform before,23 this is the first time to interpolate the 
radioligand binding parameters, especially for the association and dissociation 
rates, into functional data derived from patch clamp assays. 
A B
Figure 5. (A) Concentration-dependent inhibition of 21 and 38 for the Kv11.1 tail cur-
rent in electrophysiological experiments. (B) Time-dependent inhibition of the Kv11.1 
tail current by 21 and 38 (1 µM). Experiments were performed at room temperature using 
HEK293Kv11.1 cells. 
Conclusion
Although affinity and association rates of compounds at the Kv11.1 channel have 
been found to differ vastly and are correlated to each other, this study is the 
first to verify that Kv11.1 blockers can possess very different RTs, with up to a 
more than 300-fold difference (37 versus 38) at the channel. Furthermore, this 
comprehensive investigation on derivatives of dofetilide, E-4031, clofilium and 
pyridinium over a range of scaffolds is the first to illustrate the impact of sever-
al parameters outlined above on association rates and RTs of compounds at the 
Kv11.1 channel in addition to their binding affinity. Notably, unlike the consisten-
cy of SARs for all compounds, SKRs are more chemical scaffold-dependent, in 
particular the structure-RT relationships. According to these findings and helped 
by the substantial differences in affinity, association and dissociation rate con-
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map, and divided all these compounds into four quadrants (toxic for quadrant II, 
safe for quadrant IV and suspicious for quadrant I and III in Figure 4), which 
might provide valuable information for pharmaceutical researchers to devise bet-
ter strategies for assessing Kv11.1 liability. Additionally, the association rates of 
two selected compounds were found to correspond well with their current block 
rates in the patch clamp studies, and their distinct RTs are a possible reason for 
their differences in functional potency when compared to their binding affinity. 
Although far from complete this analysis further indicates that kinetic parameters 
(kon and RTs) should be taken into consideration as well as affinity (Ki) during 
the investigation of Kv11.1-mediated adverse reactions. To conclude, the new 
finding of large variations in RTs promotes the extensive analysis of structure-RT 
relationships, and the combination of SARs and SKRs opens a new avenue for 




All commercially available chemicals and solvents were used without purification, 
except for ethyl acetate, which was distilled before usage. Demineralized water 
will be referred to as H2O, unless otherwise stated. Reactions were monitored by 
thin-layer chromatography (TLC) using TLC silica gel 60 F254 aluminum sheets. 
TLC visualization was performed by a LAMAG UV-light at a wavelength of 254 
or 366 nm. Grace Davison Davisil silica column material (LC60A 30-200 micron) 
was used for purification by column chromatography. 1H and 13C NMR spectra 
were recorded on a Bruker AV400 or AV600 spectrometer. Deuterated solutions 
CDCl3, DMSO or MeOD were used for sample preparation. Chemical shifts (δ) 
are given in ppm and coupling constants (J) in Hertz. Trimethylsilane was used 
as internal standard for calibrating chemical shift for 1H, 13C NMR spectroscopy. 
HPLC-analysis was carried out on a Phenomenex Gemini reversed-phase C18 
column (50 mm × 4.6 mm × 3 μm) coupled to a UV-detector at 254 nm. Final 
compounds were dissolved in either a mixture of acetonitrile:tert-butanol:water 
(1:1:1) or in pure acetonitrile and were eluted from the column at a flow rate of 
1.3 mL·min-1 with 10/90 acetonitrile/water + 10% TFA, decreasing polarity of 
this mixture in time. LC-MS analysis was performed on an LCQ Advantage Max 
(Thermo Finnigan) ion-trap spectrometer (ESI+) coupled to a Surveyor HPLC 
system (Thermo Finnigan) equipped with a C18 column (Phenomenex Gemini, 
50 mm x 4.6 mm, 5 μm). A linear gradient of 10/90 acetonitrile/water + a constant 
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10% of an 1% TFA in water solution was used as the mobile system. The purity of 
all final compounds was > 95%. High-resolution mass spectral analysis (HRMS) 
was performed by Leiden Institute of Chemistry by direct injection (2 μL of a 2 
μM solution in water/MeCN; 50/50; v/v and 0.1% formicacid) on a LTQ-Orbitrap 
FTMS operated in a positive ionization mode with an electrospray ionization 
(ESI) source (source voltage 3.5 kV, sheath gas flow 10%, capillary temperature 
275 ˚C) with resolution R = 60000 at m/z 400 (mass range m/z = 150-2000) and 
calibrated for dioctylphthalate (m/z = 391.28428). All microwave reactions were 
performed in a Biotage initiator 2.5 in a sealed microwave vial.
3-(P-tolyl)prop-2-yn-1-ol (S13). To a solution of 4-iodotoluene (5.45 g, 25 
mmol) in THF (33 mL) and Et3N (7.3 mL) were added PdCl2(PPh3)2 (35 mg, 0.5 
mmol) and CuI (327 mg, 1.7 mmol). The mixture was stirred for 30 minutes and 
a solution of propargyl alcohol (1.48 mL, 25 mmol) in THF (10 mL) was added 
dropwise. The mixture was stirred at r.t. for 12 hours and filtered on Celite. The 
solvents were evaporated and the crude residue was purified by flash chroma-
tography on silica gel (33% EtOAc-Petroleum ether) to afford pure S13 (2.54 g, 
70%) as an oil. Spectral data were in agreement with literature.50
3-(P-tolyl)prop-2-yn-1-yl 4-methylbenzenesulfonate (S14). To a stirred 
solution of S13 (1 g, 6.8 mmol) in diethylether (45 mL) at 0 °C was added tosyl 
chloride (1.6 g, 8.2 mmol) followed, portionwise, by freshly powdered KOH (3.8 
g, 68 mmol). After the addition was complete, the reaction mixture was stirred at 
room temperature for 3.5 h and then poured into water (90 mL). The layers were 
separated and the aqueous phase was extracted with EtOAc (3 × 40 mL). The 
combined organic extract was dried, filtered, concentrated in vacuo and chroma-
tographed (25% EtOAc - Petroleum ether) to obtain the title compound S14 (1.9 
g, 91%). 1H NMR (400 MHz, CDCl3) δ 7.87 (d, J = 8.2 Hz, 2H), 7.34 (d, J = 8.2 
Hz, 2H), 7.17 (d, J = 8.1 Hz, 2H), 7.11 (d, J = 8.1 Hz, 2H), 4.97 (s, 2H), 2.42 (s, 
3H), 2.36 (s, 3H) ppm.
General Sonogashira coupling procedure (S23a-e). 
PdCl2(PPh3)2 (148 mg, 0.21 mmol, 0.05 eq.) and CuI (121 mg, 0.63 mmol, 0.15 
eq.) was added to a solution of 2,6-dibromopyridine (1000 mg, 4.22 mmol, 1.0 
eq.) in Et3N (10 mL) and stirred for 30 min under a nitrogen atmosphere. The 
appropriate alkyne (10.1 mmol, 2.4 eq.) was added drop wise, and the mixture 
was stirred overnight at room temperature after which full conversion was shown 
by TLC. The reaction mixture was adsorbed on silica and purification by FCC 
yielded the desired compound.
2,6-di(hex-1-ynyl)pyridine (S23a). Prepared from hex-1-yne. FCC (petro-
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mg) 63%; 1H NMR (400MHz, CDCl3): δ 7.52 (t, J = 8.0 Hz, 1H), 7.25 (d, J = 8.0 
Hz, 2H), 2.42 (t, J = 7.0 Hz, 4H), 1.64-1.56 (m, 4H), 1.52-1.42 (m, 4H), 0.93 (t, 
J = 7.4 Hz, 6H).
2,6-Di(hept-1-ynyl)pyridine (S23b). Prepared from hept-1-yne. FCC (pe-
troleum ether:dichloromethane 4:1 tot 2:1) gave the desired product in a yield of 
(241 mg) 21%. 1H NMR (400MHz, CDCl3): δ 7.53 (t, J = 7.6 Hz, 1H), 7.25 (d, 
J = 7.6 Hz, 2H), 2.41 (t, J = 6.8 Hz, 4H), 1.64-1.60 (m, 4H), 1.44-1.31 (m, 8H), 
0.91 (t, J = 7.2 Hz, 6H).
2,6-Di(non-1-ynyl)pyridine (S23c). Prepared from non-1-yne. FCC (petro-
leum ether:dichloromethane 30:1 tot 4:1) gave the desired product in a yield of 
(247 mg) 18%. 1H NMR (400MHz, CDCl3): δ 7.52 (t, J = 7.6 Hz, 1H), 7.25 (d, 
J = 8.0 Hz, 2H), 2.41 (t, J = 7.2 Hz, 4H), 1.65-1.57 (m, 4H), 1.45-1.39 (m, 4H), 
1.35-1.26 (m, 12H), 0.89 (t, J = 6.4 Hz, 6H).
2,6-Di(dec-1-ynyl)pyridine (S23d). Prepared from dec-1-yne. FCC (petro-
leum ether:dichloromethane 5:1 to 3:1) gave the desired product in a yield of (210 
mg) 14%. 1H NMR (400MHz, CDCl3): δ 7.53 (t, J = 8.0 Hz, 1H), 7.25 (d, J = 7.6 
Hz, 2H), 2.41 (t, J = 7.2, 4H), 1.65-1.57 (m, 4H), 1.45-1.39 (m, 4H), 1.30-1.24 
(m, 16H), 0.88 (t, J = 6.8 Hz, 6H).
2,6-Di(dodec-1-ynyl)pyridine (S23e). Prepared from dodec-1-yne. FCC 
(petroleum ether : dichloromethane 5:1 to 2:1) gave the desired product in a yield 
of 79% (1131 mg). 1H NMR (400MHz, CDCl3): δ 7.53 (t, J = 7.6 Hz, 1H), 7.25 
(d, J = 8.0 Hz, 2H), 2.41 (t, J = 7.2 Hz, 4H), 1.64-1.57 (m, 4H), 1.44-1.39 (m, 
4H), 1.32-1.26 (m, 24H), 0.88 (t, J = 6.4 Hz, 6H). 
General procedure for reduction of pyridine alkynes (S24a-e).
The appropriate alkyne (S23a) (600 mg, 2.52 mmol) was dissolved in THF (3 
mL) and MeOH (3 mL) under a N2 atmosphere. 10% Pd/C (120 mg, 1.14 mmol) 
was added and H2 was introduced via a balloon. The mixture was stirred over-
night at r.t. after which the reaction mixture was filtered over Celite. The filtrate 
were concentrated under reduced pressure and FCC (petroleum ether:ethyl ace-
tate 20:1) gave the desired compound.
2,6-Dihexylpyridine (S24a). Prepared from S23a and purified by FCC (pe-
troleum ether:ethyl acetate 20:1) which gave the desired product in a yield of 
(469 mg) 75%. 1H NMR (400MHz, CDCl3): δ 7.48 (t, J = 7.6 Hz, 1H), 6.94 (d, J 
= 7.6 Hz, 2H), 2.75 (t, J = 7.6 Hz, 4H), 1.73-1.65 (m, 4H), 1.39-1.26 (m, 12H), 
0.88 (t, J = 6.8 Hz, 6H).  
2,6-Diheptylpyridine (S24b). Prepared from S23b and purified by FCC (pe-
troleum ether:dichloromethane 4:1 to 1:2) which gave the desired product in a 
yield of (106 mg) 43%. 1H NMR (400MHz, CDCl3): δ 7.47 (t, J = 7.6 Hz, 1H), 
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6.93 (d, J = 7.6 Hz, 2H), 2.75 (t, J = 7.6 Hz, 4H), 1.71-1.66 (m, 4H), 1.34-1.23 
(m, 16H), 0.87 (t, J = 6.8 Hz, 6H).
2,6-Dinonylpyridine (S24c). Prepared from S23c and purified by FCC (pe-
troleum ether:dichloromethane 4:1 to 1:2) which gave the desired product in a 
yield of (91 mg) 78%. 1H NMR (400MHz, CDCl3): δ 7.47 (t, J = 7.6 Hz, 1H), 
6.93 (d, J = 7.6 Hz, 2H), 2.75 (t, J = 8.0 Hz, 4H), 1.73-1.65 (m, 4H), 1.36-1.16 
(m, 24H), 0.86 (t, J = 4.4 Hz, 6H).
2,6-Didecylpyridine (S24d). Prepared from S23d and purified by FCC (pe-
troleum ether:dichloromethane 3:1 to 1:1) which gave the desired product in a 
yield of (153 mg) 71%. 1H NMR (400MHz, CDCl3): δ 7.48 (t, J = 7.6 Hz, 1H), 
6.94 (d, J = 7.6 Hz, 2H), 2.74 (t, J = 8.0 Hz, 4H), 1.73-1.65 (m, 4H), 1.32-1.25 
(m, 28H), 0.88 (t, J = 6.8 Hz, 6H).
2,6-Didodecylpyridine (S24e). Prepared from S23e and purified by FCC 
(petroleum ether:dichloromethane 4:1 to 1:1) which gave the desired product in 
a yield of (440 mg) 86%. 1H NMR (400MHz, CDCl3): δ 7.48 (t, J = 7.6 Hz, 1H), 
6.94 (d, J = 7.6 Hz, 2H), 2.75 (t, J = 7.6 Hz, 4H), 1.73-1.65 (m, 4H), 1.35-1.25 
(m, 36H), 0.88 (t, J = 6.8 Hz, 6H).
2,6-Bis((trimethylsilyl)ethynyl)pyridine (S32). 2,6-dibromopyridine (9.00 
g, 38.0 mmol), Pd(PPh3)4 (2.20 g, 1.90 mmol), CuI (361 mg, 1.90 mmol), diiso-
propylamine (9 mL) and toluene (100 mL) were stirred at r.t. and trimethylsilyla-
cetylene (13.0 mL, 91.2 mmol) was added. The mixture was stirred overnight fol-
lowed by filtration over Celite using CH2Cl2. The filtrate was concentrated under 
reduced pressure, dissolved in CH2Cl2, and washed with an 1M aqueous NH4Cl 
solution. The organic layer was dried over MgSO4, filtered and evaporated to dry-
ness. Yield quantitative and used in the next step without further purification. 1H 
NMR (CDCl3): δ 7.61 (t, J = 8.0 Hz, 1H), 7.38 (d, J = 7.6 Hz, 2H), 0.25 (s, 18H).
2,6-Bis((4-bromophenyl)ethynyl)pyridine (S33). To a solution of CuCl 
(346 mg, 3.50 mmol), PPh3 (918 mg, 3.50 mmol) and potassium benzoate (11.3 
g, 70.7 mmol) in 38 mL DMI (1,3-dimethyl-2-imidazolidinone) were added com-
pound S32 (9.60 g, 35.4 mmol) and 1-bromo-4-iodobenzene (20.0 g, 70.7 mmol) 
at r.t. The mixture was stirred at 120 °C for 4 h after which full consumption of 
S32 was seen. The mixture was cooled down, quenched with a 3M HCl (aq.) 
solution. The organics were extracted with CH2Cl2, and washed with subsequent-
ly NaHCO3 and brine. The organic layer was dried over MgSO4, filtered and the 
solvents were evaporated under vacuum. FCC (petroleum ether:dichloromethane 
10:1 to 2:1) gave the desired product. Yield (4.44 g) 29%; 1H NMR (CDCl3): δ 
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General Suzuki reaction procedure yielding compounds S34a-e. 
Compound S33 (0.2 mmol, 1.0 eq.), the respective substituted-phenylboronic 
acid (0.4 mmol, 2.0 eq.), 2M K2CO3 (10 eq.) (aq.) were dissolved in a mixture of 
3 mL toluene and 0.4 mL of ethanol. Pd(PPh3)4 (0.02 mmol, 0.1 eq.) were added 
and the mixture was heated in the microwave at 100 °C under a nitrogen atmo-
sphere for 24 h. After cooling down to room temperature, EtOAc was added and 
a precipitate was formed (S34b-e). The precipitate was collected by filtration, 
resulting in the desired products. 
2,6-Bis((2’-methylbiphenyl-4-yl)ethynyl)pyridine (S34a). Prepared from 
2-methylphenyl boronic acid according to the general procedure, but a precipi-
tate was not formed after addition of EtOAc. The organic layer was washed with 
a 2 × 0.5 M NaOH solution, dried over MgSO4, filtered and the solvents were 
evaporated in vacuo. Used this as a crude mixture in the next reaction. Yield (37 
mg) 50%. ESI-MS: 460.2 [M+H]+.
2,6-Bis((3’-methylbiphenyl-4-yl)ethynyl)pyridine (S34b). Prepared from 
3-methylphenyl boronic acid according to the general procedure. Yield (17 mg) 
16%; 1H NMR (CDCl3): δ 7.72-7.67 (m, 5H), 7.60 (d, J = 8.4 Hz, 4H), 7.50 (d, J 
= 8.0 Hz, 2H), 7.42 (d, J = 8.8 Hz, 4H), 7.35 (t, J = 7.2 Hz, 2H), 7.19 (d, J = 7.2 
Hz, 2H), 2.43 (s, 6H).
2,6-Bis((4’-methylbiphenyl-4-yl)ethynyl)pyridine (S34c) was obtained as 
a white solid. Yield (13 mg) 18%; 1H NMR (CDCl3): δ 7.72-7.70 (m, 5H), 7.59 
(d, J = 8.0 Hz, 4H), 7.52-7.49 (m, 6H), 7.30-7.24 (m, H), 2.41 (s, 6H).
2,6-Bis((4’-methoxybiphenyl-4-yl)ethynyl)pyridine (S34d). Prepared from 
4-methoxyphenyl-boronic acid according to the general procedure. Yield (55 mg) 
49%; 1H NMR (CDCl3): δ 7.72-7.64 (m, 5H), 7.57-7.45 (m, 9H), 7.00 (d, J = 8.0 
Hz, 4H), 7.30-7.24 (m, H), 2.41 (s, 6H).
2,6-Bis((4’-chlorobiphenyl-4-yl)ethynyl)pyridine (S34e). Prepared from 
4-chlorophenyl boronic acid according to the general procedure. Yield (56 mg) 
49%; 1H NMR (CDCl3): δ 7.74-7.65 (m, 5H), 7.59-7.47 (m, 10H), 7.43 (d, J = 
8.4 Hz, 4H).
4’-Bromo-3-methoxybiphenyl (S43a). Palladium acetate (40.0 mg, 0.18 
mmol) was added to mixture of 1-bromo-4-iodobenze (500 mg, 1,77 mmol), 
3-methoxy-phenylboronic acid (269 mg, 1.77 mmol), triphenylphosphine (139 
mg, 0.53 mmol), a 2M K2CO3 aqueous solution (5 mL) in toluene (15 mL) and 
EtOH (2 mL). This mixture was heated at 50 °C for 24 h., after which it was 
cooled to room temperature and partitioned between ethyl acetate and water. The 
organic layer was washed with brine, dried over MgSO4, filtered and evaporated. 
FCC (petroleum ether:ethyl acetate 1:0 to 4:1) gave the desired product. Yield 
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(126 mg) 27%; 1H NMR (CDCl3): δ 7.55 (d, J = 8.4 Hz, 2H), 7.45 (d, J = 8.8 Hz, 
2H), 7.36 (t, J = 8.0 Hz, 1H), 7.15-7.13 (m, 1H), 7.08 (t, J = 2.4 Hz, 1H), 6.93-
6.90 (m, 1H), 3.86 (s, 3H).
4’-Bromo-3-chlorobiphenyl (S43b). Prepared from 1-bromo-4-iodobenzene 
and 3-chloro-phenylboronic following the procedure of 4-bromo-3-methoxybi-
phenyl (S43a). The reaction was performed at 80° C for 20 h. FCC (petroleum 
ether) gave the compound 190 mg, 40%. 1H NMR (CDCl3): δ 7.56 (d, J = 8.4 Hz, 
2H), 7.53 (t, J = 1.6 Hz, 1H), 7.47-7.43 (m, 3H), 7.36 (t, J = 8.0 Hz, 1H), 7.34-
7.31 (m, 1H). 
General procedure for Sonogashira coupling between 4’-bromo-3-subs-
tituted-biphenyl and ethynyltrimethylsilane. Compound S43a (126 mg, 0.48 
mmol), PdCl2(PPh3)2 (7.0 mg, 0.01 mmol), CuI (4.0 mg, 0.02 mmol), PPh3 (5.0 
mg, 0.02 mmol) and trimethylsilylacetylene (123 μL, 0.86 mmol) were dissolved 
in THF (1 mL) and piperidine (200 μl) was added. This was heated in the mi-
crowave at 120 °C for 12 min. The mixture was extracted with diethyl ether and 
washed with aq. H2SO4 (10%), water and brine. The organic layer was dried over 
MgSO4, filtered and evaporated. FCC (petroleum ether:ethyl acetate 1:0 to 10:1) 
gave the desired ((3’-Methoxybiphenyl-4-yl)ethynyl)trimethylsilane (S44a). 
Yield (104 mg) 78%. 1H NMR (CDCl3): δ 7.53 (s, 4H), 7.35 (t, J = 8.0 Hz, 1H), 
7.18-7.15 (m, 1H), 7.12-7.00 (m, 1H), 6.90 (dd, J1 = 8.0 Hz, J2 = 2.8 Hz, 1H), 
3.86 (s, 3H), 0.27 (s, 9H).
((3’-Chlorobiphenyl-4-yl)ethynyl)trimethylsilane (S44b). Following the 
procedure of S44a starting from S43b. Yield (49 mg) 64%.1H NMR (CDCl3): δ 
7.56 (t, J = 2.0 Hz, 1H), 7.53 (d, J = 8.4 Hz, 2H), 7.50 (d, J = 8.8 Hz, 2H), 7.45 
(dt, J1 = 7.6 Hz, J2 = 1.6 Hz, 1H), 7.36 (t, J = 7.6 Hz, 1H), 7.32 (dt, J1 = 8.0 Hz, 
J2 = 2.0 Hz, 1H), 0.27 (s, 9H). 
4’-Ethynyl-3-methoxybiphenyl (S45). To a solution of S44a (104 mg, 0.37 
mmol) in diethyl ether (3 mL) was added methanol (3 mL) and 2M NaOH (1 
mL). After 10 min of stirring at room temperature the mixture was neutralized 
with 2M HCl (aq.). The layers were separated and the organic layer was washed 
with brine and water, dried, filtered over MgSO4 and concentrated. The product 
was used without further purification. 
2,6-Bis((2’-methoxybiphenyl-4-yl)ethynyl)pyridine (S46). Reaction con-
ditions according to the general Sonogashira coupling procedure (S23a-e), start-
ing from S45 and S21. Purified by FCC (petroleum ether:ethyl acetate 4:1 to 1:1). 
Yield (23 mg) 25%. 1H NMR (CDCl3): δ 7.72-7.65 (m, 5H), 7.60 (d, J = 8.4 Hz, 
4H), 7.51 (d, J = 7.6 Hz, 2H), 7.38 (t, J = 8.4 Hz, 2H), 7.20 (d, J = 8.0 Hz, 2H), 
7.14 (s, 2H), 6.93 (dd, J1 = 8.2 Hz, J2 = 2.0 Hz, 2H), 3.88 (s, 6H).
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compounds S21 and S44b. FCC (petroleum ether:dichloromethane 20:1 to 1:2). 
Yield (16 mg) 19%. 1H NMR (CDCl3): δ 7.70-7.66 (m, 4H), 7.59-7.55 (m, 6H), 
7.53 (d, J = 5.2 Hz, 1H), 7.50-7.44 (m, 4H), 7.39 (t, J = 8.0 Hz, 2H), 7.34 (d, J = 
8.0 Hz, 2H).
N-Ethyl-N-(3-(p-tolyl)prop-2-yn-1-yl)heptan-1-amine (19). To a solution 
of S14 (300 mg, 1 mmol) in DMF (5 mL) was added K2CO3 (415 mg, 3 mmol) 
followed by N-ethylheptylamine (280 µL, 1.5 mmol). The mixture was stirred 
at r.t. for 1 hour and diluted with water (5 mL), extracted with EtOAc (3 × 10 
mL) and the organic layers were dried on MgSO4, filtered and the solvent was 
removed in vacuo. The crude residue was purified by flash chromatography on 
silica gel (20% EtOAc-Petroleum ether) to afford pure 19 as an oil. Yield (228 
mg) 84%; 1H NMR (400 MHz, CDCl3) δ 7.32 (d, J = 8.0 Hz, 2H), 7.10 (d, J = 
8.0 Hz, 2H), 3.62 (s, 2H), 2.61 (q, J = 7.2 Hz, 2H), 2.53 (t, J = 7.6 Hz, 2H), 2.34 
(s, 3H), 1.52–1.49 (m, 2H), 1.31–1.26 (m, 8H), 1.11 (t, J = 7.2 Hz, 3H), 0.88 (t, 
J = 7.2 Hz, 3H) ppm; 13C NMR (101 MHz, CDCl3) δ 137.9, 131.6, 129.0, 120.3, 
85.0, 83.8, 53.6, 47.7, 42.1, 31.9, 29.3, 27.6, 27.5, 22.7, 21.4, 14.1, 12.7 ppm. 
HPLC: tR = 7.39 min; HRMS (ESI): m/z [M + H]
+ calcd for C19H29N: 272.2373, 
found: 272.2370. 
N-Ethyl-N-propyl-3-(p-tolyl)prop-2-yn-1-amine (20). To a solution of S14 
(300 mg, 1 mmol) in DMF (5 mL) was added K2CO3 (415 mg, 3 mmol) followed 
by N-ethylpropylamine (180 µL, 1.5 mmol). The mixture was stirred at r.t. for 1 
hour and diluted with water (5 mL), extracted with EtOAc (3 × 10 mL) and the 
organic layers were dried on MgSO4, filtered and the solvent was removed in vac-
uo. The crude residue was purified by flash chromatography on silica gel (20% 
EtOAc- Petroleum ether) to afford pure 20 as oil. Yield (170 mg) 79%; 1H NMR 
(400 MHz, CDCl3) δ 7.32 (d, J = 8.0 Hz, 2H), 7.10 (d, J = 8.0 Hz, 2H), 3.62 (s, 
2H), 2.61 (q, J = 7.2 Hz, 2H), 2.50 (t, J = 7.6 Hz, 2H), 2.34 (s, 3H), 1.53 (sex, J 
= 7.6 Hz, 2H), 1.11 (t, J = 7.2 Hz, 3H), 0.93 (t, J = 7.6 Hz, 3H) ppm; 13C NMR 
(101 MHz, CDCl3) δ 137.9, 131.6, 129.0, 120.3, 85.0, 83.8, 55.6, 47.6, 42.1, 21.4, 
20.8, 12.7, 12.0 ppm. HPLC: tR = 5.70 min; HRMS (ESI): m/z [M + H]
+ calcd for 
C15H21 : 216.1747, found: 216.1745.
General methylation procedure to yield pyridines 24, 25, 27-30, 39-44 and 
46. 
The respective compound S23e, S24a-e, S34a-e, S46 and S47 (1.0 eq.) was dis-
solved in CH2Cl2 (40 mL per mmol) and stirred at 0 °C under a N2 atmosphere. 
Methyl trifluoromethanesulfonate (2.8 eq.) was added and the mixture was stirred 
overnight. After adsorption of the crude on silica, FCC gave the desired com-
pound eluting with a mixture of dichloromethane:methanol.
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2,6-Dihexyl-1-methylpyridinium trifluoromethanesulfonate (24). Pre-
pared from S24a and purified by FCC (dichloromethane:methanol 60:1 to 20:1) 
to give the desired product. Yield (660 mg) 85%; 1H NMR (400MHz, CDCl3): δ 
8.20 (t, J = 8.0 Hz, 1H), 7.64 (d, J = 8.0 Hz, 2H), 4.21 (s, 3H), 3.12 (t, J = 7.6 Hz, 
4H), 1.81-1.74 (m, 4H), ), 1.52-1.45 (m, 4H), 1.39-1.29 (m, 8H), 0.91 (t, J = 6.8 
Hz, 6H); 13C NMR (101 MHz, CDCl3): δ 159.7, 144.2, 126.0, 39.7, 34.5, 31.4, 
28.9, 27.6, 22.5, 14.1 ppm. HPLC purity: 99.3% (tR 8.24 min); ESI-MS: 262.27 
[M].
2,6-Diheptyl-1-methylpyridinium trifluoromethanesulfonate (25). Pre-
pared from S24b and purified by FCC (dichloromethane:methanol 30:1 to 20:1) 
to give the desired product. Yield (143 mg) 86%; 1H NMR (400MHz, CDCl3): δ 
8.18 (t, J = 7.6 Hz, 1H), 7.63 (d, J = 8.0 Hz, d), 4.22 (s, 3H), 3.13 (t, J = 8.0 Hz, 
4H), 1.82-1.74 (m, 4H), 1.52-1.44 (m, 4H), 1.41-1.36 (m, 12H), 0.90 (t, J = 6.4 
Hz, 6H); 13C NMR (101 MHz, CDCl3): δ 159.8, 144.1, 126.0, 122.4, 119.2, 39.7, 
34.6, 31.7, 29.3, 29.0, 27.7, 22.7, 14.2 ppm. HPLC purity: 97% (tR 8.96 min); 
ESI-MS: 290.33 [M].
2,6-Dinonyl-1-methylpyridinium trifluoromethanesulfonate (27). Pre-
pared from S24c and purified by FCC (dichloromethane:methanol 30:1 to 15:1) 
to give the desired product. Yield (87 mg) 65%; 1H NMR (400MHz, CDCl3): δ 
8.18 (t, J = 8.0 Hz, 1H), 7.63 (d, J = 8.0 Hz, 2H), 4.22 (s, 3H), 3.12 (t, J = 7.6 Hz, 
4H), 1.82-1.74 (m, 4H), 1.50-1.46 (m, 4H), 1.44-1.28 (m, 20H), 0.89 (t, J = 6.4 
Hz, 6H); 13C NMR (101 MHz, CDCl3): δ 159.9, 144.0, 126.0, 39.8, 34.6, 32.0, 
29.5, 29.4, 27.7, 22.8, 14.2 ppm. HPLC purity: 100% (tR 10.21 min); ESI-MS: 
346.40 [M].
2,6-Didecyl-1-methylpyridinium trifluoromethanesulfonate (28). Pre-
pared from S24d and purified by FCC (dichloromethane:methanol 60:1 to 10:1) 
to give the desired product. Yield (166 mg) 74%; 1H NMR (400MHz, CDCl3): δ 
8.18 (t, J = 8.0 Hz, 1H), 7.63 (d, J = 8.0 Hz, 2H), 4.22 (s, 3H), 3.13 (t, J = 8.0 Hz, 
4H), 1.82-1.74 (m, 4H), 1.50-1.44 (m, 4H), 1.39-1.28 (m, 24H), 0.89 (t, J = 6.8 
Hz, 6H); 13C NMR (101 MHz, CDCl3): δ 159.7, 144.0, 125.9, 39.6, 34.4, 31.9, 
29.5, 29.4, 29.3, 29.2, 27.6, 22.7, 14.1 ppm. HPLC purity: 100% (tR 10.77 min); 
ESI-MS: 374.40 [M].
2,6-Didodecyl-1-methylpyridinium trifluoromethanesulfonate (29). Pre-
pared from S24e and purified by FCC (dichloromethane:methanol 30:1 to 20:1) 
to give the desired product. Yield (536 mg) 87%; 1H NMR (400MHz, CDCl3): δ 
8.19 (t, J = 8.0 Hz, 1H), 7.63 (d, J = 7.6 Hz, 2H), 4.21 (s, 3H), 3.12 (t, J = 8.0 Hz, 
4H), 1.81-1.73 (m, 4H), 1.51-1.44 (m, 4H), 1.38-1.27 (m, 32H), 0.88 (t, J = 6.8 
Hz, 6H); 13C NMR (101 MHz, CDCl3): δ 159.8, 144.1, 126.0, 39.7, 34.6, 32.0, 
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(tR 11.84 min); ESI-MS: 430.53 [M].
2,6-Di(dodec-1-ynyl)-1-methylpyridinium trifluoromethanesulfonate 
(30). Prepared from S23e and purified by FCC (dichloromethane:methanol 40:1 
to 20:1) to give the desired product. Yield (675 mg) 94%; 1H NMR (400MHz, 
CDCl3): δ 8.38 (t, J = 8.0 Hz, 1H), 7.90 (d, J = 8.0 Hz, 2H), 4.49 (s, 3H), 2.65 (t, J 
= 7.2 Hz, 4H), 1.74-1.65 (m, 4H), 1.48-1.41 (m, 4H), 1.30-1.27 (m, 24H), 0.88 (t, 
J = 6.8 Hz, 6H); 13C NMR (101 MHz, CDCl3): δ 144.3, 139.5, 130.7, 112.8, 72.9, 
45.1, 32.0, 29.7, 29.5, 29.4, 29.2, 29.1, 27.6, 22.9, 20.3, 14.2 ppm. HPLC purity: 
100% (tR 11.57 min); ESI-MS: 422.40 [M].
2,6-Di([4-(2-methylphenyl)phenyl]ethynyl)-1-methylpyridinium trifluo-
romethanesulfonate (39). Prepared from S34a and purified by FCC (dichloro-
methane:methanol 30:1 to 20:1) and preparative HPLC to give the desired prod-
uct. Yield (1 mg) 96%; 1H NMR (400MHz, CDCl3): δ 8.47 (t, J = 8.0 Hz, 1H), 
8.10 (d, J = 8.0 Hz, 2H), 7.77 (d, J = 8.0 Hz, 4H), 7.46 (d, J = 8.0 Hz, 4H), 
7.31-7.09 (m, 8H), 4.74 (s, 3H), 2.30 (s, 6H). HPLC purity: 96% (tR 9.97 min); 
ESI-MS: 474.33 [M].  
2,6-Di([4-(3-methylphenyl)phenyl]ethynyl)-1-methylpyridinium trifluo-
romethanesulfonate (40). Prepared from S34b and purified by FCC (dichloro-
methane:methanol 30:1 to 20:1) to give the desired product. Yield (18 mg) 78%. 
1H NMR (400MHz, CDCl3): δ 8.40 (t, J = 8.0 Hz, 1H), 8.03 (d, J = 8.0 Hz, 2H), 
7.73 (d, J = 8.0 Hz, 4H), 7.65 (d, J = 8.0 Hz, 4H), 7.41-7.37 (m, 4H), 7.35 (t, J = 
7.6 Hz, 2H), 7.22 (d, J = 7.2 Hz, 2H), 4.65 (s, 3H), 2.41 (s, 6H); 13C NMR (101 
MHz, CDCl3): δ 145.0, 143.9, 139.5, 138.9, 133.5, 129.4, 129.1, 128.1, 127.7, 
124.4, 117.5, 109.0, 81.2, 45.5, 21.7 ppm. HPLC purity: 98.65% (tR 10.24 min); 
ESI-MS: 474.33 [M].
2,6-Di([4-(3-methoxyphenyl)phenyl]ethynyl)-1-methylpyridinium tri-
fluoromethanesulfonate (41). Prepared from S46 and purified by FCC (di-
chloromethane:methanol 20:1 to 10:1) to give the desired product. Yield (12 mg) 
36%; 1H NMR (400MHz, CDCl3): δ 8.39 (t, J = 8.0 Hz, 1H), 8.02 (d, J = 8.0 Hz, 
2H), 7.73 (d, J = 8.0 Hz, 4H), 7.65 (d, J = 8.4 Hz, 4H), 7.37 (t, J = 7.6 Hz, 2H), 
7.18 (d, J = 8.0 Hz, 2H), 7.11 (s, 2H), 6.94 (dd, J1 = 8.2 Hz, J2 = 2.0 Hz, 2H), 4.63 
(s, 3H), 3.86 (s, 6H); 13C NMR (101 MHz, CDCl3): δ 160.3, 144.6, 143.9, 140.9, 
139.3, 133.5, 130.8, 130.3, 127.7, 119.7, 117.7, 114.0, 113.0, 108.8, 81.3, 77.4, 
55.5, 45.5, 29.9 ppm. HPLC purity: 99% (tR 9.56 min); ESI-MS: 506.33 [M].
2,6-Di([4-(3-chlorophenyl)phenyl]ethynyl)-1-methylpyridinium trifluo-
romethanesulfonate (42). Prepared from S47 and purified by FCC (dichloro-
methane:methanol 20:1 to 10:1) to give the desired product. Yield (9 mg) 45%; 
1H NMR (400MHz, CDCl3): δ 
1H NMR (400 MHz, CDCl3): δ 8.43 (t, J = 8.0 Hz, 
1H), 8.08 (d, J = 8.0 Hz, 2H), 7.78 (d, J = 8.0 Hz, 4H), 7.65 (d, J = 8.0 Hz, 4H), 
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7.57 (s, 2H), 7.48 (d, J = 7.2 Hz, 2H), 7.42-7.37 (m, 4H), 4.70 (s, 3H); 13C NMR 
(101 MHz, CDCl3/MeOD): δ 143.8, 143.4, 141.0, 139.3, 134.9, 133.3, 130.7, 
130.3, 128.5, 127.6, 127.1, 125.3, 117.9, 108.5, 80.8, 45.0, 29.5 ppm. HPLC pu-
rity: 99% (tR 10.20 min); ESI-MS: 514.33 [M].
2,6-Di(4-(4-methylphenyl)phenylethynyl)-1-methylpyridinium trifluoro-
methanesulfonate (43). Prepared from S34c and purified by FCC (dichlorometh-
ane:methanol 30:1 to 5:1) to give the desired product. Yield (27 mg) 48%; 1H 
NMR (400MHz, CDCl3): δ 8.43 (t, J = 8.0 Hz, 1H), 8.06 (d, J = 8.0 Hz, 2H), 7.75 
(d, J = 8.4 Hz, 4H), 7.67 (d, J = 8.4 Hz, 4H), 7.52 (d, J = 8.0 Hz, 4H), 7.29-7.26 
(m, 4H), 4.68 (s, 3H), 2.41 (s, 6H); 13C NMR (101 MHz, CDCl3/MeOD): δ 144.9, 
143.9, 139.4, 138.8, 136.3, 133.4, 133.3, 130.6, 129.8, 127.4, 127.0, 117.0, 109.1, 
80.9, 77.3, 21.1 ppm. HPLC purity: 99% (tR 10.28 min); ESI-MS: 474.40 [M].
2,6-Di([4-(4-methoxyphenyl)phenyl]ethynyl)-1-methylpyridinium tri-
fluoromethanesulfonate (44). Prepared from S34d and purified by FCC (di-
chloromethane:methanol 30:1 to 10:1) to give the desired product. Yield (42 mg) 
58%; 1H NMR (400MHz, CDCl3): δ 8.42 (t, J = 8.0 Hz, 1H), 8.04 (d, J = 8.0 Hz, 
2H), 7.73 (d, J = 8.4 Hz, 4H), 7.65 (d, J = 8.4 Hz, 4H), 7.57 (d, J = 8.8 Hz, 4H), 
7.00 (d, J = 8.8 Hz, 4H), 4.67 (s, 3H), 3.86 (s, 6H); 13C NMR (101 MHz, CDCl3/
MeOD): δ 160.1, 144.5, 143.7, 139.3, 133.3, 131.6, 130.4, 128.3, 127.0, 116.5, 
114.5, 109.3, 80.7, 55.4, 44.9 ppm. HPLC purity: 100% (tR 9.78 min); ESI-MS: 
506.33 [M].
2,6-Di([4-(4-hydroxyphenyl)phenyl]ethynyl)-1-methylpyridinium tri-
fluoromethanesulfonate (45). 44 (27 mg, 0.04 mmol) was dissolved in 2 mL 
CH2Cl2 and cooled to -78 °C under a nitrogen atmosphere. An 1M solution of 
BBr3 in CH2Cl2 (0.4 mL) was added and the reaction mixture was allowed to 
warm up to room temperature and stirring was continued for 2 h at room tempera-
ture, after which as shown by TLC (dichloromethane:methanol 30:1) full conver-
sion was reached. The reaction mixture was re cooled to -78 °C and quenched 
with H2O. After an hour the precipitate was filtered off and washed with H2O and 
CH2Cl2 respectively and dried in vacuo. Yield (12 mg) 48%. 
1H NMR (400MHz, 
DMSO): δ 9.81 (s, 2H), 8.56 (t, J = 8.4 Hz, 1H), 8.36 (d, J = 7.6 Hz, 2H), 7.89 
(d, J = 8.0 Hz, 4H), 7.83 (d, J = 8.4 Hz, 4H), 7.64 (d, J = 8.4 Hz, 4H), 6.90 (d, J 
= 8.8 Hz, 4H), 4.58 (s, 3H); 13C NMR (151 MHz, DMSO): δ 158.2, 143.6, 143.2, 
133.3, 130.6, 129.1, 128.2, 126.3, 116.4, 115.9, 106.0, 81.7, 45.2 ppm. HPLC 
purity 99% (tR 8.38 min); ESI-MS: 478.33 [M].
2,6-Di([4-(4-chlorophenyl)phenyl]ethynyl)-1-methylpyridinium trifluo-
romethanesulfonate (46). Prepared from S34e and purified by FCC (dichloro-
methane:methanol 30:1 to 10:1) to give the desired product. Yield (42 mg) 58%; 
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7.79 (d, J = 8.4 Hz, 4H), 7.67 (d, J = 8.4 Hz, 4H), 7.56 (d, J = 8.4 Hz, 4H), 7.46 
(d, J = 8.4 Hz, 4H), 4.74 (s, 3H); 13C NMR (101 MHz, CDCl3/MeOD): δ 143.8, 
143.6, 139.3, 137.7, 134.8, 133.4, 130.6, 129.2, 128.4, 127.4, 117.6, 108.6, 80.9, 
45.0 ppm. HPLC purity: 99% (tR 10.39 min); ESI-MS: 514.27 [M]. 
Biology
Chemical and regents
[3H]Dofetilide (specific activity 82.3 Ci·mmol-1) was purchased from Perkin-
Elmer (Groningen, The Netherlands). Astemizole was purchased from Sigma 
Aldrich (Zwijndrecht, The Netherlands). Bovine serum albumin (BSA, fraction 
V) was purchased from Sigma (St. Louis, MO, USA). G418 was obtained from 
Stratagene (Cedar Creek, USA). All the other chemicals were of analytical grade 
and purchased from standard commercial sources. Human embryonic kidney 
cells stably expressing the Kv11.1 channel (HEK293Kv11.1) were kindly provid-
ed by Dr Eckhard Ficker (University of Cleveland, USA).
Cell culture and membrane preparation
HEK293Kv11.1 cells were cultured and membranes were prepared and stored as 
described previously.51
Radioligand displacement assay
The binding affinity of all tested compounds was evaluated at 25 ºC in a [3H]
dofetilide competitive displacement assay as reported earlier.2
Radioligand competition association assay
The binding kinetics of unlabeled compounds were determined at 25 ºC using a 
[3H]dofetilide competition association assay as described before,2 and the con-
centrations of unlabeled compounds used in this assay were equivalent to their 
IC50 values. 
Patch clamp assay
HEK293Kv11.1 cells were cultured on 10 mm glass coverslips and placed in a 
perfusion chamber (Cell Microcontrols, Norfolk, USA) at room temperature and 
perfused with control or test solutions. Whole cell patch clamp measurements and 
data acquisition were performed using an Axopatch-200B amplifier controlled by 
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the pClamp software package version 10 (Axon Instruments, Foster City, CA). 
Patch pipettes were made with a Sutter P-2000 micropipette puller (Sutter Instru-
ment Company, Novato, USA) and had resistances of 1.5-2.5 MΩ after having 
been fire polished and filled with pipette solution. Control bath perfusion solu-
tion contained (mM): 140 NaCl, 4 KCl, 10 HEPES, 2 CaCl2, 1 MgCl2 (pH 7.2, 
NaOH), and the pipette filling solution consisted of (mM): 10 KCl, 125 K-Glu-
conate, 0.6 CaCl2, 2 MgCl2, 5 HEPES, 4 Na2ATP, 5 EGTA (pH 7.2, KOH). After 
establishing the whole cell configuration, capacitive transients and pipette access 
resistance were compensated for by 80%. 
The pulse protocol for whole cell voltage clamp measurements of Kv11.1-me-
diated ion currents was as following. Cells were depolarized to 20 mV from a 
holding potential -80 mV for 4000 ms, allowing a step current due to activation 
and inactivation of the Kv11.1 channels. This was followed by repolarization to 
a test potential of -50 mV for 5000 ms, during which a tail current was induced 
by the fast recovery from inactivation and slow deactivation of the channels. The 
peak tail currents were used for data analysis, and current inhibition was derived 
from dividing the mean tail current in the presence of selected compounds by the 
mean tail current under control conditions. Concentration-dependent effects of 
compounds 21 and 38 on Kv11.1 currents were tested at five different concentra-
tions with an equilibrium time of 6.5 min for each concentration in a perfusion 
system. To determine time-dependent effects, wash-in experiments were per-
formed with a perfusion of bath solution containing 1 µM 21 or 38. Clampfit 10.4 
(Axon Instruments, Foster City, CA) and Prism v. 5.1 (GraphPad, San Diego, CA, 
USA) were used in analyzing, processing and plotting the data.  
Data analysis
All experimental data were analyzed using the non-linear regression curve fitting 
program Prism v. 5.1 (GraphPad, San Diego, CA, USA). Apparent inhibitory 
binding constants (Ki values) were derived from the IC50 values according to 
the Cheng-Prusoff equation with the KD value obtained from saturation assay.
2, 35 
Association and dissociation rates for unlabeled compounds were calculated by 
fitting the data into the competition association model using “kinetics of compet-
itive binding”:34
KA = k1[L] + k2
KB = k3[I] + k4
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Where X is the time (min), Y the specific binding of [3H]dofetilide, k1 and 
k2 are the kon (M
-1·min-1) and koff (min
-1) of [3H]dofetilide, L the concentration of 
[3H]dofetilide (nM), Bmax the maximum specific binding (dpm) and I the concen-
tration of the unlabelled compound (nM). Fixing these parameters allowed the 
following parameters to be calculated: k3, which is the kon value (M
-1·min-1) of the 
unlabelled compound and k4, which is the koff value (min
-1) of the unlabelled com-
pound. The association and dissociation rates were used to calculate the kinetic 
KD values from the following equation: KD = koff/kon. The residence time (RT) was 
calculated according to the formula: RT = 1/koff. All values in this study are means 
of at least three independent experiments with SEM. 
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In this thesis I have explored the allosteric modulation and the kinetics of ligands 
at the Kv11.1 channel. The research in this thesis may provide valuable informa-
tion and potential approaches for relieving the Kv11.1-induced cardiotoxicity of 
drug candidates in the future. This chapter will summarize the major findings 
from these studies, and propose the future directions of this research field.
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Conclusions of this thesis
Allosteric modulations of the Kv11.1 channel
Nowadays, Kv11.1 blockade by potential drug candidates has received much at-
tention since it potentially causes proarrhythmic side effects. However, at the 
start of this research allosteric modulation of the Kv11.1 channel as an alternative 
way of drug interaction had not been studied in any significant detail. The unique 
structural features of the Kv11.1 channel, which were thoroughly reviewed in 
Chapters 1 and 2, imply the presence of multiple ligand binding sites at the 
channel with possible allosteric interactions between them. In Chapter 3, the 
allosteric effects of a plethora of compounds as well as potassium ions on the 
Kv11.1 channel were evaluated in both [
3H]astemizole and [3H]dofetilide bind-
ing assays. LUF6200 was identified as a negative allosteric modulator, whereas 
potassium ions behaved as positive allosteric modulators. Moreover, LUF6200 
and potassium ions acted on distinct allosteric sites at the Kv11.1 channel, and 
these binding sites showed positive cooperativity. This investigation is the first 
to provide direct evidence for allosteric modulation of the Kv11.1 channel using 
radioligand binding assays. 
Subsequently, a novel negative allosteric modulator LUF7244 was character-
ized with several different [3H]dofetilide binding assays (Chapter 4). LUF7244 
was found to decrease the affinity of the prototypical Kv11.1 blockers dofetilide, 
astemizole, sertindole and cisapride. Moreover, the antiarrhythmic propensity of 
this compound was revealed in a newly validated neonatal rat ventricular myo-
cyte (NRVM) model. Pretreatment of the NRVM monolayers with LUF7244 
relieved the arrhythmic events induced by astemizole, sertindole and cisapride. 
Importantly, LUF7244 per se did not significantly affect the action potential du-
rations of NRVMs. Concomittantly, LUF7244 displayed no obvious cytotoxicity 
upon a long exposure to NRVMs, and exerted negligible effects on astemizole 
at its intentional target (the human histamine H1 receptor). Taken together, this 
study has introduced allosteric modulation of the Kv11.1 channel as a new and 
effective strategy to reduce the unintended binding of drugs to the channel’s 
central cavity and to further prevent the proarrhythmic changes associated with 
this binding. This opens a promising avenue for abolishment of Kv11.1-induced 
cardiotoxicity of drug candidates via pharmacological combination therapy. Fol-
lowing this chapter, a series of compounds with the same scaffold as LUF7244 
were synthesized and further assessed for their allosteric effects on [3H]dofetilide 
binding to the Kv11.1 channel in Chapter 5. Structure-activity relationships were 
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timization of allosteric modulators of the Kv11.1 channel. Specifically, compared 
to LUF7244 several more potent negative allosteric modulators like 7f and 7p 
were obtained, implicating improved potency in subsequent ex vivo and in vivo 
antiarrhythmic studies. 
Kinetics studies of ligands at the Kv11.1 channel
Previous studies on Kv11.1 blockers have primarily focused on their equilibrium 
parameters such as affinity or potency at the channel. The kinetics of the interac-
tion between a drug and the Kv11.1 channel has rarely been investigated though, 
albeit that its importance has been reported with respect to other targets, like 
enzymes and G protein-coupled receptors. In Chapter 6, a novel [3H]dofetilide 
competition association assay was successfully developed and validated to char-
acterize the kinetic binding parameters of unlabeled compounds at the Kv11.1 
channel. The association rates of fifteen prototypical, structurally diverse Kv11.1 
blockers obtained in this assay were extremely divergent, with e.g., a 50,000-fold 
difference between moxifloxacin and clofilium, and correlated excellently to their 
affinity values at the channel. Meanwhile, membrane affinity determined in an 
immobilized artificial membrane column and other calculated physiochemical 
properties (molecular weight, pKa, and logD) did not correlate with the binding 
affinity and kinetics of these blockers at the channel. Collectively, these results 
lead to the conclusion that a compound’s affinity at the Kv11.1 channel is mainly 
regulated by its association rate instead of its dissociation rate. This finding is 
against the general dogma that affinity values of ligands for their targets are main-
ly dominated by their dissociation rates with diffusion limited association rates. 
In this case, association rates can therefore be used to evaluate the Kv11.1 liability 
of drug candidates, apart from the affinity. Since the dissociation rates of the se-
lected Kv11.1 blockers in Chapter 6 only exhibited a 10-fold difference between 
the fastest and slowest dissociating compounds, we therefore aimed to search for 
and design compounds with a wide range of RTs, i.e. reciprocal of dissociation 
rates at the channel, in Chapter 7 in order to explore the role of the dissociation 
process in Kv11.1 blockade. 
In Chapter 7, the association rates and RTs as well as affinity values of four 
compound series (dofetilide, E-4031, clofilium and pyridinium derivatives) at 
the Kv11.1 channel were determined and evaluated. Based on the results, the 
structure-kinetics relationships of these Kv11.1 blockers were explored next to 
their structure-affinity relationships. Interestingly, the RTs of these compounds, 
in particular the newly synthesized series of pyridinium derivatives, were up to 
300-fold different, in addition to dramatic differences in affinity and association 
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rates. For instance, compound 38 had a RT of 105 ± 4 min at the Kv11.1 channel, 
while 37 displayed a short RT that was only 0.34 ± 0.04 min. Subsequently, a 
“kon-koff-KD
” kinetic map was constructed to putatively categorize all compounds 
based on their potential Kv11.1 liability, together with three reference drugs (pos-
itive control astemizole, negative control ranolazine, and dofetilide). Lastly, two 
representative compounds were tested in patch clamp assays, and their patch 
clamp IC50 values and current inhibition rates were in agreement with the RTs 
and association rates derived from radioligand binding experiments, respectively. 
Altogether, the importance of incorporating kinetic binding parameters (associa-
tion and dissociation rates or RTs) into the current affinity-dominated paradigm is 
strongly suggested by our studies in order to more comprehensively and accurate-
ly evaluate the Kv11.1 liability of drug candidates. Overall, this work offers a new 
avenue for drug researchers to efficiently design ligands with less Kv11.1-induced 
cardiac side effects by considering ligand binding kinetics in the drug develop-
ment trajectory.
Future perspectives
Allosteric modulator as a therapeutic agent
Although the antiarrhythmic property of a negative allosteric modulator 
(LUF7244) was evidenced in a NRVM model (Chapter 4), the capability of this 
modulator to counteract the proarrhythmic effects of unintentional Kv11.1 block-
ers should be further investigated in human subjects due to a species difference 
in Kv11.1 characteristics between humans and rats.
1-3 Recent access to human-in-
duced pluripotent stem cell (hiPSC) derived cardiomyocytes (hiPSC-CMs) has 
offered a window of opportunity to overcome this bottleneck induced by spe-
cies-to-species differences. hiPSC-CMs have been demonstrated to exhibit the 
expected genomic, biochemical, mechanical and electrophysiological behavior 
of human cardiomyocytes as evidenced by RT-PCR, patch clamp, and/or immu-
nofluorescence techniques.2, 4-6 Most importantly, the IKr current mediated by the 
Kv11.1 channel has been observed in these hiPSC-CMs.
2, 5, 6 To date, different 
techniques have been explored to assess the drug-induced electrophysiological 
alterations of hiPSC-CMs, including whole-cell patch clamp, impedance-based 
cellular and multi-electrode array (MEA) assays.7, 8 For example, the cardiotox-
ic effects of selective Kv11.1 blockers E-4031 and dofetilide were successfully 
detected with the label-free xCELLigence RTCA Cardio system,9 and the MEA 
assays have been widely utilized to screen the Kv11.1 liability of compounds 
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technique can be introduced to further investigate the antiarrhythmic effects of 
LUF7244 in a hiPSC-MC model. In addition, a simple and low-cost integrated 
platform has been recently reported to mimic the functional properties of native 
heart by creating large areas of aligned hiPSC-CMs.11 Thus, the latter platform 
may produce more clinically and physiologically relevant data for drug screen-
ing, which can be applied to the follow-up studies on allosteric modulation of the 
Kv11.1 channel. Interestingly, Kv7.1 and Kv11.1 activators have shown compen-
satory effects on long QT syndromes (LQTSs) caused by dysfunctions of either 
channel type.13-15 Recently, Zhang et al. established a patient- and disease-specific 
model with hiPSC-CMs from family members affected by the Kv7.1-mediated 
LQTS type 1, and found that modulation of the Kv11.1 channel by ML-T531 
restored the action potential prolongation caused by this inherited dysfunction of 
the Kv7.1 channel.
16 As ML-T531 was identified as a negative allosteric modula-
tor in Chapter 4 of this thesis, Kv11.1 modulators are supposed to possess anti-
arrhythmic roles in congenital cardiac diseases.16 Therefore, hiPSC-CM models 
with different patient-specific LQTSs can be used to evaluate the proarrhythmic 
propensities of LUF7244 and other more potent modulators like 7f and 7p. Tak-
en together, negative allosteric modulators of the Kv11.1 channel can enable the 
rescue of inherited LQTSs alone as well as prevent drug-induced arrhythmias 
via combination therapy, making them an attractive and promising therapy in the 
future. 
The hiPSC-CM differentiation system mentioned above has brought unique 
in vitro cellular- or tissue-based assays for the future development of Kv11.1 mod-
ulators as a novel alternative to current antiarrhythmic treatments. However, a 
myriad of ex vivo and in vivo preclinical studies like Langendorff and animal ex-
periments as well as clinical evaluations are still required to eventually translate 
our negative allosteric modulators into a new class of therapeutic agents for both 
acquired and inherited arrhythmias. Currently, a zebrafish model of Kv11.1-me-
diated LQTS type 2 has been used as a high-throughput screening approach for 
compounds that are able to reverse the lengthened myocardial repolarization.12 
This high-throughput in vivo functional whole-organism model provides an effi-
cient opportunity for the future preclinical investigations of Kv11.1 modulators.
Of note, the current generation of negative allosteric modulators of the Kv11.1 
channel are not very potent (active in the micromolar range), which may raise 
concerns about their specificity and potential for cardiac and non-cardiac side 
effects. Thus, the characterization of the binding site of these modulators at the 
channel will be of particular interest in follow-up studies to facilitate the devel-
opment of more potent and specific modulators. Here, computational methods, 
mutational studies and crystallization of the Kv11.1 channel will bring useful in-
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formation for such research in the future.17, 18 Furthermore, more potent allosteric 
modulators can be synthesized according to the structure-activity relationships 
concluded in Chapter 5.
Binding kinetics of Kv11.1 blockers
Ligand binding kinetics in patch clamp assays
Radioligand binding assays are high-throughput and useful in the early assess-
ment of ligand binding to the Kv11.1 channel, yet they do not provide a func-
tional endpoint.19, 20 Conversely, voltage patch clamp assays have capabilities to 
produce the highest quality and most physiologically relevant data of precise and 
detailed activity of the channel function among all available methods, albeit with 
relatively low throughput.19, 21 Historically, potency of Kv11.1 blockers has been 
measured using patch clamp techniques due to the mandatory requirements of 
the ICH S7B guideline, while the binding kinetics of drugs at the channel were 
not.19, 22-24 Thus, it appears attractive and meaningful to establish patch clamp as-
says that can be used to directly determine the binding and unbinding kinetics of 
ligands at the Kv11.1 channel. In Chapter 7, two compounds with distinguished 
kinetic parameters, in particular RTs, were selected to evaluate their binding ki-
netics in the whole-cell patch clamp assay. Although the Kv11.1 current inhibition 
rates of tested compounds were in the same rank order as their association rates 
derived from the radioligand binding assay, the IKr currents displayed insignifi-
cant recovery from the inhibition by both ligands during the washout experiments 
(data not shown). Subsequently, whole-cell radioligand binding assays, which 
are different from membrane radioligand binding assays used in the whole thesis, 
were performed in cells with or without expression of the Kv11.1 channel. In 
this case, [3H]dofetilide exhibited comparable binding at empty HEK293 cells 
to that at HEK293 cells expressing the Kv11.1 channel (data not shown). Col-
lectively, we speculated that these Kv11.1 blockers with an intracellular binding 
site at the channel could be trapped within the cell after diffusing through the cell 
membrane, which made the direct measurement of ligand’s unbinding kinetics 
impossible. Therefore, a so-called inside-out patch clamp recording without drug 
trapping phenomena will be particularly useful to verify our speculation, as this 
technique will allow for accurately determining the “true” binding kinetics of 
ligands with an intracellular binding pocket at the Kv11.1 channel.
25 
Ex vivo and in vivo investigations
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to the lack of arrhythmogenic data for the screened compounds. Monophasic ac-
tion potentials of isolated Langendorff-perfused heart preparations can be record-
ed to assess ex vivo proarrhythmic liability of Kv11.1 blockers,
26-28 and various 
animal models such as AV dogs and rabbits are widely applied to evaluate the 
in vivo arrhythmic propensities of drug candidates.29, 30 Accordingly, the Kv11.1 
blockers from Chapter 7 should be further assessed in these different ex vivo and 
in vivo experiments in order to define a more educated and reliable “kon-koff-KD” 
map that allows for a better indication of torsadogenic risks of compounds. No-
tably, ex vivo and in vivo preclinical studies are commonly carried out on animal 
hearts or whole animals that are unlikely to mimic diseased human subjects and 
therefore might not be predictive of the clinical situation.3, 27, 31, 32 Hence, this ki-
netic map could be even further improved by incorporating affinity and kinetic 
parameters of more reference drugs like astemizole, ranolazine and dofetilide, 
which are selective Kv11.1 blockers and have already been assessed for their 
proarrhythmic profiles in clinical trials. Ultimately, a more complete translational 
model based on all in vitro, ex vivo and in vivo data can hopefully be elucidated to 
improve the predictive index of Kv11.1 liability of drug candidates in the future. 
Rechanneling the Kv11.1 liability paradigm
The current assessment of proarrhythmic risks of Kv11.1 blockers is predomi-
nantly dependent on their IC50 values.
3, 33 However, this approach does not take 
into account drug binding kinetics, which can have a major impact on cardiac 
arrhythmias of drug candidates.24, 34, 35 In 2013 a Comprehensive in vitro Proar-
rhythmia Assay (CiPA) was proposed as a new paradigm to replace the current 
regulatory strategy by the Cardiac Safety Research Consortium, and the CiPA 
was expected to be operational worldwide by July 2015.34, 36, 37 In this new CiPA 
paradigm in silico modeling is one of the most important components. In this 
regard, the best simulation model is suggested to be selected before the release of 
the CiPA assay, and more sophisticated models that include both simple channel 
blockade affinity and additional drug binding kinetics are inferred to significantly 
improve the proarrhythmic assessment for drug candidates.36 Thus, incorporat-
ing association and dissociation rates of e.g., the compounds from Chapter 6 
and 7 with their binding affinity may lead to a more efficient, readily applicable 
computational model for the forthcoming CiPA implementation. As a branch of 
this extended research, a large library of Kv11.1 blockers with varied affinity and 
kinetic parameters should also be synthesized and evaluated to provide enough 
data for the representative in silico model in the near future. Hopefully, the ul-
timate, optimized CiPA paradigm will demonstrate much better predictive value 
for proarrhythmic risks of pharmaceutical products, compared to the traditional 
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strategy recommended by ICH S7A and S7B guidelines.38, 39
Final note
Kv11.1-induced cardiotoxicity has emerged as an unanticipated adverse effect of 
many pharmacological agents and has become a major obstacle in drug devel-
opment over the past decades. In this thesis, allosteric modulation of the Kv11.1 
channel has been extensively explored, and negative allosteric modulators were 
shown to relieve the proarrhythmic effects of structurally and therapeutically di-
verse Kv11.1 blockers. The most potent modulators can be further assessed in in 
vitro assays based on hiPSC-CM models, ex vivo and in vivo studies, and may 
be developed as a new class of antiarrhythmic medications in the future. On the 
other hand, kinetic binding parameters of a wide range of Kv11.1 blockers at the 
channel have been thoroughly investigated in this thesis. Association and dis-
sociation rates or residence times are strongly suggested to be integrated with 
equilibrium affinity values in the future strategies for a better and more compre-
hensive evaluation of Kv11.1 liability of drug candidates. The “kon-koff-KD” ki-
netic map provides a first and promising classification of Kv11.1 blockers, which 
could be beneficial and indicative for drug researchers to design compounds with 
less Kv11.1-mediated cardiac side effects in the early stage of drug development. 
Functionally determining the kinetic parameters of Kv11.1 blockers at the chan-
nel, e.g., by using inside-out patch clamp assays, will facilitate the incorporation 
of ligand-channel binding kinetics into the novel CiPA paradigm. Hopefully, all 
findings in this thesis have brought new insights into Kv11.1-induced cardiac ar-
rhythmias, and will offer opportunities for restoring or preventing this kind of 
arrhythmias in the near future.
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Summary
The superfamily of ion channels is a major focus of drug discovery and devel-
opment programs in the pharmaceutical industry due to their involvement in a 
number of physiologic functions. However, the binding of several drugs to ion 
channels is also responsible for a huge number of side effects, and pharmaceuti-
cal safety is routinely required by regulatory agencies for certain ion channels, in 
particular cardiotoxicity mediated by the Kv11.1 channel. All these subjects have 
been generally discussed in Chapter 1 of this thesis. 
Chapter 2 is a literature-based review describing research progress on the 
Kv11.1 channel. In this chapter, we focused on kinetic studies of the channel, 
including the unique gating kinetics and ligand binding kinetics. In addition, bi-
ological production and degradation, structural features, physiological functions, 
and on- and off-target applications of the Kv11.1 channel were briefly introduced. 
A thorough analysis of the Kv11.1 channel is beneficial for the improvement of 
drug design and reduction of unwanted arrhythmic side effects caused by the 
blockade of this channel.
In Chapter 3, a previously disclosed series of compounds together with three 
reference compounds, were selected and evaluated for the allosteric modulation 
of the Kv11.1 channel in [
3H]astemizole and [3H]dofetilide binding assays. One 
potent negative allosteric modulator (LUF6200) was identified in radioligand dis-
sociation assays, while potassium ions were found to be positive allosteric mod-
ulators. These two modulators interacted with the Kv11.1 channel via separate 
allosteric sites with positive cooperativity towards each other. Taken together, 
this investigation provides direct evidence for allosteric modulation of the Kv11.1 
channel.
As an extension of the research described in chapter 3, three compounds 
(ML-T531, VU0405601 and LUF7244) were extensively evaluated for their neg-
ative allosteric effects on the Kv11.1 channel using different [
3H]dofetilide bind-
ing assays in Chapter 4. The novel modulator LUF7244 was further assessed for 
its possible antiarrhythmic propensity in radioligand binding experiments and 
voltage sensitive optical mapping in a newly validated neonatal rat ventricular 
myocyte (NRVM) model. The channel affinity of three blockbuster drugs (astem-
izole, sertindole and cisapride) that have all been withdrawn from market due to 
their Kv11.1 blockade, was diminished in the presence of LUF7244. Furthermore, 
the heterogeneous prolongation of the action potential duration (APD) and/or a 
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high incidence of early afterdepolarizations (by astemizole and sertindole only) 
induced by these Kv11.1 drugs were normalized by pretreatment with 10 µM 
LUF7244 in the NRVM cultures. Intriguingly, LUF7244 per se did not affect the 
APD and the viability, excitability and contractility of the cardiomyocytes, and 
exerted no obvious influence on the intentional blockade of the human histamine 
H1 receptor by astemizole. Accordingly, these results indicate that further devel-
opment of LUF7244 raises an opportunity for antiarrhythmic drugs via combina-
tion therapy.
Subsequently, in Chapter 5 the synthesis and allosteric evaluation of 29 com-
pounds, which share the same chemical scaffold as LUF7244, were described. 
Most compounds emerged as negative allosteric modulators at the Kv11.1 chan-
nel, and the structure-activity relationships of all these ligands were established. 
Importantly, compounds 7f and 7p were more potent than LUF7244 in negatively 
modulating the channel, implying promising antiarrhythmic propensities superior 
to LUF7244.
A new [3H]dofetilide competition association assay was successfully vali-
dated in Chapter 6, and was further utilized to determine the kinetic parameters 
of fifteen prototypical Kv11.1 blockers. In contrast to a classical ligand-receptor 
interaction mechanism, the affinity of these blockers was predominantly regulat-
ed by their association rates instead of dissociation rates, implicating the role of 
association rates in Kv11.1 blockade. Thereafter, membrane affinity of all these li-
gands was measured in an immobilized artificial membrane column using HPLC. 
Similar to general calculated physiochemical properties, it is shown in chapter 6 
that membrane interactions of Kv11.1 blockers did not significantly impact their 
affinity and ligand binding kinetics. 
Since dissociation rates or residence times (RTs) of all Kv11.1 blockers in 
chapter 6 only exhibited a 10-fold difference, a library of 46 compounds over a 
wide range of chemical scaffolds were tested for their affinity and kinetic data in 
Chapter 7. Kv11.1 blockers were discovered with up to a 300-fold difference in 
RTs (0.34 min for compound 37 versus 105 min for 38), which enabled the inves-
tigation of the structure-kinetics relationships next to structure-affinity relation-
ships. Afterwards, a “kon-koff-KD” kinetic map was constructed based on the kinet-
ic parameters of these compounds together with those of three reference blockers 
(astemizole, ranolazine and dofetilide). This kinetic map offers a probable frame-
work for a further and more precise categorization of Kv11.1 blockers, inferring 
distinct proarrhythmic risks. Additionally, two representative compounds, 21 and 
38, were measured in a whole-cell patch clamp assay. It was found that the poten-
cy (IC50) of these two ligands was influenced by their RTs, while the IKr inhibition 
rates were in line with their association rates. Therefore, association rates and RTs 
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of Kv11.1 blockers are strongly suggested to be incorporated next to their affinity 
values into the future paradigm for proarrhythmia safety assessment.
Finally, general conclusions of all these chapters were summarized and the 
corresponding future research directions based on all findings in this thesis were 
proposed in Chapter 8. In conclusion, allosteric modulation and ligand bind-
ing kinetics at the Kv11.1 channel have been intensively discussed in this thesis. 
Negative allosteric modulators of the Kv11.1 channel open a new avenue for mit-
igating unintentional, arrhythmic effects of drug candidates via pharmacological 
combination therapy. Likewise, incorporation of ligand binding kinetics, next to 
affinity for the Kv11.1 channel, into the new Comprehensive in vitro Proarrhyth-
mia Assay (CiPA) could improve the traditional screening paradigm for assess-
ment of Kv11.1-induced cardiotoxicity. Hopefully, considering kinetic parameters 
of Kv11.1 blockers at the channel will lead to the design of safer drug candidates 
as well as to less drug attrition in the near future.

Samenvatting
De familie van ionkanalen is vanwege zijn vele fysiologische functies al vele jar-
en een belangrijk aandachtsgebied voor onderzoek naar nieuwe geneesmiddelen. 
Helaas is gebleken dat verscheidene geneesmiddelen bijwerkingen vertonen die 
veroorzaakt worden door binding aan een ionkanaal, in het bijzonder door Kv11.1 
kanaal-gemedieerde cardiotoxiciteit. Daarom wordt er tegenwoordig door genee-
smiddelautoriteiten onderzoek naar ionkanaal-interacties vereist voordat goed-
keuring van een geneesmiddel kan plaatsvinden. Bovengenoemde onderwerpen 
worden besproken in hoofdstuk 1 van dit proefschrift.
Hoofdstuk 2 is een literatuurstudie die de voortgang van onderzoek naar het 
Kv11.1 kanaal beschrijft. In dit hoofdstuk hebben we ons gericht op kinetische 
studies van het ionkanaal, in het bijzonder de unieke kanaalkinetiek en ligand-
bindingskinetiek. Daarnaast worden biosynthese, degradatie, structurele eigen-
schappen, fysiologische functies en on- en off-target toepassingen van het Kv11.1 
kanaal geïntroduceerd. Het grondig bestuderen van het Kv11.1 kanaal draagt bij 
aan het verbeteren van geneesmiddelonderzoek en het verminderen van arit-
mische bijwerkingen die veroorzaakt worden door blokkering van dit ionkanaal. 
In hoofdstuk 3 is een selectie van eerder beschreven liganden, kalium ionen 
en drie referentie liganden onderzocht. Voor de geselecteerde stoffen is gekeken 
naar allostere modulatie van het Kv11.1 kanaal in [
3H]astemizol en [3H]dofetilide 
bindingsstudies. In een radioligand dissociatie studie werd gevonden dat één li-
gand, LUF6200, een potente negatieve allostere modulator is en dat kaliumionen 
zich als positieve allostere modulatoren gedragen. Deze twee modulatoren induc-
eren hun effect op het Kv11.1 kanaal via verschillende allostere bindingsplaatsen 
met een positieve coöperativiteit. Samengevat levert dit onderzoek direct bewijs 
voor allostere modulatie van het Kv11.1 kanaal.
Als toevoeging op het in hoofdstuk 3 beschreven onderzoek zijn in hoofd-
stuk 4 met behulp van verschillende [3H]dofetilide experimenten drie liganden, 
ML-T531, VU0405601 en LUF7244, uitgebreid onderzocht op hun negatieve al-
lostere eigenschappen ten opzichte van het Kv11.1 kanaal. De nieuwe modulator 
LUF7244 werd daarnaast verder onderzocht op een potentieel antiaritmisch ef-
fect met behulp van radioligand bindingsstudies en een nieuw gevalideerd model, 
het neonatal rat ventricular myocyte (NRVM) model. De affiniteit van drie block-
buster geneesmiddelen (astemizol, sertindol en cisapride) die vanwege Kv11.1 
kanaal blokkering van de markt gehaald zijn, was verminderd in aanwezigheid 
van LUF7244. Daarnaast werden de heterogene verlenging van de duur van de 
actiepotentiaal en/of een hoge incidentie van vroege napolarisaties (door en-
kel astemizol en sertindol) - veroorzaakt door deze blockbuster geneesmiddel-
en - genormaliseerd door voorbehandeling van de NRVM culturen met 10 μM 
LUF7244. Intrigerend genoeg heeft LUF7244 op zichzelf geen effect op de duur 
van de actiepotentiaal en op de levensvatbaarheid, prikkelbaarheid en contrac-
tiliteit van cardiomyocyten. Daarnaast vertoont het geen effect op de gewenste 
werking van astemizol, namelijk blokkering van de histamine H1 receptor. Deze 
resultaten tonen aan dat verdere ontwikkeling van LUF7244 de mogelijkheid 
biedt om antiaritmische geneesmiddelen te gebruiken als combinatietherapie. 
Vervolgens beschrijft hoofdstuk 5 de synthese en allostere evaluatie van 
29 liganden met een scaffold gelijk aan LUF7244. De meeste liganden bleken 
negatieve allostere modulatoren voor de blokkering van het Kv11.1 kanaal en 
structuur-activiteit relaties van al deze liganden werden beschreven. Liganden 7f 
en 7p bleken potenter dan LUF7244 in het negatief moduleren van de receptor. 
Dit is veelbelovend omdat het laat zien dat deze stoffen mogelijk betere antiarit-
mische eigenschappen hebben dan LUF7244.
De ontwikkeling van een nieuw [3H]dofetilide competitie associatie experi-
ment is beschreven in hoofdstuk 6. Dit experiment werd vervolgens verder geb-
ruikt om de kinetische parameters van vijftien prototypische Kv11.1 kanaal-blok-
kers te bepalen. In tegenstelling tot het klassieke mechanisme van ligand-receptor 
interactie werd de affiniteit van deze blokkers voornamelijk bepaald door hun 
associatie-snelheidsconstanten in plaats van hun dissociatie-snelheidsconstant-
en. Dit toont duidelijk de rol en het belang van associatie-snelheidsconstanten 
voor blokkering van het Kv11.1 kanaal. Vervolgens is voor al deze liganden de 
affiniteit voor het celmembraan bepaald met behulp van een geïmmobiliseerde 
kunstmatige membraankolom in een HPLC machine. Net zoals voor gebruikeli-
jke fysisch-chemische eigenschappen is in hoofdstuk 6 aangetoond dat de mem-
braaninteractie van  Kv11.1 kanaal-blokkers geen significant effect heeft op hun 
affiniteit en kinetiek van ligandbinding.
Vanwege het feit dat de dissociatie-snelheidsconstanten en verblijftijden van 
alle in hoofdstuk 6 beschreven Kv11.1 kanaal-blokkers slechts maximaal een fac-
tor 10 verschillen, werd in hoofdstuk 7 een bibliotheek van 46 liganden getest 
op affiniteit en kinetiek. Er werden Kv11.1 kanaal-blokkers ontdekt met een 
300-voudig verschil in verblijftijd op het ionkanaal, 0.34 min voor 37 t.o.v. 105 
min voor 38. Dit maakte het voor ons mogelijk om structuur-kinetiek relaties te 
bestuderen naast de gebruikelijke structuur-affiniteit relaties. Vervolgens is op 
basis van de kinetische parameters van deze liganden samen met die van de ref-
erentie liganden, astemizol, ranolazine en dofetilide, een kinetische “kon-koff-KD”-
kaart gemaakt. Deze kaart biedt kader voor een verdere en nauwkeuriger indeling 
van Kv11.1 kanaal-blokkers waarmee de risico’s van de verschillende blokkers 
voorspeld kunnen worden. In aanvulling hierop zijn twee representatieve ligan-
den, 21 en 38, getest in een whole-cell patch clamp experiment. Het bleek dat 
de potentie van deze liganden (IC50) werd beïnvloed door hun verblijftijd op het 
ionkanaal, terwijl de IKr inhibition rates in lijn waren met de associatie-snelheid-
sconstanten. Om bovengenoemde redenen raden wij sterk aan om bij het bepalen 
van de veiligheid van potentieel pro-aritmische liganden de verblijftijd en associ-
atie-snelheidsconstante naast de affiniteit mee te nemen ter evaluatie.
Ten slotte zijn de algemene conclusies van de hoofstukken en de bijbehorende 
mogelijkheden voor toekomstig onderzoek beschreven in hoofdstuk 8. Conclu-
derend, allostere modulatie en ligandbindingskinetiek van het Kv11.1 kanaal zijn 
uitvoerig beschreven en bediscussieerd in dit proefschrift. Negatieve allostere 
modulatoren bieden nieuwe mogelijkheden tot het verminderen van onbedoelde, 
aritmische effecten van kandidaat-geneesmiddelen via farmacologische combi-
natietherapie. Daarnaast kan het gebruikmaken van ligandbindingskinetiek, par-
allel aan de affiniteit, van het Kv11.1 kanaal in de nieuwe FDA guideline Com-
prehensive in vitro Proarrhythmia Assay (CiPA) leiden tot verbetering van de 
traditionele bepaling van toxiciteit  veroorzaakt door het Kv11.1 kanaal. Hopelijk 
zal het evalueren van kinetische parameters van Kv11.1 kanaal-blokkers in de 
toekomst leiden tot het ontwikkelen van veiliger geneesmiddelen en tot minder 
geneesmiddelen die van de markt gehaald moeten worden.
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